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ABSTRACT
The E1B55k gene in adenovirus type 5 was studied by generating recombinant
viruses in which the E1B55k gene was N-terminally tagged with either a cyan
fluorescent protein (CFP) tag or a tandem affinity purification (TAP) tag. By
infecting cells with the recombinant adenovirus expressing CFP tagged E1B55k,
localisation of the E1B55k gene during infection could be studied. Generation of
the recombinant viruses expressing TAP tagged E1B55k would allow purification
of the E1B55k protein and any cellular or viral proteins that interacted with
E1B55k. By infecting different cell types and harvesting at set time points during
infection, the proteins interacting with E1B55k at different time points during
infection could be identified. The E1B55k protein is modified by small ubiquitin
modifying protein 1 (SUMO-1) at lysine residue 104 within the SUMO consensus
sequence KxE, and SUMOylation can be abolished by mutating the lysine
residue to an arginine (Endter et al., 2001). Therefore in order to study the effect of
SUMOylation of E1B55k, on adenovirus infection, CFP and TAP tagged
recombinant adenoviruses in which the E1B55k protein was mutated to contain an
unmodifiable arginine at position 104 were also generated.
Stable cell lines expressing TAP tagged wild type (wt) E1B55k, and E1B55k in
which lysine residue 104 had been mutated to an arginine (K104R) were also
generated as an alternative method to study the interacting proteins of E1B55k.
Four different isoforms of SUMO have been identified, named SUMO1-4. Stable
cell lines expressing SUMO-2 were infected with wild type adenovirus type 5 and
harvested at set time points in order to determine if any adenoviral proteins were
modified by SUMO-2.
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INTRODUCTION
1.1 Adenoviruses
1.1.1 Adenoviruses
Adenoviruses are non-enveloped double stranded DNA viruses that contain a
linear genome of between 35 and 38 kilobases (kb). They contain inverted
terminal repeats (ITR’s) at either end of their genome (approximately 100-140bp
in length). They were first discovered in 1953, by Rowe and colleagues, who
isolated a virus that caused the degeneration of primary cell cultures derived from
adenoid tissues (Rowe et al., 1953). In 1954, Hilleman and Werner (Hilleman and
Werner, 1954) also isolated virus from respiratory secretions of military recruits
and showed that it induced cytopathic changes in cultures of human cells. The
viruses isolated by the two different groups were later shown to be related, and in
1956 these agents were termed adenoviruses (Enders et al., 1956). Since their
discovery adenoviruses have been isolated from every class of vertebrates
including fish, amphibians and reptiles.
1.1.2 The family Adenoviridae
Up until recently, the family adenoviridae only contained two genera,
Mastadenovirus and Aviadenovirus, but there were certain types of adenovirus
which did not fit properly into either genera. At the XIIth meeting of the
International Committee on Taxonomy of Viruses (ICTV), 2000, adenoviruses
were divided up into four different genera, Mastadenovirus, Aviadenovirus,
Siadenovirus and Atadenovirus. Mastadenoviruses infect mammalian hosts
exclusively (including humans, simians, bovines, equines, canines, porcines and
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opossums) whilst aviadenoviruses have been found only in birds. Atadenoviruses
were so named because of the high Adenine and Thymine (A, T) content of their
genomes and they infect various mammalian, avian and reptilian hosts as well as a
marsupial. The siadenovirus group are so named because they encode a putative
sialidase (Davison, 2002). A sialidase is an enzyme of the hydrolase class that
catalyzes the cleavage of glucosidic linkages between a sialic acid residue and a
hexose or hexosamine residue at the nonreducing terminal of oligosaccharides in
glycoproteins, glycolipids, and proteoglycans. The two siadenoviruses were
isolated from turkey (THEV / turkey adenovirus type 3) and frog (Davison et al.,
2000).
A fifth proposed genus “Ichtadenovirus” to include the fish adenovirus, which has
been partially isolated from the white sturgeon, has not yet been officially
proposed to the International Committee on Taxonomy of Viruses (Benko et al.,
2002).
1.1.3 Human Adenoviruses
There are currently 51 different serotypes of human adenovirus identified,
distinguished on the basis of their resistance to neutralisation by antisera from
other know adenovirus serotypes. Type specific neutralisation results
predominately from binding of the antibody to the hexon protein and the terminal
knob of the fibre protein (see section 1.1.4, virion structure).
The serotypes are divided into 6 species, designated A-F, based on their ability to
agglutinate red blood cells, as well as oncogenic, morphological and DNA
sequencing studies. The central shaft of the fibre protein is responsible for binding
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to erythrocytes and the hemagglutination can be inhibited using antisera from an
adenovirus of the same species, but not of a different species (Davison et al.,
2003).
Many of the human serotypes are associated with respiratory, gastrointestinal and
ocular disease. Recently studies showed that species C adenoviruses persisted and
could cause latent infections in approximately 80% of individuals investigated
(Garnett et al., 2002). Of the human adenoviruses serotypes 2 and 5 are the most
extensively studied, and they belong to species C.
1.1.4 Virion structure
Adenoviruses are non-enveloped icosahedral particles and have a diameter of 70-
100nm. Each virion consists of a protein shell surrounding a DNA containing core.
The protein shell (capsid) is composed of 252 subunits (capsomeres), of this 240
are hexons and 12 are pentons. Each penton contains a base, which forms part of
the surface of the capsid, and a projecting fibre, whose length varies among the
different serotypes. The capsid is comprised of seven known polypeptides (types
II, III, IIIa, IV, VI, VIII and IX). Of the polypeptides, the hexon protein is
composed of polypeptide II and is the most abundant, the fibre protein is
composed of polypeptide IV, and the penton base is composed of polypeptide III.
The other polypeptides are thought to act as a form of capsid cement.
The core of the virion contains four known polypeptides V, VII,  and terminal
protein, and the viral genome. Polypeptide VII is the major core protein and it is
thought to serve as a histone-like centre around which the DNA is wound.
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Terminal protein is attached to the 5’ends of the adenovirus DNA, circularising it
and acting as a primer for DNA replication.
Figure 1.1: Model of an adenovirus virion. This figure was taken from the Russell,
W. C., (2000). Update on adenovirus and its vectors. J Gen Virol 81, 2573-2604.
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The adenovirus pentons (composed of a penton base and a fibre) are responsible
for the attachment and internalisation of the adenovirus into the host cell. The N
terminus of the fibre is attached to the penton base, whilst the C terminus folds
into a “knob”. The “knob” is required for binding of the virion to the host cell, but
it is the penton base interacting with  integrins on the cell surface that triggers
virus internalisation and membrane permeabilisation. An arginine-glycine-
asparartic acid (RGD) motif which is present within the penton base of many
adenovirus serotypes serves as a recognition site for these intergrins (Shenk,
1996).
The best known adenovirus receptor is the Cocksackie B and Adenovirus Receptor
(CAR), although this receptor is not used by all serotypes. Heparin sulfate
glycosaminoglycans (HS-GAGs) have been demonstrated to mediate CAR-
independent attachment and infection by Ad2 and Ad5 (Dechecchi et al., 2000).
Adenovirus types 11, 35 and 3, which belong to subgroup B have been shown to
attach to CD46, a membrane cofactor protein (Gaggar et al, 2003). Of these Ad3
has also been shown to bind to CD80 and CD86 (which are expressed on antigen-
presenting cells) (Short et al, 2006). Adenovirus types 8, 19 and 37, which belong
to subgroup D have been shown to infect cells after attachment to (2-3)-linked
sialic acid, a common carbohydrate component of glycoproteins and glycolipids
(Arnberg et al, 2002).
Upon binding to the receptor, interaction between the penton base and intergrins
causes the virus to be internalised in a clathrin-coated vesicle and transported to
endosomes (Wickham et al, 1993). Here the acidic pH of the endosome results in
partial disassembley of the capsid and escape into the cytoplasm. From here the
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virion is transported to the nucleus via microtubules where the viral DNA
associates with the nuclear matrix, via the terminal protein and transcription of the
viral genome is initiated (Zhang and Arcos, 2005).
1.1.5 Genome organisation
The viral genome is organised into five early transcription units (E1A, E1B, E2,
E3 and E4), two early delayed/intermediate transcription units (pIX and IV2a) and
five late units (L1-L5). RNA splicing is very important in adenovirus replication
as it allows transcription units to encode a multiple number of proteins in a
relatively short DNA sequence.
Figure 1.2: The genome organisation of human adenovirus type 5. This figure was
taken from Leppard K. N., (1997). E4 gene function in adenovirus, adenovirus
vector and adeno-associated virus infections. J Gen Virol 78 (Pt 9), 2131-2138.
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1.2 The E1A region
1.2.1 The E1A region
During adenovirus infection E1A is the first viral transcription unit to be
expressed, and it is essential for adenovirus mediated cell transformation (Mymryk
et al., 1994; Shenk, 1996; Shenk and Flint, 1991) (Gallimore and Turnell, 2001;
Zhang et al., 2004). E1A has been extensively studied in adenovirus serotype 5,
and most of the published literature relates to this serotype. The two major E1A
products expressed during the early phase of infection are 289R (residue) and
243R, that differ by the 46 extra amino acids that are present in 289R. These
proteins are referred to as 13S and 12S respectively based on the sedimentation
coefficients of their mRNAs. Three more proteins are produced later in the
infectious cycle, 217R, 171R and 55R, but their function is as yet unknown
(Shenk, 1996).
Comparison of E1As between different adenovirus serotypes has shown the
presence of four highly conserved regions, CR1-4 (Avvakumov et al., 2002;
Kimelman et al., 1985). The 243R protein lacks CR3, which transactivates
expression of early viral transcription units E3 and E4, and to some extent E2 and
some cellular genes (Shenk and Flint, 1991). AdE1A exerts its effect on the target
cell, during both infection and transformation, by binding to and radically altering
the activity of a large number of cellular proteins (Straus, 1984).
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1.2.2 E1A binds p21 and related CDK inhibitors, thereby stimulating cell division
and growth
For virus replication to succeed the virus must induce the host cell to enter the S-
phase of the replication cycle, to provide optimal conditions for viral replication.
The cell cycle can be divided up into four phases: S-phase, G2-phase, M-phase
and G1-phase, which occur in this order. During S-phase the DNA is replicated
and during M-phase the cell divides, with G2-phase and G1-phase being the
intervals between these events. The cell cycle in normal cells is regulated by a
group of enzymes called the cyclin dependent protein kinases (cdks), so named
because they are activated by cyclin. Cyclin concentrations rise and fall at specific
times in the cell cycle and different cyclin-cdk complexes trigger different steps of
the cell cycle. As well as being affected by levels of cyclin, cdks are also
controlled by cdk-inhibitor proteins which can bind to and inhibit their function,
reviewed in (Elledge et al., 1996; Hunter and Pines, 1994; Nasmyth and Hunt,
1993; Peters, 1994; Sherr, 1994; Sherr, 1996). The first cdk-inhibitor to be
discovered was p21CIP1/WAF1. It was discovered independently, by several different
groups, as an inhibitor of cdk2 activity (Gu et al., 1993; Harper et al., 1993), as a
transcriptional target of the tumour suppressor p53 protein (el-Deiry et al., 1993)
and as a gene that induced senescence (Noda et al., 1994). p21CIP1/WAF1 has also
been show to inhibit DNA replication by binding to proliferating cell nuclear
antigen (PCNA) (Flores-Rozas et al., 1994; Luo et al., 1995; Waga et al., 1994). It
has also been shown to bind to and inactivate stress-activated kinases (Shim et al.,
1996).
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Keblusek et al demonstrated that adenovirus type 5 E1A could partially overcome
p21CIP1/WAF1 induced G1 arrest. Human bone osteosarcoma epithelial (U2OS) cells
were transfected with increasing amount of a plasmid expressing p21CIP1/WAF1
(pCMV-p21) and the number of cells arrested in the G1 phase analysed by
Fluorescence Activated Cell Sorter (FACS) analysis. When co-transfected with a
plasmid expressing E1A (pRSV-5E1A) the number of cells arrested in the G1
phase was reduced. Keblusek et al also demonstrated that the N-terminal domain
and the CR1 region of E1A were sufficient for binding to p21CIP1/WAF1. This was
demonstrated by performing Glutathione-S-Transferase (GST) pulldowns, using
truncated forms of E1A fused to GST (GST-E1A) and in vitro translated [35S]
methionine-labelled p21CIP1/WAF1.
The binding region of E1A on the p21protein was also determined. p21CIP1/WAF1
contains two separate domains, an N-terminal domain binding to cyclins and
cyclin-dependent kinases and a C-terminal domain binding to PCNA (Luo et al.,
1995). Results from experiments where GST fusions of the N-terminus and the C-
terminus of P21 were made and incubated with cell extracts from E1A transformed
cells indicate that E1A binds primarily to the N-terminus of p21CIP1/WAF1 (Keblusek
et al., 1999).
1.2.3 E1A binds to cyclins A and E-CDK complexes, which regulate passage into
cell DNA synthesis
As mentioned previously, progression through the different stages of the cell cycle
is regulated by a group of enzymes called the cyclin dependent protein kinases
(cdks), which are regulated by cyclin concentrations, which rise and fall during the
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cell cycle. The most extensively characterised is the mitotic cyclin, cyclin B,
which acts as a regulatory subunit of the serine / threonine protein kinase p32cdc2,
controlling entry in to M phase (Booher and Beach, 1987; Booher and Beach,
1988; Booher et al., 1989; Brizuela et al., 1989; Forsburg and Nurse, 1991;
Minshull et al., 1990; Solomon et al., 1990). The role of cyclin A is less well
defined, although experiments carried out demonstrated that when cyclins A and B
were injected into marine invertebrate oocytes that were arrested at the G2/M
border of meiosis I, M phase was induced (Swenson et al., 1986; Westendorf et al.,
1989). Other reports have also demonstrated that cyclin A is required for S phase
in mammalian cells (Girard et al., 1991; Pagano et al., 1992; Tsai et al., 1993;
Zindy et al., 1992). As well as cyclins A and B, various other cyclins have been
identified, some of which are thought to play a role in the transition from G1 to S
phase (Dulic et al., 1992; Koff et al., 1991; Koff et al., 1992; Lees et al., 1992;
Lew et al., 1991; Matsushime et al., 1991; Motokura et al., 1991; Xiong et al.,
1991).
A number of reports have described a kinase activity associated with ElA
(Giordano et al., 1991; Herrmann et al., 1991; Kleinberger and Shenk, 1991) that
was able to phosphorylate two of the ElA-associated proteins, p107 and p130
(Herrmann et al., 1991). Results of experiments undertaken suggested that cyclin
A was a component of the ElA-associated kinase activity (Giordano et al., 1991;
Herrmann et al., 1991; Kleinberger and Shenk, 1991). Faha et al have also
demonstrated that p33cdk2 is found in a stable complex with ElA (Faha et al.,
1992), and that the kinase activity associated with ElA was due, almost exclusively
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to p33cdk. Faha et al also demonstrated that ElA associates with cyclin E, and that
the kinase activity associated with ElA consists of two kinase complexes, cyclin
A-p33cdk2 and cyclin E-p33cdk2 (Faha et al., 1993).
1.2.4 E1A binds to the p300 / CBP family of transactivators and has numerous
effects
CREB binding protein and p300, are two closely related proteins, which belong to
a family of transcription co-activators, that can both activate or repress
transcription. The transcriptional co-activators do not directly bind to DNA, but
are recruited to promoters by sequence-specific DNA binding proteins, including
p53 and E2F. Experiments carried out by Kung et al and Yao et al indicate that
DNA binding proteins compete for limited amounts of p300 and CBP (Kung et al.,
2000; Yao et al., 1998). P300 and CBP are also involved in regulation of the cell
cycle and cells derived from p300-/- mice have serious proliferative defects (Yao
et al., 1998). Both proteins contain several conserved domains, of which one is a
histone acetyltransferase (HAT) domain. Histone deacetylase (HDAC) and histone
acetyltransferase (HAT) are enzymes that influence transcription by selectively
deacetylating or acetylating the -amino groups of lysine residues located near the
amino termini of core histone proteins. Chromatin acetylation correlates with
transcriptional activity, whereas deacetylation correlates with gene silencing.
Phosphorylation of p300/CBP by cyclin E/cdk2 results in stimulation of the HAT
activity of CBP, and subsequently progression into the S-phase of the cell cycle.
Perkins et al and Snowden et al discovered that the transcriptional activities of
p300 and CBP are also regulated by p21CIP1/WAF1(Perkins et al., 1997; Snowden et
40
al., 2000). Recently, a strong transcriptional repression domain, termed Cell Cycle
Regulatory domain 1 (CRD1), was discovered within p300 and CBP. Expression
of p21CIP1/WAF1 was shown to inhibit this transcriptional repression (Gregory et al.,
2002; Snowden et al., 2000). Girdwood et al recently demonstrated that SUMO
modification of CRD1 is required for CRD1-dependent transcriptional repression
(Girdwood et al., 2003).
Both CBP and p300 bind to the N-terminal domain of the transforming E1A
proteins of non-oncogenic human adenovirus 5 (Ad5) and these interactions are
important for Ad5 E1A-induced cell immortalization, transformation and
repression of neuronal differentiation (Boulukos and Ziff, 1993); for reviews see
(Hagmeyer et al., 1995; Moran, 1994; Peeper and Zantema, 1993). Dorsman et al
also demonstrated that the E1A proteins of oncogenic adenovirus type 12 can also
bind CBP and p300 (Dorsman et al., 1997). Both p300 and CBP can complex with
another co-activator protein, P/CAF, which also has intrinsic histone
acetyltransferase (HAT) activity. Reid et al demonstrated that P/CAF was able to
stimulate transcription, independently of CBP/p300, and that this was due to its
intrinsic HAT activity (Reid et al., 1998). The E1A protein was shown to displace
P/CAF from the p300/CBP co-activator complex (Yang et al., 1996). Reid et al
demonstrated that E1A does this by directly binding to P/CAF, independently of
CBP, and that residues within the E1A conserved region 1 are required for this.
Binding of E1A to P/CAF inhibits its activity as a transcriptional activator (Reid et
al., 1998).
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Chakravarti et al demonstrated that the carboxy terminus of E1A can inhibit the
HAT activity of p300 in vitro by functioning as an acetylase inhibitor. p300/CBP
have been demonstrated to acetylate p53, thus regulating both its DNA binding
and transcriptional activities (Gu and Roeder, 1997; Gu et al., 1997). Chakravarti
et al demonstrated that E1A inhibited p300-mediated acetylation of p53, and that
this was due to it interacting directly with the HAT domain of p300. E1A was also
shown to bind directly to the HAT domain on P/CAF, thus inhibiting its
transcriptional activity. Together these data demonstrate that the HAT inhibitor
activity of E1A is important for its ability to inhibit p300-dependent
transactivation in vivo (Chakravarti et al., 1999).
The cAMP dependent transcription factor (CREB), upon phosphorylation,
interacts strongly with CBP, and CREB function is dependent on the HAT activity
of CBP (Torchia et al., 1997; Yao et al., 1998). The interferon- dependent
transcription factor STAT1 also binds to CBP, and is dependent on its HAT
activity for function (Korzus et al., 1998). Perissi et al also demonstrated that E1A
inhibits the HAT activity of CBP by binding to the C/H3 domain of CBP (Perissi
et al., 1999).
The signal transducer and activator of transcription (STAT) family of proteins are
latent transcription factors that are activated by tyrosine phosphorylation in
response to cytokine or growth factor stimulation of cells. So far, seven members
have been identified in mammalian cells, named 1-7. STAT1 is involved in
mediating interferon (IFN) driven gene transcription and can be activated by both
type I IFN (/) and type II IFN (), which are involved in the innate immune
response to pathogen infection. Look et al demonstrated that mutant forms of E1A,
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which could no longer bind CBP/p300 could still interact directly with STAT1 and
block IFN-driven, STAT1-dependent gene activation. This interaction occurred
between the N-terminal of E1A and the C-terminus region of STAT1 (Look et al.,
1998).
1.2.5 E1A binds to Rb / p130 family of proteins and in doing so thus releases E2F
The E2F family of transcription factors, of which there are 7, numbered 1-7, are
extremely important in cell cycle regulation and they can be divided up into 4
distinct groups. E2Fs 1-3 are transcriptional activators, and E2Fs 4-5 are
transcriptional repressors (Dyson, 1998; Mann and Jones, 1996; Pierce et al.,
1998; Trimarchi and Lees, 2002; Wang et al., 2000; Wu et al., 2001). E2F6 and
E2F7 both form their own groups and both are thought to be transcriptional
repressors (Cartwright et al., 1998; de Bruin et al., 2003; Di Stefano et al., 2003;
Gaubatz et al., 1998; Morkel et al., 1997; Trimarchi et al., 1998). E2F1 was the
first family member to be discovered as a cellular transcription factor that binds to
a specific DNA sequence in the adenovirus E2 promoter (Kovesdi et al., 1986).
The E2F-binding sequence has since been found in the promoters of many genes
required for DNA replication. DNA binding proteins, DP1 and DP2/3 are required
by E2F family members and together they form a heterodimer of E2F and DP
(Dyson, 1998).
E2Fs 1-5 activity is regulated by the retinoblastoma RB-family of proteins, which
include retinoblastoma protein pRB, p107 and p130. The RB family of proteins
can prevent E2F transcription factors from interacting with transcription
coactivators thereby inhibiting their transactivation function (Mundle and
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Saberwal, 2003). They can also act by recruiting chromatin modifying enzymes to
silence transcription, pRB has also been demonstrated to recruit Histone
Deacetylase 1 (HDAC1) (Brehm et al., 1998).
In normal cells, cell cycle dependent phosphorylation of pRB by cyclin-cdk
complexes releases E2F1 to activate transcription of target genes required for the
S-phase of the cell cycle (Harbour and Dean, 2000; Harbour et al., 1999; Lundberg
and Weinberg, 1998).
1.2.6 E1A binds to TATA-box-binding protein (TBP) and TBP associated proteins
(TAFs)
For mRNA synthesis to occur, RNA polymerase II must assemble in a complex
with the necessary transcription factors (TFs) to form a pre-initiation complex
(PIC). The initial step of this is the binding of the TIF IID, a complex consisting of
TBP and TAFs, to core promoter sequence elements.
Geisberg et al demonstrated that the CR3 region of adenovirus E1A binds to TBP
and that this interaction was required for transactivation by E1A (Geisberg et al.,
1994).
Mazzarelli et al demonstrated that a region within the C terminus of TAFII135 can
bind to the CR3 domain of adenovirus E1A and block its ability to stimulate
transcription of an E1A inducible promoter (Mazzarelli et al., 1997).
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1.2.7 E1A is required for transformation
All human adenoviruses that have been tested can oncogenically transform
cultured rodent cells. Rodent cells do not support lytic infection of adenovirus, but
are transformed due to the integration and expression of the early region E1A and
E1B genes. This results in cell proliferation, immortalisation, and altered cell
morphology. However, only a number of adenoviruses have the ability to directly
induce the formation on tumours within rodents. Species A adenoviruses,
including serotypes 12, 18 and 31 are highly tumorigenic, whereas species E
(serotype 4) and C (serotypes 1, 2, 5 and 6) adenoviruses are not known to be
tumour inducing.
Transformation can be induced in human cell lines, as well as rodent cell lines, by
transfection with plasmids encoding E1A and E1B genes. Expression of E1A
alone is sufficient to immortalise cells, although E1B-19kDa and E1B-55kDa
proteins are required to convert cells to a fully transformed tumorigenic phenotype
(Graham et al., 1977; Shenk, 1996).
It has also been demonstrated that two early region 4 (E4) gene products of
adenovirus type 5, E4 Orf6 and E4 Orf3 proteins, can also co-operate with E1A
and E1A plus E1B to substantially enhance transformation (Moore et al., 1996;
Nevels et al., 1997; Nevels et al., 1999a; Nevels et al., 1999b).
Originally it was thought that transformed cells continually expressed the viral E1
genes, and that this was how the transformed phenotype was maintained (Graham
et al., 1977; Hutton et al., 2000; Zantema et al., 1985). Nevels et al recently
demonstrated that transfection of primary baby rat kidney (BRK) cells, with
plasmids expressing adenovirus type 5 E1A with either Ad5 E4 Orf3 or E4 Orf6,
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resulted in their transformation. The transformed cell lines were then screened by
immunoblot analysis and PCR analysis for the presence of viral proteins and viral
DNA respectively. The results demonstrated that the viral DNA/viral proteins
were not retained after transformation. Although, when plasmids were co-
expressed with a plasmid encoding E1B, E1A and E4 proteins were retained. The
transformed cell lines, which did not express viral DNA or viral proteins, were
then shown to induce tumours when injected into athymic mice. This suggests that
transient expression of the viral genes for E1A and E4 Orf6 or E4 Orf3 was
enough to induce the fully transformed phenotype. Mutagenesis assays
demonstrated E1A to be mutagenic and that both E4 Orf3 and E4 Orf6, enhanced
the mutagenic frequency compared to E1A alone (Nevels et al., 2001). These data
correlate with results from Shen et al, who reported that cells transformed by
combinations of E1A with the HCMV IE1 and IE2 genes, only transiently
expressed the HCMV proteins, but accumulated mutations in the cellular p53 gene
(Shen et al., 1997).
1.2.8 The E1A proteins induce apoptosis through a p53-dependent pathway
Expression of E1A has been shown to cause an increase in the level of p53 protein
and induce p53 dependent apoptosis (Lowe and Ruley, 1993; Querido et al.,
1997b; Teodoro et al., 1995). This is due to binding of E1A to pRB and p300,
causing release of the E2F transcription factors, which in turn up regulate
expression levels of p53 (see section 1.2.5).
Lowe et al demonstrated levels of p53 protein were stabilised in Ad5-transformed
cells as well as untransformed cells expressing E1A alone. The increased levels of
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p53 in cells expressing E1A alone were found to induce apoptosis. Cells that
survived were shown to no longer express E1A and p53 levels in these cells had
returned to normal. Apoptosis was not induced in cells that were expressing both
the E1A and E1B regions. These results indicate that the E1A region induces p53
dependent apoptosis, which is prevented by the E1B region.
Both 289R and 243R proteins are able to induce apoptosis through a p53
dependent pathway (Lowe and Ruley, 1993).
1.2.9 The E1A region also induces apoptosis via a p53-independent pathway
E1A can induce apoptosis independently of p53 or other adenoviral proteins.
Putzer et al demonstrated by FACS analysis that E1A could induce apoptosis in
p53 null (SK-OV-3) cells, as Western blot analysis confirmed that Caspase-3,
which plays a very important role in apoptosis, was cleaved into its active form.
Putzer et al also demonstrated that this apoptotic activity required both p300 and
CBP, and it could be inhibited by the E1B 19k protein and pRB (Putzer et al.,
2000).
Marcellus et al showed that in Ad5 a product of the E4 region was essential for
E1A-induced p53 independent apoptosis. It is the 289R protein of E1A that is
responsible for inducing p53 independent apoptosis (Teodoro et al., 1995). In
studies using p53 null mouse cells constitutively expressing the E1A region,
apoptosis was observed, when cells were infected with an adenovirus lacking E1A
and E1B regions, but expressing E2, E3 and E4 regions. The E4 region was
implicated when cells were infected with an adenovirus, which expressed the E1B
region but lacked the E4 region, did not die of apoptosis to the same extent. An
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adenovirus vector lacking both the E1 and E4 regions was unable to induce
apoptosis in E1A-expressing cell lines (Marcellus et al., 1996).
1.3 The E1B region
1.3.1 Proteins produced by the E1B region and their localisation patterns
Two proteins are encoded by the E1B region, E1B-55kDa and E1B-19kDa
proteins, and they cooperate with the E1A products to induce cell growth.
Zantema et al studied the localisation of the E1B proteins by immunofluorescence
using cells transformed with the complete E1 region of Ad5. Monoclonal
antibodies raised against the E1B-55kDa and E1B19k proteins, showed the
E1B19k protein to have a perinuclear localisation, with the E1B-55kDa protein
localised to the cytoplasm, as well as discrete cytoplasmic bodies. The p53 protein
was also observed in these cytoplasmic bodies and in the nucleus, but not in the
cytoplasm (Zantema et al., 1985).
1.3.2 E1B-19kDa protein
The E1B-19kDa protein is capable of cooperating with the E1A gene products in
the transformation of primary rodent cells (White and Cipriani, 1990), although it
shares no sequence homology with other transforming proteins. E1B-19kDa
protein is found associated with both cytoplasmic and nuclear envelope
membranes, as well as the intermediate filament cytoskeleton (White and Cipriani,
1989; White et al., 1984). Expression of E1B-19kDa protein destroys the
intermediate filament cytoskeleton by affecting the organisation of both vimentin-
type filaments in the cytoplasm and the lamin filament network in the nucleus
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(White and Cipriani, 1989; White and Cipriani, 1990). As well as modifying the
morphology of the infected cell, the E1B-19kDa protein also maintains the
integrity of both cellular and viral DNA within the nucleus and negatively
regulates viral gene expression and replication (Pilder et al., 1984; Takemori et al.,
1984; White et al., 1988; White et al., 1986; White et al., 1984). White et al first
proposed that the role of the E1B-19kDa protein was to prevent E1A induced
apoptosis (White et al., 1991). In support of this idea, the E1B-19kDa protein was
found to be a potent inhibitor of the cytotoxic action of tumour necrosis factor 
(TNF) or anti-Fas antibodies (Gooding et al., 1991a; Hashimoto et al., 1991;
White et al., 1992), both of which were know to induce apoptosis (Itoh et al.,
1991; Laster et al., 1988). Rao et al demonstrated that expression of the E1A
region induced programmed cell death, which could be inhibited by coexpression
of the E1B-19kDa protein or the cellular Bcl-2 proto-oncoprotein (Rao et al.,
1992). E1B-19kDa protein is a homologue of Bcl-2.
1.3.3 The E1B55kDa protein is required for efficient shutoff of host cell
replication
Babiss and Ginsberg, using Ad5 viruses with mutations in the E1B region
affecting both the E1B-55kDa and E1B-19kDa proteins, demonstrated that the
E1B-55kDa protein was required to shut off host cell protein synthesis. It was also
suggested that a 25kDa E4 protein (E4 Orf6) was required for this to occur (Babiss
and Ginsberg, 1984).
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1.3.4 E1B-55kDa and E4orf6 proteins interact
Sarnow et al developed a monoclonal antibody, 2A6, which recognises the E1B-
55kDa protein from Ad5 and Ad2 (Sarnow et al., 1982). Initial
immunoprecipitation experiments undertaken with the monoclonal antibody, using
Ad5 infected HeLa and BHK cells, demonstrated that the E1B-55kDa protein
interacted with an E4 protein that was 25kDa (E4 Orf6) (Sarnow et al., 1984).
Rubenwolf et al, using immunoprecipitation and immunoblotting, mapped the
domains in E1B-55kDa protein required for interaction with E4 Orf6 protein in
lytically infected A549 cells.
Linker insertion mutations at amino acid 143 and in the central domain of E1B-
55kDa eliminated the binding of the E4orf6 protein. Coimmunoprecipitation
assays also demonstrated that p53 is not required for the E1B-55kDa and E4 Orf6
protein interaction in adenovirus-infected cells. The region of the E4orf6 protein
required for E1B-55kDa interaction was located to the amino-terminal 55 amino
acid residues (Rubenwolf et al., 1997).
1.3.5 The E1B-55kDa protein facilitates the cytoplasmic accumulation of late
region viral mRNAs during infection
Using an Ad5 mutant (H5dl338) which contained a deletion within the E1B
region, preventing expression of E1B-55kDa protein but not the E1B-19kDa
protein, Pilder et al demonstrated a 100 fold reduction in adenovirus yield,
compared to wild type, during infection of HeLa cells. This mutant virus also
failed to transform rat cells at normal efficiency. The levels of the cytoplasmic
mRNA were monitored, using Northern analysis, at different time points in cells
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infected with either wild type virus or mutant virus H5dl338. Compared to the
wild type, infection with virus H5dl338 was shown to result in reduced levels of
mRNAs encoded by the major late transcription unit. In cells infected with
H5dl338, the amount of cellular actin mRNA was only slightly reduced, whereas
infection with wild type virus caused a several fold reduction. By measuring the
RNA synthesised in isolated nuclei using [32P]UTP, it was found that 20-24 hours
post infection the transcription rates for the late mRNA families were reduced 3-4
fold in H5dl338 virus infected cells, compared to wild type virus. The cellular
actin gene as found to be transcribed at similar rates in both mutant and wild type
infected cells, suggesting that actin levels were not affected at the level of
transcription. Therefore, in order to determine the rate at which newly synthesised
mRNA accumulated in the cytoplasm, cultures were labelled continuously with
[3H]uridine 12 hours after infection, and the rate of appearance of labelled RNA in
the infected-cell cytoplasm monitored by hybridisation. Late viral mRNAs were
shown to accumulate in the cytoplasm 2-3 fold less with H5dl338 infected cells,
compared to wild type infected cells. Accumulation of actin mRNA in the
cytoplasm was maintained at all time points monitored in H5dl338 infected cells.
In cells infected with wild type virus however, accumulation of actin mRNA in the
cytoplasm was reduced at 12 hours post infection and terminated at 16 hours post
infection. These results showed that the E1B-55kDa protein was essential for the
accumulation of viral mRNA in the cytoplasm and to prevent the accumulation of
host cell mRNAs. Pilder et al also generated mutant viruses, which did not express
the E4 Orf6 protein, and these were shown to display lytic growth characteristics
similar to H5dl338 (Pilder et al., 1986).
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Horridge and Leppard have since shown that the E1B-55kDa protein has RNA-
binding activity, which maps to a region of the protein with homology to a family
of RNA-binding proteins, and which has been shown previously to be essential for
functionality of the protein in vivo (Horridge and Leppard, 1998).
1.3.6 E4 Orf6 causes relocalisation of E1B-55kDa protein from the cytoplasm to
the nucleus
Goodrum et al determined the localization of the adenovirus type 5 E4 Orf6 and
E1B-55kDa proteins in the absence of other adenovirus proteins. When expressed
by transfection in human, monkey, hamster, rat, and mouse cell lines, the E1B-
55kDa protein was found to be predominantly cytoplasmic, whereas the E4 Orf6
protein accumulated in the nucleus. When coexpressed by transfection in human,
monkey, or baby hamster kidney cells, the E1B-55kDa protein colocalised in the
nucleus with the E4 protein. This failed to occur in rat or mouse or CHO hamster
cell lines. These results suggested that a primate cell-specific factor mediates the
functional interaction of the E1B-55kDa and E4 Orf6 proteins of adenovirus
(Goodrum et al., 1996).
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1.3.7 E4 Orf6 and E1B-55kDa proteins form a complex and shuttle between the
nucleus and the cytoplasm
Dobbelstein et al demonstrated that the E1B-55kDa and E4 Orf6 proteins form a
complex and together, shuttle between the nucleus and the cytoplasm. The E4 Orf6
protein was found to contain a nuclear export signal (NES), 10 amino acids long,
similar to sequences found in the retroviral proteins rev and rex. This sequence
was totally conserved between adenovirus types 2 and 5. Mutational analysis of
this region greatly reduced shuttling of the E1B55-kDa / E4 Orf6 complex. The
E1B55-kDa protein was essential for shuttling of both wild type and mutant E4
Orf6. A nuclear localisation signal (NLS) was also discovered to be present within
the C-terminus of E4 Orf6, which was required for the retention of the protein in
the nucleus. The retention of E4 Orf6 in the nucleus was abolished by mutation of
this sequence or the association with E1B-55kDa protein (Dobbelstein et al.,
1997).
Weigel and Dobbelstein discovered by mutational analysis that an NES within the
E4 Orf6 protein is essential for the E1B-55kDa/E4 Orf6 complex to leave the
nucleus and that virus production was severely reduced in viruses lacking the NES
(Weigel and Dobbelstein, 2000).
1.3.8 E1B-55kDa protein can shuttle between the nucleus and the cytoplasm
independently of E4 Orf6
Kratzer et al demonstrated that the E1B-55kDa protein shuttled independently
from E4 Orf6 and p53, and contained a C-terminal nuclear localization signal
(NLS) as well as a N-terminal leucine rich nuclear export signal (NES). The
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localization of E1B-55kDa was generally cytoplasmic, but became nuclear in the
presence of inhibitors that targeted the CRM1-mediated nuclear export pathway.
The E1B-55kDa protein was shown to directly participate in the export of mRNA
from the nucleus to the cytoplasm, by accompanying RNA from the nucleus,
similar to the retroviral shuttling proteins rev and rex (Kratzer et al., 2000).
Dosch et al confirmed that the E1B-55kDa protein was also exported from the
nucleus by the CRM1-dependent pathway in adenovirus-infected cells, whereas E4
Orf6 appeared to be transported via a nonspecific mechanism. It was also
confirmed that export of E1B-55kDa was inhibited by treatment with Leptomycin
B (an inhibitor of the CRM1-dependent export pathway), and by mutation of the
essential leucine residues in the NES. The NES was also demonstrated to be
transferable to heterologous proteins (Dosch et al., 2001).
1.3.9 E4 Orf3 also relocalises E1B-55kDa protein from the cytoplasm to the
nucleus
Konig et al demonstrated that E1B-55kDa protein is normally localised to the
cytoplasm, in discrete cytoplasmic bodies along with p53 protein. The E4 Orf6
protein caused relocalisation of E1B-55kDa from the cytoplasm to the nucleus,
where both proteins were found in Promyelocytic leukaemia (PML) associated
tracks. The p53 protein, no longer bound to the E1B-55kDa protein, was found
distributed over the nucleoplasm, where it was free to activate transcription.
When co-expressed with E4 Orf3 and E4 Orf6, the E1B-55kDa protein
preferentially localised with E4 Orf6. Irrespective of the presence of E4 Orf3,
E1B-55kDa and E4 Orf6 caused the inhibition and degradation of p53. In cells that
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were infected with virus expressing E4 Orf3 and not E4 Orf6, E1B-55kDa was
localised to the nucleus along with E4 Orf3, and p53 was present in the
nucleoplasm. These results suggested that during adenovirus infection, the E4 Orf3
protein which is expressed first, binds to E1B-55kDa, liberating p53. Subsequent
expression of E4 Orf6 leads to the inactivation and degradation of p53 (Konig et
al., 1999).
Leppard and Everett demonstrated an increase in the biochemical interaction
between E1B-55kDa and E4 Orf3 in the absence of Orf6, the E1B-55kDa
association with E4 Orf3 in Nuclear Domain 10 (ND10) was also found to
increase in the absence of Orf6. The E4 Orf3 is known to associate with and cause
the reorganisation of cell nucleus structures known as ND10 (Ascoli and Maul,
1991), which contain PML and other proteins such as Daxx, that are involved in a
wide range of cellular activities. The E4 Orf3 protein associates with ND10
causing their components to redistribute into tracks (Carvalho et al., 1995).
Different isoforms of PML have been shown to exist, including Small Ubiquitin
Modifying (SUMO) protein modified forms. Leppard and Everett demonstrated
that the number of PML isoforms was increased in adenovirus infected cells, and
that this was E4 Orf3 dependent (Leppard and Everett, 1999).
Corbin-Lickfett and Bridge demonstrated that the region of E4 Orf6 that is
essential for proteasome-mediated degradation of p53 was also required to
promote viral late gene expression in a complementation assay. Proteasome
inhibitors abrogated the E4 Orf6- induced viral late gene expression in the
complementation assay, suggesting that the proteasome is required for late viral
gene expression (Corbin-Lickfett and Bridge, 2003).
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1.3.10 Identification of cellular proteins that interact with E1B-55kDa protein
Ornelles and Shenk proposed that the E1B-55kDa/E4 Orf6 complex facilitated the
transport and accumulation of viral mRNAs, while simultaneously blocking the
transport of host cell mRNAs, by relocalising a cellular factor required for
nucleocytoplasmic transport of mRNAs. This correlates with the observation that
cellular splicing factors and heterogeneous nuclear ribonucleoprotein particle
(hnRNP) proteins are redistributed to the sites of viral RNA transcription and
DNA accumulation during the late phase of infection (Jimenez-Garcia et al.,
1993). Gabler et al isolated a human gene encoding a novel nuclear RNA-binding
protein of the hnRNP family, that associates with the Ad5 E1B-55kDa protein.
The regions of E1B55-kDa protein that are required for binding to this protein
were mapped and found to overlap with the regions that bound p53, and that
interaction between the two proteins is modulated by the E4 Orf6 protein.
Expression of E1B-55kDa associated protein interfered with Ad5 E1A/E1B-
mediated transformation of primary rat cells. Furthermore, stable expression of
E1B-55kDa associated protein in Ad-infected cells overcame the E1B-55kDa
dependent inhibition of cytoplasmic host mRNA accumulation (Gabler et al.,
1998).
1.3.11 The E1B55-kDa protein is phosphorylated
The E1B55-kDa protein was shown to be phosphorylated (Sarnow et al., 1982;
Yee et al., 1983) at both serine and threonine residues (Malette et al., 1983).
Teodoro et al mapped two phosphorylation sites to the extreme carboxy terminus
of the E1B55-kDa protein at Ser-490 and Ser-491. Mutation of these sites to
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alanine residues was shown to greatly reduce the transforming activity and
partially blocked repression of p53 dependent transcription by the E1B-55kDa
protein, although the mutant was demonstrated to bind p53 at normal levels.
(Teodoro et al., 1994). Subsequently, Teodoro et al demonstrated that
phosphorylation occurred exclusively at residues Ser-490, Ser-491 and at
threonine residue (Thr-495). No phosphorylated forms of E1B55-kDa protein were
detected when these sites were mutated to alanine residues, and the result was the
complete abrogation of both transcriptional repression and transformation
activities of the E1B55-kDa protein (Teodoro and Branton, 1997b).
Teodoro and Branton also demonstrated that the E1B55-kDa protein blocks E1A-
induced p53 dependent apoptosis, and that this is dependent on the
phosphorylation of E1B-55kDa protein (Teodoro and Branton, 1997a).
1.3.12 The E1B55kDa protein interacts with p53
Sarnow et al, using monoclonal antibody 2A6, raised against E1B-55kDa protein,
found that p53 protein was co-precipitated with the E1B-55kDa protein, in
immunoprecipitation experiments undertaken in transformed mouse and hamster
cells (Sarnow et al., 1982).
Modulation of the cell cycle is also regulated by the protein p53, which was first
discovered in 1979 by DeLeo et al, Lane and Crawford, and Linzer et al, (DeLeo
et al., 1979; Lane and Crawford, 1979; Linzer et al., 1979) respectively. p53 is a
tumour suppressor protein which is present at low levels during normal cell
division. Situations such as hypoxia, or DNA damage induced by ionising or UV
radiation, lead to the activation of stress signals in the cell, causing increased
57
levels of p53, resulting in inhibition of cell growth and induction of apoptosis.
Approximately 50% of cancers in man are a result of loss of normal p53 function.
The regulation of p53 is critical in allowing maintenance of the balance between
normal cell division and tumour suppression.
MDM2 protein is a key component in regulating p53, and it acts as a ubiquitin
ligase (Honda, 1997), binding to it and targeting it for ubiquitination and
subsequent degradation by the proteasome (Bottgar et al, 1997; Haupt et al, 1997;
Kubbutat et al, 1997). MDM2 is also self-regulating, through autoubiquitination,
targeting itself for degradation by the proteasome (Honda and Yasuda, 2000; Fang
et al, 2000; Midgley et al, 2000). MDM2 is also a transcriptional target of p53, so
as levels of p53 are increased, so too are levels of MDM2, resulting in a decrease
in levels of p53. The importance of MDM2 was demonstrated in an experiment
where mice were generated lacking MDM2 and the result was embryonic lethality.
This lethality was also demonstrated in mice lacking MDMX, a protein related to
MDM2 (Jackson and Berberich, 200). Phosphorylation of p53 by DNA-dependent
protein kinase decreases the interaction between p53 and MDM2, resulting in
increased levels of p53. The p19ARF protein also increases p53 levels by
interacting with MDM2, inhibiting its activity as a ubiquitin ligase for p53 (Foster
and Lozano, 2002).
P53 is a sequence-specific DNA-binding protein and a transcription factor, capable
of both activating and repressing transcription of cellular genes. An increase in
p53 levels results in increased transcription of cellular genes responsible for cell
cycle arrest (p21) and apoptosis (Bax) (Xu et al, 1998).
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1.3.13 E1B-55kDa protein regulates the levels of p53 protein
Teodoro and Branton have shown that the E1B-55kDa protein blocks p53
dependent apoptosis and that this was dependent on the phosphorylation of E1B-
55kDa protein (Teodoro and Branton, 1997b).
Querido et al demonstrated that the E1A 243R protein induced an increase in p53
levels resulting in p53-dependent apotosis, in the absence of E1B-55kDa and E1B-
19kDa proteins. Mutational analysis indicated that the increase in p53 levels was
dependent on 243R forming a complex with p300 or pRB. The E1A 243R mutants
which could not bind p300 or pRB could not induce increased levels of p53.
Increased level of p53 correlated with the induction of apoptosis (Querido et al.,
1997b).
Querido et al showed that the 289R E1A protein did not induce increased levels of
p53, and in the presence of E1B-55kDa protein, blocked that induced by E1A
243R. This inhibition was shown to require E4 Orf6, produced as a result of
transactivation by the 289R E1A protein, and E1B-55kDa proteins, suggesting that
interactions involving p53, E1B-55kDa and E4 Orf6 proteins may play a role in
preventing E1A 243R-induced accumulation of p53 (Querido et al., 1997a).
1.3.14 E1B-55kDa protein acts as a transcriptional repressor of p53
The E1B-55kDa protein binds to the amino terminus of p53 (Kao et al., 1990) and
blocks its ability to activate transcription (Yew et al., 1994), thus acting as a
transcriptional repressor.
Yew et al demonstrated this by creating a fusion protein of E1B-55kDa protein
and a GAL4 DNA binding domain, which was shown to repress transcription from
59
a variety of promoters with engineered upstream GAL4-binding sites. Mutations
that affected the transforming activity of E1B55-kDa protein and its ability to
inhibit p53-mediated trans-activation, also reduced the repression activity of the
E1B55-kDa/GAL4 fusion protein. These results demonstrated that the E1B55-kDa
protein functions as a direct transcriptional repressor that is targeted to p53-
responsive genes by binding to p53. Several domains within the E1B55-kDa
protein contribute to the stable association with p53, with the essential region lying
between residues 224 and 354 (Yew et al., 1994).
1.3.15 E1B-55kDa protein has no effect on the p53 related protein p73
Roth et al demonstrated that although the E1B-55kDa and E4 Orf6 Proteins bind
and inactivate the p53 tumour suppressor protein, they had no effect on the cellular
protein p73, which shows extensive similarities to p53 in both structure and
function. The E1B-55kDa protein did not bind p73 nor did it inhibit p73-induced
transcription, and neither E1B-55kDa protein or E4 Orf6 promoted degradation of
p73. The switching of 5 amino acids near the amino terminus, between the p53 and
p73 proteins, rendered the p53 protein resistant and the p73 protein susceptible to
E1B-55kDa/E4 Orf6 induced degradation (Roth et al., 1998).
Higashino et al, subsequently went on to demonstrate that the E4 Orf6 protein
interacted with p73, inhibiting p73-mediated transcriptional activation (Higashino
et al., 1998).
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1.3.16 The E1B55-kDa protein inhibits p53 acetylation by PCAF
The transactivation activity of p53 is dependent on its ability to bind to specific
DNA sequences near the promoter region of target genes.
It has been demonstrated that the acetylases p300, CREB binding protein (CBP)
and PCAF acetylate p53 protein, enhancing its sequence-specific DNA-binding
activity(Gu and Roeder, 1997; Gu et al., 1997; Liu et al., 1999; Sakaguchi et al.,
1998). Liu et al demonstrated that the E1B-55kDa protein specifically inhibited
p53 acetylation by PCAF in vivo and in vitro, and that the DNA binding activity of
p53 was diminished in cells expressing E1B-55kDa. Data suggested that the
E1B55-kDa protein interfered with the physical interaction between PCAF and
p53 (Liu et al., 2000).
1.3.17 The E1B-55kDa protein interacts with a mSin3A/Histone deacetylase
complex
Within the cell, DNA molecules are wound around structures known as core
histones, and the reversible acetylation of these histones is an important regulatory
mechanism for controlling gene expression. Histone acetylation is associated with
activated transcription and is carried out by histone acetyltransferases (HATs).
Deacetylation is associated with transcriptional repression and is carried out by
histone deacetyltransferases (HDACs). In mammalian cells HDAC1 and HDAC2
are found in a complex with mSin3A (a transcription corepressor protein). Punga
and Akusjarvi showed the E1B-55kDa protein interacts with HDAC1 and
mSin3A, both in an adenovirus-transformed 293 cell line and during a lytic
adenovirus infection. It was also demonstrated that the E1B-
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55kDa/HDAC1/mSin3A complex was enzymatically active, catalyzing
deacetylation of a histone substrate peptide (Punga and Akusjarvi, 2000).
1.3.18 Degradation of p53 by E1B-55kDa and E4 Orf6 proteins occurs via a novel
mechanism involving a Cullin-containing complex
It is known that E4 Orf6 and E1B-55kDa proteins inhibit transcriptional activation
by the tumour supresssor protein p53. Several different groups have shown that
these proteins function together to reduce the half-life of p53 and induce p53
degradation (Cathomen and Weitzman, 2000; Moore et al., 1996; Nevels et al.,
2000; Querido et al., 1997a; Shen et al., 2001; Steegenga et al., 1998).
Querido et al demonstrated that this degradation of p53 occurred independently of
MDM2 and p19ARF, but required an extended region of E4 Orf6 which seemed to
possess three separate biological functions; interaction with E1B-55kDa,
interaction with two cellular proteins 19kDa and 14kDa in size, and a nuclear
localization signal (NLS). Degradation was also significantly blocked by the 26S
proteasome inhibitor MG132 (Querido et al., 2001b).
Querido et al have since determined the mechanism of adenovirus-induced p53
degradation through identification of E4 Orf6-associated cellular proteins. The E4
Orf6 protein was demonstrated to assemble in a multi-protein complex consisting
of E1B-55kDa, Elongins B and C, Cul5 and the RING-H2 finger protein Rbx1,
and that this complex functioned as an E3 ubiquitin ligase that promoted the
ubiquitination and subsequent degradation of p53 in vivo. This complex is very
similar to other E3 ubiquitin ligase complexes including the von Hippel-Lindau
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(VHL) tumor suppressor and SCF (Skp1–Cul1/Cdc53–F-box) E3 ubiquitin ligase
complexes. The E4 Orf6 complex was shown to be capable of stimulating
ubiquitination of p53 in vitro in the presence of E1 activating and E2 conjugating
enzymes. In order to determine if the Cullins were essential for adenovirus-
induced p53 degradation, experiments were undertaken in Chinese hamster ovary
(CHO) cells that are temperature sensitive for the NEDD8 pathway, as Cullins are
activated via the NEDD8 pathway. Ubiquitin mediated degradation of p53 did not
occur at the nonpermissive temperature indicating that the Cullins are essential for
this to occur (Querido et al., 2001a).
Harada et al immunopurified an E1B-55kDa-associated complex from Ad5
infected HeLa cells. SDS-PAGE and mass spectrometric analysis identified these
proteins to include Cullin-5, Rbx1 and Elongins B and C, pp32 and importin-1.
Harada et al also demonstrated that this complex was capable of causing the
polyubiquitination of p53 in vitro, and that the components existed together as a
single high-molecular-weight complex in vivo (Harada et al., 2002).
Blanchette et al demonstrated that the E4 Orf6 protein contained two conserved
BC-box motifs, that are present in Elongin C-interacting proteins, and that these
mediated interactions with Elongins B and C during complex formation. These
motifs were shown to be required for E1B-55kDa/E4 Orf6 induced degradation of
p53. Data suggested that the E1B-55kDa protein did not directly bind to E4 Orf6
but bound it as part of a complex with Cul5 and Elongins B and C (Blanchette et
al., 2004).
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1.3.19 E1B-55kDa protein interacts with Daxx
Using the Yeast II Hybrid system Zhao et al discovered the E1B-55kDa protein
interacted with Daxx. Mutation of three potential phosphorylation sites (S489/490
and T494 to alanine) within the E1B 55-kDa protein did not affect its interaction
with Daxx, although such mutations were previously shown to inhibit E1B-
55kDa’s ability to repress p53-dependent transcription and to enhance
transformation. Daxx coimmunoprecipitated with E1B-55kDa protein in 293 cell
extracts, and immunofluorescence studies showed that Daxx colocalised with
E1B-55kDa protein within discrete nuclear dots, along with p53 protein (which
were distinct from ND10). Overexpression of PML dramatically increased the
colocalisation of Daxx and PML, and reduced the colocalisation of Daxx, p53 and
E1B-55kDa. Expression of the E1B-55kDa protein in Saos2 osteosarcoma cells
led to a reduction in the number of ND10, leading to the suggestion that
E1B55kDa and PML compete for the available Daxx within the cell (Zhao et al.,
2003).
1.4 The E2 region
The E2 region, divided into E2A and E2B regions, encodes three different
proteins, all of which are directly involved in DNA replication. The gene product
of E2A is the abundant nuclear DNA-binding protein (DBP), with the E2B region
encoding the precursor terminal protein (pTP) and the viral DNA polymerase
(pol). E2A expression is mediated by the E1A region (Shenk and Flint, 1991).
Viral DNA replication requires all three E2 proteins, plus two cellular proteins,
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nuclear factor I (NFI) and nuclear factor III (NFIII) (Challberg and Rawlins,
1984).
Replication of adenoviral DNA is initiated at the origin of DNA replication (ori),
which is located within the terminal 51bp of the ITRs (Hay and Russell, 1989). A
complex of two viral proteins, pTP and pol bind here. The pTP protein is
synthesised as an 80kDa protein, which is active in initiation of replication
(Challberg et al., 1980; Stillman et al., 1981). During virus assembly it is
processed by proteolysis to generate a 55kDa fragment, TP, that is covalently
attached to the 5’ end of the adenoviral genome, where it is thought to be an
additional cis-acting component of ori (Challberg and Kelly, 1981). The pol
protein contains both 5to 3 polymerase and 3 to 5 exonuclease activity that
probably serves as a proofreading function during polymerisation (Field et al,
1984). The pTP and pol proteins bind to the ori as a heterodimer. NFI and NFIII
also bind within this 51bp region and act by stabilising binding of the pTP-pol
complex.
The pTP protein acts as a primer for DNA replication (Rekosh et al., 1977),
preserving the integrity of the terminal sequence of the viral chromosome during
subsequent rounds of DNA replication. DNA replication is initiated by a protein
priming mechanism in which a covalent linkage is formed between the -
phosphoryl group of the terminal residue, dCMP, and the -hydroxyl group of a
serine residue in pTP, a reaction catalysed by pol (Challberg et al., 1980). Chain
elongation then requires pol and DBP. The role of DBP was established by the
generation of viruses with temperature-sensitive mutations in the DBP gene that
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were unable to replicate viral DNA at non-permissive temperatures (Ensinger and
Ginsberg, 1972).
1.5 The E3 region
The E3 region, which is dispensable for the replication of adenovirus, encodes a
range of proteins that subvert the host immune response. The E3 promoter
contains NFkB-binding sites that can be induced by cytokines such as tumour
necrosis factor (TNF) (Deryckere et al., 1995).
The adenovirus E3-19kDa glycoprotein (gp19k) is a glycoprotein localised in the
membrane of the endoplasmic reticulum (ER), where it binds to major
histocompatability complex (MHC) class I antigens, preventing their export from
the ER to the cell surface. It is the presence of a lysine based motif (KKXX) that is
responsible for retention in the ER (Jackson et al., 1993).
The E3-10.4kDa/14.5kDa complex (RID/) also inhibit TNF and Fas ligand-
induced cell death by internalising their receptors (TNFR1, Fas and TNF-related
apoptosis-inducing ligand (TRAIL)-R1) (Elsing and Burgert, 1998; Gooding et al.,
1991b; Shisler et al., 1997; Tollefson et al., 1998) and promoting their degradation
in lysosomes (Elsing and Burgert, 1998; Shisler et al., 1997; Tollefson et al.,
1998). RID/ localise to the plasma membrane, Golgi and ER and to vesicles
within the cell (Tollefson et al., 1998).
The E3-14.7kDa protein (14.7k) inhibits apoptosis through the TNFR, Fas and
TRAIL pathways (Chen et al., 1998b; Gooding et al., 1988; Krajcsi et al., 1996),
with the effect on Fas being less pronounced. The E3-14.7kDa protein is localised
in the cytosol and nucleus (Li et al, 1998) and functions by binding to cellular
66
proteins that mediate apoptosis including NEMO/IKK. Apoptosis induced by
transfecting cells with NEMO/IKK, is reversed by 70%
in the presence of E3-14.7kDa protein (Li et al., 1999).
The E311.6kDa adenovirus death protein (ADP) is the only E3 protein not
involved in subverting the host cell immune response. It is produced late in
infection and induces cell death, resulting in the release of progeny virus from the
cell.
1.6 The E4 region
1.6.1 The E4 region encodes 7 different proteins
Transcripts from the E4 region are subject to alternate splicing events, leading to
the production of approximately 18 distinct mRNAs, which are predicted to
encode 7 different proteins named Open Reading Frame 1 (Orf1), Orf2, Orf3,
Orf4, Orf3/4, Orf6, Orf6/7 (Virtanen et al., 1984). All, except Orf3/4 have been
demonstrated to exist in infected cells. To date, all of the adenoviruses sequenced
appear to have an E4 region, with the exception of chicken embryo lethal orphan
virus (CELO), which is an avian adenovirus (Chiocca et al., 1996).
1.6.2 The E4 region is required for efficient DNA replication, late gene expression
and shutoff of synthesis of host cell proteins
Halbert et al confirmed the requirement of early region 4 for efficient DNA
replication, late gene expression and shutoff of synthesis of host cell proteins by
generating mutant Ad5 viruses carrying defined lesions in the E4 region. Mutant
virus dl366, which lacked the majority of the E4 region was severely defective,
67
and could only be propagated on stable Vero (monkey kidney) cells expressing the
E4 region. Virus dl355, which lacked 14bp within the segment encoding the E4
Orf6 protein, showed a delayed onset of viral DNA synthesis. Expression of late
viral proteins was reduced in both dl355 and dl366, although more
severely in dl366. Shutoff of host protein synthesis was also less efficient with the
mutant viruses, more so with virus dl366 (Halbert et al., 1985).
Attempts to identify the specific role of each of the E4 proteins, by mutational
analysis of each of the E4 Orfs, have been unsuccessful. This was due to the fact
that only a mutation in the E4 Orf6 region demonstrated any phenotypic effect on
virus growth, and this effect was minimal compared to deletion of the entire E4
region.
1.6.3 E4 Orf1
The E4 Orf1 protein, in a variety of different adenovirus serotypes, is thought to be
involved in transformation, but only when expressed at sufficient levels (Javier,
1994; Ohman, 1995). Orf1 sequences appear to be related to dUTPase enzymes,
although they lack an essential conserved dUTPase motif and are inactive in
dUTPase assay (Weiss et al., 1997). Although it has been shown that the avian
adenovirus CELO has a putative dUTPase gene in a location analogous to E4 Orf1
(Chiocca et al., 1996). The CELO E4 Orf1 gene contains the essential conserved
dUTPase motif and is active in a dUTPase assay (Weiss et al., 1997). The role of
Orf1 in lytic infection has yet to be determined. E4 Orf1 deficient Ad5 shows no
growth defect in HeLa cells (Leppard, 1997).
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1.6.4 E4 Orf2
There is at present no functional information regarding the E4 Orf2 protein,
although it has been shown to be localised to the cytoplasm in infected HeLas, is
produced at early times during adenovirus infection, and is not detected in a
complex with other proteins (Dix and Leppard, 1995).
1.6.5 The E4 Orf3 and E4 Orf6 proteins can compensate for each other
The role of E4 Orf3 proteins and E4 Orf6 proteins has been discussed earlier in
relation to E1B-55kDa and p53 proteins.
Bridge and Ketner demonstrated that the E4 products Orf3 and Orf6 could
compensate for each other. By generating a series of Ad5 mutants with deletions in
the E4 region it was demonstrated viral late protein synthesis was essentially
normal in viruses that were unable to express either Orf3 or Orf6. In mutants that
could not express both Orf3 and Orf6, late protein synthesis was dramatically
reduced and plaques formed with an efficiency less than 10-6 that of wild type
virus. Mutants that lacked Orf3 or Orf6 formed plaques with only slightly less
efficiency than wild type virus (Bridge and Ketner, 1989).
Huang and Hearing also generated mutant Ad5 viruses in order to assign specific
function to each of the E4 gene products. Mutant viruses which expressed Orf6 but
lacked Orf3, behaved like wild type virus. Mutant viruses which expressed Orf3
but lacked Orf6 displayed a delay in the onset of viral replication, reduced levels
of viral late protein synthesis and inefficient shutoff of host cell protein synthesis,
and a 10 to 20 fold reduction in virus yield. Mutant viruses lacking both Orf3 and
Orf6 displayed a significant lag in the onset of viral replication, a dramatically
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reduced level of viral late protein synthesis, no obvious shutoff of host cell protein
synthesis and up to a 105 reduction in virus yield (Huang and Hearing, 1989).
Viruses that lack the E4 region show a number of severe phenotypes, including
defects in viral mRNA accumulation, transcription, splicing, late protein synthesis,
host cell shutoff and viral DNA replication. This defect is due in part to the
production of genome concatemers (Weiden and Ginsberg, 1994), caused by the
covalent joining of viral genomes, and resulting in molecules that exceed the
packaging capacity of the capsid. Concatemerisation is mediated by the host cell,
through a Mre11/Rad50/Nbs1 complex (Boyer et al., 1999; Stracker et al., 2002).
In Ad5 expression of E4 Orf6 and E1B-55kDa proteins results in the proteasome-
mediated degradation of the Mre11 complex members (Stracker et al., 2002). The
E4 Orf3 protein is able to exclude Mre11, Rad50 and Nbs1 from the viral
replication centres.
Analyses of infections with serotypes Ad4 and Ad12 demonstrated that the
degradation of Mre11/Rad50/Nbs1 proteins is a conserved feature of the
E1b55K/E4orf6 complex. The transfection of expression vectors for the E4orf3
proteins of Ad4 and Ad12 did not alter the localization of Mre11 complex
members (Stracker et al., 2005).
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1.6.6 E4 Orf4
E4 Orf4 also regulates protein phosphorylation in the infected cell by binding to
protein phosphatase 2A (PP2A) (Muller, 1992), resulting in the selective
hypophosphorylation of some proteins, including E1A. The hypophosphorylated
E1A residues have been mapped, and at least one of these residues is a known
target for mitogen-activated protein kinase (Whalen et al., 1997). Bondesson et al
demonstrated that E4 Orf4 negatively regulates both E4 and E1A transcription,
dependent on PP2A activity, and represses E1A-mediated activation of the E4
promoter (Bondesson et al., 1996). These data suggest the presence of a regulatory
loop in which E1A activates expression of the E4 region. Expression of the E4
Orf4 protein results in the negative regulation of both E1A and E4 regions
(Leppard, 1997).
Mannervik et al demonstrated that adenovirus E1A activation of the viral E2
promoter was abrogated by coexpression of the E4 Orf4 protein. The abrogation of
E1A activation of the E2 promoter was deemed to occur through the E2F DNA
binding sites present on the E2 promoter, demonstrated by the fact that E4 Orf4
inhibited E2F-1/DP-1 mediated transactivation, as well as E2 mRNA expression
during virus growth (Mannervik et al., 1999).
1.6.7 E4 Orf3/4
This protein is predicted to exist, based on analysis of Ad2 mRNA structure in
HeLa cells (Virtanen et al., 1984), although the protein has not yet been detected
in infected cells.
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1.6.8 E4 Orf6/7
E4 Orf6/7 dimerises to link two E2F molecules, thus facilitating binding at two
E2F sites present in the Ad2 promoter, and activating transcription (Cress and
Nevins, 1994; Huang and Hearing, 1989; Obert et al., 1994).
O’Connor and Hearing showed that the E4 Orf6/7 gene product induces binding of
the cellular transcription factor E2F to the viral E2A promoter region, which is
directly correlated with the transcriptional activation of the E2A promoter in vivo.
The E4 Orf6/7 protein acts by functionally compensating for the E1A proteins. In
the absence of E1A, expression of E4 Orf6/7 is sufficient to displace the
retinoblastoma protein family members from E2Fs, leaving E2Fs free to activate
transcription of the E2A promoter (O'Connor and Hearing, 2000).
1.7 Intermediate and late genes
As well as the five early transcription units, the adenovirus genome contains two
delayed early units (IX and IVa2) and one major late unit which is processed to
generate five families of late mRNAs (L1-L5), all of which are transcribed by
polymerase II. There are also two viral-associated (VA) RNAs, transcribed by
polymerase III, that play a role in combating cellular defence mechanisms
(Mathews and Shenk, 1991).
After the onset of virus DNA replication, the IVa2 and IX genes are expressed at
high levels, activating transcription of the major late promoter (MLP) and resulting
in expression of the late genes, which are expressed under the control of the MLP
(Lutz et al., 1997; Tribouley et al., 1994).
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The proteins encoded by the late region include all of the structural proteins (II –
IX, see section 1.1.4), and the proteins involved in their production and assembly.
1.8 Viral replication
As stated in section 1.1.4, the adenovirus binds to the host cell via a receptor, the
best known of which is the Cocksackie B and Adenovirus receptor (CAR).
Binding is mediated via the adenovirus pentons, and interactions with v intergrins
on the cell surface result in virus internalisation, in clathrin-coated vesicles, where
they are transported to endosomes. Here the acidic pH of the endosome results in
partial disassembly of the capsid and escape into the cytoplasm. From here the
virion is transported to the nucleus via microtubules where the viral DNA
associates with the nuclear matrix, via the terminal protein, and transcription of the
viral genome is initiated (Zhang and Arcos, 2005).
During DNA replication the E1B-55kDa protein functions in complex with E4
Orf6 to stimulate the cytoplasmic accumulation and translation of viral mRNAs,
which is accompanied by shut off of host protein synthesis and host mRNA
nuclear export (Babiss and Ginsberg, 1984; Pilder et al., 1986). After their
production, hexon and penton capsomeres accumulate in the nucleus where
assembly of the virion occurs. Assembly appears to begin with the formation of an
empty capsid (Philipson, 1984; Sundquist et al., 1973) and, subsequently, a viral
DNA molecule enters the capsid (Hasson et al., 1992; Hasson et al., 1989). The
DNA-capsid recognition event is mediated by the packaging sequence, a cis-acting
DNA element present near the left end of the viral chromosome (Grable and
73
Hearing, 1992; Hammarskjold and Winberg, 1980; Hearing et al., 1987; Tibbetts,
1977).
After assembly of the virions, their release is mediated via two mechanisms.
Expression of the E1B-19kDa protein destroys the intermediate filament
cytoskeleton by affecting the organisation of both vimentin-type filaments in the
cytoplasm and the lamin filament network in the nucleus (White and Cipriani,
1989; White and Cipriani, 1990). Late in the infectious cycle, the viral proteinase
cleaves the cellular cytokeratin protein K18, rendering it ineffective at
polymerising to form filaments (Chen et al., 1993). Disruption of the filaments
combined with expression of the adenovirus death protein (ADP) which induces
cytolysis, results in the release of virus from the cell (Tollefson et al., 1996a;
Tollefson et al., 1996b).
1.9 Adenovirus as a viral vector
1.9.1 Why are people interested in studying adenoviruses
The growth characteristics of adenovirus make it ideal to use as a gene therapy
vector. These include the ability to infect both dividing and non-dividing cells.
Adenoviruses deliver their genome to the nucleus of the host cell where the viral
genome will exist as an episome, but will rarely integrate into the host cell
chromosome. They also infect a wide variety of different cell types including
highly differentiated tissues such as skeletal muscle, brain and heart. Adenovirus is
also relatively easy to work with and can easily be grown to high titres.
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1.9.2 Adenovirus as a gene therapy vector
Packaging restraints of the adenovirus genome limit the amount of foreign DNA
that can be added to approximately 2kb. In order to increase the amount of foreign
DNA packaged, some of the viral genome must be deleted.
The first generation of adenovirus vectors had the E1 and E3 regions deleted.
Removal of the E1 region rendered the virus replication incompetent and these
viruses had to be propagated on transcomplementing cell lines such as 293, 911 or
PER.C6 cells ( Graham et al., 1977; Fallaux et al., 1996 and Fallaux et al., 1998,
respectively). As the E3 region is responsible for modulating the host cell immune
response these vectors elicited a strong inflammatory and immune response,
resulting in transient transgene expression. These vectors were also shown to
replicate, producing replication competent adenovirus as a result of “leaky”
expression. Recently it was discovered in cells lacking E1A, that the E4ORF6/7
protein could functionally compensate for E1A (O'Connor and Hearing, 2000),
which could explain the occurrence of replication competent virus.
1.9.3 Adenovirus in cancer therapy
dl520 (ONYX-015) is an adenovirus with the E1B-55kDa gene deleted, which has
been demonstrated to have anti-tumoural activity in patients with recurrent head
and neck cancer. In adenovirus infected cells E1B-55kDa functions by targeting
the tumour suppressor protein for degradation. In a large percentage of tumour
cells the p53 gene is mutated and does not function, therefore, it was expected that
ONYX-015 would selectively replicate in tumour cells lacking normal p53, and
target them for degradation (Bischoff et al., 1996). Although there has been some
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success in phase II clinical trials, it is now realised that replication is not limited to
p53 negative cells (Hay et al., 1999; Vollmer et al., 1999), and that combinations
of gene therapy and chemotherapy may be required for total regression (Heise et
al., 1997).
dl922-947 is an E1A deleted adenovirus that has been demonstrated to replicate
specifically in cancer cells. During adenoviral infection the E1A gene activates
cell proliferation, by binding to and inactivating the pRB protein, which prevents
progression from the G1-phase to the S-phase of the cell cycle. In normal
quiescent cells, adenovirus lacking normal E1A function cannot induce cell
proliferation and viral replication. In tumour cells proliferation is uncurbed,
allowing E1A deleted adenovirus to replicate. This mutant adenovirus has
demonstrated relatively potent antitumoural activity in vivo against a wide variety
of tumours (Fueyo et al., 2000; Heise et al., 2000).
1.10 Small Ubiquitin Modifying protein (SUMO)
1.10.1 Introduction to SUMO
Small Ubiquitin Modifying protein (SUMO) is a ubiquitin-related protein that
covalently binds to other proteins using a mechanism analogous to, but distinct
from, ubiquitin. Whereas ubiquitin targets proteins to the proteasome for
degradation, SUMO conjugation results in a diverse range of effects. Since the
discovery of ubiquitin, it has emerged that there is a whole family of ubiquitin-like
proteins (UBLs). In 1992 Loeb and Haas discovered the first of the family
members ISG15, a protein covalently conjugated to cellular proteins upon
induction by interferon. It was not until 1996 that SUMO-1 was discovered
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independently by several different groups and is therefore also known as sentrin,
GMP1, UBL1, and PIC1 (Boddy et al., 1996; Matunis et al., 1996; Meluh and
Koshland, 1995; Okura et al., 1996; Shen et al., 1996).
SUMO is present in all eukaryotes and equivalent proteins are also present in
yeast, Smt3 in Saccharomyces cerevisiae and Pmt3 in Schizosaccharomyces
pombe. Deletion of Smt3 in S. cerevisiae is lethal, whereas deletion of Pmt3 is S.
pombe results in poor growth. So far four different isoforms of SUMO have been
identified termed SUMO-1, SUMO-2, SUMO-3 (Chen et al., 1998a) and SUMO-4
(Bohren et al., 2004). When comparing sequences, SUMO 2 and 3 are 97%
identical to each other but only approximately 50% identical to SUMO-1. SUMO-
4 has approximately 86% sequence identity with SUMO-2. When compared with
ubiquitin, SUMO-1 has only 18% sequence similarity, although both proteins have
remarkably similar three-dimensional structures. The main differences between the
two are firstly that SUMO-1 has a flexible 20-residue N-terminal extension which
is absent in ubiquitin, and secondly the surface charge distribution of the two
proteins is dramatically different. Under normal conditions SUMO-1 seems to be
the most prominently conjugated isoform (with a molecular weight of 11kD),
whereas SUMO-2 and SUMO-3 appear to be preferentially conjugated under
stress conditions (Saitoh and Hinchey, 2000). There are exceptions however where
SUMO-2 and SUMO-3 have been shown to modify substrates under normal
physiological conditions (Azuma et al., 2005; Eaton and Sealy, 2003). SUMO-2,
SUMO-3 and SUMO-4, unlike SUMO-1, have a SUMO attachment consensus site
and have been shown to form SUMO chains in vitro and in vivo (Bohren et al.,
2004; Tatham et al., 2001).
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Studies of SUMO modified proteins have demonstrated that SUMO modification
occurs at the Lysine residue (K) within the consensus sequence KxE, where 
represents a hydrophobic amino acid such as L, I, V or F, x represents any amino
acid and E is Glutamate. This sequence can be transferred to non SUMO-modified
proteins, making them substrates for SUMO in vitro, although a nuclear
localisation signal is also required for them to be modified in vivo (Rodriguez et
al., 2001).
SUMOylation is a reversible process and it is thought that the
SUMOylation/deSUMOylation process is highly dynamic. SUMO modification is
similar to ubiquitination, in that they both require an E1 activating enzyme and an
E2 conjugating enzyme and an E3 ligase, although SUMOylation can occur in
vitro without the requirement for an E3 ligase.
SUMO is synthesized as a precursor with a short C-terminal extension, which
must be removed before it can be conjugated to substrates. This is done by SUMO
specific proteases, which cleave four residues from the C-terminal end, exposing
the carboxyl group of Gly97.
The first SUMO specific proteases were discovered in S. cerevisiae and were
termed Ulp1 and Ulp2 (Ubiquitin-Like modifier Proteases) (Hochstrasser, 2000; Li
and Hochstrasser, 1999; Schwienhorst et al., 2000). Ulp1 is a cysteine protease
whose active site appears to be structurally related to those of adenoviral
processing proteases. Experiments demonstrated that Ulp1, like other SUMO
specific proteases acts as dual function enzyme, acting as a protease to process the
SUMO precursor into its active form, and acting as an isopeptidase to release
SUMO from its conjugated substrate, enabling it to re-enter the conjugation
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pathway (Li and Hochstrasser, 1999). Ulp2 has been demonstrated to function as
mainly as a deSUMOlyating enzyme with some processing activity (Li and
Hochstrasser, 2000; Schwienhorst et al., 2000). Ulp1 is distributed in the nuclear
periphery, whereas Ulp2 displays uneven nuclear distribution. S. pombe has only
one SUMO specific protease, SpUlp1, which carries out both activities. The
distribution of SpUlp1 appears to be regulated by the cell cycle. Localisation is in
the nuclear envelope during S and G2 phases, and nuclear during mitosis (Taylor
et al., 2002). Comparison of sequence analysis has led to the suggestion that there
are six Ulp genes in mammals, although so far only four have been characterised.
These include SENP3/SMT3IP1 (Nishida et al., 2000) shown to be localised to the
nucleolus, SENP6/SUSP1 which is localised to the cytoplasm (Kim et al., 2000),
SENP1/SuPr-2 which is detected in the nucleus (Bailey and O'Hare, 2004; Gong et
al., 2000) and finally SENP2/Axam and its isoforms produced as a result of
alternative splicing (Best et al., 2002; Nishida et al., 2001). All SUMO-specific
proteases share a conserved C-terminal sequence of approximately 200 residues,
which contains the catalytic domain, whereas the N-termini are very divergent.
Activation of SUMO is ATP dependent, and involves the E1 activating enzyme,
which is a heterodimer of SAE2-SAE1(Desterro et al., 1999). The SUMO
activation enzymes are both nuclear proteins, with a diffuse localisation (Azuma et
al., 2001). In S. cerevisiae, both subunits of E1 are essential for viability consistent
with an essential function of SUMO modification (Dohmen et al., 1995; Johnson
et al., 1997). Activation results in SUMO being linked by a thioester to a cysteine
residue in SAE2. The activated SUMO is then transferred, in a transesterification
reaction, to a cysteine residue of the E2 conjugating enzyme Ubc9. In most species
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studied the genes encoding Ubc9 are essential, the exception being again S.
pombe, in which SUMO conjugation is not required for viability (Ho and Watts,
2003; Johnson, 2004; Jones et al., 2002; Seufert et al., 1995). As with the SUMO
activating enzyme, Ubc9 is a predominantly nuclear protein (Seufert et al., 1995).
Ubc9 proteins are well conserved with approximately 56% identity between the
mammalian and S. cerevisiae orthologues. Ubc9, in conjunction with the E3 ligase
then conjugates SUMO to the substrate protein. So far three different types of E3
ligases have been identified, PIAS (Protein Inhibitor of Activated STAT), RanBP2
and PC2 (a polycomb group protein). To date, no SUMO E3 activity has been
found to be essential in yeast.
RanBP2 was actually one of the first SUMO targets identified, although the first
SUMO modified protein identified was RanGAP1, a cytosolic protein which is
targeted to the cytoplasmic filaments of the nuclear pore complex (NPC) upon
modification by SUMO-1. Here it interacts with the RanBP2, which acts as a
binding site for Ran, and as a SUMO E3 ligase (Lee et al., 1998; Mahajan et al.,
1997; Mahajan et al., 1998; Matunis et al., 1996; Matunis et al., 1998; Pichler et
al., 2002). This interaction results in activation of the GTPase activity of the
cytosol/nucleus shuttling factor Ran, resulting in the release of the cargo from
exportins that exit the nucleus in a complex with RanGTP. This in turn allows the
released GDP to form complexes with importins and their cargo, which can then
be imported into the nucleus. In vitro data suggests that SUMO-dependent
localisation of RanGAP to the NPC is critical for nuclear import (Mahajan et al.,
1997).
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SUMOylation and deSUMOylation is a dynamic process, resulting in only a
percentage of substrates being SUMOylated at any one time, and hence it is likely
that only a small proportion of SUMO substrates have been identified. However
the number of SUMO substrates identified is rapidly increasing, due to the
awareness of this modification, the use of proteomics methods for studying
protein-protein interactions, and the application of procedures preventing rapid
deSUMOylation upon cell lysis (Johnson and Blobel, 1999). The proteins that
have been identified as SUMO targets so far are involved in a wide variety of
cellular functions from signal transduction and transcriptional replication to DNA
damage repair and chromosome segregation. SUMO modification has been
demonstrated to alter the activity of proteins, their ability to interact with other
proteins and their subcellular localisation (Melchior, 2000).
1.10.2 Viral proteins that are modified by SUMO
Since the discovery of SUMO, a large number of viral proteins have been shown
to be modified by SUMO-1, although the role of this remains unclear.
There are currently six viral proteins known to be SUMOylated across three
different DNA virus families; Adenovirus, Papillomavirus and Herpesvirus. All of
these proteins are early gene products with important regulatory roles in viral
transcription or replication. There are also three viral families that encode
proteases related to the SUMO proteases (Adenovirus, Asfarvirus and Poxvirus).
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1.10.3 The Cytomegalovirus immediate-early 1 (CMV-IE1) and immediate early 2
proteins (CMV-IE2) are modified by SUMO
The first viral protein discovered to be SUMOylated was the human
Cytomegalovirus immediate-early 1 protein (CMV-IE1). The SUMOylated form
was observed as a higher molecular weight version of the protein (Muller and
Dejean, 1999). CMV-IE1 is a multifunctional viral kinase that phosphorylates
itself and several other substrates, effecting gene regulation, cell cycle regulation
and preventing apoptosis. (McElroy et al., 2000; Pajovic et al., 1997; Stenberg and
Stinski, 1985; Zhu et al., 1995). It is also responsible for the disruption of the
Promyelocytic Leukaemia Nuclear Bodies (PML NBs) during infection (Ahn and
Hayward, 1997; Kelly et al., 1995; Korioth et al., 1996). The SUMOylation site
has been mapped to lysine 450 (Spengler et al., 2002; Xu et al., 2001), and
mutational analysis where the lysine has been changed to an arginine, have shown
that the mutant has the same distribution and activity as the wild type protein (Xu
et al., 2001).
The second viral protein discovered to be SUMOylated, was human
Cytomegalovirus immediate-early 2 protein, when SUMO-1, SUMO-3 and Ubc9
were pulled down in a yeast two hybrid screen (Hofmann et al., 2000). Hofmann et
al also demonstrated that CMV-IE2 was modified by SUMO during the course of
a lytic infection. In 2001, Ahn et al mapped the SUMO conjugation site to lysine
residues K175 and K180, and demonstrated that CMV-IE2 was SUMOylated in
vitro. CMV-IE2 acts as a transcriptional promoter for early viral proteins, and for
other heterologous promoters (Hagemeier et al., 1992; Klucher et al., 1993;
Malone et al., 1990). It also acts as a transcriptional repressor for its own promoter
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(Hermiston et al., 1990; Pizzorno et al., 1988). Studies using double mutants,
where both lysines were mutated to arginines, demonstrated SUMOylation has no
effect on cellular localisation or protein stability, although it does reduce the
protein’s ability to act as a transcriptional activator (Ahn et al., 2001; Hofmann et
al., 2000).
1.10.4 The papillomavirus E1 (PV-E1) protein is modified by SUMO
The papillomavirus E1 protein (PV-E1) was the third viral protein discovered to be
SUMO modified. It is an ATP-dependent DNA helicase that binds to specific
sequences in the viral DNA, unwinds it, and initiates its replication (Wilson et al.,
2002). It also recruits cellular factors required for DNA replication such as DNA
polymerase- (Bonne-Andrea et al., 1995; Conger et al., 1999; Masterson et al.,
1998; Park et al., 1994). The initial discovery of human Ubc9 resulted from a yeast
II hybrid screen using human papillomavirus type 16 E1 protein (Yasugi and
Howley, 1996). In 2000, Rangasamy and Wilson demonstrated that Bovine
papillomavirus E1 also interacted with Ubc9.
The major SUMO-1 attachment site of BPV-E1 is at K514, which lies in the
sequence IKAP, differing slightly from the accepted SUMO consensus sequence.
(Rangasamy et al., 2000).
In vitro transfection experiments using Green Fluorescent Protein (GFP) fusions of
wild type or K514R mutants demonstrated that SUMOylation affects localisation
but not stability of the protein. Wild type BPV-E1 accumulated in the nucleus,
whereas the K514R mutant accumulated at the periphery of the nucleus. Upon co-
transfection into mammalian cells, a plasmid expressing wild type BPV-E1 could
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stimulate expression of a BPV-origin containing plasmid, whereas a plasmid
expressing K514R mutant of BPV-E1 could not (Rangasamy and Wilson, 2000).
1.10.5 The Epstein-Bar virus immediate-early protein BZLF1 (EBV-Z) is
modified by SUMO
The Epstein-Bar virus immediate-early protein BZLF1 (EBV-Z) is one of the first
proteins expressed during the lytic form of viral infection, and acts as a
transcriptional activator inducing expression of the EBV early genes (Kieff, 2001).
It also inhibits cell cycle progression (Cayrol and Flemington, 1996), activates the
p38 and c-Jun signalling cascades (Adamson et al., 2000) and alters CBP and p53
function (Adamson and Kenney, 1999; Zhang et al., 1994), respectively. Adamson
and Kenney demonstrated that EBV-Z is SUMOylated during lytic infection and
mapped the SUMO modification site to lysine residue 12 (Adamson and Kenney,
2001). Mutation analysis of residues 12 and 13 impair the replicative function of
this protein (Sarisky et al., 1996).
1.10.6 The human herpes virus 6 immediate-early 1 (HHV6-IE1) protein is
modified by SUMO
The human Herpes virus immediate-early genes (IE) are the first viral products
synthesised upon viral infection. Similar to other human IE herpesvirus proteins,
herpes virus 6 immediate-early 1 (HHV6-IE1) induces the transcription of
heterologous promoters. Two variants of this protein are produced termed variants
A and B, and they vary in their ability to transactivate the HHV-LTR promoter
(Gravel et al., 2002). Gravel was the first to demonstrate that the HHV6-IE1
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proteins are SUMOylated in vivo by performing coimmunoprecipitation
experiments in infected mammalian cells. This was confirmed by Stanton et al
(Stanton et al., 2002).
1.10.7 The adenovirus E1B-55kDa protein is modified by SUMO
The E1B-55kDa protein of adenovirus type 5 was first discovered to be SUMO
modified in 2001 by Endter et al. Upon discovering the presence of the SUMO
consensus sequence Endter et al undertook experiments to determine if in fact
E1B-55kDa was SUMOylated. Plasmids encoding wild type E1B-55kDa or E1B-
55kDa K104R were transfected into H1299 cells along with a plasmid encoding
SUMO-1. Total cell extracts were then prepared and immunoblotted, with
appropriate antibodies. In cells transfected with only E1B-55kDa, a major band of
55kDa, corresponding to the E1B-55kDa was detectable. In cells co-transfected
with E1B-55kDa and SUMO-1, an additional band of approximately 75kDa was
observed corresponding to SUMO conjugated E1B-55kDa. This 75kDa band was
absent in cells co-transfected with SUMO-1 and E1B-55kDa K104R,
demonstrating that lysine 104 is the SUMO modification site. Endter et al also
demonstrated the presence of the 75kDa form of E1B-55kDa in adenovirus type 5
infected cells, indicating the E1B-55kDa is SUMOylated in vivo.
To determine if SUMOylation of E1B-55kDa affected localisation, Endter et al
generated baby rat kidney (BRK) cells stably expressing either wild type E1B-
55kDa or E1B-55kDa K104R. In both of these cell lines the distribution of E1B-
55kDa was cytoplasmic. Both cell lines were then transfected with a plasmid
expressing SUMO-1. In the cells expressing wild type E1B-55kDa the E1B-55kDa
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was directed to the nucleus where it co-localised with SUMO-1 in either track-like
or dot-like structures. In contrast, the cells expressing E1B-55kDa K104R retained
the E1B-55kDa in the cytoplasm.
Endter et al also demonstrated that SUMOylation of adenovirus type 5 E1B-55kDa
is required for complete transformation of BRK cells and inhibition of p53
transactivation. Transformation assays were carried out on BRK cells. Co-
transfection of plasmids encoding E1A and wild type E1B-55kDa resulted in a
more than seven fold increase in foci formation, compared with E1A alone. In
comparison the E1B-55kDa K104R mutant did not aid focus formation (Endter et
al., 2001).
Lethbridge et al demonstrated that adenoviruses that did not express E4 Orf6
during infection, showed enhanced SUMOylation of E1B-55kDa protein. The
amount of SUMO-1 modified E1B-55kDa protein was not related to its association
with ND10. It is known that the SUMOylation of PML is required for it to form
ND10 structures (Muller, 1998). Duprez et al demonstrated that PML is modified
by SUMO-1 both in vivo and in vitro (Duprez et al., 1999). It is possible that the
SUMOylation of E1B-55kDa protein is related to its localisation at the nuclear
matrix (Lethbridge et al., 2003).
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1.11 Proteomics methods for studying protein interactions
1.11.1 Proteomics methods
Studying the sequences of different adenovirus genomes provides useful
information on how adenoviruses have evolved. Although it is important to
determine the sequence of the different adenovirus genomes, in order to fully
understand how adenoviruses replicate, it is necessary to determine how each of
the viral proteins interact with each other and with the host cell proteins during
infection and subsequent replication.
Proteomics methods are being deployed to help understand theses interactions.
Proteomics refers to the study of all of the proteins (or proteome) expressed by an
organism.
There are two different types of proteomics, expression proteomics and interaction
proteomics. In expression proteomics, the total protein complement of the cell is
examined under two different physiological states (e.g. normal and diseased), and
the differences in protein expression are examined. This can be done using several
different methods, including 2D gel electrophoresis, Stable Isotope Labelling by
Amino acids in Cell culture (SILAC), Multidimensional protein identification
technology (MudPIT) or shotgun proteomics followed by mass spectrometric
analysis.
Stable Isotope Labelling by Amino acids in Cell culture (SILAC) involves
growing mammalian cell lines in media lacking a standard essential amino acid,
but supplemented with a non-radioactive, isotopically labelled form of that amino
acid. Growth of cells maintained in this media is no different from cells grown in
normal media, and the labelled amino acids become totally incorporated into the
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cells. Protein populations from control and experimental samples are mixed and
identified by mass spectrometric analysis. From the results it is possible to
determine if the levels of a specific protein have increased or decreased in the
experimental sample by comparing the relative signal intensity of labelled and
unlabelled peptide pairs. (Ong et al., 2002).
Multidimensional protein identification technology (MudPIT) is a technique for
the separation and identification of complex protein mixtures that does not require
the protein mixture to be separated by SDS-PAGE (Graumann et al., 2004).
MudPIT relies on digestion in solution of the protein mixture to be analysed and
separation of the resulting complex peptide mixture by multidimensional capillary
chromatography connected on-line to an ion trap or Q-TOF mass spectrometer
(Link et al., 1999; McCormack et al., 1997). This technique was developed in an
attempt to alleviate the problems associated with SDS-PAGE including limits of
dynamic range of detection, variable elution efficiencies of peptides from the SDS-
PAGE gel and potential selection against proteins with properties that impede
analysis by SDS-PAGE (Gavin et al., 2002; Ho et al., 2002).
Shotgun proteomics is a gel-free approach, based on multidimensional liquid
chromatography separation of complex peptide mixtures, coupled to mass
spectrometry. A protein population is first prepared from a biological source using
protein purification strategies including chromatographic or electrophoretic
fractionation, or affinity purification. Enzymatic or chemical digestion then takes
place to generate a mixture of peptides, which are subsequently separated using
multidimensional chromatographic techniques before being introduced into a mass
spectrometer (Swanson and Washburn, 2005).
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Interaction proteomics is used to study what other proteins interact with a specific
protein. There are three different methods of studying interaction proteomics,
immunoprecipitation, yeast II hybrid system and affinity purification where the
protein is fused to an affinity tag and is immunoprecipitated with an antibody
specific to the tag, or purified using a column that the tag binds to (e.g. calmodulin
or GST). Since purification of the protein of interest is solely dependent on the tag
used, it is important to choose the best tag. One tag can be coupled to the protein
for single-step affinity purification, for example the FLAG tag, or two tags can be
coupled to the protein for tandem affinity purification. Tandem affinity
purification reduces the amount of contaminants purified. The tandem affinity
purification tag, consisting of a calmodulin binding peptide (CBP) fused to a
Protein A binding site via a tobacco etch virus (TEV) protease cleavage site, was
developed by Rigaut et al (Rigaut et al., 1999).
1.11.2 Immunoprecipitation
Immunoprecipitation requires antibodies specific to the protein of interest. Cell
extracts are incubated with the specific (primary) antibody. The antibody and
bound protein are then purified using immunoaffinity or protein A or G column
chromatography. For immunoaffinity the column is packed with beads that are
coated with a secondary antibody that binds to the primary antibody. In column
chromatography the primary antibody will bind directly to the protein A or G
within the column. Following binding, the column is washed to release any
unbound material. The protein of interest is then eluted along with any interacting
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proteins, which can then be analysed by SDS-PAGE and mass spectrometric
analysis.
1.11.3 Yeast II Hybrid
This method involves the generation of a cDNA library. The protein of interest is
expressed in yeast, as a fusion to the DNA binding domain of a transcription
factor, lacking a transactivation domain. This yeast strain also encodes one or
more reporter genes with binding sites for the DNA binding domain. A plasmid
library that expresses cDNA encoded proteins fused to a transcription activation
domain is then introduced into the yeast strain. The cDNA encoded proteins that
interact with the protein of interest will activate the transcription factor and cause
expression of the reporter gene, allowing cells containing the interacting proteins
to be identified (Fields and Song, 1989).
1.11.4 Tandem Affinity Purification
Tandem Affinity Purification (TAP) was developed by Rigaut et al in 1999 and it
allows purification of specific proteins expressed at their physiological levels.
TAP expression vectors have been created in which the protein of interest can
either be C or N terminally tagged. The TAP tag vector contains a multiple cloning
site (MCS), a calmodulin binding peptide (CBP), a tobacco etch virus (TEV)
protease cleavage site and a protein A IgG binding unit of Staphylococcus aureus.
These tags were selected because they showed highly efficient recovery of
proteins that were present at low levels. The gene of interest is cloned into the
MCS of the vector so that it is expressed as a TAP tag fusion protein. This
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construct is then introduced into the host cell or organism, and cells that are
expressing the fusion protein at, or close to, its natural level are selected for. The
specified protein and any host cell proteins that interact with it are then recovered
by affinity purification.
In the first affinity purification step, cell extracts are put through a column
containing an IgG matrix. Fusion proteins bind the IgG via the Protein A site.
After washing, TEV protease is added to release the bound material, The eluate is
then incubated with calmodulin-coated beads in the presence of calcium, thus
allowing binding of the fusion protein to the calmodulin beads via the CBP. After
washing the bound material is release by native elution with EGTA (see figures 3
and 4). Proteins can then be analysed using SDS-PAGE and mass spectrometry.
The advantages of this system are that proteins can be purified, without prior
knowledge of their composition, activity or function. The proteins are also
expressed at, or close to their natural levels, and they can be purified even if they
are present at low concentrations. The other advantage is that all proteins that
interact with the protein of interest, could in theory, be identified in a single
experiment. The results if interpreted properly may also give an indication of the
relative proportions of identified proteins (Rigaut et al., 1999).
1.11.5 Mass Spectrometry
Recent advances in the field of mass spectrometry, as well as the availability of
large databases containing the known mass and amino acid sequence of many
proteins, have made identification of proteins much easier than it was previously.
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Figure 1.3: Tandem Affinity Purification Procedure. The Tandem Affinity Purification (TAP) tag and the target protein
are produced as a fusion protein. The TAP tag consists of a calmodulin binding peptide, a TEV protease cleavage site and a
protein A binding site. Cell extracts are passed through the first affinity column which consists of IgG beads, to which the
protein A binds. The column is washed to eliminate contaminating proteins. TEV protease is then added to the column,
releasing the target protein (which is still fused to the calmodulin binding peptide) and any interacting proteins. The eluates
are then passed through a second affinity column consisting of calmodulin beads, to which the calmodulin binding peptide
binds. Again contaminating proteins are washed away. The target protein and any interacting proteins are then eluted using
EGTA, and analysed by SDS-PAGE and Mass Spectrometric analysis.
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gaa ttc gcc ctt gcc acc atg gac aca agt gcc cac gat gaa gcc gta gac aac aaa ttc
E F A L A T M D T S A H D E A V D N K F
aac aaa gaa caa caa aac gcg ttc tat gag atc tta cat tta cct aac tta aac gaa gaa
N K E Q Q N A F Y E I L H L P N L N E E
caa cga aac gcc ttc atc caa agt tta aaa gat gac cca agc caa agc gct aac ctt tta
Q R N A F I Q S L K D D P S Q S A N L L
gca gaa gct aaa aag cta aat ggt gct cag gcg ccg aaa gta gac aac aaa ttc aac aaa
A E A K K L N D A Q A P K V D N K F N K
gaa cga caa aac gcg ttc tat gag atc tta cat tta cct aac tta aac gaa gaa caa cga
E Q Q N A F Y E I L H L P N L N E E Q R
aac gcc ttc atc caa agt tta aaa gat gac cca agc caa agc gct aac ctt tta gca gaa
N A F I Q S L K D D P S Q S A N L L A E
Gct aaa aag cta aat ggt gct cag gcg ccg aaa gta gac gcg aat tca gcg ggt aag
A K K L N G A Q A P K V D A N S A G A
Agc gag aac ttg tac ttc cag ggc gga aga tcg atg gaa aag aga aga tgg aaa aag aat
S E N L Y F Q G G R S M E K R R W K K N
ttc ata gcc gtc tca gca gcc aac cgc ttt aag aaa atc tca tcc tcc ggg gca ctt gat
F I A V S A A N R F K K I S S S G A L D
tat gat att cca act gct ctg gaa gtt ctg ttc cag ggg ccc ctg gga tcc aga tct ggt
Y D I P T A L E V L F Q G P L G S R S G
acc acg cgt atc gat aag ctt gca tgc ctg cag gtc gac tct aga gta tcg cgg gtg gca
T T R I D K L A C L Q V D S R V S R V A
tcc ctg tga
S L *
Figure 1.4: Sequence of Tandem affinity purification tag. The sequence of the TAP tag is shown with the protein
A sequence in red,the TEV protese cleavage site in green, the calmodulin binding peptide in blue and the polylinker
containing the MCS in pink. The BamH1 site that the E1B55k gene (+/-K104R mutation) was cloned into is underlined.
The Kozak sequence prior to the start codon is also highlighted.
Kozak
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Prior to the development of mass spectrometry, Edman degradation was used to
determine the sequence of proteins, this method relied on the identification of
amino acids, as they were chemically cleaved from the amino end of the protein.
Any proteins, which were modified at their amino terminus, could not be
sequenced using this method. Therefore, mass spectrometry has become the
technique of choice, used to identify proteins resulting from proteomics
experiments. Mass spectrometry involves the ionisation of molecules, and the
measurement of their mass, which is calculated based upon their specific
trajectories in a vacuum system. Compared to Edman degradation, mass
spectrometry is much more sensitive, quicker and does not require proteins to be
purified to homogeneity.
In techniques such as tandem affinity purification, hundreds of proteins, can be co-
purified with the protein of interest, leading to a complex mixture of proteins in
the resulting eluates. In order to reduce the complexity of the sample, the eluates
are generally first separated according to molecular weight by SDS-PAGE. The
lane containing the sample is then excised in different gel slices, which are then
subjected to in-gel digestion and LC-ESI-MS/MS separately.
Even though it is possible to measure the mass of intact proteins, there are several
reasons why proteins are first cleaved into peptides. One of the main reasons is
that proteins are not always soluble under the same conditions, and by cleaving the
proteins into peptides there is no issue regarding solubility. Although it is possible
to use detergent to solubilise proteins, detergents can interfere with mass
spectrometry, as they can ionise well, and are in huge excess relative to the
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proteins. Proteins can be also be modified, for example by phosphorylation, which
can increase their mass, making it more difficult to identify a specific protein, if
there are different forms of the same protein within the sample. Therefore,
obtaining the accurate mass of an intact protein is insufficient to allow its
identification. The most reliable way of identifying a protein is by cleaving it into
peptides. As mass spectrometry is most efficient for determining the mass of
peptides up to twenty residues long accurately, sequence specific proteases are
used to cleave the proteins into peptides. The most common protease used is
trypsin, although others can be used such as Lys-C, Asp-N and Glu-C. Trypsin
cleaves proteins on the carboxy terminus of arginine and lysine residues. Less
sequence-specific proteases are avoided as they divide the peptide signal into
many overlapping species and generate unnecessarily complex mixtures.
Proteomics experiments generally result in complex peptide mixtures. Therefore,
prior to mass spectrometric analysis, it is necessary to separate the peptides,
usually by reverse phase chromatography to reduce the complexity at any one
analysis point. This can be done using a microscale capillary high-performance
liquid chromatography (HPLC) column. In electrospray ionisation (ESI) MS/MS
the HPLC is coupled to the mass spectrometer and column eluates are analysed
on-line. Although matrix assisted laser desorption (MALDI) ionisation does not
allow direct on-line coupling to HPLC, LC fractions can be spotted onto a target
plate and subsequently analysed (off-line) (see below for description of ionisation
techniques). In HPLC the peptides are eluted from the column using a solvent
gradient, which caused them to be eluted in terms of their hydrophobicity. As the
signal intensity in the mass spectrum is directly proportional to the analyte
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concentration, the peptides are eluted in as small a volume as possible. Upon
reaching the end of the column, the peptide mixture has to be transferred into the
gas phase and ionised. Two new “soft” ionisation techniques that were developed
in the late 1980’s, first allowed the practical analysis of biomolecules; these
techniques were MALDI and ESI. In MALDI (Karas and Hillenkamp, 1988), the
analyte is mixed with a large excess of ultraviolet-absorbing matrix, which is
normally a low molecular weight aromatic acid. On irradiation with a focused
laser beam of the appropriate wavelength, the excess matrix molecules cause the
transfer of the embedded non-volatile analyte molecules into the gas phase. After
numerous ion-molecule collisions in the plume of ions and molecules, singly
protonated analyte ions are formed, which are accelerated by electric potential into
the mass spectrometer. MALDI mass spectrometers are primarily used to
determine the accurate masses of the peptides in the mixture. In ESI (Fenn et al.,
1989), when a peptide arrives at the end of the column, it flows through the tip of a
metal needle, held at a high electrical potential, causing it to be electrostatically
dispersed. Highly charged droplets are generated, and once the droplets become
airborne the solvent evaporates, resulting in a decrease in size and an increase in
charge density. Droplet fission eventually results in each droplet containing on
average one ion, which can then be analysed using a mass spectrometer.
There are several different types of mass spectrometers including Quadrupole,
Time of Flight (TOF), Quadrupole ion traps, standard ion traps and Fourier-
transform ion cyclotron resonance (FTICR).
Quadrupole mass spectrometers work by applying different sinusoidal potentials
with each one allowing the passage of ions with a specific m/z ratio. In FTICR
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ions are confined within the high magnetic field of a super-conducting-magnet,
where they circle with frequencies that are inversely proportional to their m/z
ratio. This circling induces a current which constitutes a frequency spectrum of the
ion motion. This is converted by Fourier transformation into a mass spectrum.
TOF is based on the time it takes ions to travel through an electric-field-free flight
tube. In the ion source, all ions are accelerated to the same kinetic energy. As
kinetic energy is a function of mass, the lighter ions fly faster than the heavier ions
and therefore reach the detector sooner. In ion traps, the ions are first caught in a
dynamic electric field, and are then ejected onto the detector with the aid of
another electric field, according to their m/z ratio. In addition there are also mass
spectrometers that combine principles such as Quadrupole Time of Flight (Q-TOF)
mass spectrometers. Each of these instruments generates a mass spectrum, which
is a recording of the signal intensity of the mass-to charge (m/z) ratio, of each ion.
Individual protein samples can be identified by peptide mass fingerprinting (PMF)
but for mixtures it is necessary to generate sequence information from peptides.
This is done by tandem MS, also known as MS/MS. In tandem MS a particular
peptide ion is isolated and fragmented, by bombardment with an inert gas, such as
nitrogen, argon or helium, resulting in an MS/MS spectrum. As each peptide
fragment in a series differs from its neighbour by one amino acid, this allows the
amino acid sequence to be determined, by considering the mass difference
between neighbouring peaks in a sequence. MS/MS data can be generated from
ions generated by either ESI or MALDI.
The resulting MS/MS spectra are then searched against a protein database, using a
programme such as the Mascot search engine. The proteins, which could result
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from the peptides are then listed in terms of probability, along with details such as
percentage protein coverage. Proteins for which there are several high scoring
MS/MS spectra, are likely to be true hits, whereas proteins with lower scores may
need to have their presence confirmed using other techniques such as Western
blotting. The identification of a protein is dependent on several factors including
the amount of protein, the degree of post-translational modifications, and whether
or not the protein has previously been registered on the database (Steen and Mann,
2004).
1.11.6 Aim of Work
The aim of this work was to generate four recombinant replication competent
adenoviruses, using plasmid pSCB-AdFL, which expressed the full length
adenovirus type 5 genome. The recombinant viruses were designed express
Tandem Affinity Purifiction (TAP) tagged or Cyan Fluorescent Protein (CFP)
tagged E1B55k, with tags located on the N-terminus. As E1B55k protein is
modified by SUMO-1 at lysine residue 104, recombinant viruses were also
generated in which the lysine residue was mutated to an arginine residue, thus
abolishing SUMOylation of the E1B55k protein. The tandem affinity purification
tag was to allow the identification of interacting proteins (both viral and cellular),
and the CFP tag would allow localisation to be studied using live cell imaging. By
comparison of results generated in which the E1B55k protein could be modified
by SUMO, with those in which it could not, it was hoped to identify the
importance of SUMOylation during adenovirus infection.
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Stable HeLa cell lines were also generated, which expressed TAP tagged E1B55k
and TAP tagged E1B55k K104R. By tandem affinity purifying these stable cell
lines both uninfected, and infected with wild type adenovirus 5, it would be
possible to determine cellular and viral proteins that interact with the E1B55k
protein. This method was established as an alternative method of generating
results, without the recombinant adenoviruses.
Stable HeLa cell lines expressing TAP tagged SUMO2 protein, generated in the
laboratory by Dr Akihiro Nakamura, were also tandem affinity purified, both
uninfected, and infected with wild type adenovirus 5. The aim of this work was to
determine if any of the adenoviral proteins were modified by SUMO2 protein.
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2. MATERIALS AND METHODS
2.1 DNA cloning and analysis
2.1.1 Polymerase chain reaction
DNA was amplified using Pfu DNA polymerase (Promega UK, or produced in-
house), using a GeneAmp PCR system 2400.
2.1.2 Clean-up of DNA after PCR
PCR products were separated by agarose gel electrophoresis, to allow separation
from any contaminating products. Appropriate bands were then excised from the
gel and DNA was purified using the High Pure PCR product purification kit
(Roche) according to the manufacturer’s instructions.
2.1.3 Agarose gel electrophoresis
Agarose gels were made by melting powdered agarose (Biogene) in TAE buffer
(0.04M Tris-acetate, 0.001M EDTA, pH 8.0) to achieve the desired percentage.
Ethidium bromide was added to a concentration of 0.125g/mL and gels were cast
in an H1-set gel rig or a Midi Excel gel rig (both Bioscience Services). Gels were
run at a constant voltage of 60V in TAE buffer.
2.1.4 Purification of DNA from agarose gels
The DNA band to be purified was excised from the gel and purified using the High
Pure PCR product purification kit (Roche) according to the manufacturer’s
instructions.
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2.1.5 Restriction digest of DNA for cloning
1g of DNA was incubated with 10U of restriction enzyme(s) in the appropriate
buffer (Promega UK, New England Biolabs, UK), in a total volume of 10L at the
appropriate temperature for 2-4 hours.
2.1.6 Dephosphorylation of linearised vector DNA
1g of DNA was incubated with 1U of Calf Intestinal Alkaline Phosphatase
(CIAP) in the buffer supplied with the CIAP (Promega, UK) at 37C for 40
minutes, and DNA purified using the Roche High Pure PCR product purification
kit, according to manufacturer’s instructions, prior to ligation.
2.1.7 Ligation of DNA
Vector and insert DNA were prepared by digestion with appropriate restriction
enzymes and mixed with T4 DNA ligase and buffer supplied with the ligase (New
England Biolabs) in a total reaction volume of 20L Reactions were incubated at
16C overnight or for 2 hours at room temperature.
2.1.8 Bacterial strains
Escherichia coli (E. coli) strain DH5 were used in the preparation of DNA
(genotype: 80dlacZM15, rec A1, end A1, gyr A96, thi-1, hsd R17 (rk-, mk+),
s_p E44, rel A1, deoR, (lacZYA-argF)_169).
Electrocomp GeneHogs E. coli strain DH10 (Invitrogen) were used in the
preparation of plasmid pSCB-AdFL DNA (genotype: F-mcrA(mrr-hsdRMS-
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mcrBC) 80lacZM15 lacX74 deoR recA1 araD139(ara-leu)7697 galU galK
rpsL (StrR) endA1 nupG fhuA::IS2 (confers phage T1 resistance).
E. coli strain BJ5183 were used in the preparation of plasmid pSCB-AdFL-5’ITR
(genotype: , end A1, sbc BC, rec BC, gal K, met, thi-1, bio T, hsd R (strr)).
2.1.9 Preparation of transformation competent E. coli
A 250mL culture of DH5 was grown up from a glycerol stock, in Luria-Bertani
broth (L-broth, see section 2.1.13) at 37C, until the Optical Density (O.D) at
600nm was between 0.6 and 0.7. Cells were then transferred to prechilled 50mL
Falcon tubes and incubated on ice at 4C for 30 minutes. Cells were then spun at
2,800rpm for 5 minutes at 4C. The cell pellet was then resuspended in 12.5mL of
100mM CaCl2 and 12.5mL of freshly made 40mM MgSO4 and incubated on ice
for 30 minutes. Cells were then spun at 2,800rpm for 5 minutes at 4C. The cell
pellet was then resuspended in 2.5mL of 100mM CaCl2 and 2.5mL 40mM
MgSO4. Cells were incubated on ice at 4C overnight. Glycerol was then added to
a final concentration of 10%, cells were dispensed into 200L aliquots, snap
frozen in liquid nitrogen and stored at -70C.
CaCl2, MgSO4, and glycerol solutions were sterilised by autoclaving and were
prechilled on ice prior to use.
2.1.10 Preparation of electrocompetent E. coli
A 1L culture of DH5 was grown up from a glycerol stock, in L-broth at RT, until
the O.D. at 600nm was 0.5. Cells were then transferred to 4 x 250mL centrifuge
pots and chilled on ice, at 4C overnight. Cells were then spun at 4,000 rpm for 15
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minutes at 4C. The cell pellet was resuspended in a total volume of 1L 1mM
Hepes pH7.0. Cells were spun at 4,000 rpm for 15 minutes at 4C. The cell pellet
was then resuspended in a total volume of 500mL 1mM Hepes pH7.0. Cells were
respun at 4,000 rpm at 4C. The cell pellet was resuspended in 10% glycerol,
transferred to a 15mL Falcon tube and spun at 3,000rpm for 15 minutes at 4C.
The cell pellet was then resuspended in 2mL 10% glycerol, dispensed into 200L
aliquots, snap frozen in liquid nitrogen and stored at -70C. Hepes and glycerol
solutions were sterilised by autoclaving and prechilled on ice prior to use.
2.1.11 Transformation of transformation competent E. coli
DNA ligation reactions, or 100ng of plasmid DNA, was mixed on ice with 50L
of transformation competent E. coli and incubated on ice for 20 minutes. The
sample was heat shocked at 42C for 50 seconds then placed on ice for 2 minutes.
Following this, L-broth was added (900L) and sample incubated at 37C for 1
hour. After centrifugation at 14,000rpm for 1 minute the cell pellet was
resuspended in 100L L-broth and plated onto an L-agar plate containing the
appropriate antibiotic to select for the plasmid. The plates were then incubated at
37C overnight.
2.1.12 Electroporation of electrocompetent E. coli
Prior to electroporation, ligation reactions or DNA samples, were dialysed by
being placed on 0.025m, 13mm Millipore dialysis discs (VSWP01300), on a
petri dish of sterile water, for 1 hour at RT. Samples were then added to 2mm
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electroporation cuvettes (Equibio, ECU-102), prechilled on ice, and 50L
electrocompetent E. coli added and mixed. The sample was incubated on ice for 20
minutes and electroporated using an Easyject Prima Electroporator (Equibio) at
2,500 volts. L-broth (900L) was then added and the sample incubated at 37C for
1 hour. The sample was then centrifuged at 14,000rpm for 1 minute to pellet cells.
The cell pellet was resuspended in 100L of L-broth and plated onto an L-agar
plate containing the appropriate antibiotic to select for the plasmid. The plates
were incubated at 37C overnight.
2.1.13 Media used for E. coli
E. coli cultures were grown in L-broth (10g tryptone, 5g yeast extract, 10g NaCl
made up in 1 litre water). Concentrations of antibiotics used were as follows:
Antibiotic: Stock solution: Concentration used at:
Ampicillin 100mg/mL (H2O) 100g/mL
Kanamycin 50mg.mL (H2O) 50g/mL
Tetracyclin 10mg/mL (80% ethanol) 10g/mL
Chloramphenicol 20mg/mL (80% ethanol) 20g/mL
The ampicillin, kanamycin and tetracyclin were all purchased from Sigma, and the
chloramphenicol from Duchefa.
2.1.14 Purification of plasmid DNA
In general plasmids were transformed or electroporated into E. coli DH5, then
plated onto L-agar plates containing the appropriate concentration of antibiotic,
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and incubated at 37C overnight. Individual colonies were then grown up in L-
broth, containing the appropriate antibiotic, in the shaker incubator at 37C
overnight. The cells were then lysed and DNA was purified from cultures using
the Qiagen miniprep spin kit or the Qiagen maxiprep kit according to
manufacturer’s instructions.
Plasmids pSCB-AdFL and pSCB-AdFL-5’ITR were electroporated into
Electrocomp GeneHogs E. coli (Invitrogen), plated onto L-agar plates
containing the appropriate antibiotic and incubated overnight at 30C. Individual
colonies were then grown up in L-broth, containing the appropriate antibiotic, in a
shaker incubator at 30C overnight.
DNA was then purified using the alkali lysis method (see below).
2.1.15 Purification of DNA using alkali lysis miniprep method
1mL of the bacterial culture was pelleted by spinning at 13,000rpm for 1 minute.
The cell pellet was resuspended in 100L of ice cold Solution I (50mM glucose,
25mM Tris-HCl pH8.0, 10mM EDTA pH8.0). Freshly prepared Solution II
(200L, 0.2M NaOH, 1% SDS) was then added and mixed by inverting. 150L of
ice cold Solution III (3M Potassium acetate (KAc) pH5.5) was then added, mixed
by inverting and placed on ice for 5 minutes. The sample was spun at 13,000rpm
for 5 minutes and the supernatant phenol/chloroform purified and ethanol
precipitated (see later for details). The resulting DNA was then resuspended in
50L sterile water.
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2.1.16 Purification of DNA using alkali lysis maxiprep method
500mL of bacterial culture was pelleted by spinning at 6,000rpm for 15 minutes.
The cell pellet was resuspended in 60mL of Solution I (15mM Tris-HCl pH8.0,
10mM EDTA, 100g/ml Ribonuclease A (Sigma). Freshly prepared Solution II
(60mL of 0.2M NaOH, 1% SDS) was then added, mixed and incubated at RT for 5
minutes. Solution III (60mL of 3M KAc pH5.5) was then added and incubated on
ice for 10 minutes. The sample was spun at 6,000rpm for 10 minutes at 4C and
the supernatant added to 160mL of isopropanol and incubated on ice for 10
minutes. The sample was spun at 6,000rpm for 15 minutes at 4C, supernatant was
discarded and pellet resuspended in 5mL of 70% ethanol. The sample was then
spun at 6,000rpm for 5 minutes, supernatant discarded and the DNA pellet
resuspended in 500L sterile water, dispensed into 20L aliquots and stored at -
20C.
2.1.17 Quantification of DNA
DNA was quantified by measuring the absorbance at 260nm using a
spectrophotometer equipped with a quartz cuvette. The concentration in g/mL is
equal to the absorbance at 260nm x 50 x the dilution factor. The quality of the
DNA can be analysed by measuring the ratio of A260nm/A280nm (good quality
DNA should be between 1.7 and 1.9).
2.1.18 Phenol chloroform purification and ethanol precipitation of DNA
To the DNA sample was added an equal volume of
phenol:choloroform:isoamylalcohol (25:24:1) which was mixed by vortexing. The
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sample was spun at 13,000rpm for 5 minutes and the top layer dispensed into a
fresh tube. To this was added an equal volume of chloroform, which was mixed by
vortexing. The sample was spun at 13,000rpm for 5 minutes and the top layer
dispensed into a fresh tube. To this was added 0.1 volumes of 3M NaAc pH5.2 and
2 volumes of 100% ethanol, and incubated on ice for 30 minutes. The sample was
spun at 13,000rpm for 10 minutes and the cell pellet resuspended in 200L of 70%
ethanol. The sample was then spun at 13,000rpm for 10 minutes, the supernatant
discarded and the pellet air dried. The DNA pellet was then resuspended in an
appropriate volume of sterile water.
2.1.19 Use of radiolabelled probes for the detection of positive colonies
Normally colonies resulting from cloning were screened by restriction digest
analysis. But when large numbers of colonies were to be screened, this was done
using a radiolabelled probe. A gene sequence known to be present in the “insert”
DNA was amplified by PCR and purified by agarose gel electrophoresis. The PCR
product was then labelled with [-32P]dCTPs using the Ready-To-Go DNA
labelling beads (-dCTP) from Amersham Biosciences.
DNA (25-50ng) was added to 44L sterile water and denatured at 100C for 3
minutes then immediately placed on ice for 2 minutes. The DNA was then added
to one of the Ready-To-Go DNA labelling beads. When dissolved, 5L (50Ci) of
[-32P]dCTP was added and mixed by pipetting, and incubated at 37C for 15
minutes. The PCR product was then labelled and ready to use.
Colonies that were to be screened were first plated onto 2 separate plates of L-agar
with the appropriate antibiotic. A gridded membrane was placed in one of the
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plates, and each grid numbered (Hybond N+ 82mm gridded discs, Amersham
Biosciences). The other plate was gridded and numbered identically. Colonies
were plated onto specific grids on each plate, and plates incubated at 37C
overnight. Membranes, on which the colonies had grown, were then screened
using the radiolabelled probe.
The membranes were placed in 10% SDS for 3 minutes, followed by Denaturing
solution (0.5M NaOH, 1.5M NaCl) for 5 minutes, then Neutralisation solution
(1.5M NaCl, 0.5M Tris pH7.4) for 5 minutes, and finally 20 x SSC for 5 minutes.
This process lysed the colonies, releasing the DNA onto the membrane. The
membranes were then placed between 2 pieces of Whatman 3MM filter paper and
placed in a vacuum oven at 80C for 2 hours, in order to fix the DNA onto the
membrane. The membranes were then placed in roller bottles and incubated in
10mL of hybridisation buffer (PerfectHybTM Plus hybridisation buffer, Sigma)
containing 50L of labelled probe, in the hybridisation oven at 65C overnight.
The membranes were then washed at 65C in a total volume of 2L 2 x SSC
(preheated to 65C) over a period of 4 hours, with SSC being changed regularly.
The membranes were then placed in a cassette along with a preblanked screen for
1 hour prior to being read on the Phosphorimager (Fujix BAS1000, MacB
software).
Colonies that were identified as positives by hybridisation, could then be picked
from the duplicate plate and screened by restriction digest and sequence analysis.
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2.1.20 DNA sequence analysis
DNA sequencing was either carried out in house by Alex Houston using an
automated ABI PRISM DNA sequencer or was analysed by the University of
Dundee DNA sequencing service using an ABI 3730 capillary DNA sequencer.
2.2 Cell culture
2.2.1 Growth and maintenance of cells
HeLas (Human cervical carcinoma) and 293 (Human embryonic kidney cells) cell
lines were maintained in exponential growth in Dulbecco’s Modified Eagle’s
Medium (DMEM) supplemented with 10% Foetal Calf Serum (FCS) and 2mM
glutamine. Cell monolayers were grown in humidified incubators at 37C, in 5%
CO2.
HeLa spinners and 293 spinners were maintained in exponential growth in Joklik
medium supplemented with 10% Newborn Calf Serum (NCS). Spinner cultures
were grown in suspension, at 37C.
2.2.2 Freezing down cells
Cells were frozen down in 40% appropriate growth media, 40% FCS/NCS, 20%
DMSO, in sterile screw capped vials. Cells were first stored at -70C for up to 1
week prior to being transferred to liquid nitrogen.
2.2.3 Recovering cells from liquid nitrogen
Cells were thawed on ice for 10 minutes then at 37C for 5 minutes. When thawed,
1mL of FCS was added to the cells and 10mL of growth medium. The cells were
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spun at 1,200rpm for 5 minutes at RT. The cell pellet was then resuspended in
7mL of appropriate growth medium, transferred to a 25cm2 flask and placed in the
incubator, at 37C, until confluent.
2.2.4 Transient transfection of cells
Cell monolayers were grown to approximately 50-80% confluency and were
transfected using FuGENE 6 transfection reagent (Roche) at a 3L:1g ratio of
FuGENE 6: DNA, according to the manufacturer’s instructions. DNA and
FuGENE 6 were mixed in serum free OptiMEM1 GlutaMAX1 medium
(Gibco) in 100L total volume.
2.2.5 Immunofluorescence
For immunofluorescence analysis, coverslips were sterilised in 100% ethanol and
air dried, then placed in 12 or 24 well plates. The cells were then added to plates
and grown until appropriate confluency, then fixed and analysed as follows:
The media was removed and cells washed 3 times in 1mL Phosphate Buffered
Saline (PBS)/ 1mM MgCl2 /0.5mM CaCl2. The cells were then fixed in 3% w/v
paraformaldehyde/ PBS for 10 minutes, then washed 3 times in PBS. The cells that
were transiently transfected with plasmids expressing Cyan Fluorescent Protein
(CFP) were mounted onto microscope slides using 6L of movial/4’-6-Diamidino-
2-pheylindole (DAPI) and viewed at this stage. Otherwise cells were washed 2
times in 100mM Glycine/ PBS for 10 minutes then washed 3 times in PBS. At this
point the coverslips could be stored in PBS at 4C overnight. The cells were
washed once in 0.2% TritonX-100/PBS for 10 minutes, then washed 3 times in
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PBS. The cells were washed 3 times in 0.2% Bovine Serum Albumin (BSA)/PBS
over a 5 minute period. The primary antibody at 1/200 dilution was then added in
0.2% BSA/PBS for 45 minutes, then cells were washed 3 times in 0.2% BSA/PBS,
over a 5 minute period. The secondary antibody (anti-mouse Fluorescein
isothiocyanate (FITC) conjugate, Santa Cruz Biotechnology, Germany) was then
added at a 1/500 dilution in 0.2% BSA/PBS and incubated in darkness for 30
minutes. The cells were then washed 3 times in 0.2% BSA/PBS, then washed
twice in PBS. The coverslips were then mounted onto microscope slides using 6L
of movial/DAPI and viewed with a Nikon Microphot-FXA immunofluorescence
microscope.
2.2.6 Making recombinant adenoviruses
Plasmids pSCB-Ad5FL-5’ITR linearised with I-SceI, and pGEM + LHendAd5
linearised with Sal1, were transfected simultaneously into a 25cm2 flask of 80%
confluent 293 cells using FuGENE 6 transfection reagent. Both DNA samples
were purified by agarose gel electrophoresis after restriction digest. Transfection
reactions contained 1g of each linearised DNA sample, 6L FuGENE 6 and the
volume was made up to 100L with OptiMEM1 GlutaMAX1 medium. After
transfection the growth medium was changed every two days until plaques were
visible, approximately day ten post transfection.
The viruses were then harvested. The cells were scraped into the media and
pelleted by centrifugation at 1,200rpm for 5 minutes. The supernatant was
aliquoted and kept, and the cell pellet was resuspended in 100L PBS and freeze
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thawed 3 times in dry ice and methanol to release virus from cells. All samples
were then frozen at -70C.
2.2.7 Isolation of recombinant viruses by end point dilution
Each well of a 96 well plate was seeded with HeLa cells in DMEM supplemented
with 10%FCS and 2mM glutamine. When cells were approximately 60%
confluent and ready to infect, a series of 10 fold dilutions of recombinant virus
was prepared (100L of virus in 900L of media) from 10-1 down to 10-12. The
medium was then removed from the 96 well plate and the pre-prepared virus
dilutions added in columns of 8, from 10-2down to 10-12, with medium only being
added to the last column as a control. The plate was then returned to 37C, 5%
CO2. The plates were monitored daily for evidence of plaque formation and the
medium changed every three days, or sooner if it became acidic. After ten days the
virus was harvested from the end point wells. Cells were place in a sterile screw
capped vial and were freeze thawed 3 times in dry ice and methanol then stored at
-70C. This whole procedure was then repeated another two times using the cell
lysate from one well, chosen at random (with the other two being stored at -70C
as back up).
2.2.8 Screening of recombinant adenoviruses
Plaques picked were used to infect 1x75cm2 flask of 80% confluent HeLas. After
two to three days, when plaques became visible, the virus was harvested by arcton
extraction (see below). DNA was then isolated and purified from the arcton
112
extracted virus using the Qiagen QIAamp DNA Blood minikit (see below). Viral
DNA was then subject to PCR and DNA sequence analysis.
Recombinant viruses were also screened using Western blot analysis. A 1x25cm2
flask of HeLas cells was infected with virus. After 48 hours cells were harvested
by scraping the cells into the media. The cells were pelleted by centrifugation at
1,200rpm for 5 minutes. The cells were then washed in PBS, repelleted, then lysed
in 200L of RIPA buffer (25mM Tris pH8.2, 50mM NaCl, 0.5% NP40, 0.5%
deoxycholate, 0.1% SDS, 0.1% sodium azide). The RIPA buffer had protease
inhibitors added to it just prior to use; one complete mini (EDTA free) protease
inhibitor tablet (Roche) was dissolved in 2mL of RIPA buffer, then 1mL of SDS
sample buffer (0.15M Tris-HCl pH6.7, 5% SDS, 30% glycerol plus 0.1%
bromophenol blue) and 60L of 500mM iodoacetamide was added. The RIPA
buffer (without the protease inhibitors and the SDS sample buffer) could be stored
at 4C. The SDS sample buffer could be stored at RT.
-mercaptoethanol was added to each sample (10L) and samples sonicated
briefly (at 5mA for 30 seconds). The samples were then boiled and run on a 10%
SDS-PAGE gel, transferred onto Immobilon-P membrane overnight then analysed
by Western blot analysis using E1B55k monoclonal antibody 2A6 (a kind gift
from Dr Keith Leppard).
2.2.9 Extraction of viral DNA using the Qiagen QIAamp DNA Blood minikit
To arcton extracted virus from 0.5x 75cm2 flask was added 100L of RNase A
(10mg/mL) and incubated at 37C for 30 minutes. After this 62.5L of protease
and 500L of buffer AL were added and the sample incubated at 70C for 10
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minutes. The sample was then loaded onto a column and spun through at
13,000rpm for 1 minute. The column was then washed through with 500L of
buffer AW1, then 500L of buffer AW2, spinning at 13,000rpm after each wash.
The DNA was then eluted from the column in 50L sterile water.
2.2.10 Amplification of recombinant viruses
From the plaque pick, virus was scaled up into 1x75cm2 flask of HeLas, then
20x75cm2 flasks of HeLas, then into 5L of HeLa spinners. The virus was arcton
extracted between each scale up.
2.2.11 Infecting HeLa and 293 spinners with adenovirus
As the volume of the spinner cell culture was so large, to ensure that all of the cells
came into contact with the virus during infection, the cells were centrifuged at
4,000rpm for 30 minutes to pellet them. Cells were then resuspended in 500mL of
serum free Joklik medium, the virus was added to this, and cells incubated, with
spinning at 37C for 1 hour. The volume was then made back up to 5L with
Joklik/2% NCS and incubated spinning at 37C until the cells showed signs of
infection.
2.2.12 Arcton extraction of adenovirus
Arcton (1,1,2-Trichlorotrifluoroethane, Aldrich) was used to extract virus from the
cytoplasmic membrane of cells. Cells infected with adenovirus were pelleted by
centrifugation at 1,200rpm for 5 minutes. The cell pellet was then washed in PBS
and repelleted. The cell pellet was then resuspended in an appropriate amount of
114
PBS and an equal volume of arcton added. This was mixed by shaking vigorously
for 30 minutes at RT, after which the sample was spun at 4,000rpm for 15 minutes
at RT. The aqueous (top) phase containing the virus was removed, dispensed into
aliquots and stored at -70C. This can be further purified by Caesium chloride
(CsCl) gradient.
2.2.13 Virus purification by CsCl gradient
Prior to CsCl purification the arcton extracted virus was spun at 4,000rpm for 10
minutes at RT to pellet any cell debris. The CsCl gradient was then set up by
gently layering 2mL of 2M CsCl onto 3mL of 3M CsCl in an ultracentrifuge tube
for either an SW40Ti rotor or an SW41Ti rotor. The tubes were presterilised prior
to setting up the gradient by spraying with 70% ethanol and allowing to air dry.
The virus was then gently layered onto the gradient, taking care not to disrupt any
of the layers. The samples were then spun in an ultracentrifuge at 30,000rpm for 2
hours at RT in either SW40Ti or SW41Ti rotor. After spinning, the virus was
present as an opalescent band between the 3M and 2M solutions. The cell debris
and empty virus particles were visible above the actual viral band. The viral band
was removed using a 19 gauge needle and 2mL syringe, by piercing the side of the
tube. The virus was then placed in a Slide-A-Lyzer cassette (Pierce) and dialysed
in 2L of dialysis buffer (1mM MgCl2, 135mM NaCl, 10mM Tris-HCl pH7.8, 10%
glycerol) at 4C for 4 hours. The dialysis buffer was then replaced and virus
dialysed overnight. The virus was then aliquoted into sterile screw capped vials
and stored at -70C. CsCl was made up in STE buffer (100mM NaCl, 10mM Tris-
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HCl pH7.8, 1mM EDTA) and was autoclaved prior to use. Dialysis buffer was
also autoclaved prior to use.
2.2.14 Titration of virus stocks
Viruses were titrated using end point dilution. Each well of a 96 well plate was
seeded with HeLa cells in DMEM supplemented with 10%FCS and 2mM
glutamine. When cells were approximately 60% confluent and ready to infect a
series of 10 fold dilutions of recombinant virus was prepared (100L of virus in
900L of media) from 10-1 down to 10-12. The medium was then removed from the
96 well plate and the pre-prepared virus dilutions added in columns of 8, from 10-
2down to 10-12, down the plate, with medium only being added to the last column
as a control. The plate was then returned to 37C, 5% CO2. The plates were
monitored daily for evidence of plaque formation and the medium changed every
three days, of sooner if it became acidic. After ten days each well of the 96 well
plate was scored +/- for the presence of plaques.
2.2.15 Determination of the optimum concentration of puromycin required to kill
HeLa cells
Puromycin (Melford) was made up to a stock concentration of 50mM in sterile
water. This was then added to 9x50mL aliquots of growth media (DMEM
supplemented with 10% FCS and 2mM glutamine) to give concentrations of
25M, 20M, 15M, 12.5M, 10M, 7.5M, 5M, 2.5M and 1M. Twelve
well plates of HeLa cells were set up in normal growth medium. When the cells
were 80% confluent, media containing puromycin at the different concentrations
116
was added to each well. This was performed in duplicate. Some of the wells were
maintained in normal growth medium only as a control. The media was changed
regularly for 7 to 10 days, with media containing the appropriate concentration of
puromycin being added to the appropriate well. At this point the optimum
concentration of puromycin required to kill the HeLa cells was determined to be
5M.
2.2.16 Generating HeLa stable cell lines
Stable cell lines were generated using the pEFIRES-PURO construct (Hobbs et al.,
1998), which was a kind gift from Dr Pablo De Felipe. By cloning the gene of
interest into the pEFIRES-PURO vector and transfecting into cells, which are then
grown in puromycin containing media, cells expressing the construct are selected
for.
Approximately 5g of the pEFIRES-PURO construct, expressing TAP/E1B55k or
TAP/E1B55k K104R, was transfected into a 75cm2 flask of 80% confluent HeLa
cells, using FuGENE 6 transfection reagent (Roche). Twenty four hours later the
flask was trypsinised and the cells split between 4 petri dishes (150mm diameter),
with 2 dishes each containing 45% of the cells and the remaining 2 containing 5%
of the cells. The cells were grown in normal growth medium overnight before the
addition of growth medium containing puromycin at a concentration of 5M. The
medium was changed regularly over a 10 to 14 day period, at which point
puromycin resistant colonies of cells had developed. Individual colonies were
picked using a 1mL pipette and transferred to 1 well of a 12 well plate, where they
were expanded in medium containing puromycin. Colonies were then screened by
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immunofluorescence and Western blot analysis for expression of the TAP/E1B55k
or TAP/E1B55k K104R genes, using a monoclonal antibody to the E1B55k gene
as a primary antibody. Colonies that were deemed to be expressing recombinant
protein at sufficient levels, were expanded and stocks frozen down in liquid
nitrogen (see section 2.2.2 for details).
2.3 Protein purification and analysis
2.3.1 Quantification of protein using Bradford Assay
Protein concentrations were determined using Bradford’s method (Bradford,
1976). Protein samples were mixed with 1mL of Bradford reagent (BioRad) for 10
minutes at RT, then the absorbance measured at 595nm using a spectrophotometer.
Protein absorbance was converted to mg/mL concentrations using a standard curve
constructed by measuring the absorbance of a range of different concentrations of
BSA.
2.3.2 SDS-PAGE
To make a standard 10% gel the following recipe was used. The TEMED and
10%APS were added just prior to the gels being poured. BioRad Protean II gel rigs
were used.
Separating gel:
Separating gel buffer (1.5M Tris-HCl pH 8.9, 0.4% SDS) 3.95mL
30% polyacrylamide/0.8% bis-acrylamide 4mL
H2O 6.9mL
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10% APS 150L
TEMED 10L
Stacking gel:
Stacking gel buffer (0.5M Tris-HCl pH6.7, 0.4% SDS) 1.776mL
30% polyacrylamide/0.8% bis-acrylamide 1.2mL
H2O 4mL
10% APS 112L
TEMED 20L
Samples to be analysed by SDS-PAGE were boiled at 100C for 5 minutes in SDS
boiling mix prior to loading (0.15M Tris-HCl pH6.7, 5% SDS, 30% glycerol plus
0.1% bromophenol blue). The gel was run in 1x SDS running buffer (25mM Tris,
200mM Glycine, 0.35mM SDS) at 150 volts for approximately 1 hour. Prestained
marker was run alongside the protein samples. Gels were then either Coomassie
stained or used in western blot analysis.
2.3.3 Coomassie staining
Coomassie stain was used to detect proteins. The gel was stained in Coomassie
stain (40% v/v methanol, 10% v/v glacial acetic acid, 0.1% w/v Coomassie
brilliant blue R-250) for approximately 10 minutes. Excess stain was then removed
from the gel by soaking in destain (20% v/v methanol, 10% v/v glacial acetic
acid). The gel was then transferred into ultrapure water.
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2.3.4 Western blotting
Proteins resolved on SDS-PAGE gel were transferred to Immobilon-P (PVDF
membrane, Sigma) presoaked in methanol. The proteins were transferred using a
wet transfer system (BioRad) in Transfer buffer (200mM Tris-HCl, 185mM
Glycine, 20% v/v methanol) at 400mA for 2 hours or at 40mA overnight. The
membranes were then blocked in blocking buffer (5% w/v skimmed milk powder,
0.1% Tween 20 in PBS) at RT for 1 hour. The primary antibody (E1B55k mouse
monoclonal antibody), at 1/500 dilution, was added to membrane, diluted in
blocking buffer and incubated at RT for 1 hour. The secondary antibody
(Horseradish peroxidase conjugated anti-mouse IgG, Amersham) was added at
1/3000 dilution, diluted in blocking buffer and incubated at RT for 1 hour. The
membranes were washed in 0.1% Tween 20 in PBS in between blocking and
addition of antibodies, and after addition of the secondary antibody. Western
blotting was then performed using Enhanced Chemiluminescent (ECL) detection.
2.3.5 Tandem Affinity Purification method for TAP/SUMO2 cells
120 petri dishes (150mm in diameter) of TAP-SUMO2 or TAP HeLa stable cell
lines were harvested when 100% confluent and subjected to tandem affinity
purification. The cells were harvested in batches of 5 plates. The media was
removed and the plate washed twice in approximately 15mL PBS, then SDS lysis
buffer added (50mM Tris-HCl pH8.0, 2% w/v SDS, 10mM iodoacetamide, 1mM
EDTA, plus 1x complete EDTA free protease inhibitor tablet (Roche) per 100mL).
The petri dish was rocked to ensure even coverage of the lysis buffer then cells
were scraped into the lysis buffer using a sterile cell scraper (5mL of lysis buffer
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was used for each set of 5 plates). Cell lysates were then frozen in 4x50mL Falcon
tubes at -70C or the procedure continued. If the cell lysates were frozen at -70C,
they were thawed in a waterbath at RT, then placed on ice. The contents of each
Falcon tube were then sonicated approximately 10x for 15 seconds at 10mA to
shear the genomic DNA. The samples were then spun at 14,000rpm for 5 minutes
at RT to pellet any cell debris. The cells were then split evenly between 2x1L
durans of Renaturation buffer (50mM Tris-HCl pH8.0, 1M NaCl, 1% NP40,
10mM iodoacetamide, 0.5mM EDTA, 1mM PMSF). Each 1L sample was then
passed through a 5mL column containing 1.2mL of IgG sepharose beads, pre-
washed in Renaturation buffer. The samples were passed through the columns
using gravity flow, and took approximately 4 hours to pass through the column.
The columns were then washed with 5 bed volumes of Renaturation solution, then
50mL of Tobacco Etch Virus (TEV) protease cleavage buffer (50mM Tris-HCl
pH8.0, 1M NaCl, 1% NP40, 1mM DTT, 0.5mM EDTA) using gravity flow. Each
set of beads was then resuspended in 900L TEV cleavage buffer and 50L of
TEV protease at 1mg/mL added. The samples were incubated, rotating on a daisy
wheel at 4C overnight.
The TEV protease cleaved beads were then transferred to 2x5mL columns and the
sample eluted from the beads with 7mL of calmodulin binding buffer (50mM Tris-
HCl pH8.0, 1M NaCl, 1mM DTT, 1mM magnesium acetate, 1mM imidazole, 1%
NP40, 2mM CaCl2), which was collected in 2x15mL Falcon tubes. Simultaneously
2x5mL columns were set up with 1mL of calmodulin beads in each, and washed
with 10mL of calmodulin binding buffer. The beads were then transferred into the
15ml Falcon tubes and the volume made up to 15mL with calmodulin binding
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buffer. The samples were then incubated, rotating on a daisy wheel at 4C for 4
hours. The beads were then transferred back into the 2x5mL columns and washed
through with 30mL of calmodulin binding buffer.
Protein was then eluted from the calmodulin beads using calmodulin elution buffer
( 50mM Tris-HCl pH8.0, 1M NaCl, 1mM DTT, 1mM Magnesium acetate, 1mM
imidazole, 1% NP40, 10mM EGTA). Each of the columns were plugged prior to
the addition of 1.5mL of calmodulin elution buffer, and incubated at 4C for 10
minutes. Protein was then allowed to elute by gravity flow and this process was
repeated. All 4x1.5mL aliquots were then stored at -70C until ready to analyse by
SDS-PAGE and Mass Spectrometric analysis. Eluates were then thawed on ice and
TCA precipitated (see below).
2.3.6 Tandem affinity purification method for TAP/E1B55k (+/-K104R)*
60 petri dishes (150mm diameter) of TAP/E1B55k or TAP/E1B55k K104R HeLa
stable cell lines were harvested when 100% confluent and subjected to tandem
affinity purification. The cells were harvested in batches of 10 plates. The media
was removed and plates were washed twice in approximately 15mL PBS. The
cells from each plate were then scraped into 2mL PBS, transferred to a 50mL
Falcon tube and pelleted by centrifugation at 1,200rpm for 2 minutes. The cell
pellets were then resuspended in a total volume of 60mL lysis buffer (50mM Tris-
HCl pH7.4, 150mM NaCl, 1mM EDTA, 1% NP40, 15% glycerol, 1mM PMSF),
and incubated at 4C for 30 minutes. The lysis buffer was made up in 100mL
volume and contained 1x complete EDTA free protease inhibitor tablet (Roche).
The cell lysates were then spun at 14,000rpm for 15 minutes at 4C to pellet any
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cell debris. The supernatant was then split evenly between 6x 15mL Falcon tubes
and 200L of IgG sepharose (Sigma) added to each tube, and samples were
incubated with rotation at 4C for 4 hours. The IgG beads were then pelleted by
centrifugation at 2,000rpm for 2 minutes at 4C. The beads were then washed 3x
in TBS/0.05% Tween-20 with the beads being pelleted in between washes. The
beads were then washed in TEV cleavage buffer (10mM Tris pH8.0, 150mM
NaCl, 0.1% NP40, 0.5mM EDTA, 1mM DTT) before being resuspended in a total
volume of 200L of TEV cleavage buffer. TEV protease was added (20L at
1mg/mL concentration) and the sample incubated at 4C, overnight, with rotation,
in an eppendorf tube.
The beads were pelleted by centrifugation at 13,000rpm for 3 minutes at RT. The
supernantant was transferred to a clean tube, to which was added 3 volumes of
calmodulin binding buffer and 3L of 1M CaCl2 (per mL of supernatant).
Calmodulin beads (200L) were then transferred to a disposable 2mL polystyrene
column (Pierce) and washed in 5mL of calmodulin binding buffer (10mM -
mercaptoethanol, 10mM Tris pH8.0, 150mM NaCl, 1mM Magnesium acetate,
1mM imidazole, 2mM CaCl2, 0.1% NP40). The supernatant was then added to the
washed calmodulin beads and incubated at 4C for 2 hours, with rotation. After
incubation the sample was added to disposable 2mL polystyrene columns and
allowed to drain by gravity flow. The beads were then washed in approximately
30mL of calmodulin binding buffer. Proteins were then eluted into 1.5mL of
calmodulin elution buffer (10mM -mercaptoethanol, 10mM Tris pH8.0, 150mM
NaCl, 1mM magnesium acetate, 1mM imidazole, 2mM EGTA, 0.1% NP40). The
column was plugged prior to the addition of 1.5mL of elution buffer, then
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incubated at 4C for 10 minutes. The protein was then eluted by gravity flow. The
protein eluates were stored at -70C until ready to analyse by SDS-PAGE and
Mass Spectrometric analysis. Eluates were then thawed on ice and TCA
precipitated.
* This is the basic protocol before any modifications were made in order to
optimise the tandem affinity purification procedure. Optimisation of this protocol
is discussed in results chapter 3.
2.3.7 Dignam and Roeder method for harvesting nuclear extracts
Cells were scraped into PBS and are pelleted by centrifugation at 1,500rpm at 4C.
The cell pellet is then resuspended in 3 volumes of Dignam A buffer (10mM
Hepes-KOH pH7.9, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, 0.5mM PMSF) and
incubated on ice for 15 minutes. The cells are lysed by pushing several times
through a 25 gauge needle. The nuclei are then pelleted by centrifugation at
14,000rpm for 30 minutes, and are resuspended in 1.5 volumes of Dignam C
buffer (20mM Hepes pH7.9, 25% glycerol, 0.42M NaCl, 1.5mM MgCl2, 0.2mM
EDTA, 0.5mM DTT, 0.5mM PMSF), by incubation at 4°C for 30 minutes, with
rotation. The cell membranes are pelleted by centrifugation at 15,000rpm for 30
minutes, and the supernatant, containing the nuclear extract, is dialysed against
Dignam buffer D (20mM Hepes pH7.9, 20% glycerol, 0.1M KCl, 0.2mM EDTA,
0.5mM DTT, 0.5mM PMSF).
2.3.8 TCA precipitation
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Protein samples were aliquoted into 1mL aliquots, then 1/3 volume (0.33mL) of
100% w/v TCA/ 0.5% sodium deoxycholate was added to each aliquot and
incubated on ice for 15 minutes. The sample was then centrifuged at 14,000rpm
for 20 minutes at 4C and the supernatant discarded. Each pellet was then washed
twice in 1mL of neat acetone and respun at 14,000rpm for 2 minutes. Protein
pellets were then air dried in the fume hood and resuspended in a total volume of
30L of SDS boiling mix.
The sample were then run on a 10% SDS-PAGE gel at 100 volts for 1.5 hours,
Coomassie stained, then destained. The lane of the gel containing the sample was
then cut into separate “chunks”, approximately 10-15 chunks per track, which
were then subjected to in-gel digestion and LC-ESI-MS/MS analysis.
2.3.9 LC-ESI-MS/MS analysis
The gel track was excised into approximately 10-15 sections. Each section was cut
into 1mm cubes and the gel cubes for each section were split between 2 wells of
the 96 well plate if necessary. These were then subjected to in-gel digestion, using
a ProGest Investigator in-gel digestion robot, using standard protocols. Briefly the
gel cubes were destained by washing with acetonitrile and subjected to reduction
and alkylation before digestion with trypsin at 37C. The peptides were extracted
with 10% formic acid and concentrated down to 20L (SpeedVac, ThemoSavant).
They were then separated using an UltiMate nanoLC (LC Packings, Amsterdam)
equipped with a PepMap C18 trap and column. The eluent was sprayed into a Q-
Star Pulsar XL tandem mass spectrometer (Applied Biosystems, Foster City, CA)
and analysed in Information Dependent Acquisition (IDA) mode. MS/MS data for
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doubly and triply charged precursor ions was converted to centroid data, without
smoothing, using the Mascot Daemon 2.1 (Matrix Science, London) data import
filter for Sciex Analyst. The MS/MS data file generated was analysed using the
Mascot search engine against MSDB July 2005. The data was searched with
tolerances of 0.2Da for the precursor and fragment ions, trypsin as the cleavage
enzyme, one missed cleavage, carbamidomethyl modification of cysteine as a
fixed modification and methionine oxidation selected as variable modifications.
3. GENERATION OF RECOMBINANT ADENOVIRUSES
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3.1 Introduction
3.1.1 Introduction
Four recombinant adenoviruses expressing tagged E1B55k were generated. The
adenoviruses were constructed from plasmid pSCB-AdFL which contains the full
length wild type adenovirus 5 genome, to allow the study of the this protein. The
recombinant adenoviruses expressed E1B55k that was N-terminally tagged with
either Cyan Fluorescent Protein (CFP), or Tandem Affinity Purification (TAP) tag.
The CFP tag would allow the localisation of the E1B55k gene to be studied during
infection, using the Delta Vision microscope, which can be used for live imaging.
The TAP tag would enable the purification of the E1B55k protein along with any
interacting host cell or viral proteins, which could then be identified using SDS-
PAGE and LC-ESI/MS/MS. As discussed previously, the E1B55k protein is
modified by SUMO protein (Endter et al, 2001), and it is a lysine residue at amino
acid 104, that lies within the SUMO consensus sequence KxE, that is essential
for SUMO modification. By mutating the lysine to an arginine, modification of
E1B55k by SUMO is abolished but the charge remains unchanged (Endter et al,
2001). Therefore, E1B55k K104R versions of the recombinant adenoviruses were
made, to study the impact of SUMO modification on the E1B55k protein, both in
terms of localisation, and interacting proteins, during the infection process.
The four recombinant adenoviruses generated were:
 TAP/E1B55k
 TAP/E1B55k K104R
 CFP/E1B55k
 CFP/E1B55k K104R
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3.1.2 Strategy for generating the recombinant viruses
The construct pSCB-AdFL was used to generate the recombinant adenoviruses,
which consists of a bacmid backbone, and the full length wild type adenovirus 5
genome flanked by I-Sce1 restriction sites. This construct was a kind gift from
Philip Moullier (Inserm, Nantes). See figure 3.1.
The strategy for making the recombinant viruses involved cloning the left hand
end of the adenovirus genome, containing the E1B55k gene, into a standard
cloning vector. Thus, by dramatically reducing the size of the DNA fragment, this
would allow the E1B55k gene to be replaced with the tagged version plus or minus
the K104R (+/- K104R) mutation, using standard molecular biology techniques. In
order to simplify the cloning procedure, the left hand end of the adenovirus
genome was cloned in such a way, that unique restriction sites (Xba1 and BsaB1)
would be present either side of the E1B55k gene, allowing it to be replaced easily,
with the tagged version +/- K104R mutation.
Cyan fluorescent protein (CFP) tagged E1B55k and E1B55k K104R constructs
were a kind gift from Tony Vaughan. These constructs had been generated by
cloning the E1B55k and E1B55k K104R genes into the EcoR1/ BamH1 restriction
sites of the multiple cloning site (MCS) of vector pECFP-C1 (Clontech). The
E1B55k genes had been amplified by PCR, and the primers designed to have the
necessary restriction sites, to facilitate cloning into the pECFP-C1 vector (see
figure 3.2).
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TAP tagged E1B55k and E1B55k K104R were generated by amplifying the
E1B55k genes from the CFP constructs and cloning into vector pCMV5/TAP, a
kind gift from Maria Deak (University of Dundee). The PCR primers used were
designed to have BamH1 restriction sites, to allow cloning into the BamH1 site of
the MCS of pCMV5/TAP (see figure 3.3).
5’ITR
3’ITR
Figure 3.1: Bacmid pSCB-AdFL. This map illustrates Bacmid pSCB-AdFL
containing the full length wild type adenovirus 5 genome, flanked by I-Sce1
restriction sites.
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Figure 3.2: Plasmid pECFP-C1. This figure illustrates plasmid pECFP-C1 into which the
E1B55k gene, and E1B55k K104R gene,were cloned by Tony Vaughan. The E1B55k
genes were cloned between EcoR1 and BamH1 restriction sites of the MCS.
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Figure 3.3: Plasmid pCMV5/TAP. The genes encoding E1B55k and E1B55k K104R were
amplified from plasmid pECFP-C1 using primers p9 and p10A which were designed to include
BamH1 restriction sites. PCR products were digested and cloned into the BamH1 site in the
MCS, of plasmid pCMV5/TAP.
(BamH1/Kpn1/HindIII/Sal1/Xba1)
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After generation of the TAP tagged and CFP tagged versions of E1B55k, +/-
K104R mutation (TAP-E1B55k, TAP-E1B55k K104R, CFP-E1B55k and CFP-
E1B55k K104R), overlap PCR was used to flank each of the tagged proteins, with
adenovirus type 5 DNA homologous to the regions either side of wild type
E1B55k. During the original cloning, the left hand end of Adenovirus type 5 had
been cloned into the standard cloning vector in such a way, that unique restriction
sites were present either side of the E1B55k gene. The overlap PCR products was
designed to incorporate these restriction sites, allowing the wild type E1B55k gene
to be replaced with the tagged versions +/- K104R mutation (see figure 3.4).
Generation of the recombinant adenoviruses was achieved by co-transfection of
two different constructs, one containing the left hand end of Ad5 and the other
containing the remainder of the Ad5 genome, with both plasmids having a
homologous region of adenoviral DNA, allowing homologous recombination to
occur (see figure 3.5).
The second construct required was generated by knocking out the left hand
Inverted Terminal Repeat (ITR) of plasmid pSCB-AdFL, using homologous
recombination (see figure 3.6). Overlap PCR was used to generate an antibiotic
resistance gene, flanked by regions homologous to either side of the region to be
knocked out. Co-electroporation of the overlap PCR product and pSCB-AdFL
(linearised with I-Sce1) into recombinogenic BJ5183 cells, resulted in homologous
recombination and generation of positive colonies, which could be selected for by
growing on plates containing the appropriate antibiotic.
Sal1 Xho1
E1B55k
Xba1 BsaB1
TAG E1B55k+/-K104R mutation
Xba1 BsaB1
Ad5 Ad5
PCR1 PCR2 PCR3
Xba1
BsaB1
Figure 3.4: Generation of overlap PCR products. This diagram illustrates how overlap PCR was used to
replace E1B55k in the left hand region of Ad5 with the tagged version, +/- the K104R mutation.The
region of PSCB-AdFL that was cloned into the pGEM-5zf(+) vector is shown in A. The overlap PCR
product used to generate tagged versions of E1B55k+/- the K104R mutation, flanked on either side by the
appropriate adenovirus type 5 DNA (containing the unique restriction sites Xba1and BsaB1), are shown
by B. The resulting plasmids generated by replacing the E1B55k with the tagged version +/- K104R
mutation are illustrated by C.
TAG-E1B55k
TAG E1B55k+/-K104R mutation
Sal1 Xho1
6A.
Xba1 BsaB1
6B.
6C.
13 3
5’
Ad 5 LH end
Ad5 RH end
Homologous recombination
3’
5’ 3’Recombinant Ad5
Cmr
ITR ITR
Tagged E1B55k+/-K104R
Tagged E1B55k+/-K104R
pGEM-5zf(+) + LHendAd5
pSCBadFL-5’ITR
Figure 3.5: Homologous recombination occurs to generate full length recombinant virus. Linearised
plasmids pGEM-5zf(+)+LHendAd5 and pSCBAdFL-5’ITR are co-transfected into permissive tissue
culture cells. Homologous recombination results in the generation of recombinant adenovirus.
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5’ITR
3’ITR
Figure 3.6: Knocking out the 5' ITR of pSCB-AdFL using chloramphencil resistance gene.The 5'
ITR was knocked out of plasmid pSCBAdFL and replaced with the Chloramphenicol resistance gene
from plasmid pACYC184 (New England Biolabs). Overlap PCR was used to generate the
chloramphenicol resistance gene flanked by the appropriate Baculovirus and Ad5 DNA either side.
Plasmid pSCBAdFL was then partially digested with restriction enzyme I-SceI (to cleave it at the
5'ITR only) and gel purified. Linearised plasmid was then co-electroporated into recombinogenic
BJ5183 cells along with purified PCR product. Homologous recombination resulted in formation of
plasmid pSCBAdFL-5’ITR.
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Recombinant adenovirus was generated by co-transfecting each of the linearised
constructs into tissue culture cells, permissive for adenovirus growth. Homologous
recombination occurring between segments of homologous DNA in each of the
plasmids resulted in the formation of recombinant adenovirus (see figure 3.5). This
was indicated by the appearance plaques on the cell monolayer, approximately ten
days post-transfection.
3.2 Results
3.2.1 Initial strategies for cloning the left hand end of Ad5 into a standard cloning
vector
The original cloning strategy for making the recombinant adenoviruses was
devised using a basic restriction map of plasmid pSCB-AdFL, as there was
initially no sequence information available.
The original strategy for cloning the left hand end of the adenovirus genome into
the pUC19 vector required modification of the MCS. This was achieved by using
linkers L3 and L4, which were designed to include an I-Sce1 restriction site, and
knock out the Xba1 site in the MCS of pUC19. Linkers L1 and L2 which had been
originally been designed for the same purpose, had an error which prevented the
Xba1 site from being knocked out. Linkers L3 and L4 were cloned successfully
into pUC19, verified by restriction digest and sequence analysis, using primers
pUC19F and pUC19R, which were designed to sequence through the MCS.
Plasmid pSCB-AdFL was cut with restriction enzymes I-Sce1 and Sal1 generating
5 fragments of 19.4kb, 13kb, 8.8kb, 7.3kb and 0.3kb, with the 8.8kb band being
the desired fragment. This 8.8kb DNA fragment was purified by agarose gel
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electrophoresis, to remove any contaminating DNA bands, and ligated into the
modified pUC19 vector also digested with Sal1 and I-Sce1. The modified pUC19
vector, after restriction digest, had also been purified by agarose get
electrophoresis to remove any contaminating DNA bands. Prior to ligation DNA
was quantified by agarose gel electrophoresis, to ensure there was sufficient DNA
present for the ligation reaction to occur.
All initial cloning attempts resulted in empty vector suggesting that one of the
restriction enzymes was not cutting properly. Restriction digests were carried out
first with I-Sce1, as this restriction enzyme requires a 6bp overhang, followed by
Sal1, which requires a 3bp overhang. A control ligation reaction was also set up,
with modified pUC19 vector cut with I-Sce1 and Sal1, to ensure that the vector
was not religating, which could occur if only one of the restriction enzymes had
cut.
PCR of the insert DNA, using primers to the E1B55k gene (P9 and P10A),
confirmed that the correct fragment was being used for the cloning.
After ligation the DNA samples were transformed into transformation competent
DH5, but all resulting colonies screened consisted of empty vector. Subsequent
attempts at electroporating the DNA into electrocompetent DH5 also resulted in
colonies consisting of empty vector. The MCS of the modified pUC19 plasmid
was reanalysed by sequence analysis, and found to be mutated, explaining why the
cloning attempts had proved unsuccessful (see figure 3.7).
5’ G’AATTC TAGGGATAACAGGGTAAT A’CTAGA 3’
3’ CTTAA’G ATCCCTATTGTCCCATTA TGATC’T 5’
EcoR1 I-Sce1 Xba1
5’AATTC TAGGGATAACAGGGTAAT A 3’
MCS
pUC19
Apo1/EcoR1
BanII/Sac1
Acc651/Kpn1
Ava1/BsoB1/
Sma1/ Xma1
BamH1
Xba1
Acc1/HincII/Sal1
BspM1/BfuA1
Sbf1
Pst1
Sph1
HindIII
3’ G ATCCCTATTGTCCCATTA TGATC 5’
EcoR1 I-Sce1 Xba1
Figure 3.7: Linkers used to modify the MCS of pUC19 vector. Linkers L3 and L4 were designed to
incorporate an I-Sce1 restriction site into the MCS, but knock out the Xba1 restriction site. Linkers L3
and L4 were designed to be cloned into pUC19 digested with EcoR1 and Xba1. After initial cloning,
sequence analysis confirmed that the sequence of the MCS was as it should have been. When sequenced
subsequently, after cloning attempts had failed, the sequence of the MCS was found to read
EcoR1 - I-Sce1 - unidentifiable sequence - EcoR1 - I-Sce1 - Sal1 - Xba1, suggesting that some sort of
mutation had occurred.
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3.2.2 The second strategy for cloning the left hand end of Ad5 into a standard
cloning vector
The second attempt at cloning the left hand end of Ad5 was based on sequence
data of pSCB-AdFL, which had kindly been sent by Christophe Darmon. The
second strategy was to clone the left hand end of Ad5 into pUC19 by cutting
plasmid pSCB-AdFL with Sal1 only, and ligating the fragment containing the left
hand end of Ad5 into the Sal1 site of unmodified pUC19. Digestion of pSCB-
AdFL with Sal1 generated 6 fragments of 20.8kb, 10.4kb, 10.2kb, 6.9kb, 0.3kb,
0.2kb, of which the 10.2kb band was the desired fragment. The 10.2kb fragment
containing the left hand end of Ad5 was purified by agarose gel electorphoresis,
and ligated into the pUC19 vector. The pUC19 vector had been digested with Sal1,
purified by agarose gel electrophoresis, and treated with Calf-intestinal alkaline
phosphatase (CIAP) to prevent religation. The ligation reactions were then
transformed into DH5, and plated onto ampicillin plates. Resulting colonies were
screened by hybridisation using the E1B55k PCR product (amplified using primers
P9 and P10A) labelled with 32P. This method proved unsuccessful. Although
colonies were generated, all colonies screened consisted of religated bacmid
backbone. This was caused by contamination of the 10.2kb band with 10.4kb
band, which was the bacmid backbone, and which was ampicillin resistant.
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3.2.3 Final strategy for cloning the left hand end of Ad5 into a standard cloning
vector
The final strategy for cloning the left hand end of Ad5 involved digesting plasmid
pSCB-AdFL with Xho1, generating fragments of 17.6kb, 14.5kb, 7.8kb, 4.9kb,
2.4kb, 1.4kb and 1kb. This time the 7.8kb band was well separated from other
bands and was purified by agarose gel electrophoresis, then digested with Sal1
yielding fragments of 6.5kb, 1.3kb and 0.2kb, of which the 6.5kb band was the
desired fragment, containing the left hand end of the adenovirus genome. The
6.5kb band was purified by agarose gel electrophoresis to remove any
contaminating DNA bands and cloned into pGEM-5zf(+) vector (see figures 3.8
and 3.9). The pGEM-5zf(+) vector had been digested with Sal1, purified by
agarose gel electrophoresis and CIP treated, to prevent religation (Sal1 and Xho1
restriction enzymes have compatible overhangs). Following ligation, samples were
transformed into DH5 and plated onto ampicillin plates. Resulting colonies were
screened by hybridisation using E1B55k PCR product labelled with 32P. Cloning
using this strategy was successful.
3.2.4 Strategy for replacing wild type E1B55k with the tagged E1B55k +/- K104R
mutation
Overlap PCR was used to generate the tagged E1B55k +/- K104R mutation,
flanked on either side by Ad5 DNA, homologous to the regions on either side of
the wild type E1B55k. The strategy for cloning the left hand end of the adenovirus
genome was designed so that unique restriction sites would be present on either
side of the E1B55k, allowing it to be replaced easily with the tagged
Figure 3.8: Left hand end of adenovirus released by cleaving pSCB-AdFL with
restriction enzymes Sal1 and Xho1. Plasmid pSCB-AdFL was digested with Xho1 to
yield fragments of 7.7kb, 2.3kb, 1.6kb, 1.1kb, 14.6kb, 4.7kb and 17.4kb, with the 7.7kb
band containing the left hand end of the Ad5 genome and part of the Bacmid backbone.
The 7.7kb band was gel purified and further digested with Sal1 to yield fragments of
6.5kb, 1.3kb and 0.2kb. The 6.5kb fragment (between the underlined Sal1 and Xho1
restriction sites), containing the left hand end of the Ad5 genome and part of the bacmid
backbone was gel purified and ligated into the pGEM-5zf(+) vector.
E1B55k
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Figure 3.9: The pGEM-5zf(+) vector (Promega). The 6.5kb gel purified fragment
from pSCB-AdFL containing the left hand end of the adenovirus genome contained
Sal1 / Xho1 overhangs and was cloned into the Sal1 restriction site of pGEM-5zf(+).
Sal1 and Xho1 restriction sites have compatible overhangs.
Sal1 restriction site: G’TCGAG
CAGCT’G
Xho1 restriction site: C’TCGAG
GAGCT’C
Sal1/Xho1: G’TCGAG
CAGCT’G142
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version +/- K104R mutation. Hence the overlap PCR product was designed to
include the regions homologous to the regions either side of the wild type E1B55k,
including these unique restriction sites (see figure 3.10). The following plasmids
were used as templates during generation of the overlap PCR product;
TAP/E1B55k, TAP/E1B55k K104R, CFP/E1B55k, CFP/E1B55k K104R and
pGEM-5zf(+)+LHendAd5 (the Ad5 regions either side of the E1B55k gene were
amplified from this plasmid).
In the initial round of overlap PCR each of the three DNA regions that make up
the final product were amplified separately. These were the region downstream of
the E1B55k gene (product 1, using primers P1 and P2, or P1 and P3), the tagged
E1B55k gene plus or minus the K104R mutation (product 2, using primers P4 and
P6, or P5 and P6), and the region upstream of the E1B55k gene (product 3, using
primers P7 and P8). The primers used differed, depending on whether they were
used for the amplification of the CFP or the TAP tagged E1B55k genes. The PCR
products were purified by agarose gel electrophoresis to remove any
contaminating products, prior to being used in the second round of overlap PCR.
In the second round, products 1 and 2 were combined in equal quantities and
amplified using primers P1 and P6, to generate product 4. The DNA concentration
was assessed by agarose gel electrophoresis. Products 2 and 3 were also combined
in equal quantities and amplified using primers P4 and P8, or P5 and P8, to
generate product 5. Again both of the resulting PCR products were purified by
agarose gel electrophoresis prior to being used in the final round of overlap PCR.
In the final round of amplification products 4 and 5 were combined in equal
quantities and amplified using primers P1 and P8 (see figure 3.11).
Ad5 TAG-E1B55k Ad5
PCR1 PCR2 PCR3
Xba1
BsaB1
Primers
CGC TCTAGA GAATGCAATAGTAGTACGGATAGCTGTGAC5’ 3’ (P1)
CTCAAAATATTTCCTATT CGGTGG TAC CTGTGTTCACGGGTG TAP (P2)5’
3’ AAAATATTTCCTATTCGGTGG TAC CACTCGTTCCCGCTCCTC 5’ CFP (P3)
5’ GAGTTTTATAAAGGATAA GCCACC ATG GACACAAGTGCCCAC 3’ TAP (P4)
5’ GAGTTTTATAAAGGATAA GCCACC ATG GTGAGCAAGGGCGAG 3’ CFP (P5)
PCR2 3’TCGCTACTTCTATGTCTAACT CCATGACTTTACACACCCGCA 5’ (P6)
5’ AGCGATGAAGATACAGAT TGA GGTACTGAAATGTGTGGGCGT 3’ (P7)
PCR3 3’TTTTGGTCTGAGACAAACCTAAACCTAGTTCGTTCACAGA 5’ (P8)
Xba1
PCR1
BsaB1
3’
Figure 3.10: Primers used to generate the overlap PCR products. The primers used to replace E1B55k
with the tagged E1B55k gene plus or minus the K104R mutation, differed depending on whether they were
used to amplify the TAP/E1B55k genes or the CFP/E1B55k genes. Primers P1, P2, P4, P6, P7 and P8 were
used to generate the TAP tagged E1B55k overlap PCR products. Primers P1, P3, P5, P6, P7 and P8 were
used to generate the CFP tagged E1B55k overlap PCR products.
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Ad5 Ad5TAG-E1B55k +/-K104R
P1
P2/3
P4/5 P7
P6 P8
Product 1 Product 3Product 2
Xba1
BsaB1
Ad5 TAG-E1B55k +/-K104R
P1
P6
Xba1
Ad5TAG-E1B55k +/-K104R
P4/5
P8
BsaB1
Product 5Product 4
Ad5 Ad5TAG-E1B55k +/-K104R
P1
P8
Xba1
BsaB1
Stage 1.
Stage 2.
Stage 3.
Figure 3.11: The separate stages of overlap PCR. In Stage 1, each of the products were amplified separately
using appropriate primers, generating three separate products 1,2 and 3. In Stage 2, products 1 and 2 were
combined in equal quantities and amplified using primers P1 and P6 to generate product 3. Products 2 and 3
were combined in equal quantities and amplified using primers P4 or P5, and P8 to generate product 4. In
Stage 3 products 4 and 5 were combined in equal quantities and amplified using primers P1 and P8 to
generate the final product.
Final product
145
146
The final PCR product was purified by agarose gel electrophoresis, then
subsequently cleaved with restriction enzymes Xba1 and BsaB1, ready to be
cloned into the pGEM-5Zf(+)+LHendAd5 vector.
3.2.5 Replacing the E1B55k gene in pGEM-5zf(+) with the tagged version +/-
K104R mutation using Xba1 and BsaB1 restriction sites
Problems were encountered when cutting both overlap PCR products and vector
DNA with the restriction enzymes Xba1 and BsaB1. The Xba1 enzyme cleaved
normally, but when DNA was digested with the BsaB1 enzyme and loaded onto
the agarose gel, the DNA did not run into the gel upon application of the electrical
current, but remained in the well. Various different methods were tried in order to
solve this problem, including adding 0.25% SDS, treating the DNA with
Proteinase K, heat inactivating the enzyme, denaturing the enzyme and purifying
the DNA from the restriction digest using the Roche High Pure PCR product
purification kit, prior to running it on the agarose gel. This problem was eventually
resolved by setting up the restriction digests in 50L reaction volumes, thus
reducing the concentration of the DNA, and cutting for 30 minutes to 1 hour, as
opposed to 20L reaction volumes for 1-2 hours.
When the pGEM-5zf(+)+LHendAd5 vector was successfully cleaved with Xba1
and BsaB1, the fragment that released was 1.6kb, instead of the expected 2.7kb. In
order to determine if this was due to the BsaB1 enzyme affecting how the DNA
ran into the agarose gel, or if it was due to the presence of another BsaB1
restriction site within the pGEM5zf(+)+LHendAd5 plasmid, the entire fragment of
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DNA which had been cloned into the pGEM-5zf(+) vector was sequenced.
Fourteen different primers were used to sequence the entire 6587bp region (see
figure 3.12). The expected sequence was put together as a DNA Strider file. The
sequence data generated was then aligned with the expected sequence using the
BLAST sequence alignment programme. Three mutations were detected in the
entire sequence; at 85bp the sequence read tc instead of ct (no restriction sites
were introduced), at 795bp there was a c missing (this introduced an SfaN1 site),
at 5747bp there was a c instead of a g (no restriction sites were introduced). The
mutations at 85bp and 795bp were present in the bacmid backbone and not in the
adenovirus sequence. The third mutation lay outwith the E1B55k region (the Xba1
site lay at 2133bp, the BsaB1 site at 4855bp and the E1B55k gene was from 2814
to 4304bp). The restriction enzyme Xba1 has no isoschizomers, and the enzyme
BsaB1 has six (Bsc81, Bsh13651, BsiB1, BsrBR1, Mam1), and not SfaN1.
Therefore the restriction pattern generated by the pGEM-5zf(+) vector when
digested with Xba1 and BsaB1 could not be explained by the introduction of the
SfaN1 site.
Although the restriction pattern did not look correct, the sequence information did
not highlight any mutations, therefore the cloning was attempted. The overlap
PCR products digested with Xba1 and BsaB1, were ligated into the pGEM-5Zf(+)
vector digested with Xba1 and BsaB1. The ligation reaction was then dialysed,
prior to electroporation into DH10s. Resulting colonies were screened by
hybridisation using 32P labelled TAP PCR product (amplified using primers P19
and P21). The colonies resulting from cloning the CFP E1B55k genes could
I-Sce1
Xho1
E1B55k
Sal1
P1 P9 S2 S4 S3 P7
S1A P10A P8
S6S5 S8
M13F M13R
Left hand end of adenovirus genomebacmid
Figure 3.12: Different primers used to sequence the left hand end of the adenovirus genome.
This figure shows the approximate location of the primers that were used to sequence the fragment
of plasmid pSCB-AdFL that was cloned into the pGEM-5zf(+) vector, containing the left hand
region of the adenovirus type 5 genome.
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not be screened as primers had not yet been designed to amplify the CFP gene.
Two colonies that appeared positive by hybridisation (clone 32 and clone 134),
were analysed by DNA sequence analysis using primers P2, P4, P6 and P7.
Sequencing with primer P2 should generate sequence homologous to the region
downstream of E1B55k, primer P4 should generate TAP sequence, primer P6
should generate E1B55k sequence and the P7 primer should generate sequence
homologous to the region upstream of E1B55k. The results of the sequencing by
primers P4 and P6 were very unexpected, as sequence data generated by P4 was
not only TAP sequence, but also E1B55k sequence for clone 32, and E1B55k as
well as adenovirus type 5 sequence for clone 134 (see figure 3.13).
3.2.6 Replacing the E1B55k gene in pGEM-5zf(+)+LHendAd5 with the tagged
version +/- K104R mutation using homologous recombination
In order to rule out any possibilities that this could be due to the restriction
enzymes used, the cloning was attempted by homologous recombination. A unique
Kpn1 site present within the E1B55k gene in the pGEM-5zf(+)+LHendAd5
vector, was used to linearise the DNA. The linearised DNA was then co-
electroporated, with the overlap PCR product into recombinogenic BJ5183 cells.
Homologous recombination should occur between the overlapping regions of Ad5
DNA, upstream and downstream from the E1B55k, generating tagged E1B55k +/-
K104R mutation. Initial attempts at cloning proved unsuccessful. In order to
increase the cloning efficiency DNA concentrations were varied, and the
competency of the electrocompetent cells was checked and found to be sufficient
at ~1 x 108 cfu/µg. A control for the homologous
Ad5 TAP E1B55k Ad5
Xba1
BsaB1
P4
P2
P7
P6
Ad5 E1B55k Ad5
Xba1
BsaB1
pGem-5zf(+)
Clone 32 Clone 134
P2
P4 ? ?
P6 ?
P7
Results of sequencing
Figure 3.13: Sequence of clones generated from cloning the left hand end of Ad5 into pGEM-5zf(+) vector using Xba1 and
BsaB1 restriction sites. Sequencing results of two clones (32 and 134) resulting from the cloning of the TAP/E1B55k gene into
pGEM-5zf(+)+LhendAd5 using Xba1 and BsaB1 restriction sites. Sequencing with primer P4 should generate TAP sequence
only. Sequencing clone 32 with P4 has generated both TAP and E1B55k sequence. Sequencing clone 134 with P4 has
generated TAP, E1B55k And Ad5 sequence. Sequencing with primer P6 should only generate E1B55k sequence, whereas
clone134 sequenced with P6 has generated E1B55k and Ad5 sequence.
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recombination was also developed using the pFastBac vector (see figure 3.14). For
the control reaction the ampicillin gene was removed from the pFastBac vector
using NaeI and SacII restriction sites. This was then co-electroporated into BJ5183
cells along with the vector DNA, with the ampicillin gene removed using BspH1
restriction sites. Regions of homology between the NaeI and the BspH1 restriction
site, and the BspH1 and the SacII restriction site, were sufficient for homologous
recombination to occur, and the ampicillin gene to be cloned back into the vector.
During subsequent attempts at cloning, the control reaction generated recombinant
colonies, whereas the actual cloning resulted in no colonies.
3.2.7 Replacing the E1B55k gene in pGEM-5zf(+)+LHendAd5 with the tagged
versions using Xba1 and Kpn1 restriction sites
Although cloning using this method proved unsuccessful, it led to the realisation
that the Kpn1 site could be used for the generation of the CFP and TAP tagged
versions of pGEM-5zf(+)+LHendAd5, by digestion of both the overlap PCR
products and the vector DNA with restriction enzymes Xba1 and Kpn1. The Kpn1
restriction site lay just after the start of the E1B55k gene, prior to lysine 104.
Vector DNA and overlap PCR products were digested with Xba1 and Kpn1,
purified by agarose gel electrophoresis, ligated, dialysed and electroporated into
DH10s. Resulting colonies were screened using 32P labelled TAP or CFP PCR
products, generated using primers P19/P21 and P22/P23 respectively.
Positive colonies were verified by DNA sequence analysis.
pFastBac vector 4775bp
Am
p
BspH1
BspH1
Nae1
SacIIAreas of homology
BspH1-SacII 1224bp
Nae1-BspH1 407bp
Figure 3.14: Control used for homologous recombination. In order to generate a control reaction for
the overlap PCR product containing the tagged E1B55k gene, plus or minus the K104R mutation, and
plasmid pGEM-5zf(+)+LHendAd5 linearised with Kpn1, the ampicillin resistance gene was removed
from pFastBac using restriction enzymes Nae1 and SacII. This was then co-electroporated into
recombinogenic BJ5183 cells along with pFastBac vector digested with BspH1 and gel purified.
Homologous recombination would result in formation of the complete plasmid, which could be
selected for on ampicillin plates.
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3.2.8 Replacing the E1B55k gene in pGEM-5zf(+)+LHend Ad5 with the tagged
versions containing the K104R mutation, using Xba1 and Mun1 restriction sites
Possible ways of generating the CFP/E1B55k K104R and TAP/E1B55k K104R
plasmids were explored by analysing the restriction map of vector pGEM-
5zf(+)+LHendAd5. Fortunately, a unique Mun1 restriction site located at 3942bp
within the Ad5 region (with the E1B55k gene lying between base pairs 2019 and
3509, and the BsaB1 site at 4061bp. This unique restriction site would not have
been present, had the original fragment been cloned, from the I-Sce1 site to the
Sal1 site. The presence of this unique Mun1 site meant that the original overlap
PCR products could still be used to generate the last two constructs, but they and
the vector DNA would be digested with Xba1 and Mun1, rather than Xba1 and
BsaB1. After restriction digest, products were purified by agarose gel
electrophoresis, ligated, dialysed and electroporated into DH10s. Colonies were
screened by hybridisation using 32P labelled TAP or CFP PCR products. The
TAP/E1B55k K104R construct was successfully generated using this cloning
strategy, and verified by DNA sequence analysis. The CFP/E1B55k K104R
construct was also generated but sequence analysis indicated the presence of a
mutation within the E1B55k gene, which affected an amino acid, changing a
tyrosine (tac) to a histidine (cac). The overlap PCR product was regenerated from
the beginning and the cloning repeated but the mutation was still present in
colonies screened.
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3.2.9 Generation of the CFP/E1B55k K104R construct using E1B55k K104R from
TAP/E1B55k K104R, and cloning into CFP/E1B55k using Kpn1 and Mun1
restriction sites
In order to generate the CFP/E1B55k K104R construct, it was decided to remove
the E1B55k K104R gene from TAP/E1B55k K104R construct, using Kpn1 and
Mun1 restriction sites, and clone it into the CFP/E1B55k construct, also cut with
Kpn1 and Mun1. Restriction digest of the CFP/E1B55k construct revealed a
problem, as the product released should have been 1.8kb, but was approximately
3kb. All of the other constructs generated so far were then screened by restriction
digest with Kpn1 and Mun1. pGEM-5zf(+)+LHendAd5 generated a 3kb fragment
as did the TAP-E1B55k construct, whereas the TAP/E1B55k K104R construct
generated a product of the correct size (1.8kb). These results indicated that the
problem had arisen when the LHend of Ad5 had originally been cloned into the
pGEM-5zf(+) vector. As the entire insert had been sequenced, all 6587bp, this
sequence was rechecked by eye, rather than using the BLAST sequence alignment
programme. It was discovered that the sequence data generated from one of the
primers aligned perfectly with the E1B55k gene, and then this alignment ended
abruptly. The remaining half of this sequence data was good quality data, but it did
not align with the E1B55k gene, or any other part of the expected sequence. This
sequence was then searched against the BLAST database and was found to be
homologous to Insertion Sequences and Transposons, one of which was the E. coli
K12 transposon. Sequencing of the other constructs, which also dropped out a 3kb
fragment upon digestion with Kpn1 and Mun1, confirmed the presence of a
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transposon. The exact location of the transposon in the constructs was mapped by
restriction digest and DNA sequence analysis.
3.2.10 Remaking the TAP/E1B55k and CFP/E1B55k, pGEM-5zf(+) constructs
The TAP/E1B55k and CFP/E1B55k constructs were remade. The overlap PCR
products were regenerated from the beginning and used to replace the E1B55k
gene in the pGEM-5zf(+)+LHendAd5 vector using Xba1 and Mun1 restriction
sites. As the transposons were present within the E1B55k gene of the original
constructs, digestion with Xba1 and Mun1 ensured removal of the transposon.
3.2.11 Generation of the CFP/E1B55k K104R construct using E1B55k K104R
from TAP/E1B55k K104R, and cloning into CFP/E1B55k using Kpn1 and Mun1
restriction sites
Three of the four constructs were now generated, TAP/E1B55k, CFP/E1B55k and
TAP/E1B55k K104R. As stated previously, when trying to generate the
CFP/E1B55k K104R construct, using the overlap PCR product, a mutation was
detected within the E1B55k gene, changing a tyrosine (tac) to a histidine (cac).
This mutation occurred even when the PCR product was made from the beginning.
Therefore, generation of the CFP/E1B55k K104R construct was achieved by
removing the E1B55k K104R gene from the TAP/E1B55k K104R construct, using
Kpn1 and Mun1 restriction enzymes and cloning it into the CFP/E1B55k vector
also cleaved with Kpn1 and Mun1. Colonies were screened by hybridisation using
32P labelled E1B55k PCR product. Positive colonies were checked by restriction
digest and DNA sequence analysis. Sequence analysis highlighted the presence of
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a mutation with the E1B55k gene of the CFP/E1B55k K104R construct, where an
amino acid was changed from an arginine (cgg) to a leucine (ctg). The
TAP/E1B55k K104R construct was also checked and found to contain the same
mutation, which had been missed when the construct was checked by sequence
analysis previously.
3.2.12 Removal of the mutations from the CFP/E1B55k K104R and TAP/E1B55k
K104R constructs, using the E1B55k K104R from the original CFP/E1B55k
K104R pECFP-C1 construct
In order to remove the mutation from both constructs it was decided to cut the
E1B55k K104R gene from the original CFP/E1B55k K104R pECFP-C1 construct,
which was generated by Tony Vaughan. Restriction sites Kpn1 and HindIII were
used to replace the mutated E1B55k K104R in the TAP construct, and HindIII to
replace the E1B55k K104R in the CFP construct. The CFP construct required
HindIII only, due to the presence of a HindIII restriction site, just upstream from
the EcoR1 site and BamH1 site in the pECFP-C1 vector into which the E1B55k
genes had been cloned.
This cloning strategy was successful and colonies that were positive by
hybridization were verified by restriction digest and DNA sequence analysis.
Unfortunately, sequence analysis indicated that both of the constructs generated
had a mutation in the E1B55k gene, where an amino acid was changed from a
tyrosine (tac) to a histidine (cac). This was the exact same mutation as that
detected when trying to make the construct using the overlap PCR product,
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explained by the fact that this original construct was used as a template to make
the overlap PCR product.
3.2.13 Removal of the mutation in the original CFP/E1B55k K104R pECFP-C1
construct
The original CFP/E1B55k K104R pECFP-C1 construct generated by Tony
Vaughan was sequenced again and the raw sequence data checked by eye. At the
point of the mutation two peaks were visible, one for a thymidine and the other a
cytosine, indicating a mixed population of DNA. Other than this one point
mutation the rest of the sequence was exactly as it should have been, and the
sequence data generated was good quality.
The original CFP/E1B55k K104R pECFP-C1 DNA was transformed into DH5.
The resulting colonies were screened by DNA sequence analysis using primer P9.
Approximately 20 colonies were screened and all but one had the tyrosine to
histidine mutation. The colony not containing the mutation was picked and grown
in L-broth containing kanamycin and DNA was extracted using the Qiagen
maxiprep kit.
This DNA was then used to generate the CFP/E1B55k K104R and the
TAP/E1B55k K104R constructs. The original constructs containing the tyrosine to
histidine mutation were digested with Kpn1 and Mun1 and the E1B55k K104R
gene replaced, with the non-mutated version. These constructs were then
sequenced with primer P9 to verify that the tyrosine to histidine mutation was not
present and that amino acid 104 was an arginine. This was confirmed and these
constructs were then used to generate the recombinant viruses.
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3.2.14 Making the pSCB-AdFL-5’ITR construct
When designing the overlap PCR primers to knock out the 5’ ITR using an
antibiotic resistance gene, the sequence data was not yet available for plasmid
pSCB-AdFL. As the Ad5 sequence is available online, it was only necessary to
sequence the bacmid backbone region upstream of the 5’ ITR. The initial primer
designed to sequence this region (S1) gave poor sequence data, which was due to
it binding to the ITR. A second primer (S1A) was designed to bind further back
from the ITR, and produced good quality sequence data.
3.2.15 Initial strategy for generating the pSCB-AdFL-5’ITR construct using the
kanamycin resistance gene
The initial strategy for knocking out the 5’ ITR of pSCB-AdFL involved using the
Kanamycin resistance gene from plasmid pET30a+ (Novagen). The overlap PCR
products were generated using plasmids pET30a+ and pSCB-AdFL as templates.
Each of the three separate parts of the overlap PCR product were initially
amplified separately. Primers P14 and P15 were used to amplify the bacmid
backbone region, generating product 1. Primers P16 and P17 were used to amplify
the Kanamycin resistance gene, generating product 2. Primers P18 and P8 were
used to amplify the Ad5 region downstream of the wild type E1B55k gene,
generating product 3. Products were then purified by agarose gel electrophoresis
prior to commencing with the second round of amplification. Here products 1 and
2 were combined in equal quantities, and amplified using primers P14 and P17,
generating product 4. Products 2 and 3 were also combined in equal quantities and
amplified using primers P16 and P8, generating product 5. Products 4 and 5 were
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then purified by agarose gel electrophoresis, combined in equal quantities, and
amplified using primers P14 and P8. The final PCR product was purified by
agarose gel electrophoresis and co-transformed into recombinogenic BJ5183 cells,
along with plasmid pSCB-AdFL, and plated onto Kanamycin plates incubated at
37C overnight. All of the colonies isolated were analysed by DNA sequence
analysis and were found to contain no adenoviral DNA. It was discovered that
there was a neomycin resistance gene present within the bacmid backbone.
Homologous recombination between the ITR’s was likely to have caused
circularisation of the bacmid backbone, resulting in the adenovirus DNA being
excised. Therefore in order to carry out the cloning successfully it would be
necessary to use a different antibiotic resistance gene.
3.2.16 Strategy for generating the pSCB-AdFL-5’ITR construct using the
chloramphenicol resistance gene
It was decided to use the chloramphenicol resistance gene from plasmid
pACYC184 (New England Biolabs). Primers P15, P16, P17 and P18 had to be
redesigned to amplify the Chloramphenicol resistance gene, rather than the
Kanamycin resistance gene, these primers were named P15a, P16a, P17a and P18a
respectively. Overlap PCR was carried out as previously, this time using plasmids
pACYC184 and pSCB-AdFL as templates. The overlap PCR product was co-
transformed into transformation competent, recombinogenic BJ5183 cells, along
with plasmid pSCB-AdFL, and plated onto chloramphenicol plates to allow
selection for positive colonies. This method proved unsuccessful, therefore
electroporation was tried using electro-competent BJ5183 cells, in order to
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increase the efficiency of DNA penetration (electroporation is several times more
efficient than transformation). In order to increase the efficiency of homologous
recombination, it was decided to linearise the pSCB-AdFL DNA. As there were no
unique restriction sites present that would allow linearization of the DNA within
the correct region, the DNA was partially digested with restriction enzyme I-Sce1,
of which there were two sites within the plasmid. Partial digestion of the DNA was
found to be optimal using a 1 in 10 dilution of enzyme and with DNA being
digested for 10-15 seconds. When partially digested pSCB-AdFL (in ng quantities)
was co-electroporated with the overlap PCR product (in g quantities) into
electrocompetent BJ5183 cells, plated onto chloramphenicol plates and grown at
30C overnight, 1 colony was generated. The colony was also confirmed to be
ampicillin resistant, by plating onto ampicillin plate and incubating at 30C
overnight. A colony was picked from the ampicillin plate and grown in L-broth
containing chloramphenicol for 2 to 3 hours at 30C. DNA was extracted using
alkaline lysis DNA extraction, transformed into DH5, plated onto an ampicillin
plate and incubated at 30C overnight. The aim of this was to get the DNA out of
the recombinogenic bacteria and into stable bacteria, before any mutations could
occur. A colony was then picked from this plate and grown up in L-broth
containing chloramphenicol overnight at 30C. DNA was extracted using the
alkaline lysis method. The construct was then analysed by restriction digest and
sequence analysis and was found to be correct, pSCB-AdFL-5’ITR.
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3.2.17 Generating the recombinant viruses
Generation of the recombinant viruses was achieved by co-transfection of the
pGEM-5zf(+) construct expressing TAP/E1B55k, CFP/E1B55k, TAP/E1B55k
K104R or CFP/E1B55k K104R, along with plasmid pSCB-AdFL-5’ITR. Both
constructs were linearised with Sal1 prior to transfection into HeLa cells.
Homologous recombination occurring between both plasmids, resulted in the
generation of full length recombinant adenovirus type 5, which was evident by the
appearance of plaques approximately 10 days post-infection.
3.2.18 Screening of recombinant viruses by DNA sequencing and Western blot
analysis
When the recombinant viruses expressing TAP/E1B55k and CFP/E1B55k were
made, they were only sequenced across the junctions between the tag and the
E1B55k gene, using primers P2 and P4, or P3 and P5 respectively. Only this
region was sequenced, as the DNA constructs that had been used to generate the
viruses had been sequenced comprehensively, with the TAP/E1B55k construct
having been sequenced with primers P1, P2, P4, P9, P10A and P7, and the
CFP/E1B55k construct sequenced with primers P1, P3, P5, P9, P10A and P7. No
mutations were found in either of the constructs.
In Western blot analysis of these recombinant viruses, the tagged E1B55k fusion
protein appeared to be truncated. The tagged E1B55k protein, when expressed
should be approximately 76kDa. But when cells that were infected with
recombinant virus expressing TAP/E1B55k were lysed and analysed by Western
blot analysis using a monoclonal antibody to E1B55k, there were two products of
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approximately 32kDa and 25kDa. When cells that are infected with recombinant
adenovirus expressing CFP/E1B55k were lysed and analysed by Western blot
analysis using the same monoclonal, there were two products of approximately
45kDa and 32.5kDa (see figure 3.15).
When the TAP/E1B55k K104R and CFP/E1B55k K104R viruses were made, they
were sequenced with primers P4, P9 and P10A, or P5, P9 and P10A respectively.
Again this was due to the fact that the constructs that had been used to generate the
viruses had been sequenced comprehensively. Sequencing of both viruses with
these primers gave good quality sequence data and no mutations appeared to be
present.
In Western blot analysis of these recombinant viruses however, the tagged E1B55k
K104R fusion protein appeared to be truncated. The tagged E1B55k K014R
protein, when expressed should be approximately 76kDa. But when cells that were
infected with recombinant virus expressing TAP/E1B55k K104R were lysed and
analysed by Western blot using a monoclonal antibody to E1B55k, there were two
products of approximately 32kDa and 25kDa. When cells that were infected with
recombinant adenovirus expressing CFP/E1B55k K104R were lysed and analysed
by Western blot using the same monoclonal, there were two products of
approximately 45kDa and 32.5kDa.
3.2.19 Plaque purification of the recombinant viruses and generation of stocks
Although by Western blot analysis, the tagged E1B55k gene appeared truncated in
all of the recombinant viruses, sequencing analysis indicated that there were no
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Figure 3.15: Western blots of recombinant
adenoviruses generated. The first round plaque
purifications of the recombinant adenoviruses
were probed with E1B55k monoclonal antibody.
Figure A shows CFP-E1B55k K104R
recombinant adenovirus, expressing products of
approximately 40 and 32.5kDa. Figure B shows a
TAP-E1B55k K104R recombinant adenovirus,
expressing products of approximately 32.5 and
25kDa. The tagged E1B55k proteins should
be approximately 76kDa in size.163
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mutations present. Therefore viruses were plaque purified 3 times by end point
dilution. Stocks of recombinant virus were grown up initially in 20x150cm2 flasks
of HeLa cells, which was then scaled up to 5L cultures of HeLa spinner cells.
Virus was then purified by arcton extraction and caesium chloride purification. All
virus stocks were stored at -80C.
3.2.20 Analysis of recombinant viruses following plaque purification
After plaque purification, the recombinant viruses were again analysed by Western
blot analysis, and again the products appeared truncated, as previously shown. In
order to confirm that no mutations had been introduced, the sequencing that had
been performed previously was reanalysed, and further sequencing was carried
out.
On closer inspection, the sequencing of both recombinant E1B55k K104R viruses
with primer P9, revealed the presence of a mutation within the E1B55k K104R
gene. This sequence was towards the end of the sequence data generated with
primer P9, where the quality of the sequence data had degenerated. An extra
guanine had been introduced within the sequence, which resulted in the remainder
of the E1B55k gene being thrown out of frame, and the introduction of a stop
codon further downstream, within the E1B55k gene. Sequence analysis carried out
using primers S2 and S4, which sequence within the E1B55k gene, confirmed the
presence of this mutation.
The truncated products shown by Western blot analysis could be explained by the
introduction of the stop codon, within the E1B55k K104R gene, of both
recombinant viruses.
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In order to try to determine the source of this mutation, the sequence data of the
constructs used to generate these viruses was reanalysed.
The E1B55k K104R gene from the CFP/E1B55k K104R pECFP-C1 construct had
been used to generate the TAP/E1B55k K104R and CFP E1B55k K104R
constructs, which had subsequently been used to generate the recombinant viruses.
This construct, kindly supplied by Dr Tony Vaughan, had been sequenced
comprehensively prior to use, using primers P1, P3, P5, P9, P10A and P7, and was
found to be completely mutation free, with one exception. Analysis of the raw
sequence data had indicated that at one specific base pair within the sequence of
the E1B55k gene, two separate peaks identical in height were present. One peak
represented cytosine and the other thymidine, which seemed to indicate a mixed
population of DNA. When this construct had been used to generate the overlap
PCR product, the final PCR product was found to contain a mutation. At this
specific base pair, only one peak was present for cytosine, which resulted in this
base and the following two bases encoding the amino acid histidine (cac) instead
of tyrosine (tac). In order to eliminate this problem, which seemed to be due to a
mixed population of DNA, the DNA was retransformed into E. coli and individual
colonies were screened by sequence analysis. A colony was selected which only
had one peak at this specific base pair, which was a thymidine. The E1B55k
K104R gene from this construct was then used to generate the TAP/E1B55k
K104R and CFP/E1B55k K104R constructs that were used to make the
recombinant viruses. When this colony was picked and analysed by sequence
analysis, only the first part of the E1B55k gene was sequenced. This was due to
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the fact that the entire 2.1kb had been sequenced previously and appeared to be
exactly as it should have been.
In order to determine if this construct had been the source of the mutation, the
remainder of the E1B55k gene was sequenced using primers to provide
comprehensive coverage. The results confirmed that this construct had been the
source of the mutation present in the recombinant viruses, as an extra guanine was
found at exactly the same location as in the recombinant viruses.
Reanalysis of the sequence data for the TAP/E1B55k and CFP/E1B55k
recombinant viruses has failed to indicate any mutations which could be causing
truncated expression of the E1B55k gene. Further sequence analysis of the plaque
purified viruses also failed to reveal any mutations. This discrepancy between the
sequence data and the Western blot result may be explained by further sequence
analysis of viral DNA extracted from the recombinant viruses. It is possible that a
mutation may have been introduced during the homologous recombination, which
has not yet been detected.
3.3 Discussion
The aim of generating these recombinant viruses was to be able to study the
localisation of the E1B55k protein, and to identify which viral and cellular
proteins interact with the E1B55k protein, during adenovirus infection, and to
determine the effect of SUMOylation.
Different cell types would be infected with the recombinant viruses expressing the
CFP tagged E1B55k protein and live imaging carried out using the Delta Vision
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microscope. This would have allowed the localisation of the E1B55k protein to be
determined at specific time points during infection. As two different versions of
the recombinant virus were generated, one in which the E1B55k protein could be
modified by SUMO (E1B55k), and one which could not (E1B55k K104R), this
would allow the effect of SUMOylation on localisation to be determined.
By generating the recombinant viruses expressing the TAP tagged E1B55k (+/-
K104R) protein, cell lines infected with the recombinant viruses could be
harvested at set time points, and tandem affinity purification would identify the
cellular proteins and viral proteins that interacted with E1B55k at these set times
during infection. Comparison of the results from the recombinant viruses
expressing E1B55k and E1B55k K104R, would provide information as to whether
SUMOylation alters the proteins that interact with E1B55k.
When undertaking such studies it was essential that no mutations were present
within the E1B55k gene, as any mutations could influence the results.
Unfortunately the discovery of several mutations during the making of these
recombinant viruses has hindered progress dramatically, therefore no data has yet
been generated using these viruses.
Although the recombinant viruses expressing TAP/E1B55k and CFP/E1B55k have
been made and plaque purified 3 times, Western blot analysis of cells infected with
the recombinant viruses, show the tagged E1B55k protein to be truncated. DNA
sequence analysis however, has not indicated the presence of any mutations that
could be causing this, although further sequence analysis has to be undertaken in
order to confirm this.
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The recombinant viruses expressing TAP/E1B55k K104R and CFP/E1B55k
K104R have also been generated and plaque purified 3 times. DNA sequence
analysis of these viruses however, has demonstrated the presence of a mutation
resulting in the introduction of a stop codon within the E1B55k gene. Western blot
analysis of cells infected with these viruses, show the tagged E1B55k gene to be
truncated, which can be explained by the introduction of the stop codon. However,
a comprehensive strategy has been developed for the generation of these
recombinant viruses and many technical issues have been resolved. Therefore
provided a source of the E1B55k K104R gene can be found which is mutation
free, remaking the recombinant viruses should be straightforward.
One of the major technical problems encountered, was the insertion of a
transposon into several of the constructs. Attempts to locate the source of the
transposon by DNA sequence analysis proved unsuccessful, as transposons have
very high sequence homology. It was suspected that the source of the problem may
have been the competent cells, therefore all competent cell were discarded and
fresh stocks made.
The mutation present within the CFP/E1B55k K104R pECFP-C1 construct was
unfortunately not discovered at an earlier stage. When the mutation was
discovered, DNA sequence analysis of the E1B55k gene indicated a mixed
population of DNA, due to the fact that two peaks were present at one specific
base pair (one for cytosine and one for thymidine). When the DNA sample was
transformed and colonies were screened by DNA sequence analysis, a colony
chosen that only had the one peak corresponding to thymidine. It was assumed that
the remainder of the E1B55k sequence was as it should be, as when the
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CFP/E1B55k K104R pECFP-C1 construct had been sequenced originally, no other
mutations had been detected. This assumption led to the generation of recombinant
viruses containing a mutation within the E1B55k gene.
The source of the mutation within the TAP/E1B55k K104R construct is unknown,
although it may have arisen during PCR amplification, as no mutations were
detected in the original pCMV5-TAP/E1B55k K104R construct generated.
In conclusion it is very important to be diligent when analysing sequence data,
especially when sequencing such large DNA fragments, as it is very easy to
overlook mutations that are present.
170
4. TANDEM AFFINITY PURIFICATION OF TAP/SUMO2 CELL LINES
INFECTED WITH ADENOVIRUS TYPE 5
4.1 Introduction
4.1.1 Introduction
A stable HeLa cell line expressing Tandem Affinity Purification (TAP) tagged
SUMO-2 protein was generated by Dr Akihiro Nakamura, a former member of the
group. The stable cell line was generated in order to identify cellular proteins that
are modified by SUMO-2 protein. Proteins, upon modification by SUMO, become
covalently attached to the SUMO protein. To ensure that only proteins modified
by SUMO were purified during the tandem affinity purification procedure, the
TAP procedure was modified by Dr Akihiro Nakamura, to include a harsh cell
lysis (see materials and methods). This would disrupt any unspecific interactions
with the SUMO-2 protein, allowing only proteins that are true substrates of
SUMO-2 to be identified.
The aim was to carry out tandem affinity purification of the TAP/SUMO-2 cells,
infected with wild type adenovirus 5, and compare the results generated from
tandem affinity purification carried out in uninfected cells. By comparing the two
sets of data it would be possible to determine if infection of cells with adenovirus
type 5 affected the SUMOylation of cellular proteins by SUMO-2 protein.
Stable HeLa cell lines expressing the TAP tag alone, were also generated by Dr
Akihiro Nakamura, as a negative control. Tandem affinity purification was also
carried out with this cell line.
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4.1.2 Generation of TAP/SUMO-2 stable cell lines
As stated previously, the TAP/SUMO-2 HeLa cells were generated by Dr Akihiro
Nakamura. The SUMO-2 gene was amplified by PCR, using primers designed
with the appropriate restriction sites, to allow cloning into the MCS of the
pCMV5/TAP vector, and generation pCMV5 TAP/SUMO-2. TAP/SUMO-2 was
then amplified by PCR, using primers designed with appropriate restriction sites,
to allow cloning into the MCS of the pEFIRES-P construct (Hobbs et al, 1998).
The pEFIRES-P construct contains a puromycin resistance gene, allowing for the
selection of cells which are expressing the construct, by growing in medium
containing puromycin.
The pEFIRES-P construct, expressing the TAP/SUMO-2 fusion protein, was
transfected into HeLa cells using FuGENE 6 transfection reagent (Roche). Cells
expressing the construct were selected for using puromycin in the cell media.
Puromycin resistant colonies of cells were then selected and expanded. Expression
of TAP/SUMO2 from selected cell colonies was confirmed by Western blot
analysis. A clone that was expressing TAP/SUMO2 at consistent levels was used
to generate the stable cell lines. The cells were grown up in media containing
puromycin, and stocks frozen down in liquid nitrogen.
4.1.3 Generation of the TAP stable cell lines
As discussed above, the TAP tag stable cell lines were generated by Dr Akihiro
Nakamura. The TAP gene was amplified from the pCMV5/TAP vector using
primers designed to have appropriate restriction sites to allow cloning into the
MCS of the pEFIRES-P vector. The pEFIRES-P construct, expressing the TAP
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protein was then transfected into HeLa cells using FuGENE 6 transfection reagent
(Roche). Cells expressing the construct were selected for by the presence of
puromycin in the cell media and resistant cell colonies were then selected and
expanded. Expression of the TAP protein was confirmed by Western blot analysis
and a clone that was expressing TAP at consistent levels was used to generate the
stable cell lines. Cells were grown up in media containing puromycin, and stocks
frozen down in liquid nitrogen (see section 2.2.2 for method).
4.1.4 Amplification of adenovirus type 5
One vial, containing 1mL of wild type Ad5, produced by John Nicholson in the
laboratory, and dated 18/6/02, was used to inoculate 2x5L cultures of 293 spinners
at approximately 80% confluency. After 4 days, each of the 5L cultures was split
equally into 2x5L cultures as the media was becoming acidic, generating 20L of
cells in total.
Six days from the day of inoculation, all cells showed signs of viral infection and
were harvested by arcton extraction and caesium chloride purification. The virus
was titrated, in triplicate, using end point dilution. The titre of the purified virus
was 2x1011pfu/mL, but the total volume was only 900L, much less than would
have been expected. The virus was aliquoted and stored at -80C.
In order to generate more virus, 4x100L aliquots of this stock, were used to
inoculate 2x5L cultures of 293 spinners. After 3 days the cells were split equally
into 3x5L cultures, as the media was becoming acidic. Four days post inoculation,
all 15L were harvested by arcton extraction and caesium chloride purification. The
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virus was then titrated, in triplicate, using end point dilution, and found to be
2.3x1012 pfu/mL. The virus was aliquoted and stored at -80C.
4.1.5 Experiments undertaken
For the experiments undertaken using the stable cell lines, one vial of cells was
recovered from liquid nitrogen in a 25cm2 flask, which was then scaled up to
1x75cm2 flask, to 12x75cm2 flasks, and finally to 120 petri dishes (150mm
diameter). Cells were grown in Dulbecco’s Modified Eagles Medium (DMEM)
supplemented with 10% FCS, 2mM glutamine and puromycin (2g/mL). From the
initial vial that was resuscitated, 10 vials of cells were frozen down so as not to
deplete stocks. Upon completion of each separate experiment, remaining cells
were thrown away and a fresh vial used for any new experiments undertaken. This
was to prevent the expression levels of the protein from dropping, by passaging the
cells too many times.
Four separate TAP experiments were undertaken, once conditions had been
optimised and the experimental procedures were shown to be working. For each
separate experiment 120 petri dishes (150mm diameter) of cells were used.
1. Uninfected TAP/SUMO-2 cells
2. TAP/SUMO-2 cells infected with Ad5 at a M.O.I of 10 for 20 hours
3. TAP/SUMO-2 cells infected with Ad5 at a M.O.I of 10 for 24 hours
4. TAP cells, uninfected as a negative control
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4.1.6 Tandem Affinity Purification procedure
For each of the experiments undertaken, all 120 petri dishes (150mm diameter)
were harvested when 100% confluent, by scraping the cells directly into the lysis
buffer. The cell extracts (approximately 120mL) were then stored at -80C until
they were subjected to Tandem Affinity Purification.
The cells were then thawed in a water bath at room temperature, place on ice, then
sonicated in order to shear the genomic DNA. Any cell debris was pelleted by
centrifugation, to allow the sample to pass through the affinity columns more
easily. The sample was then split evenly between 2x1L solutions of renaturation
buffer, and passed through the first affinity purification column, using gravity
flow.
The TAP tag consists of two IgG binding domains of Staphylococcus aureus
protein A, and a calmodulin binding peptide separated by a TEV protease cleavage
site.
The first affinity column contains IgG sepharose, to which the protein A of the
TAP tag binds. Any contaminating proteins are eluted when the column is washed
through with renaturation solution. The protein of interest and any interacting
proteins, are then cleaved from the IgG sepharose using TEV protease. The
cleaved proteins are eluted from the IgG sepharose into calmodulin binding buffer
(containing calcium), to which calmodulin beads are added. The calmodulin
binding peptide of the TAP tag binds to the calmodulin beads, with the calcium
acting as a co-factor. Any contaminating proteins are eluted when the column is
washed through with calmodulin binding buffer. The protein of interest and any
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interacting proteins are then eluted in calmodulin elution buffer, containing EGTA,
which acts by chelating the calcium (see figure 1.3).
After elution the proteins are concentrated into a smaller volume, to allow the
sample to be loaded into one lane of an SDS-PAGE gel, this is done by TCA
precipitation. Once the proteins have been separated according to molecular
weight, by SDS-PAGE, the proteins are visualised by Coomassie staining of the
gel. Protein bands are then excised from the gel and are subjected to in-gel
digestion followed by analysis by LC-ESI-MS/MS.
Each gel slice that was analysed by LC-ESI-MS/MS produced its own set of data.
Where possible, all of these data were combined to include all the gel slices from
the entire lane of the gel, and then searched against the MSDB database using the
Mascot search engine. This was done in order to obtain an overall list,
encompassing all proteins identified during the experiment. In some cases though,
the data sets were too large. In these cases the data was split into two or three
different sets, and then searched against the Mascot database.
4.2 Results
The Mascot programme generates a list of predicted protein hits. Each protein is
allocated an overall score, which is based on the number of peptides that matched
the protein and how many MS/MS fragment ions are matched for each peptide,
with the most probable hits having the highest overall scores, and proteins that are
questionable as being true hits having the lowest scores.
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4.2.1 TAP cell line
The purpose of carrying out the Tandem Affinity Purification, using TAP stable
HeLas, was as a means of identifying false positives. These are proteins that
interact with the TAP tag only, and not the SUMO2 protein. The list of proteins
resulting from this experiment was subtracted from the list of proteins generated in
subsequent experiments. The Coomassie stained SDS-PAGE gel on which the
TCA precipitated eluates from the TAP procedure were run can be seen in figure
4.1. The list of proteins generated from this experiment can be seen in appendix
(7.2). The proteins that have been identified in this experiment may interact
directly with part of the TAP tag, or else they may be particularly “sticky”
proteins, present in abundance, that have not been separated from the TAP tag
during the washing stages.
4.2.2 TAP-SUMO2 cell line uninfected
After TCA precipitation of the TAP eluates, the sample was resuspended in SDS
boiling mix and boiled prior to running on the gel. When the sample had been
loaded there still seemed to be material present in the bottom of the eppendorf
tube. Therefore more SDS boiling mix was added, and the sample boiled and
loaded onto the next lane of the SDS-PAGE gel (see figure 4.2). As it is very
costly to have whole lanes analysed by LC-ESI-MS/MS, all of the first lane, and
only part of the second lane containing sample was analysed. In the second lane
most of the proteins evident by Coomassie staining were above the 47.5KDa
molecular weight, and below this very little protein was visible except for the
SUMO2 protein, which was also very abundant in the first lane. Hence only the
Figure 4.1: SDS-PAGE gel showing eluates from Tandem affinity purification experiment using
TAP stable cell lines.120 petri dishes (150mm diameter) of TAP-HeLa cells were grown to 100%
confluency, lysed and subjected to Tandem Affinity Purification. Protein eluates were then
TCA precipitated, resuspended in SDS boiling mix and run on a 10% SDS-PAGE
gel (Coomassie stained) The lane containing the sample (3) was excised from the gel
into 10 separate chunks and subjected to LC-ESI-MS/MS.
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Figure 4.2: SDS-PAGE gel showing eluates from Tandem affinity purification of TAP-SUMO2 stable
cell lines. A TAP pulldown was carried out using cell extracts from 120 petri dishes (150mm diameter)
of TAP-SUMO2 cells. Eluates were TCA precipitated, resuspended in SDS boiling mix and run
on a 10% SDS-PAGE gel, which was Coomassie stained. The bands indicated by brackets were
excised and proteins identified by LC-ESI-MS/MS.
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proteins above the 47.5KDa marker were excised.
This experiment generated a large amount of data, and subsequently the data
generated could not be combined into one file for searching against the MSDB
database. Instead the data sets were split into three compromising of the top,
middle and bottom regions of the SDS-PAGE gel. Data set one consisted of gel
slices 1,3,7 and 14; data set two consisted of gel slices 2,4,5,6,8 and 15; data set
three consisted of gel slices 10, 11, 12 and 13. The data generated from the TAP
HeLa stable cell lines was subtracted from all three sets of data. See Appendix
(7.3). The data generated consisted of 1566 proteins, after subtraction of the TAP
HeLa data.
4.2.3 TAP-SUMO2 cell line infected with Ad5 at a M.O.I of 10 for 20 hours
The TAP-SUMO2 cells were infected with a M.O.I of 10 to ensure that all of the
cells would come into contact with virus and become infected simultaneously. The
time point of 20 hours post infection was chosen as the early viral genes would be
expressed, but the late viral genes would not. The aim of the experiment was to
determine the effect of the expression of the early viral genes on SUMOylation of
cellular proteins. After TCA precipitation of the TAP eluates, the sample was
resuspended in SDS boiling mix and boiled prior to running on the gel. When the
sample had been loaded there still seemed to be material present in the bottom of
the eppendorf tube. Therefore more SDS boiling mix was added, and the sample
boiled and loaded onto the next lane of the SDS-PAGE gel (see figure 4.3). Only
the first lane containing the sample was excised and analysed by LC-ESI-MS/MS
as bands seemed in equal proportions to those in the second lane, and protein
Figure 4.3: SDS-PAGE gel showing
eluates from Tandem affinity
purification of TAP-SUMO2 cells
infected with Ad5 at an M.O.I of 10 for
20 hours. 120 petri dishes (150mm
diameter) of TAP-SUMO 2 cells
were grownto 80% confluency and
infected with wild type Ad5 at a
M.O.I. of 10, for 20 hours.
Cells extracts were then
Tandem affinity purified and
eluates TCA precipitated,
resuspended in SDS boiling
mix and run on a 10%
SDS-PAGE gel which was
coomassie stained. Bands
indicated were excised from the
gel and the proteins identified using
LC-ESI-MS/MS.
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levels appeared to be abundant enough to be identified by mass spectrometric
analysis. As this experiment generated less data than anticipated, as a result all of
the gel slices could be combined and searched against the Mascot database. After
subtraction of TAP HeLa data, the data set consisted of only 255 proteins (data not
shown).
One of the proteins identified however, was the Lamina Associated Polypeptide 2
isoforms beta (lap2) and gamma (lap2) protein with an overall score of 92.
Isoforms beta and gamma had also previously been identified in the experiment
using the uninfected TAP-SUMO2 stable cell lines, in data set two, with an overall
score of 189. There are three different isoforms of lamina associated polypeptide,
,  and , which have identical N-termini, sharing their first 189 amino acids.
Peptides that were identified included peptides that were present in all three
isoforms, as well as peptides that were unique to lap2 and lap2. Although the
peptides that were identified did not contain a SUMO consensus sequence
themselves, three possible SUMO consensus sequences were identified in both
lap2 and lap2. All three possible SUMO consensus sequences were shared
between both lap2 and lap2, LKSE beginning at amino acid 16, and LKLE,
beginning at amino acid 94. The third possible SUMO consensus sequence VKSE
began at amino acid 400 in lap2 and at amino acid 291 in lap2. It should be
noted that proteins with a score of 60 or above were considered as being a genuine
hit. In order to determine if this was really a true positive, as only one lane of the
gel had been excised and the rest of the gel remained intact, proteins were
transferred onto PVDF membrane and analysed by Western blot, using mouse
serum raised against lap2. A band of the correct molecular weight indicated that
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lap2 was pulled out during the tandem affinity purification, indicating that it is
probably modified by SUMO2 protein (see figure 4.4).
When the LC-ESI-MS/MS data was searched against the viral database, no
adenoviral proteins were identified. This was surprising as it is known that
E1B55k protein is SUMOylated, although, experiments that demonstrated this,
were undertaken using SUMO1 (Endter et al., 2001). In order to determine if
E1B55k protein was actually being expressed after 20 hours, when the TAP-
SUMO2 cells were infected with a M.O.I of 10, a time point experiment was
undertaken to monitor expression levels of the E1B55k protein.
4.2.4 Experiment to determine expression levels of the E1B55k protein
A total of 24 petri dishes (150mm diameter) were set up of TAP-SUMO2 cells,
which were grown to 80% confluency, then half of the dishes were infected with
Ad5 at an M.O.I of 10. At specific time points, 1 infected Petri dish and 1
uninfected Petri dish were harvested. The medium was removed and cells washed
in PBS, then 5mL of lysis buffer was added to each plate and cells scraped into the
lysis buffer using a sterile cell scraper. Samples were then sonicated in order to
shear genomic DNA, and centrifuged to pellet any cell debris. Equal amounts of
each sample were then loaded onto SDS-PAGE gels. After running, proteins were
transferred to PVDF membranes, and analysed by Western blot analysis using
E1B55k monoclonal antibody. The levels of E1B55k protein were monitored at 0,
5, 7, 9, 11, 13, 15, 17, 19, 20, 22 and 24 hours post infection (see figure 4.5). Time
points were only taken up to 24 hours as the aim was to harvest the cells prior to
the expression of the late viral genes. It was deemed that after 24 hours post
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Figure 4.4: Western blot of eluates from tandem affinity purification
experiment using TAP-SUMO2 stable cell lines infected with wild
type Ad5 at an M.O.I of 10, for 20 hours, probed with LAP2 antibody.
The eluates resulting from Tandem affinity purification of 120 petri
dishes (150mm diameter) of TAP-SUMO2 Cells, infected with Ad5,
were TCA precipitated and run on an SDS-PAGE gel. Bands were
excised from one lane for mass spectrometric analysis, as shown in
figure 4. The other lane of the gel was transferred to PVDF membrane
and probed with mouse serum against LAP2.
LAP2
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infection the viral late genes would be being expressed. From the data it is evident
that at 22 hours post infection, the levels of E1B55k expression appear to be very
similar to the expression levels at 20 hours post infection. Therefore it was decided
to repeat the tandem affinity purification experiment, this time harvesting the cells
at 24 hours post infection, when levels seemed to be substantially higher.
4.2.5 TAP-SUMO2 cell line infected with Ad5 at a M.O.I of 10 for 24 hours
Following TCA precipitation of the TAP eluates, the protein pellet was
resuspended in SDS boiling mix and loaded onto one lane of an SDS-PAGE gel.
This time no sample appeared to be remaining in the bottom of the eppendorf tube.
The lane of the gel containing the sample was cut into 18 slices which were
analysed by LC-ESI-MS/MS. Far more data was generated than in the previous
experiment where the cells were harvested 20 hours post infection. The data set
was too large to combine and search against the MSDB database. Therefore the
data set was split into two, data set 1 consisting of gel slices 1-9 and data set 2
consisting of gel slices 10-18 (see figure 4.6). The data generated from the TAP
HeLa stable cell lines was subtracted from both sets of data. The data generated
consisted of 735 proteins, after subtraction of the TAP HeLa data (see Appendix
(7.4)). When the data was searched against the MSDB database, lap2 protein was
present in both data sets. In data set 1, with an overall score of 152, and in data set
2, with an overall score of 63. Lap2 is 454 amino acids long, with a molecular
weight of 50.5kDa. Therefore, when SUMO modified, the molecular weight of
lap2 is expected to be approximately 75kDa, as it appears in figure 4.4. Lap2
protein is present in both data sets, 1-9 which includes proteins with a
Figure 4.5: Time point of TAP-SUMO2 cells infected with adenovirus type 5. Western blot of cell
lysates probed with E1B55k monoclonal.150mm diameter petri dishes of TAP-SUMO2 HeLa’s were
grown to 80% confluency then infected with wild type Ad5 at a M.O.I of 10. Cell extracts were
harvested from petri dishes at set time points in SDS lysis buffer, separated on 10% SDS-PAGE gels,
transferred onto PVDF membranes and analysed by Western blot analysis using E1B55k monoclonal
antibody. Time points are indicated as hours post infection (P.I.), infected (I) or uninfected controls (U).
From the data it is evident that E1B55k expression was maximal at the 24 hour time point.
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Figure 4.6: SDS-PAGE gel showing eluates from tandem
affinity purification experiment using TAP/SUMO21 cells
infected with Ad5 at and M.O.I of 10 for 24 hours.
120 petri dishes (150mm diameter) of TAP-SUMO2 cells
were grown to 80% confluency, then infected
with wild type Ad5 at an M.O.I. of 10. After 24
hours cells were harvested and subjected to
Tandem Affinity Purification. Protein eluates
were then TCA precipitated and run on a
10% SDS-PAGE gel and Coomassie stained.
The bands indicated by brackets were
cut out and proteins identified by LC-ESI-MS/MS.
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molecular weight greater than 47.5kDa, and data set 10-18 which includes all
proteins with a molecular weight less than 47.5kDa. This is likely due to
degradation of the SUMOylated protein. When the data was searched against the
viral database, this time adenovirus proteins were identified, see below:
Gel slice accession number adenoviral protein identified*
1 FOADM2 minor core protein pV – human
adenovirus 2, 297 (33%)
3 AAC13964 L19443 NID: Human adenovirus
F, 39 (8%)
4 Q6VGU4_9ADEN E2A DNA binding protein – human
adenovirus C, 67 (4%)
5 Q6VGU4_9ADEN E2A DNA binding protein – human
adenovirus C, 111 (7%)
6 Q9IIH5_ADEF1 Hexon – Frog adenovirus 1, 38
(4%)
8 Q6VGU4-9ADEN E2A DNA binding protein – human
adenovirus C, 70 (4%)
Table 1: Adenoviral protein identified in TAP/SUMO2 cells infected with wild
type adenovirus 5. (*The numbers given are the overall score, followed by
percentage peptide coverage).
188
Although no E1B55k protein was identified, the E2A DNA binding protein and
pV from adenovirus were identified. As the E1B55k protein has only been
demonstrated to be modified by SUMO1 (Endter et al, 2001), this result is as
expected. The adenovirus DNA binding protein (DBP), has not been shown to be
modified by SUMOylation, therefore this result needs to be confirmed by
repeating the tandem affinity purification, and analysing the eluates by western
blot analysis using an antibody to DBP. Protein V (pV) has previously been shown
to be modified by SUMO (Rodriguez, Desterro and Hay, unpublished results).
4.3 Discussion
A large number of proteins have been demonstrated to be modified by SUMO2 in
vitro. These include proteins involved in transcriptional regulation, mRNA
metabolism, chromatin remodelling, nucleocytoplasmic transport, signal
transduction, SUMOylation, ubiquitination, DNA replication, vesicle trafficking,
DNA repair, translation, cell cycle and cell division, cytoskeletal regulation,
energy metabolism as well as molecular chaperone proteins (see appendices 1-3).
As well as identifying proteins that have already been confirmed as SUMO2
substrates, these experiments have also demonstrated that Lamina associated
polypeptide 2 (LAP2) protein is a substrate of SUMO2. LAP2 is a lamin-
binding protein of the LAP2 family, of which there are 6 different isoforms. It is a
type II integral protein of the inner nuclear membrane, which appears to be
involved in the spatial organisation of the interface between nucleoplasma, lamina
and nuclear envelope (Dreger et al., 1999). It binds to lamin B and the DNA-
bridging protein barrier-to-autointegration factor (BAF), and may link the nuclear
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membrane to the underlying lamina and provide docking sites for chromatin
(Dechat et al., 2000).
When comparing the data from both sets of TAP experiments, lots of proteins
were identified in the adenovirus infected TAP/SUMO2 cells that were not
identified in the uninfected cells (430 proteins in total). For proteins to be taken as
true hits, the criteria chosen was that they should have an overall Mascot score of
above 60. These proteins were compared to data generated previously by Dr
Akihiro Nakamura who had undertaken experiments using uninfected
TAP/SUMO2 cells and heat shocked TAP/SUMO2 cells, and had used similar
amounts of cells (unpublished results). Of the proteins with Mascot scores above
60, only 5 proteins had previously been identified in experiments undertaken by
Dr Akihiro Nakamura. These were; dna-K type molecular chaperone, accession
number A27077; L-Lactate dehydrogenase chain H, accession number DEHULH;
Alpha enolase, accession number ENOA_HUMAN; phosphoglycerate kinase,
accession number KIHUG; Glyceraldehyde-3-phosphate dehydrogenase, accession
number G3P1_HUMAN.
Proteins that were identified in only the adenovirus infected TAP/SUMO2 cells
include;
General transcription factor 3, accession number AAF19786; Threonyl-tRNA
synthetase, accession number A47363; DNA recombination and repair protein,
accession number AAD10197; Ribosomal protein S3, accession number R3HUS3.
Although similar types of proteins have been previously identified in experiments
undertaken by Dr Akihiro Nakamura including; Transcription factor IIIC box B-
binding chain, accession number I38414; Leucyl t-RNA synthetase, accession
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number Q9NSE1; Post-replication repair protein hRAD18, accession number
AAA70430; Ribosomal protein S5, accession number S55916. So in order to
determine if the proteins identified during these experiments are SUMOylated
specifically upon adenovirus infection the experiments would need to be repeated
and Western blot analysis of the TAP eluates carried out with antibodies specific
to the proteins of interest. This would confirm that the LC-ESI-MS/MS was
identifying proteins present in the eluates, but in order to confirm that the protein
was actually SUMOylated, a SUMOylation assay would have to be undertaken.
The purified protein would be incubated with SUMO2, and the essential
components of the SUMO pathway. SDS-PAGE and Western blot analysis would
then confirm if SUMOylated forms of the protein became apparent following
incubation with SUMO2. Sequence analysis would allow determination of
possible SUMOylation sites, and mutation analysis could be undertaken to identify
the specific SUMO modification site and the effect of SUMOylation on the
protein. The effect of SUMOylation on localisation could be determined by
generation of fluorescently tagged mutant and wild type forms of the protein, and
analysis by microscopy. Another way of determining whether certain proteins
were SUMOylated upon adenovirus infection would be to undertake SILAC
experiments with uninfected and infected cells. By comparing the results from
TAP-SUMO2 cells that were uninfected, from TAP-SUMO2 cells infected with
adenovirus type 5, the relative amounts of specific proteins in each could be
compared. Therefore if a protein was present at double the concentration in
adenovirus infected cells, it can be taken that adenoviral infection increases the
amount of that specific protein that is SUMOylated.
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In conclusion, a lot of data has been generated by these experiments, however a lot
more work has to be undertaken in order to validate the results.
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5. GENERATION OF STABLE CELL LINES EXPRESSING TAP/E1B55K
AND TAP/E1B55K K104R
5.1 Introduction
5.1.1 Introduction
Stable cell lines expressing tandem affinity purification (TAP) tagged E1B55k and
E1B55k K104R were generated, with the aim of undertaking tandem affinity
purification experiments in both uninfected cells, and in cells infected with
adenovirus type 5 lacking E1B55k (dl338). The aim of these experiments was to
identify both host cell and adenoviral proteins that interact with E1B55k. This was
devised as an alternative method for identifying such hits, due to the problems
experienced generating the recombinant adenoviruses (see chapter 3).
5.1.2 Generating the stable cell lines
The pCMV5-TAP vectors expressing E1B55k and E1B55k K104R that were
generated in results chapter 1, were used as templates in PCR reactions. The
TAP/E1B55k and TAP/E1B55k K104R genes were amplified using primers P19
and P20, which were designed to include Xho1 and Xba1 restriction sites
respectively. The PCR products were then digested with Xho1 and Xba1 and
cloned into the MCS of the pEFIRES-PURO vector, a kind gift from Dr Pablo De
Felipe. The constructs were then verified by DNA sequence analysis. Western blot
analysis, using a monoclonal antibody to E1B55k, confirmed expression of the
tagged E1B55k proteins from both constructs (see figure 5.1).
The stable cell lines were generated, by transfecting the pEFIRES-PURO
constructs, expressing TAP/E1B55k and TAP/E1B55k K104R, into petri dishes
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Figure 5.1: Western blot of HeLa cells expressing
TAP/E1B55k and TAP/E1B55k K104R
constructs. A monoclonal antibody to the E1B55k
protein was used in the western blots. Figure 1a
Illustrates TAP/E1B55k and figure 1b illustrates
TAP/E1B55k K104R. Both products appear to be
the correct size (approximately 76kDa).
1a 1b
E1B55k
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(150mm diameter) of HeLa cells. The presence of puromycin in the growth
medium selected for cells that were expressing the constructs. After 1 to 2 weeks,
puromycin resistant colonies were picked and expanded in 24 well plates. Clones
were screened by immunofluorescence (see figure 5.2) and Western blot analysis
for expression of TAP/E1B55k and TAP/E1B55k K104R. Clones that were
expressing at the highest levels were chosen for use in tandem affinity purification
experiments.
5.1.3 Preparation of adenovirus dl338
A 20L culture of 293 spinner cells was infected with Ad5 dl338 (supplied by John
Nicholson in the laboratory) and harvested by arcton extraction and caesium
chloride purification, when cells showed signs of infection. The virus was
aliquoted and stored at -80C. The titre of the virus was subsequently determined
using end point dilution and found to be 1x1012 pfu/ml.
5.1.4 Experiments undertaken
For each experiment, one vial of cells was resuscitated from liquid nitrogen and
the population expanded to 60 petri dishes (150mm diameter). Cells were grown in
Medium supplemented with puromycin. The aim was to undertake four
experiments, but only the first two experiments were carried out.
1. Uninfected TAP/E1B55k stable cell lines
2. Uninfected TAP/E1B55k K104R stable cell lines
3. TAP/E1B55k stable cell lines infected with Ad5 dl338
4. TAP/E1B55k K104R stable cell lines infected with Ad5 dl338
14B 311E
Figure 27a: Clone 14B, expressing
TAP/E1B55k K104R.
Figure 27b: Clone 311E, expressing
TAP/E1B55k.
Figure 5.2: Immunofluorescence analysis of stable cell lines expressing E1B55k and E1B55k K104R.
Stable HeLa cell lines were generated, expressing TAP/E1B55k (Figure 27a) and TAP/E1B55k K104R
(figure 27b). Immunofluorescence was carried out using an E1B55k monoclonal antibody, and
anti-mouse FITC conjugated secondary antibody.
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5.1.5 Tandem Affinity Purification procedure
For each experiment, all 60 petri dishes (150mm diameter) were harvested when
100% confluent, by scraping the cells directly into PBS. The cell extracts were
then pelleted and resuspended in lysis buffer. After lysis the cells were centrifuged
to pellet any cell debris. IgG sepharose was then added to supernatant, to which
the protein A of the TAP tag binds. After incubation the IgG beads were pelleted
by centrifugation and washed in TBS/Tween. The protein of interest and any
interacting proteins, were then cleaved from the IgG beads using TEV protease.
Following cleavage, the samples were centrifuged to pellet the IgG beads. The
supernatant was removed and to it was added calmodulin binding buffer
(containing calcium), and calmodulin beads. The protein of interest and any
associated proteins, bind to the calmodulin beads via the calmodulin binding
peptide of the TAP tag. The calmodulin beads were then washed with calmodulin
binding buffer to remove any contaminants, and proteins were eluted from the
beads in calmodulin elution buffer containing EGTA, which acts by chelating the
calcium.
After elution the proteins were concentrated into a smaller volume, to allow the
sample to be loaded into one lane of an SDS-PAGE gel, by TCA precipitation.
Once proteins have been separated according to molecular weight, by SDS-PAGE,
the proteins were visualised by Coomassie staining of the gel. Protein bands were
then excised from the gel, subjected to in-gel digestion and analysis by LC-ESI-
MS/MS.
The MS/MS data file generated for each gel slice, was analysed using the Mascot
search engine. Where possible all of these data were combined to include all of the
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gel slices from the entire lane of the gel, and then searched against the MSDB
database, using the Mascot search engine. This was done in order to acquire an
overall list, encompassing all of the proteins purified during the experiment.
5.2 Results
5.2.1 Initial experiment using TAP/E1B55k K104R stable cell line (14B)
The first experiment was carried out using 60 petri dishes of uninfected
TAP/E1B55k K104R stable cell line. Following tandem affinity purification, TCA
precipitation and SDS-PAGE, no proteins were visible by Coomassie staining
(data not shown). When part of the lane was analysed by mass spectrometry only
keratin was detected. However, when the calmodulin beads which had been used
in the experiment, were boiled and run on an SDS-PAGE gel, E1B55k protein was
confirmed as being present by mass spectrometric analysis. This indicated that the
E1B55k protein was not being eluted from the calmodulin beads.
5.2.2 Initial experiment using TAP/E1B55k stable cell line (311E)
The second experiment was carried out using 60 petri dishes of uninfected
TAP/E1B55k stable cell line. Following tandem affinity purification, TCA
precipitation and SDS-PAGE, no proteins were visible by Coomassie staining.
When the lane containing the sample was analysed by mass spectrometry, only
keratin was detected. However, Western blot analysis had confirmed that E1B55k
protein was present in the eluates prior to TCA precipitation, indicating that the
proteins had been lost during the TCA precipitation.
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5.2.3 Optimisation of the tandem affinity purification procedure
The tandem affinity purification procedure was optimised in order to minimise
protein loss. At key stages of the protocol, protein loss was minimised by making
the following changes:
 A substantial amount of the E1B55k protein appeared not to bind to the
IgG sepharose. The incubation time with the IgG sepharose was extended
from 4 hours to 5 hours in order to increase binding.
 To ensure that all of the bait protein was cleaved from the IgG sepharose,
the amount of TEV protease used was increased from 100 units to 500
units.
 To ensure elution of the protein from the calmodulin beads the amount of
EGTA in the elution buffer was increased from 2mM to 10mM.
 Extra care was taken when TCA precipitating the samples and all
supernatant removed was stored at -80C as back up.
Also, in order to minimise the level of keratin contamination, eluates were run on a
precast NuPAGE Novex 4-12% Bis-Tris gel, on an XCell SureLock gel rig
using NuPAGE MOPS SDS Running Buffer (Invitrogen). The gel rig, precast
gels and premade running buffer were specifically purchased for use in tandem
affinity purification procedures, and used solely for this purpose.
After the tandem affinity purification procedure had been optimised the
experiments using the uninfected stable cell lines were repeated and, this time,
proteins were visible by Coomassie staining for each of the experiments (see
figure 5.3). Bands were excised from the gel and subjected to in-gel digestion,
14B 311E
175
83
62
47.5
32.5
25
Figure 5.3: SDS-PAGE analysis of eluates from Tandem
affinity purification experiments carried out with stable
cell lines expressing E1B55k and E1B55k K104R.
60 petri dishes (150mm diameter) of each
stable cell line were grown to 100% confluency,
lysed and subjected to tandem affinity Purification.
Protein eluates were TCA precipitated, resuspended
in SDS boiling mix and run on a 10% SDS-PAGE
gel (Coomassie stained). Lane 3 contains the
eluates from the TAP/E1B55k K104R stable
cell line (clone 14B) and lane 5 contains the eluates
from the TAP/E1B55k stable cell line (clone 311E).
The lanes containing the samples were excised from
the gel and subjected to tryptic digestion and
LC-ESI-MS/MS.
1 2 3 4 5
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followed by LC-ESI-MS/MS analysis. The data generated was then searched
using the Mascot search engine, to generate a list of proteins that possibly interact
with E1B55k. Each protein is allocated an overall score, which is based on the
quality of the individual MS/MS spectra and the number of peptides that matched
the protein, with the most probable hits having the highest overall scores, and
proteins that are questionable as being true hits having lower scores. The criteria
chosen for proteins to be considered as a true hit, was that the overall score should
be higher than 60. As a means of ensuring that the experiments had worked
efficiently, the data was first checked for the presence of E1B55k protein.
5.2.4 Results from TAP/E1B55k K104R stable cell line (14B)
The lane containing all proteins interacting with E1B55k, non-SUMO modifiable,
was divided up into 16 separate fragments, which were searched individually
against the human database and the all species database. The first hit in nearly of
all of the samples was keratin, and the highest overall Mascot score was 619. In
fact almost all of the high scoring proteins were identified as keratin, with the
exception of dna-K type molecular chaperone protein, which had an overall
Mascot score of 512. When searched against the all species database, only one of
the fragments contained peptides that matched the E1B55k protein from human
adenovirus type 1 (accession number Q71BY4).
These results were not as anticipated, as it was expected that the E1B55k protein
would be present in abundance. In order to look in more detail for the adenovirus
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E1B55k protein, the data generated for each of the 16 fragments was searched
individually against the virus database.
Of the 16 separate fragments, E1B55k protein from human adenovirus type 5
(Q1AD55) was found in fragments 7, 9, 11, 12, 13 and 14 with an overall Mascot
score of 31, 108, 39, 46, 49 and 55 respectively. Although the score of 108 appears
high, further scrutiny showed that for this overall score, 6 peptides matched, with
the highest score for an individual peptide being 51. Of the peptides that were
identified, only 3 had scores which identified the protein as being E1B55k. The
remaining peptides had scores that indicated only homology with E1B55k protein.
5.2.5 Results from TAP/E1B55k stable cell line (311E)
The lane containing this sample was divided up into 22 separate fragments, which
were searched individually against the human database. Again, the first hit in
nearly of all of the samples was keratin, and the highest overall Mascot score for
keratin being 300. In fact almost all of the high scoring proteins were identified as
keratin, with the exception of dna-K type molecular chaperone protein, which had
an overall Mascot score of 498. The results were also combined and searched
against the human database and against the all species database. E1B55k from
human adenovirus type 5 (Q1AD55) was detected in the combined search against
the all species database, with an overall score of 90 with 7 peptides matching,
although the highest score for an individual peptide was 45.
In this experiment the E1B55k protein from adenovirus type 5 had been identified,
although the overall score was much lower than expected. In order to look in more
detail for E1B55k protein, the data generated for each of the 22 fragments was
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searched individually against the virus database. Of the 22 separate fragments,
E1B55k protein from adenovirus type 5 was detected in fragments 12, 13, 19, 20
and 21 with an overall score of 35, 29, 45, 28 and 31 respectively. The highest
score for any individual peptide was 45. In these results only one of the peptides
had a score which identified the protein as being E1B55k. The remaining peptides
had a score which indicated only homology with E1B55k protein.
5.2.6 Results of preliminary experiments suggest inefficient cell lysis
Although the tandem affinity purification procedure was initially demonstrated to
work, it appeared to be very inefficient, even with the steps implemented to try to
optimise purification of the tagged proteins.
Some preliminary experiments were undertaken to ensure that the cells were being
lysed efficiently prior to tandem affinity purification. This was due to the fact that
the E1B55k protein had lower overall scores in the stable cell line expressing wild
type E1B55k, where the localisation was nuclear, compared to the stable cell line
expressing E1B55k K104R, where the localisation was cytoplasmic. A sonication
step was added to the existing tandem affinity purification protocol, in order to
increase disruption of cell membranes. It was decided not to alter the salt
concentration in the lysis buffer as this could disrupt interaction between the
E1B55k protein and any interacting host cell or viral proteins. The aim was to
directly compare this modified method to the Dignam and Roeder method for
purifying nuclear cell extracts. By comparing these methods for the TAP/E1B55k
stable cell lines, where the localisation of the E1B55k protein is nuclear, it would
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be possible to determine if the cell nucleus was lysed sufficiently to allow its
contents to be released.
Prior to the completion of these experiments, this project was ceased, in order to
focus on other aspects of the project.
5.3 Discussion
Stable cell lines expressing TAP/E1B55k and TAP/E1B55k K104R have been
successfully generated and the tandem affinity purification procedure has been
demonstrated to work, although it requires further optimisation. Western blot
analysis of washes and eluates taken throughout the TAP procedure illustrated that
a considerable proportion of the E1B55k protein was lost during the initial binding
to IgG beads. Thus the incubation time for this step was increased from 4 to 5
hours. This may not solve the problem though as the inefficient binding could also
be due to the conformation of the N-terminally TAP tagged E1B55k protein. The
tertiary structure of the protein may prevent the Protein A of the TAP tag from
binding efficiently to the IgG beads. To investigate whether this is a problem, a C-
terminally TAP tagged E1B55k stable cell line could be generated and compared,
to see if there is a difference in binding efficiency. The Western blot results also
demonstrated that a small amount of the protein was lost due to inefficient
cleavage of the TEV protease, preventing release of the E1B55k protein from the
IgG beads. This was overcome by increasing the amount of TEV protease used
from 100 units to 500 units. Finally in order to ensure complete elution of the
protein from the calmodulin beads the amount of EGTA in the elution buffer was
increased from 2mM to 10mM.
204
Keratin contamination from skin and hair was also highlighted as a problem during
these tandem affinity purification experiments. Steps were taken to reduce keratin
contamination including; wearing gloves, ensuring the work area was cleaned
prior to the start of the experiment, soaking the gel rig in detergent prior to use,
making the buffers and solutions required using new glassware ordered
specifically for this purpose and storing them in sterile cell culture flasks rather
that in Durans and using a separate stock of chemicals to make up the buffers and
not the general lab stock. During the course of these experiments an XCell
SureLock gel and precast NuPAGE Novex 4-12% Bis-Tris gels were ordered
specifically for these experiments, along with NuPAGE MOPS SDS Running
Buffer (Invitrogen). By having a specially designated gel rig only to be used for
tandem affinity purification and using precast gels and premade running buffer it
was hoped that keratin contamination would be dramatically reduced.
Although E1B55k protein was detected in the tandem affinity purification
experiments undertaken in each of the cell lines, the E1B55k protein did not
appear to be in abundance. This could be caused by inefficient lysis of the cells. In
order to determine if the lysis procedure was sufficient to release the contents of
both the nucleus and the cytoplasm, it was planned to compare results, by Western
blot, between, the standard lysis method, the lysis method with an added
sonication step, and the Dignam and Roeder method for lysing nuclear extracts.
The plan was to do these experiments using the TAP/E1B55k stable cell line,
where the localisation of the E1B55k protein is nuclear. Unfortunately work was
ceased on this project prior to completion of these experiments.
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It should also be noted that when run on a SDS-PAGE gel, the tagged E1B55k
protein would be expected to run between the 83kDa and 62kDa markers. In both
stable cell lines however, following TAP purification, the tagged E1B55k protein
appeared to be present in gel slices excised that lay between the 83kDa and 25kDa
markers, indicating that the tagged E1B55k protein was being degraded. In
Western blot analysis of the pEFIRES-PURO constructs used to generate the
stable cell lines however, the tagged proteins appeared to be the correct size
(approximately 76kDa). Perhaps the E1B55k protein is being degraded during the
TAP procedure, this could be possibly be prevented by increasing the amount of
protease inhibitors used.
TAP experiments undertaken with the TAP-SUMO2 stable cell lines, showed that
when 120 petri dishes (150mm diameter) were used, many protein bands were
visible by Coomassie staining upon SDS-PAGE analysis of eluates. By increasing
the amount of petri dishes used in these experiments up to 120, far more proteins
that interact with E1B55k could be identified.
In conclusion, by optimising a few more of the parameters, it would seem likely
that these experiments could yield data.
206
6. FUTURE WORK
6.1 Generation of the recombinant adenoviruses
The recombinant adenoviruses expressing TAP/E1B55k and CFP/E1B55k have
been generated, plaque purified 3x, and stocks have been frozen down at -80C. In
western blot analysis of these recombinant viruses however, the tagged E1B55k
protein appears to be truncated, although DNA sequencing has not indicated the
presence of any mutations within the DNA sequence which would cause this. The
recombinant viruses have only been partially sequenced therefore, before any
experiments are undertaken the remainder of the tagged E1B55k gene should be
sequenced to ensure that no mutations are present.
Provided that both recombinant viruses are mutation free tandem affinity
purification experiments can be undertaken with the virus expressing
TAP/E1B55k. Different cell lines could be infected with the recombinant virus and
harvested at different time points during infection, in order to determine what
cellular and viral proteins interact with E1B55k at specific time during infection.
Live cell imaging could be undertaken with different cell types infected with the
recombinant virus expressing CFP/E1B55k. This would allow the localisation of
the E1B55k gene to be monitored throughout infection, and if localisation patterns
differed between different cell types.
The recombinant adenoviruses expressing TAP/E1B55k K104R and CFP/E1B55k
K104R, where the E1B55k gene cannot be modified by SUMO, will need to be
remade. It is essential that the E1B55k K104R gene used to generate the constructs
is mutations free. As a method has been developed for cloning the constructs
required to generate the recombinant viruses, remaking the viruses should be
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straight forward. Generation of these viruses will allow a direct comparison
between the recombinant viruses, where the E1B55k gene can be modified by
SUMO. This would enable a better understanding of the effect of SUMOylation on
the E1B55k protein.
6.2 Tandem affinity purification of TAP/SUMO2 stable cell lines infected with
adenovirus type 5
A large amount of data has been generated from both the uninfected TAP/SUMO2
cells, and from TAP/SUMO2 cells infected with adenovirus type 5. The list of
proteins resulting from the tandem affinity purification of 120 petri dishes of
TAP/SUMO2 cells, totals 1566 cellular proteins. The list of proteins generated
from tandem affinity purification of 120 petri dishes of TAP/SUMO2 cells
infected with Ad5 at a M.O.I of 10 for 24 hours, totals 427 cellular proteins. This
is a huge number of possible SUMO2 substrates, although a substantial number of
the proteins indicated to be SUMO2 substrates in this experiment have previously
been confirmed as substrates. In order to confirm if any further proteins identified
in these experiments are real substrates of SUMO2, the experiments will need to
be repeated and western blot analysis carried out on eluates, using an antibody to
the protein of interest. This method has already been used to confirm that lamina
associated polypeptide (Lap) 2 is modified by SUMO2.
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6.3 Generation of stable cell lines expressing TAP/E1B55k and TAP/E1B55k
K104R
Stable cell lines expressing TAP/E1B55k and TAP/E1B55k K104R have been
successfully generated and the tandem affinity purification procedure has been
demonstrated to work, although it requires further optimisation. Measures taken to
increase the efficiency of the TAP procedure have included increasing incubation
time with IgG beads, increasing the amount of TEV protease, and increasing the
amount of EGTA in the elution buffer.
The inefficient binding to the IgG beads may however be due to the tertiary
structure of the TAP/E1B55k fusion protein, preventing the protein A binding
domain from binding to the IgG beads. It would be interesting to generate C-
terminally tagged E1B55k stable cell lines to compare the binding efficiencies.
In order to determine if the lysis procedure is sufficient to release the contents of
both the nucleus and the cytoplasm a comparison should be undertaken between
the standard lysis method, the lysis method with an added sonication step, and the
Dignam and Roeder method for lysing nuclear extracts. This should be done using
the TAP/E1B55k stable cell line, where the localisation of the E1B55k protein is
nuclear.
The experiments should also be repeated with double the amount of cells (120
petri dishes instead of 60 petri dishes), as experiments undertaken with this
quantity of TAP/SUMO2 cells gave vast quantities of data.
Lastly these experiments when optimised should be repeated on the stable cell
lines infected with adenovirus dl338. This would allow identification of any
adenoviral proteins that interact with E1B55k, as well as cellular proteins.
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APPENDIX
7.1 Details of primers used (Table 2: Sequence of primers used for sequence
analysis, PCR and overlap PCR)
Primer name Sequence ( 5’-3’)
L1 AATTCTAGGGATAACAGGGTAATT
L2 AGCTAATTACCCTGTTATCCCTAG
L3 AATTCTAGGGATAACAGGGTAATA Linkers for inserting I-Sce1 site into pUC19
L4 CTAGTATTACCCTGTTATCCCTAG
S1 CCCACGCCCCGCGCCACGTCACAAACTCCA Primers for sequencing bacmid backbone of
S1A CACATCCGTCGCTTACATGTGTTCCG pSCB-AdFL
S2 CTTGTGAGGCTAC
S3 CCTGTGATGCTGG
S4 GGCCAATACCAAC
S5 CCATTGTAATGAGACGC Primers for sequencing left hand end of Ad5 cloned into
S6 GATCGAAGAGGTACTGG pGEM-5zf(+)
S7 GTAGATGATCCAGTCGTAG
S8 CGTAGTTACCCTCACAG
P1 CGCTCTAGAGAATGCAATAGTAGTACGGATAGCTGTGAC
P2 GTGGGCACTTGTGTCCATGGTGGCTTATCCTTTATAAAACTC
P3 CTCCTCGCCCTTGCTCACCATGGTGGCTTATCCTTTATAAAA Overlap PCR primers
P4 GAGTTTTATAAAGGATAAGCCACCATGGACACAAGTGCCAC for replacing E1B-55k
P5 GAGTTTTATAAAGGATAAGCCACCATGGTGAGCAAGGGCGAG with E1B-55k
P6 ACGCCCACACATTTCAGTACCTCAATCTGTATCTTCATCGCT +/-K104R
P7 AGCGATGAAGATACAGATTGAGGTACTGAAATGTGTGGGCGT
P8 AGACACTTGCTTGATCCAAATCCAAACAGAGTCTGGTTTT
P9 AATGGATCCGAGCGAAGAAACCCATC
P10A CCGGGATCCTCAATCTGTATCTTCAT Primers for sequencing the
P11 GCCGTCTCAGCAGCCAACCGC pCMV5-TAP vector
P12 TTAAACGAAGAACAACGAAAC
P13 CTGAGCATCATTTAGCTTTTT
P14 ACCGCTGCGCATAGTTTTTCTGTAATTTACAACAGTGCT Overlap PCR products
P15 TTCCCGTTGAATATGGCTCATATCAGCAACTATATATTGATA for knocking out the
P16 TATCAATATATAGTTGCTGATATGAGCCATATTCAACGGGAA 5’ ITR of pSCB-AdFL
P17 GGCTGCTGCAAAACAGATACAGAAAAACTCATCGAGCATCAA
P18 TTGATGCTCGATGAGTTTTTCTGTATCTGTTTTGCAGCAGCC
P15 ACCGATCAACGTCTCATTTTCGATCAGCAACTATATATTGATA Redesigned overlap
P16 ATATCAATATATAGTTGCTGATCGAAAATGAGACGTTGATCGG PCR primers
P17 AGGCTGCTGCAAAACAGATACATTACGCCCCGCCCTGCCACTC for knocking out the 5’
P18 AGAGTGGCAGGGCGGGGCGTAATGTATCTGTTTTGCAGCAGCC of pSCB-AdFL
PUC19F CCGCACAGATGCGTAAGGAG
PUC19R CAGCTGGCACGACAGGTTTC Primers for sequencing the MCS of pUC19
P19 GTTTCTCGAGGCCCTTGCCACC
P20 GTATTCTAGAGTCGACCTGCAG Primers designed to amplify TAP-E1B-55kDa
P21 CTGGAACAGAACTTCCAG 3’ primer for amplifying TAP only
P22 GTAAACGGCCACAAGTTC
P23 CTTGTACAGCTCGTCCATG Primers designed to amplify CFP
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7.2 TAP CELL LINES UNINFECTED (see figure 4.1)
Accession number, name of protein and overall Mascot score
1.AAG41947 Keratin 1 (2300)
2.KRHU2 keratin 1, type II, cytoskeletal (1509)
3.Q8N175_HUMAN Keratin 10 (1454)
4.ABHUS serum albumin precursor [validated] (1443)
5.Q96CL4_HUMAN Keratin 6A (1336)
6.CAA19927 OTTHUMP00000016001 protein (1318)
7.Q7RTN9_HUMAN Type II keratin K6h (1315)
8.K2C6C_HUMAN Keratin, type II cytoskeletal 6C (Cytokeratin 6C) (1307)
9.K2C6E_HUMAN Keratin, type II cytoskeletal 6E (Cytokeratin 6E) (1300)
10.KRHUEB keratin 6b, type II (1260)
11.K1CP_HUMAN Keratin, type I cytoskeletal 16 (Cytokeratin 16) (1239)
12.K2C6F_HUMAN Keratin, type II cytoskeletal 6F (Cytokeratin 6F) (CK 6F)
(K6f keratin)(1184)
13.K1CN_HUMAN Keratin, type I cytoskeletal 14 (Cytokeratin 14) (1167)
14.CAA82315 Cytokeratin 9 (1163)
15.Q6PI71 Keratin 5 (856)
16.A44861 keratin, 67K type II epidermal (756)
17.Q7L3S5_HUMAN JUP protein (721)
18.AAA36145 Keratin K5 (607)
19.K1CQ_HUMAN Keratin, type I cytoskeletal 17 (Cytokeratin 17) (591)
20.IJHUG1 desmoglein 1 precursor (444)
21.TFHUP transferrin precursor [validated] (379)
22.ATBOG actin gamma - bovine (tentative sequence) (376)
23.S60712 band-6-protein (371)
24.AAH59367 Transferrin (365)
25.UQBO ubiquitin - bovine (tentative sequence)(348)
26.BAA23486 Polyubiquitin (338)
27.BAB71634 CDNA FLJ25308 fis, clone SYN00939, highly similar to Ig
gamma immunoglobulin heavy chain (332)
28.CAA23759 Unnamed protein product (324)
29.BAC04926 CDNA FLJ39691 fis, clone SMINT2010672, highly similar to
Homo sapiens immunoglobulin lambda heavy chain (318)
30.BAD08204 anti-HBs antibody heavy chain (317)
31.Q9NSA9_HUMAN Cytokeratin (313)
32.HBCZ hemoglobin beta chain – chimpanzee (311)
33.BAC85237 Unnamed protein product (307)
34.AAH66642 AcOrf-12 peptide (304)
35.Q6PJ95_HUMAN Hypothetical protein (303)
36.CAA75030 IMMUNOGLOBULIN KAPPA HEAVY CHAIN
PRECURSOR (303)
37.AAH67091 IGHG1 protein (303)
38.BAC85529 Unnamed protein product (302)
39.BAC04226 CDNA FLJ36487 fis, clone THYMU2017844, highly similar to
Homo sapiens immunoglobulin lambda heavy chain (301)
40.BAC85171 Unnamed protein product (301)
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41.G2HU Ig gamma-2 chain C region (292)
42.1C3TA 1d8 ubiquitin mutant YES (291)
43.BAC85202 Unnamed protein product (262)
44.KRHU5 keratin 15, type I, cytoskeletal
45.1BUWB Chain B, Crystal Structure Of S-Nitroso-Nitrosyl Human
Hemoglobin A (257)
46.JE0242 Ig kappa chain NIG26 precursor (254)
47.Q6V0K9_HUMAN Mutant hemoglobin beta chain (Fragment) (253)
48.Q6FH51_HUMAN SFN protein (244)
49.BAC85434 Unnamed protein product (240)
50.MYLK2_HUMAN Myosin light chain kinase 2, skeletal/cardiac muscle (EC
2.7.1.117) (MLCK2) (232)
51.Q96KX8_HUMAN MGC27165 protein (226)
52.Q701L8_HUMAN Keratin 3 (221)
53.1IGAA iga1 chains a and b, heavy, chains c and d, light, chain A (219)
54.BAC86513 Unnamed protein product (216)
55.Q7Z3Y8_HUMAN Type I inner root sheath specific keratin 25 irs3 (215)
56.BAC85432 Unnamed protein product (213)
57.Q5XKE5_HUMAN Keratin 6L (206)
58.CAC10254 Immunoglobulin heavy chain (Fragment) (205)
59.1B56 fatty acid binding protein (205)
60.BAC01698 Immunoglobulin kappa light chain VLJ region (Fragment) (202)
61.CAC10219 Immunoglobulin heavy chain (Fragment) (201)
62.K1CM_HUMAN Keratin, type I cytoskeletal 13 (Cytokeratin 13)(198)
63.CAD48782 Sequence 29 from Patent EP1229047 (197)
64.Q96PQ8_HUMAN Factor VII active site mutant immunoconjugate (196)
65.1MCOH Immunoglobulin g1 (igg1) (mcg) with a hinge deletion, chain H
(195)
66.Q6GMW0_HUMAN Hypothetical protein (190)
67.Q8TC63_HUMAN IGHG4 protein (191)
68.Q5XG83_HUMAN Hypothetical protein (Fragment) (190)
69.CAC10224 Immunoglobulin heavy chain (Fragment) (183)
70.CAB58611 SEQUENCE 1 FROM PATENT WO9318147 (181)
71.Q9HB00_HUMAN Desmocollin 1b (180)
72.CAC21968 Sequence 2 from Patent WO0073481 (Fragment) (179)
73.1FVDB Fab fragment of humanized antibody 4d5, version 4, chain B
(178)
74.Q5SP17_HUMAN Heat shock 70kDa protein 1A (177)
75.CAD19028 Sequence 33 from Patent EP1158004 (175)
76.BAC01711 Immunoglobulin kappa light chain VLJ region (Fragment) (175)
77.1AD0B Ig heavy chain Fab fragment, antibody a5b7, chain B (175)
78.BAA82105 Anti-Entamoeba histolytica immunoglobulin kappa light chain
(Fragment) (165)
79.AAD29608 Kappa 1 immunoglobulin light chain (165)
80.AAS85992 Immunoglobulin heavy chain (157)
81.Q6FGZ8_HUMAN TUBB protein (Fragment) (145)
82.ITHU alpha-1-antitrypsin precursor [validated] (143)
83.AAS85981 Immunoglobulin heavy chain (141)
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84.Q7Z795_HUMAN Keratin 2p (141)
85.AAR32408 Immunoglobulin heavy chain variable region (138)
86.AAH42911 LGAL7S protein (138)
87.CAI18215 Heat shock 10kDa protein 1-like (137)
88.Q8NA87_HUMAN Hypothetical protein FLJ35741 (137)
89.BAC86537 Unnamed protein product (136)
90.A24903 tubulin alpha-1 chain - Chinese hamster (134)
91.AAR02477 Immunoglobulin heavy chain variable region (134)
92.EF2_HUMAN Elongation factor 2 (EF-2) (132)
93.Q7RTT2_HUMAN Keratin 5b (132)
94.PSHUAM 14-3-3 protein zeta (132)
95.UBRTA tubulin alpha chain – rat (131)
96.GTP_HUMAN Glutathione S-transferase P (EC 2.5.1.18) (GST class-pi)
(GSTP1-1) (129)
97.AAS86018 Immunoglobulin heavy chain (129)
98.AAR32428 Immunoglobulin heavy chain variable region (129)
99.S25740 Ig lambda chain (128)
10.S14675 Ig lambda chain (125)
101.BAA82101 Anti-Entamoeba histolytica immunoglobulin gamma heavy
chain (Fragment) (125)
102.AAR32393 Immunoglobulin heavy chain variable region (125)
103.BAB18260 Anti HBs antibody heavy-chain Fab (Fragment) (124)
104.AAS85965 Immunoglobulin heavy chain (124)
105.AAA20163 IMMUNOGLOBULIN LIGHT CHAIN (FRAGMENT) (123)
106.AAS85983 Immunoglobulin heavy chain (122)
107.AAS86007 Immunoglobulin heavy chain (121)
108.S23624 Ig heavy chain V region (fragment) (121)
109.C3HU complement C3 precursor [validated] (121)
110.AAR32411 Immunoglobulin heavy chain variable region (119)
111.AAA16946 IMMUNOGLOBULIN KAPPA CHAIN (FRAGMENT) (118)
112.AAP23227 Antibody light chain (Fragment) (118)
113.BAC85347 Unnamed protein product (118)
114.Q8WU19_HUMAN K-ALPHA-1 protein (118)
115.CSHUA peptidylprolyl isomerase (EC 5.2.1.8) A (117)
116.1B3EA serum transferrin n-terminal lobe (117)
117.BAC86532 Unnamed protein product (117)
118.A36040 Ig heavy chain V-III region (ART)
(fragments) (117)
119.A36898 maspin (116)
120.AAR02542 Immunoglobulin heavy chain variable region (116)
121.AAR32417 Immunoglobulin heavy chain variable region (116)
122.Q8WZ42_HUMAN Titin (115)
123.1A8JL immunoglobulin lambda light chain dimer (mcg), chain L (115)
124.S25754 Ig lambda chain (fragment) (115)
125.AAR32418 Immunoglobulin heavy chain variable region (115)
126.Q7KZS6_HUMAN Tubulin, beta, 4 (112)
127.A49444 Ig gamma-1 heavy chain (New)(fragment) (111)
128.AAR32424 Immunoglobulin heavy chain variable region (111)
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129.AAA35597 Beta-globin (109)
130.Q9BYX7_HUMAN FKSG30 (109)
131.AAR88369 anti-HIV-1 gp120 immunoglobulin 48d heavy chain (109)
132.AAF05685 Anti-phospholipid immunoglobulin heavy chain VH-D-J
region (fragment) (108)
133.AAR02563 Immunoglobulin heavy chain variable region (108)
134.1VGEH tr1.9 fab fab fragment of a igg1 kappa autoantibody, chain H
(108)
135.AAR32532 Immunoglobulin heavy chain variable region (108)
136.AAS54980 anti-HIV-1 gp120 immunoglobulin X5 heavy chain (108)
137.AAR02564 AY393691 NID (108)
138.HACZ hemoglobin alpha chain – chimpanzee (108)
139.AAA87670 IMMUNOGLOBULIN HEAVY CHAIN FD REGION V-D-J-
CH1 (FRAGMENT) (107)
140.AAR32526 Immunoglobulin heavy chain variable region (107)
141.AAS86010 Immunoglobulin heavy chain (107)
142.3FCTB metal chelatase catalytic antibody fab fragment, chain B (106)
143.BAA82104 Anti-Entamoeba histolytica immunoglobulin gamma heavy
chain (Fragment) (106)
144.AAS85976 Immunoglobulin heavy chain (106)
145.S01713 tubulin beta-7 chain – chicken (106)
146.AAS68223 Immunoglobulin heavy chain (106)
147.AAG30516 Immunoglobulin heavy chain (Fragment) (105)
148.AAA52865 IMMUNOGLOBULIN HEAVY CHAIN PRECURSOR
(FRAGMENT) (104)
149.1AV1A apolipoprotein a-i lipid-binding domain mutant N-TERMINAL
MET, DEL(1-43), chain A (103)
150.Q9NXG7_HUMAN Hypothetical protein FLJ20261 (102)
151.BAA00861 Immunoglobulin lambda light chain (100)
152.CAC10747 Immunoglobulin heavy chain variable region (Fragment) (99)
153.OQHU hemopexin precursor [validated]
154.CAA85581 IMMUNOGLOBULIN HEAVY CHAIN VARIABLE
REGION (FRAGMENT) (96)
155.Q7RTS7_HUMAN Keratin 5c (95)
156.AAA69737 (CLONE A5VL) IMMUNOGLOUBLIN LIGHT CHAIN
MRNA, V-REGION (FRAGMENT) (93)
157.AAQ05732 Ig heavy chain variable region (92)
158.CAF31289 Immunoglobulin heavy chain variable region (92)
159.K2C8_HUMAN Keratin, type II cytoskeletal 8 (Cytokeratin 8) (92)
160.ANXA2_HUMAN Annexin A2 (Annexin II) (Lipocortin II) (Calpactin I
heavy chain) (Chromobindin 8) (p36) (Protein I) (90)
161.K3HUB6 Ig kappa chain V-III region (B6) (tentative sequence) (88)
162.AAH69647 Keratin, hair, basic, 4 (87)
163.AAF61432 Keratin 12 (87)
164.AAH33679 Beta-tubulin 1, class VI (86)
165.Q6S380_HUMAN Plectin 6 (86)
166.Q6S379_HUMAN Plectin 7 (84)
167.Q7Z3M3_HUMAN Hypothetical protein DKFZp686L04275 (Fragment)
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(82)
168.CAD97642 Hypothetical protein (81)
169.G02520 plectin (80)
170.Q6S376_HUMAN Plectin 11 (79)
171.AAA99717 Complement C4B precursor (79)
172.AAC08331 MONOCLONAL ANTIBODY RL1 IMMUNOGLOBULIN
HEAVY CHAIN VARIABLE REGION (FRAGMENT) (79)
173.AAQ05356 Ig heavy chain variable region, VH3 family (78)
174.Q10466_HUMAN Titin, heart isoform N2-B (EC 2.7.1.-) (Connectin) (76)
175.AAT96423 Imuunoglobulin variable region VL kappa domain (75)
176.Q9UE12_HUMAN Type I hair keratin 1 (75)
177.CAF31287 Immonoglobulin heavy chain variable region (75)
178.AAQ05367 Ig heavy chain variable region, VH3 family (75)
179.CAD89465 Immunoglobulin gamma heavy chain variable region
(Fragment) (75)
180.CAF28440 Immunoglobulin heavy chain variable region (74)
181.CAA06862 ANTI-(ED-B) SCFV (FRAGMENT) 74
182.CAA00206 1-ALPHA-1-ANTITRYPSIN (FRAGMENT)(74)
183.AAL59372 Anti-cardiolipin immunoglobulin heavy chain (Fragment) (73)
184.CAF00450 Unnamed protein product (73)
185.CAD88649 Immunoglobulin heavy chain (Fragment) (73)
186.Q7RTM4_HUMAN Spectrin-like protein of the nuclear envelope and Golgi
(71)
187.SYNE1_HUMAN Nesprin 1 (Nuclear envelope spectrin repeat protein 1)
(Synaptic nuclear envelope protein 1) (71)
188.CAF14734 Unnamed protein product (71)
189.Q7Z3Y9_HUMAN Type I inner root sheath specific keratin 25 irs2 (70)
190.A38973 beta-catenin (69)
191.AAB59530 Fibrinogen gamma-prime chain (69)
192.HSHUB1 histone H2B.1 (69)
193.DEHUG3 glyceraldehyde-3-phosphate (69) dehydrogenase
(phosphorylating) (EC 1.2.1.12) [validated] (69)
194.I37459 keratin Ha3-II, type I, hair (fragment) (68)
195.AAP87378 Immunoglobulin gamma heavy chain (Fragment) (66)
196.Q8WW89_HUMAN SERPINB5 protein (66)
197.BAB18615 Heat shock cognate protein 54 (64)
198.Q5S007_HUMAN Leucine-rich repeat kinase 2 (64)
199.S55024 nebulin, skeletal muscle (63)
200.Q9ULL0_HUMAN KIAA1210 protein (Fragment) (62)
201.AAB31910 IgM autoantibody heavy chain; heavy chain; anti-GPIIb (62)
202.CAB46473 IMMUNOGLOBULIN LIGHT CHAIN VARIABLE REGION
(FRAGMENT) (61)
203.Q9UL88_HUMAN Myosin-reactive immunoglobulin heavy chain variable
region (Fragment) (61)
204.AAQ05553 Ig heavy chain variable region, VH3 family (60)
205.BAC01921 Immunoglobulin heavy chain VHDJ region (Fragment) (60)
206.FZFB fibrinogen fragment double-d, chain B (60)
207.Q86UQ4_HUMAN ABC A13 (59)
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208.AAQ05543 Ig heavy chain variable region, VH3 family (59)
209.Q96ST0_HUMAN Hypothetical protein FLJ14658 (57)
210.CAE45480 Immunoglobulin heavy chain variable region (56)
211.EZRI_HUMAN Ezrin (p81) (Cytovillin) (Villin 2) (56)
212.AAB34564 Type 1 keratin K16 (56)
213.CAC17313 Sequence 1 from Patent WO0066730 precursor (Fragment)
(56)
214.Q8WZ53_HUMAN Novex-3 Titin Isoform (55)
215.CAF14727 Unnamed protein product (55)
216.Q5TBT2_HUMAN Bullous pemphigoid antigen 1, 230\/240kDa (55)
217.AAP35912 golgi autoantigen, golgi subfamily a, 2 (54)
218.FGHUB fibrinogen beta chain precursor [validated] (53)
219.T03454 ALR protein (53)
220.1FZAB fibrinogen fragment d, chain B (52)
221.AAQ05521 Ig heavy chain variable region, VH3 family (52)
222.NBHU apolipoprotein H precursor [validated] (52)
223.Q5T9P7_HUMAN PRP18 pre-mRNA processing factor 18 homolog
(Yeast)(PRPF18) (Fragment) 52)
224.Q14467_HUMAN KIAA0068 protein (Fragment) (52)
225.AAD30784 IMMUNOGLOBULIN HEAVY CHAIN VARIABLE
REGION (FRAGMENT) (51)
226.Q7Z7D6_HUMAN Bromodomain PHD finger transcription factor (51)
227.BPA1_HUMAN Bullous pemphigoid antigen 1 isoforms 1/2/3/4/5/8 (230
kDa bullous pemphigoid antigen) (BPA) (51)
228.BAB13468 KIAA1642 protein (50)
229.Q6NZA0_HUMAN HIST1H2BA protein (50)
230.1GSN glutathione reductase (EC 1.6.4.2) (gsh 1030) sulfenic acid group
in cea63, cea234, cea284 cea423 (50)
231.Q86U12_HUMAN Full-length cDNA clone CS0CAP007YF18 of Thymus
(49)
232.HHHU84 heat shock protein 90-beta [validated] (49)
233.CAC36022 OTTHUMP00000031430 protein (49)
234.Q14491_HUMAN Hemoglobin gamma-G (Fragment) (49)
235.Q5SQI3_HUMAN Calmodulin-like 5 (48)
236.O15021_HUMAN KIAA0303 protein (Fragment) (47)
237.AAM75821 Immunoglobulin heavy chain variable region (Fragment) (47)
238.T00050 hypothetical protein KIAA0400 (47)
239.Q5T2M3_HUMAN OTTHUMP00000017872 (Fragment) (47)
240.CAA65055 IMMUNOGLOBULIN HEAVY CHAIN (FRAGMENT)
(47)241.AAC17470 alpha actinin:
242.M3HUPM Ig heavy chain V-III region (Pom) (tentative sequence) (47)
243.Q8N9Z3_HUMAN Hypothetical protein FLJ36025 (47)
244.AAC96152 T-CELL RECEPTOR BETA CHAIN (FRAGMENT) (47)
245.AAB86742 Possible J 56 gene segment (Fragment) (47)
246.Q5T8W5_HUMAN Novel PH domain-containing protein (47)
247.DMD_HUMAN Dystrophin (47)
248.Q5QFI2_HUMAN SRF-dependent transcription regulation associated protein
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(47)
249.AAP69525 protein kinase, DNA-activated, catalytic polypeptide (47)
250.Q5VU43_HUMAN Phosphodiesterase 4D interacting protein (Myomegalin)
(47)
251.NFASC_HUMAN Neurofascin precursor (46)
252.Q9UPV0_HUMAN KIAA1052 protein (Fragment) (46)
253.AAA17933 IMMUNOGLOBULIN HEAVY CHAIN VARIABLE
REGION (FRAGMENT) (46)
254.PC2205 interferon-alpha LCA-2b binding subtype (fragment) (46)
255.A57099 DNA-activated protein kinase, catalytic subunit (46)
256.AAF65317 Beta V spectrin (46)
257.AAQ05496 Ig heavy chain variable region, VH3 family (46)
258.AAP23228 Antibody heavy chain (Fragment) (46)
259.ADHUA fructose-bisphosphate aldolase (EC 4.1.2.13) A [validated] (46)
260.Q6S362_HUMAN Usher syndrome 2A isoform B (Autosomal recessive,
mild) (46)
261.CAF15132 Unnamed protein product (45)
262.Q7LG11_HUMAN KIAA1758 protein (Fragment)(45)
263.CAD44428 Sequence 16 from Patent WO02055701 (45)
264.Q5T154_HUMAN Peroxiredoxin 1 (45)
265.Q5SZ57_HUMAN OTTHUMP00000040139 (Utrophin) (Homologous to
dystrophin) (45)
266.B27725 small proline-rich protein spr2 (45)
267.AAC50434 Trans-golgi p230 (45)
268.A35715 fodrin alpha chain (44)
269.VBHU transthyretin precursor [validated] (44)
270.CAA18150 HS454M7 NID (44)
271.Q9ULM0_HUMAN KIAA1200 protein (Fragment) (44)
272.Q9UJU1_HUMAN Cytovillin 2 (Fragment) (44)
273.A46127 radixin (44)
274.AAD29949 Myosin heavy chain IIb (44)
275.CAB51722 IMMUNOGLOBULIN HEAVY CHAIN VARIABLE
REGION (FRAGMENT) (43)
276.Q96M50_HUMAN Hypothetical protein FLJ32825 (43)
277.Q5VTR3_HUMAN Glutamate receptor, ionotropic, N-methyl-D-aspartate
3A (43)
278.AAH00729 A-kinse anchor protein 1, isoform 1 precursor (43)
279.Q9H3U1_HUMAN SMAP-1b (Smooth muscle cell associated protein-1) (43)
280.POP1_HUMAN Ribonucleases P/MRP protein subunit POP1 (EC 3.1.26.5)
(hPOP1) (43)
281.BAA11498 KIAA0181 protein (43)
282.Q7Z3D7_HUMAN Hypothetical protein DKFZp686E2459 (43)
283.AAK27700 Immunoglobulin heavy chain variable region (Fragment) (43)
284.ZN294_HUMAN Zinc finger protein 294 (43)
285.Q5T4S7_HUMAN Retinoblastoma-associated factor 600 (RBAF600) (43)
286.ENOB_HUMAN Beta enolase (EC 4.2.1.11) (2-phospho-D-glycerate
hydro-lyase) (Muscle-specific enolase) (MSE) (42)
287.Q96RW7_HUMAN Hemicentin (42)
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288.A54849 collagen alpha 1(VII) chain precursor (42)
289.1QABA transthyretin, chain A (42)
290.Q8TC04_HUMAN Keratin 23, isoform a (42)
291.Q5T1H6_HUMAN OTTHUMP00000060196 protein (42)
292.LUHU annexin I (42)
293.AAA52935 HUMAN IG REARRANGED GAMMA-CHAIN MRNA V-
REGION, PARTIAL CDS (FRAGMENT) (42)
294.BAB40659 Membrane glycoprotein LIG-1 (42)
295.AAQ05705 Ig heavy chain variable region, VH3 family (42)
296.AAA18808 IMMUNOGLOBULIN HEAVY-CHAIN SUBGROUP VIII
V-D-J REGION (FRAGMENT) (42)
297.AAO45432 Immunoglobulin heavy chain variable region (42)
298.Q8WX70_HUMAN BA165P4.2 (Centrosomal protein 1) (41)
299.AAC96148 T-CELL RECEPTOR BETA CHAIN (FRAGMENT
300.MCON calmodulin – salmon (41)
301.1DH5L immunoglobulin vl kappa domain (41)
302.AAH20257 Neurofibromin 2, isoform 1 (41)
303.Q6AI24_HUMAN Hypothetical protein DKFZp686F19113 (41)
304.CAA07619 lysine-ketoglutarate reductase /saccharopine dehydrogenase
(41)
305.AAD50326 Truncated RAD50 protein (41)
306.Q5TF21_HUMAN OTTHUMP00000017175 protein (41)
307.CAF00512 Unnamed protein product (40)
308.LPHUB apolipoprotein B-100 precursor (40)
309.AAF98175 ATP-binding cassette transporter 1 (40)
310.CAE99963 Unnamed protein product (40)
311.AAF21617 Ig heavy chain (fragment) (40)
312.Q5THJ4_HUMAN Vacuolar protein sorting 13D (Yeast)
(OTTHUMP00000044487) (40)
313.Q6PID4_HUMAN PTK2B protein tyrosine kinase 2 beta, isoform a (40)
314.CAF00248 AX886110 NID (40)
315.Q8WXQ6_HUMAN Protein kinase A anchoring protein Ht31 (40)
316.AAC50431 Dystrobrevin-epsilon (40)
317.5VW21_HUMAN Microtubule-actin crosslinking factor 1 (40)
318.CAI19320 ARFGEF2 (40)
319.AAL76042 partitioning-defective 3 protein splice variant a (40)
320.AAH04246 MutS homolog 6 (39)
321.Q8WXQ5_HUMAN Serine/threonine protein kinase kkialre-like 1 (39)
322.Q7Z3R8_HUMAN DNA-directed RNA polymerase (EC 2.7.7.6) (39)
323.CAD20680 Sequence 1 from Patent WO0196561 (39)
324.CAD54734 Extracellular matrix protein (39)
325.AAF86276 ABCA1 (39)
326.LMO7_HUMAN LIM domain only protein 7 (LOMP) (F-box only protein
20) (39)
327.Q5MJ67_HUMAN CMYA3 (39)
328.CABL1_HUMAN CDK5 and ABL1 enzyme substrate 1 (Interactor with
CDK3 1) (Ik3-1) (39)
329.AAD05492 Kinesin superfamily motor KIF4 (39)
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330.Q8IXT1_HUMAN Hypothetical protein FLJ25416 (39)
331.Q5VZK9_HUMAN OTTHUMP00000039401 protein (39)
332.Q6IQ38_HUMAN USP36 protein (39)
333.Q6TV07_HUMAN Breast cancer-associated antigen SGA-72M (39)
334.CAF00143 Unnamed protein product (39)
335.CAF17088 Unnamed protein product (39)
336.CAF01896 Unnamed protein product (39)
337.AAC95297 PITSLRE protein kinase beta SV2 isoform (39)
338.Q6RUV3_HUMAN Brain leucine zipper protein (Fragment) (38)
339.BCHUCF calgranulin A [validated] (38)
340.TLN2_HUMAN Talin 2 (38)
341.Q76E58_HUMAN Epiplakin (38)
342.Q86TC5_HUMAN Hypothetical protein DKFZp451J094 (38)
343.AAR03497 KIAA1985 protein (38)
344.A59188 ATP-binding cassette transporter ABC3 (38)
345.CAD13085 Sequence 5 from Patent WO0174851 (38)
346.AAH47793 TRNA splicing endonuclease 54 homolog (38)
347.Q5T6T8_HUMAN Novel protein (Fragment) (38)
348.CAC88605 Sequence 19 from Patent WO0166748(38)
349.AAG13956 (N6-adenosine) methyltransferase (38)
350.SERA_HUMAN D-3-phosphoglycerate dehydrogenase (EC 1.1.1.95) (3-
PGDH) (37)
351.CAF18161 Unnamed protein product (37)
352.Q6ZWH5_HUMAN Hypothetical protein FLJ41066 (37)
353.Q8WTT2_HUMAN AD24 (Chromosome 10 open reading frame 117) (37)
354.Q9NXI4_HUMAN Hypothetical protein FLJ20227 (37)
355.Q5VW03_HUMAN OTTHUMP00000063495 protein (37)
356.Q92616_HUMAN KIAA0219 protein (Fragment) (37)
357.1A5Y protein tyrosine phosphatase 1b catalytic domain, residues 1 321
(EC 3.1.3.48) (fragments) (37)
358.S12712 small proline-rich protein spr2-1 (37)
359.AAD42883 NY-REN-62 antigen (37)
360.O95412_HUMAN Beta globin (Fragment) (37)
361.Q6IE36_HUMAN Ovostatin-2 (Fragment) (36)
362.Q8NCD3_HUMAN Hypothetical protein FLJ90328 (Fetal liver expressing
gene 1) (36)
363.Q8IZC6_HUMAN Collagen XXVII proalpha 1 chain precursor
(OTTHUMP00000021970) (36)
364.CAE99485 Unnamed protein product (36)
365.CAC26777 Sequence 3 from Patent WO0100669 (36)
366.Q5VV79_HUMAN SNF2 histone linker PHD RING helicase (36)
367.A57352 GPI-anchored protein p137 precursor (36)
368.BAA83821 Actin binding protein ABP620 (36)
369.CAI13370 RP11-155N3.2 (36)
370.Q6NSI7_HUMAN SLC12A6 protein (Fragment) (36)
371.Q8WYB5_HUMAN Histone acetyltransferase MOZ2 (36)
372.Q8NE76_HUMAN Hypothetical protein FLJ10786 (36)
373.Q6ZVP5_HUMAN Hypothetical protein FLJ42255 (36)
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374.Q8WVA6_HUMAN FLJ20244 protein (35)
375.AAL37885 Immunoglobulin kappa light chain variable region (Fragment)
(35)
376.CAA70844 HSPIBF1 NID (35)
377.Q5VUN8_HUMAN Ribosomal protein S6 kinase, 52kDa, polypeptide 1 (35)
378.Q5VT25_HUMAN CDC42 binding protein kinase alpha (DMPK-like) (35)
379.AAD43326 adaptor-related protein complex AP-4 epsilon subunit (35)
380.S71752 giant protein p619 (35)
381.Q8N6K3_HUMAN SNX25 protein (35)
382.S14458 laminin alpha-1 chain precursor (35)
383.Q9BUH5_HUMAN Transgelin 2 (35)
384.CAD69689 Sequence 1323 from Patent EP1270724 (35)
385.BAB32435 WDC146 (35)
386.Q86WF0_HUMAN Sarcoma antigen NY-SAR-48 (Fragment) (35)
387.Q5VST9_HUMAN OTTHUMP00000061415 (Obscurin, cytoskeletal
calmodulin and titin- interacting RhoGEF) (35)
388.NBHUH complement factor H precursor, long splice form [validated]
(34)
389.T00262 hypothetical protein KIAA0602 (fragment) (34)
390.R5RT27 ribosomal protein L27, cytosolic [validated] – rat (34)
391.Q96CE9_HUMAN Hematopoietically expressed homeobox (34)
392.Q6ZN75_HUMAN Hypothetical protein FLJ16363 (34)
393.CO4A6_HUMAN Collagen alpha 6(IV) chain precursor (34)
394.AAH14094 Regulator of G-protein signaling 14 (34)
395.AAH36013 Mitogen activated protein kinase kinase kinase kinase 5 (34)
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7.3 TAP-SUMO2 CELLS UNINFECTED (minus TAP cells uninfected data)
Accession number, name of protein, overall Mascot score and % peptide
coverage
Gel chunks 1, 3, 7 and 14 (see figure 4.2)
1.AAC08313 General transcription factor 2-I, 2593 (52%)
2.AAH04978 Tripartate motif-containing 28 protein, 1814 (41%)
3.JC5300 Ran GTPase activator 1, 1318 (43%)
4.I65237 ubiquitin / ribosomal protein L40, cytosolic [validated] – rat, 792
(64%)
5.Q6DSU6_HUMAN GTF2I repeat domain containing protein 1, 709 (25%)
6.AAA36787 Ubiquitin precursor, 657 (27%)
7.BAA09487 KIAA0129 protein, 614 (22%)
8.AAC00056 Hsp27 ERE-TATA-binding protein, 450 (21%)
9.AAC18697 Scaffold attachment factor B, 450 (23%)
10.AAH00036 Small ubiquitin-like modifier protein 3, 380 (45%)
11.KR131_HUMAN Keratin-associated protein 13-1 (High sulfur keratin-
associated protein 13.1), 341 (51%)
12.JC4760 SMT3 protein, 341 (57%)
13.AAD23914 ubiquitin-like protein activating enzyme; sentrin activating
enzyme, 333 (16%)
14.ROC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2
(hnRNP C1 / hnRNP C2), 321 (27%)
15.T00034 SART-1 protein, 320 (17%)
16.AAK57515 HBV pX associated protein 8 large isoform, 311 (17%)
17.Q969M9_HUMAN BRD8 protein, 301 (17%)
18.CAD69652 Sequence 1245 from Patent EP1270724, 292 (10%)
19.AAD17258 Trasncriptional intermediary factor 1 alpha; TIF1 alpha, 245
(14%)
20.A40493 DNA topoisomerase (ATP-hydrolyzing) (EC 5.99.1.3) alpha ,
239 (8%)
21.Q96GX7_HUMAN Selenium binding protein 1 (SELENBP1 protein)
(OTTHUMP00000059969), 238 (16%)
22.AAG43114 My001 protein, 199 (20%)
23.Q5T5X7_HUMAN OTTHUMP00000040500 protein, 190 (7%)
24.1A5R sumo-1, 188 (29%)
25.Q6P4R8_HUMAN NFRKB protein, 185 (6%)
26.Q5TG72_HUMAN Tripartite motif-containing 33, 180 (3%)
27.I38344 titin, cardiac muscle [validated], 169 (2%)
28.AAB63585 Transcription intermediary factor 1, 166 (11%)
29.HHHU27 heat shock protein 27, 156 (17%)
30.Q6Y9L9_HUMAN Desmoglein 4, 152 (3%)
31.CAC14658 BA332A4.3 protein (Fragment), 142 (17%)
32.Q5T3N1_HUMAN Annexin A1 (Fragment), 139 (17%)
33.G01872 selenium-binding protein, 139 (16%)
34.FNBP3_HUMAN Formin-binding protein 3 (Huntingtin yeast partner A)
(Huntingtin- interacting protein HYPA/FBP11), 138 (9%)
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35.AAP15181 forkhead winged/helix transcription factor mutant 2, 134
(8%)
36.CAA17879 novel protein similar to heterogeneous nuclear
ribonucleoprotein C (C1\/C2) (HNRPC), 134 (16%)
37.2GALB galectin-7, chain B, 130 (25%)
38.BAC05016 CDNA FLJ40040 fis, clone SYNOV2000426, highly similar
to Homo sapiens immunoglobulin lambda heavy chain, 129 (19%)
39.BAC05009 CDNA FLJ40031 fis, clone STOMA2009253, highly similar
to Homo sapiens immunoglobulin lambda heavy chain, 122 (18%)
40.BAB71560 CDNA FLJ25025 fis, clone CBL01928, highly similar to Ig
gamma immunoglobulin heavy chain, 120 (17%)
41.AAH78671 IGHG1 protein, 120 (18%)
42.Q96E67_HUMAN ACTB protein, 119 (17%)
43.FABPA_HUMAN Fatty acid-binding protein, adipocyte (AFABP)
(Adipocyte lipid-binding protein) (ALBP) (A-FABP), 117 (32%)
44.Q6A163_HUMAN Ka35 protein, 115 (11%)
45.CAA48197 DNA topoisomerase II, 114 (8%)
46.Q5VUQ5_HUMAN OTTHUMP00000059860 protein, 108 (9%)
47.AAH63625 KRTAP2-4 protein, 107 (45%)
48.Q5T2C6_HUMAN AT rich interactive domain 4B (RBP1-like)
(Fragment), 106 (5%)
49.AAH47687 BCLAF1 protein, 106 (14%)
50.Q8TC63_HUMAN IGHG4 protein, 105 (15%)
51.I58383 retinoblastoma binding protein 1, splice form I, 104 (5%)
52.AAG00910 Recombinant IgG2 heavy chain (Fragment), 104 (14%)
53.I54251 translation elongation factor eEF-1 alpha (fragment), 101 (24%)
54.BAA11481 KIAA0164 protein, 99 (7%)
55.EFHU1 translation elongation factor eEF-1 alpha-1 chain, 97 (14%)
56.I38346 elastic titin (fragment), 97 (2%)
57.CAD29721 High sulfur keratin associated protein 11.1, 95 (15%)
58.Q6U276_HUMAN Krev interaction trapped 1 variant, 92 (15%)
59.KPYM_HUMAN Pyruvate kinase, isozymes M1/M2 (EC 2.7.1.40)
(Pyruvate kinase muscle isozyme) (Cytosolic thyroid), 89 (17%)
60.AAN16399 Thymine DNA glycosylase, 89 (8%)
61.AAR32531 Immunoglobulin heavy chain variable region, 88 (23%)
62.AAS85969 Immunoglobulin heavy chain, 88 (27%)
63.Q5VWP1_HUMAN Ryanodine receptor 2 (Cardiac), 86 (3%)
64.Q9UEQ5_HUMAN S164 (Fragment), 85 (6%)
65.SYNE2_HUMAN Nesprin 2 (Nuclear envelope spectrin repeat protein 2)
(Syne-2) (Synaptic nuclear envelope protein), 84 (3%)
66.Q7Z600_HUMAN Apolipoprotein B (Including Ag(X) antigen), 84 (3%)
67.CAC22372 Sequence 1 from Patent WO0075319, 84 (14%)
68.CAC17371 Sequence 1 from Patent WO0066619, 82 (10%)
69.Q9NR99_HUMAN Adlican, 81 (3%)
70.AAB41132 Microtubule-associated protein 1a, 81 (4%)
71.Q5VYL3_HUMAN Asp (Abnormal spindle)-like, microcephaly associated
(Drosophila), 81 (2%)
72.CAD48779 Sequence 23 from Patent EP1229047, 80 (6%)
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73.AAR32500 Immunoglobulin heavy chain variable region, 80 (24%)
74.S69131 Ig heavy chain (DOT) (fragment), 80 (13%)
75.BAA82099 Anti-Entamoeba histolytica immunoglobulin gamma heavy
chain (Fragment), 78 (26%)
76.1PRXB horf6 mutant C91S, chain B (fragments), 78 (13%)
77.AAD56724 acinusL, 78 (6%)
78.Q6ECI4_HUMAN Zinc finger protein 470, 77 (12%)
79.PCLO_HUMAN Piccolo protein (Aczonin), 77 (3%)
80.AAB25835 retinoblastoma binding protein 1 isoform III, 77 (2%)
81.AAM77722 Midasin, 77 (3%)
82.Q8NFQ0_HUMAN Beige-like protein, 76 (3%)
83.ZCWC3_HUMAN Zinc finger CW-type coiled-coil domain protein 3, 75
(4%)
84.AAS85999 Immunoglobulin heavy chain, 75 (25%)
85.Q8TCU4_HUMAN ALMS1 protein, 74 (3%)
86.Q9BV61_HUMAN TRAP1 protein (Fragment), 73 (5%)
87.Q8TDJ6_HUMAN Rabconnectin, 73 (4%)
88.AAD02105 MKP-1 like protein tyrosine phosphatase, 72 (24%)
89.CAA04798 Ryanodine receptor 3, 72 (2%)
90.S42516 PML protein, splice form 1, 72 (3%)
91.Q8TD57_HUMAN Axonemal heavy chain dynein type 3, 71 (3%)
92.NCOR1_HUMAN Nuclear receptor corepressor 1 (N-CoR1) (N-CoR)71
(3%)
93.AAD51444 Methyl-CpG binding protein splice variant 3, 70 (10%)
94.BAA23795 Brain ryanodine receptor, 68 (2%)
95.Q6IEH8_HUMAN Transcriptional regulator, 68 (3%)
96.Q8WY20_HUMAN Centrosome-associated protein 350, 68 (3%)
97.AAD20946 Silencing mediator of retinoic acid and thyroid hormone
receptor alpha, 68 (4%)
98.Q8WXX0_HUMAN Ciliary dynein heavy chain 7, 68 (4%)
99.Q5VU48_HUMAN Phosphodiesterase 4D interacting protein
(Myomegalin),
100.MAPA_HUMAN Microtubule-associated protein 1A (MAP 1A)
(Proliferation-related protein p80) [Contains: MAP1 ligh, 68 (2%)
101.CAB35584 CALM2 P4 PROTEIN, 67 (17%)
102.Q7Z5C1_HUMAN Glycoprotein receptor gp330/megalin, 66 (1%)
103.AT2B4_HUMAN Plasma membrane calcium-transporting ATPase 4 (EC
3.6.3.8) (PMCA4) (Plasma membrane calcium pump is, 66 (9%)
104.AAC14667 Hsp27 ERE-TATA-binding protein, 65 (28%)
105.Q96L96_HUMAN Muscle alpha-kinase, 65 (6%)
106.Q5TBJ7_HUMAN OTTHUMP00000018803 protein, 65 (3%)
107.Q5VUM2_HUMAN OTTHUMP00000040303 (Laminin, alpha 2)
(Merosin, congenital muscular dystrophy), 65 (3%)
108.Q96Q15_HUMAN Phosphatidylinositol 3-kinase-related protein kinase,
64 (3%)
109.Q5TBT3_HUMAN OTTHUMP00000018069 (Fragment), 64 (17%)
110.S28261 centromere protein E , 64 (5%)
111.O95996_HUMAN APCL protein, 64 (6%)
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112.AAD50325 RAD50-2 protein, 64 (6%)
113.BAA20770 KIAA0311 protein, 63 (5%)
114.Q7Z2L3_HUMAN KIAA1749 protein, 63 (5%)
115.A42184 nuclear mitotic apparatus protein NuMA , 62 (6%)
116.ALU2_HUMAN Alu subfamily SB sequence contamination warning
entry, 61 (13%)
117.AAK00229 Myosin VI, 61 (4%)
118.AAR04774 Kinesin family member 21A, 61 (6%)
119.BAA25517 KIAA0591 protein, 61 (3%)
120.1A31A topoisomerase i core domain and c-terminal domain (EC
5.99.1.2), chain A (fragments), 61 (13%)
121.SPTN4_HUMAN Spectrin beta chain, brain 3 (Spectrin, non-erythroid
beta chain 3) (Beta-IV spectrin), 60 (5%)
122.AAS45545 Ankyrin repeat-containing factor-2, 60 (4%)
123.AAC05330 Cell adhesion kinase beta, 60 (6%)
124.Q5VU45_HUMAN Phosphodiesterase 4D interacting protein
(Myomegalin), 60 (7%)
125.ABCA1_HUMAN ATP-binding cassette, sub-family A, member 1
(ATP-binding cassette transporter 1) (ATP-binding cass, 60 (5%)
126.CAI22960 Novel protein KIAA0117, 60 (10%)
127.AAR25662 Ankyrin repeat-containing protein, 60 (4%)
128.Q6VU68_HUMAN Laminin alpha 3 splice variant b1, 59 (1%)
129.Q9H3T8_HUMAN MOP-3, 59 (4%)
130.Q695L1_HUMAN Striated muscle preferentially expressed protein
(Fragment), 59 (3%)
131.A41137 heat shock transcription factor 1, 59 (6%)
132.Q9UPW7_HUMAN KIAA1033 protein (Fragment), 59 (9%)
133.CAC20413 beta-myosin heavy chain, 59 (6%)
134.Q9UQB7_HUMAN Huntingtin, 59 (3%)
135.AAH06536 Symplekin, 58 (11%)
136.Q8IWQ9_HUMAN Helicase-like protein, 58 (5%)
137.S21054 DNA-directed RNA polymerase (EC 2.7.7.6) II largest chain ,
58 (4%)
138.H2AQ_HUMAN Histone H2A.q (H2A/q) (H2A-GL101), 58 (16%)
139.BAA23698 KIAA0402 protein, 57 (4%)
140.AAC83555 neuronal double zinc finger protein, 57 (2%)
141.ADHUC fructose-bisphosphate aldolase (EC 4.1.2.13) C, 57 (5%)
142.Q6DC95_HUMAN Interferon regulatory factor 2 binding protein 1, 57
(10%)
143.S21086 anion exchange protein 2, 57 (6%)
144.S37431 ankyrin 2, neuronal long splice form, 57 (3%)
145.DYH5_HUMAN Ciliary dynein heavy chain 5 (Axonemal beta dynein
heavy chain 5) (HL1), 56 (2%)
146.AAS85961 Immunoglobulin heavy chain, 56 (12%)
147.AAD22973 silencing mediator of retinoic acid and thyroid hormone
receptor extended isoform, 56 (3%)
148.Q96QV0_HUMAN PI-3-kinase-related kinase SMG-1, 56 (3%)
149.AAR02562 Immunoglobulin heavy chain variable region, 56 (12%)
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150.AAG42473 Spectrin beta IV, 55 (5%)
151.Q6DKQ9_HUMAN Cell division cycle 2-like 5 (Cholinesterase-related
cell division controller), 55 (4%)
152.Q5W0E7_HUMAN Neurobeachin, 55 (2%)
153.CAB45385 Trithorax homologue 2, 55 (5%)
154.AAA70227 IMMUNOGLOBULIN GAMMA-1 CHAIN
(FRAGMENT), 55 (13%)
155.A44265 trithorax homolog HTX, version 2, 54 (3%)
156.AAR08265 BCL-6 corepressor long isoform, 54 (2%)
157.CAC18956 Sequence 8 from Patent WO0068386, 54 (7%)
158.A59404 plectin [imported], 54 (3%)
159.A55144 autotaxin precursor, 54 (6%)
160.Q5VW21_HUMAN Microtubule-actin crosslinking factor 1, 53 (2%)
161.PARP1_HUMAN Poly [ADP-ribose] polymerase-1 (EC 2.4.2.30)
(PARP-1) (ADPRT) (NAD(+) ADP-ribosyltransferase-1) (Po, 53 (5%)
162.CAC10131 Sequence 26 from Patent DE19908423 (Fragment), 53
(5%)
163.CAA75436 Cxorf5 (71-7A) protein, 53 (5%)
164.PLEA6_HUMAN Pleckstrin homology domain-containing protein
family A member 6 (Phosphoinositol 3-phosphate-bindin, 53 (6%)
165.Q8IVL1_HUMAN Steerin2 protein, 52 (5%)
166.CAD32046 Sequence 1 from Patent WO0218544 (Fragment).-
synthetic construct, 52 (4%)
167.BAA20562 PKU-beta, 52 (7%)
168.PZRN3_HUMAN PDZ domain containing RING finger protein 3
(Ligand of Numb-protein X 3) (Semaphorin cytoplasmic do, 52 (7%)
169.Q5T9S5_HUMAN Sarcoma antigen NY-SAR-41 (NY-SAR-41), 52 (8%)
170.AAR32501 Immunoglobulin heavy chain variable region, 52 (28%)
171.Q6P7T4_HUMAN IQCE protein (Fragment), 52 (14%)
172.AAD01550 RAB-R protein, 51 (3%)
173.Q8IWY8_HUMAN KOX31-like zinc finger protein, 51 (6%)
174.Q7KYL3_HUMAN Protein kinase ATR, 51 (6%)
175.AAL62061 Bullous pemphigoid antigen 1 eA, 51 (2%)
176.G59434 KIAA0411 protein [imported] , 51 (7%)
177.AAC50893 FUSE binding protein 3, 51 (9%)
178.ISHUT1 DNA topoisomerase (EC 5.99.1.2), 51 (8%)
179.Q9NZA0_HUMAN FBP-interacting repressor (Fuse-binding protein-
interacting repressor, isoform b), 50 (5%)
180.SJHUA spectrin alpha chain , 50 (3%)
181.Q8IWB6_HUMAN TEX14 protein, 50 (5%)
182.HSCH2F histone H2A.F, embryonic – chicken, 50 (11%)
183.A35881 histone H2A.Z, 49 (11%)
184.Q9H1Q1_HUMAN BA145E8.1 (KIAA1074), 49 (2%)
185.AAC25051 Advillin; p92, 49 (8%)
186.TSHUP1 thrombospondin 1 precursor, 49 (5%)
187.Q5VVL9_HUMAN Protein tyrosine phosphatase, receptor type, D, 49
(5%)
188.O60498_HUMAN VAV-like protein (Fragment), 49 (13%)
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189.AAL01416 importin 9, 49 (7%)
190.MYH11_HUMAN Myosin heavy chain, smooth muscle isoform
(SMMHC), 49 (5%)
191.AAB87381 CHD1, 49 (3%)
192.TCF20_HUMAN Transcription factor 20 (Stromelysin 1 PDGF-
responsive element-binding protein) (SPRE-binding protein) (Nuclear factor
SPBP) (AR1), 49 (3%)
193.AAB51685 Wnt10B, 48 (7%)
194.AAR32489 Immunoglobulin heavy chain variable region, 48 (14%)
195.DOCK2_HUMAN Dedicator of cytokinesis protein 2, 48 (4%)
196.A30802 Ca2+-transporting ATPase (EC 3.6.3.8) 2, plasma membrane,
48 (7%)
197.Q8IVV0_HUMAN RABGAP1L protein (Expressed in hematopoietic
cells, heart, liver) (HLL), 48 (8%)
198.Q86UP3_HUMAN Zinc finger homeodomain 4 protein, 48 (3%)
199.AAD42072 Oxygen-regulated protein 1, 48 (4%)
200.AAG28523 Adenocarcinoma protein ART1, 48 (1%)
201.CAC43729 Sequence 1 from Patent WO0142294, 47 (1%)
202.Q9P2H7_HUMAN KIAA1370 protein (Fragment), 47 (3%)
203.AAD00186 Envoplakin, 47 (4%)
204.Q9P2D7_HUMAN KIAA1410 protein (Fragment), 47 (2%)
205.Q86YS8_HUMAN BRD4-NUT fusion oncoprotein, 47 (3%)
206.BAB33332 KIAA1662 protein, 47 (4%)
207.AAC41758 Nucleoporin, 47 (3%)
208.CAC34694 Sequence 1 from Patent WO0114414, 47 (1%)
209.AJHUPR phosphoribosylamine-glycine ligase (EC 6.3.4.13), 47 (7%)
210.AAR02567 Immunoglobulin heavy chain variable region, 46 (18%)
211.STRC_HUMAN Stereocilin precursor, 46 (3%)
212.CAA55632 Endosomal protein, 46 (4%)
213.Q5T791_HUMAN OTTHUMP00000016860 (Fragment), 46 (5%)
214.CHTOG_HUMAN CH-TOG protein (Colonic and hepatic tumor over-
expressed protein) (Ch- TOG protein), 46 (5%)
215.AAH30221 ABI gene family, member 3 (NESH)binding protein, 46
(5%)
216.AAR02549 Immunoglobulin heavy chain variable region, 46 (12%)
217.CAD70100 Sequence 1369 from Patent EP1270724 (Fragment), 46
(12%)
218.AAL26987 Bromodomain-containing 4, 46 (3%)
219.CAC88675 Sequence 7 from Patent WO0166747, 46 (2%)
220.ALU4_HUMAN Alu subfamily SB2 sequence contamination warning
entry, 46 (15%)
221.AAK19279 L-periaxin, 46 (4%)
222.AAB25318 ANTI-TETANUS ANTIBODY HEAVY CHAIN
VARIABLE REGION (FRAGMENT), 46 (23%)
223.Q9UCF5_HUMAN Interleukin 2 (Fragment), 46 (34%)
224.Q7Z406_HUMAN Myosin heavy chain, 46 (4%)
225.AAA52880 IMMUNOGLOBULIN HEAVY CHAIN PRECURSOR
(FRAGMENT), 46 (21%)
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226.S22393 Ca2+-transporting ATPase (EC 3.6.3.8) 2, long splice form,
46 (4%)
227.BAB18252 Anti TNF-alpha antibody heavy-chain Fab (Fragment), 46
(13%)
228.AAH10381 Nuclear matrix protein p84, 46 (3%)
229.Q5T670_HUMAN MCM10 minichromosome maintenance deficient 10
(S. cerevisiae), 46 (4%)
230.Q6IAM6_HUMAN LAP3 protein, 45 (10%)
231.Q5THZ5_HUMAN OTTHUMP00000028561protein, 45 (4%)
232.Q99736_HUMAN HsGCN1 (Fragment), 45 (2%)
233.AAD30389 GABA-B receptor R2, 45 (6%)
234.AAR02498 Immunoglobulin heavy chain variable region, 45 (14%)
235.Q9Y632_HUMAN APC2 protein (Fragment), 45 (8%)
236.A55575 ankyrin 3, long splice form , 45 (2%)
237.Q6NXF1_HUMAN VCY2IP1 protein (Fragment), 45 (3%)
238.Q5VW08_HUMAN OTTHUMP00000042245 protein, 45 (7%)
239.Q7Z6E8_HUMAN Retinoblastoma binding protein 6 isoform 2, 45 (3%)
240.BAA76857 KIAA1014 protein, 45 (6%)
241.CAC09161 Sequence 1 from Patent WO0043510, 45 (4%)
242.LRP1B_HUMAN Low-density lipoprotein receptor-related protein 1B
precursor (Low- density lipoprotein receptor-re, 45 (2%)
243.BAB17674 RFamide-related peptide precursor, 45 (11%)
244.Q5R3M6_HUMAN OTTHUMP00000028958 protein, 45 (3%)
245.Q5VW20_HUMAN OTTHUMP00000046304 (Microtubule-actin
crosslinking factor 1), 45 (2%)
246.8FABD Ig gamma chain V-C region (Fab fragment HIL), chain D ,
45 (12%)
247.AAF61929 protocadherin Flamingo 1, 45 (2%)
248.CAD33443 Sequence 170 from Patent WO0218424, 45 (2%)
249.AAK14335 ABC transporter ABCA2, 45 (3%)
250.AAA58669 HRX, 44 (2%)
251.AAG30515 Immunoglobulin heavy chain (Fragment), 44 (17%)
252.Q6PHY0_HUMAN CABIN1 protein, 44 (2%)
253.AAH68976 Phospholipase D1, phophatidlycholin-specific, 44 (5%)
254.JC5712 adrenoleukodystrophy related protein, 44 (6%)
255.Q5VZB7_HUMAN Calcium channel, voltage-dependent, alpha 1E
subunit, 44 (2%)
256.AAS85977 Immunoglobulin heavy chain, 44 (13%)
257.TPIS_HUMAN Triosephosphate isomerase (EC 5.3.1.1) (TIM) (Triose-
phosphate isomerase), 44 (6%)
258.ALU8_HUMAN Alu subfamily SX sequence contamination warning
entry, 44 (15%)
259.MLL3_HUMAN Myeloid/lymphoid or mixed-lineage leukemia protein
3 homolog (Histone- lysine N-methyltransferase, H3 lysine-4 specific MLL3)
(EC 2.1.1.43) (Homologous to ALR protein), 44 (1%)
260.Q5SYX5_HUMAN Golgi autoantigen, golgin subfamily a, 2 (Fragment),
44 (6%)
261.CGHU2B collagen alpha 2(IV) chain precursor – human, 44 (6%)
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262.1GC1H antibody 17b antigen-binding fragment, fab cd4-induced site
on gp120, chain H, 44 (10%)
263.AAS86025 Immunoglobulin heavy chain, 44 (18%)
264.AAF15590 Immunoglobulin heavy chain Fd region (fragment), 44
(15%)
265.Q6NX52_HUMAN ARHGEF1 protein, 43 (6%)
266.AAR02513 Immunoglobulin heavy chain variable region, 43 (15%)
267.Q6PJG2_HUMAN C14orf43 protein (Fragment), 43 (5%)
268.Q6YI51_HUMAN Ubiquitin ligase protein MIB1 (Mind Bomb
homologue 1 (MIB1), 43 (6%)
269.Q5T0X9_HUMAN REV3-like, catalytic subunit of DNA polymerase zeta
(Yeast), 43 (3%)
270.O00375_HUMAN Putative p150, 43 (4%)
271.CHD7_HUMAN Chromodomain-helicase-DNA-binding protein 7
(CHD-7) (Fragment), 43 (4%)
272.Q5Y190_HUMAN Anchor protein, 43 (1%)
273.AAC06147 RPOM, 43 (3%)
274.AAK82968 gamma-tubulin complex component, 43 (2%)
275.Q6NSK0_HUMAN Serine/threonine kinase 10, 43 (2%)
276.CAC38606 Sequence 229 from Patent WO0129221, 43 (3%)
277.AAH17232 Cleavage and polyadenylation specific factor 1, 160kDa,
43 (3%)
278.Q5T9Q5_HUMAN Succinate-CoA ligase, ADP-forming, beta subunit
(Fragment), 43 (14%)
279.BAA05393 KIAA0043 protein, 43 (2%)
280.Q5TCU6_HUMAN OTTHUMP00000045364 protein, 43 (3%)
281.DDX21_HUMAN Nucleolar RNA helicase II (Nucleolar RNA helicase
Gu) (RH II/Gu) (DEAD-box protein 21), 43 (5%)
282.T13163 Rab6 GTPase activating protein, GAPCenA, 43 (4%)
283.H2AX_HUMAN Histone H2A.x (H2a/x), 43 (11%)
284.AAH06192 Forkhead box M1, isoform 3, 43 (4%)
285.AAC72360 Chromosome-associated protein-E, 43 (3%)
286.Q9Y4F4_HUMAN KIAA0423 protein (Fragment), 43 (2%)
287.AAK52750 Nulcear receptor transcription cofactor, 43 (3%)
288.AAC50550 PATCHED, 43 (3%)
289.Q289.9BYW2_HUMAN Huntingtin interacting protein 1 (HSPC069
isoform a), 43 (3%)
290.AAR32425 Immunoglobulin heavy chain variable region, 42 (21%)
291.CAI16520 Karyopherin (importin) beta 3, 42 (7%)
292.AAS85947 Immunoglobulin heavy chain, 42 (13%)
293.AAR02512 Immunoglobulin heavy chain variable region, 42 (20%)
294.AAR32423 Immunoglobulin heavy chain variable region, 42 (14%)
295.Q5VZ08_HUMAN OTTHUMP00000044920 protein, 42 (3%)
296.AAF86613 Phospholipase C beta 1, 42 (5%)
297.Q5W9G1_HUMAN KIAA0216 splice variant 1 (Fragment), 42 (4%)
298.PKD1_HUMAN Polycystin 1 precursor (Autosomal dominant
polycystic kidney disease protein 1), 42 (2%)
299.Q5T714_HUMAN OTTHUMP00000060031 protein, 42 (2%)
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300.BAA14374 CCG1 protein, 42 (3%)
301.Q5TH00_HUMAN OTTHUMP00000031017
(OTTHUMP00000031013), 42 (13%)
302.Q5TYR7_HUMAN Hemicentin (FIBL-6), 42 (2%)
303.AAF15452 Immunoglobulin heavy chain variable region (fragment),
42 (24%)
304.1AQKH fab b7-15a2 fab immunoglobulin fab, chain H , 42 (13%)
305.AAC06259 mitotic checkpoint kinase Bub1, 42 (6%)
306.BAB18258 Anti HBs antibody heavy-chain Fab (Fragment), 41 (13%)
307.Q5T011_HUMAN KIAA0467 protein, 41 (2%)
308.AAC51331 CREB-binding protein, 41 (3%)
309.Q7L576_HUMAN Cytoplasmic FMR1 interacting protein 1, 41 (4%)
310.AAF04015 DNA cytosine-5 methyltransferase 3B, 41 (6%)
311.AAD27647 SH3P12 protein, 41 (8%)
312.AAH38585 tripartate motif protein 15, isoform alpha, 41 (6%)
313.Q8WXG9_HUMAN Very large G protein-coupled receptor 1b, 41 (2%)
314.Q8IU68_HUMAN EVIN2 (Large EVER2 protein) (Transmembrane
channel-like protein 8), 41 (4%)
315.AAC39746 Immunoglobulin heavy chain variable region (Fragment),
41 (17%)
316.Q5VWF1_HUMAN Protein kinase, lysine deficient 2, 41 (4%)
317.AAF75772 Ubiquitin-conjugating BIR-domain enzyme, 41 (1%)
318.JC5525 1 alpha,25-dihydroxyvitamin D3-inducible, 41 (17%)
319.Q70CQ4_HUMAN Ubiquitin-specific proteinase 31, 41 (4%)
320.CAD48627 Sequence 1 from Patent WO0210391, 41 (3%)
321.Q5T924_HUMAN Sorbin and SH3 domain containing 1, 41 (4%)
322.AAA82889 CENP-F kinetochore protein, 41 (2%)
323.Q6A165_HUMAN HHa7 protein (Fragment), 41 (2%)
324.CAC16626 Sequence 5 from Patent WO0063381, 41 (1%)
325.Q9UPF6_HUMAN CD3e-associated protein, 41 (10%)
326.AAC14573 serum-inducible kinase, 41 (5%)
327.B33481 interferon-induced viral resistance protein MxB , 41 (2%)
328.A45259 desmoyokin (fragments), 41 (4%)
329.AAR32509 Immunoglobulin heavy chain variable region, 41 (17%)
330.BAC80154 Immunoglobulin gamma heavy chain, 41 (14%)
331.ALU7_HUMAN Alu subfamily SQ sequence contamination warning
entry, 40 (13%)
332.Q8WWZ7_HUMAN ATP-binding cassette A5, 40 (2%)
333.Q9ULE0_HUMAN KIAA1280 protein (Fragment), 40 (5%)
334.AAS86021 Immunoglobulin heavy chain, 40 (11%)
335.Q6ZNJ1_HUMAN FLJ00341 protein (Fragment), 40 (4%)
336.AAR02496 Immunoglobulin heavy chain variable region, 40 (21%)
337.AAR32421 Immunoglobulin heavy chain variable region, 40 (18%)
338.D56695 transducin-like enhancer-of-split homolog TLE-3, 40 (3%)
339.Q5TCZ0_HUMAN OTTHUMP00000059186 protein, 40 (26%)
340.Q5VYC4_HUMAN OTTHUMP00000017476 protein, 40 (4%)
341.A44159 spectrin beta-G chain, 40 (5%)
342.Q6FI78_HUMAN LYAR protein, 40 (12%)
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343.CAD69623 Sequence 1187 from Patent EP1270724, 40 (21%)
344.Q6PIY4_HUMAN TIP120A protein (Fragment), 40 (4%)
345.Q8NHY3_HUMAN GAS2-related protein isoform beta, 40 (8%)
346.CO1A1_HUMAN Collagen alpha 1(I) chain precursor, 40 (7%)
347.AAR88379 anti-HIV-1 gp120 immunoglobulin 412d heavy chain, 40
(14%)
348.Q5T5C0_HUMAN Syntaxin binding protein 5 (Tomosyn), 40 (6%)
349.AAR32397 anti-HIV-1 gp120 immunoglobulin 412d heavy chain, 40
(19%)
350.Q5TIG6_HUMAN Myeloid\/lymphoid or mixed-lineage leukemia
(Trithorax homolog, Drosophila)\; translocated to, 4, 40 (2%)
351.AAR32446 Immunoglobulin heavy chain variable region, 40 (13%)
352.Q8TDM9_HUMAN Amplified in breast cancer 1, 40 (4%)
353.AAR02490 Immunoglobulin heavy chain variable region, 40 (12%)
354.MTMR1_HUMAN Myotubularin-related protein 1 (EC 3.1.3.-), 40 (7%)
355.AAC51317 karyopherin beta 3, 40 (7%)
356.I2C2_HUMAN Eukaryotic translation initiation factor 2C 2 (eIF2C 2)
(eIF-2C 2), 40 (7%)
357.Q8IWI9_HUMAN MGA protein (Fragment), 40 (6%)
358.CAA01501 RYANODINE RECEPTOR PROTEIN, 40 (1%)
359.NFL_HUMAN Neurofilament triplet L protein (68 kDa neurofilament
protein) (Neurofilament light polypeptide), 40 (9%)
360.BAA96056 KIAA1532 protein, 40 (8%)
361.BAA07652 KIAA0002 protein, 40 (9%)
362.WNK2_HUMAN Serine/threonine-protein kinase WNK2 (EC 2.7.1.37)
(Protein kinase with no lysine 2), 40 (2%)
363.AAD09135 Trip230, 40 (3%)
364.AAH64360 F-box and leucine-rich repear protein 11, 40 (2%)
365.CAI21723 testis-specific kinase 2, 40 (8%)
366.CAC15498 RP4-591C20.6, 40 (5%)
367.AAD13352 phosphatidlyinositol 4-kinase, 40 (4%)
368.O95785_HUMAN Homolog of Mus musculus wizL protein (Fragment),
40 (6%)
369.EGHU epidermal growth factor precursor [validated], 40 (4%)
370.Q86YW9_HUMAN TRALPUSH, 39 (3%)
371.S32436 collagen alpha 2(IX) chain (fragment), 39 (11%)
372.NNTM_HUMAN NAD(P) transhydrogenase, mitochondrial precursor
(EC 1.6.1.2) (Pyridine nucleotide transhydrogenase), 39 (4%)
373.Q5SU58_HUMAN OTTHUMP00000044921 protein, 39 (5%)
374.CAA67057 TCR JUNCTIONAL SEQUENCE (FRAGMENT), 39
(17%)
375.AAF69004 Ciliary dynein heavy chain 9, 39 (3%)
376.Q5VT62_HUMAN Tripartite motif-containing 46, 39 (12%)
377.Q8WXI7_HUMAN Ovarian cancer related tumor marker CA125, 39
(<1%)
378.Q5THR3_HUMAN OTTHUMP00000028872 protein, 39 (3%)
379.Q9Y4I0_HUMAN Zinc-finger helicase, 39 (2%)
380.Q96SE4_HUMAN DNA polymerase theta, 39 (4%)
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381.Q6P991_HUMAN Protein phosphatase 1D, 39 (4%)
382.Q8IWX1_HUMAN 3'-5' RNA exonuclease, 39 (7%)
383.CAA93625 ALL-1 protein, 39 (3%)
384.AAC05370 membrane associated guanylate kinase 2, 39 (5%)
385.ALU3_HUMAN Alu subfamily SB1 sequence contamination warning
entry, 39 (16%)
386.Q9Y2H9_HUMAN KIAA0973 protein (Fragment), 39 (4%)
387.AAB61453 Neuroendocrine-dlg, 39 (5%)
388.S69211 serine/threonine-specific protein kinase (EC 2.7.1.-), Rho-
associated , 39 (4%)
389.Q5T2Q6_HUMAN Novel protein (Fragment), 39 (3%)
390.CAD70045 Sequence 2055 from Patent EP1270724, 39 (7%)
391.Q6IC83_HUMAN DJ90G24.6 protein (Novel protein), 39 (5%)
392.CXA3_HUMAN Gap junction alpha-3 protein (Connexin 46) (Cx46),
39 (6%)
393.Q9UPP5_HUMAN KIAA1107 protein (Fragment), 38 (2%)
394.Q6FI71_HUMAN DKFZP434K1421 protein, 38 (7%)
395.A40201 artifact-warning sequence (translated ALU class A), 38 (8%)
396.Q66GS8_HUMAN Centrosome protein Cep290, 38 (2%)
397.AAK01925 CGI-201 protein, type II, 38 (5%)
398.AAK85155 Kinesin superfamily protein 1B, 38 (3%)
399.Q8NDZ1_HUMAN KIAA1737 protein, 38 (10%)
400.Q9NRN1_HUMAN Ancient conserved domain protein 4, 38 (10%)
401.BAB47488 KIAA1859 protein, 38 (7%)
402.Q5TH93_HUMAN Leucine zipper protein 1, 38 (4%)
403.SYHUQT multifunctional aminoacyl-tRNA synthetase, 38 (5%)
404.BAA86433 KIAA1119 protein, 38 (3%)
405.AAC07988 Centrosomal Nek2-associated protein 1, 38 (3%)
406.DOT1L_HUMAN Histone-lysine N-methyltransferase, H3 lysine-79
specific (EC 2.1.1.43) (Histone H3-K79 methyltransferase) (H3-K79-HMTase)
(DOT1-like protein), 38 (3%)
407.BAA09488 KIAA0139 protein, 38 (5%)
408.Q6V1P9_HUMAN Cadherin protein, 38 (3%)
409.A34581 oxysterol-binding protein, 38 (6%)
410.Q9NYZ5_HUMAN Calcium channel alpha1E subunit, delta19 delta40
delta46 splice variant (Fragment), 38 (2%)
411.A41275 DNA ligase (ATP) (EC 6.5.1.1) I, 38 (5%)
412.BAA23661 GCP170, 38 (5%)
413.O95001_HUMAN WUGSC:H_267D11.3 protein (Fragment), 38 (3%)
414.S32920 cell wall-associated protein precursor wapA [similarity] -
Bacillus subtilis, 38 (4%)
415.BAA82612 Neural adhesion molecule NB-3, 38 (2%)
416.Q5W0B2_HUMAN OTTHUMP00000016826 protein, 38 (2%)
417.Q709C8_HUMAN VPS13C-2A protein, 38 (3%)
418.AAH19257 Zinc finger, CW type with coiled-coil domain 1, 38 (3%)
419.Q6IQ23_HUMAN Pleckstrin homology domain containing, family A
member 2, 37 (4%)
420.Q5VU13_HUMAN Novel protein, 37 (5%)
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421.AAG60033 tRNA-guaning transglycolsylase, 37 (5%)
422.AAA51995 Antigen CD9, 37 (9%)
423.AAF21944 Integrin alpha 10 subunit, 37 (3%)
424.CAC39142 GD: RRBP1, 37 (5%)
425.DVHU3 multidrug resistance protein 3, 37 (6%)
426.Q7LC09_HUMAN STE20-like kinase (Fragment), 37 (6%)
427.CAA04154 spinocerebellar ataxia 7, 37 (7%)
428.Q5T583_HUMAN Filaggrin, 37 (1%)
429.Q9UHA8_HUMAN Splicing coactivator subunit SRm300, 37 (4%)
430.Q86X47_HUMAN Neural cell adhesion molecule 1, 37 (3%)
431.AAH06551 Lamin B2, 37 (5%)
432.AAL38980 WD repeat protein Gemin5, 37 (3%)
433.JN0607 alpha-catenin 1, 37 (4%)
434.T43483 translation initiation factor IF-2 homolog [similarity]
(fragment), 37 (3%)
435.CAA60685 Homologue of Drosophila Fat protein, 37 (2%)
436.BAA95972 KIAA1448 protein, 37 (4%)
437.Q6AZ91_HUMAN RAB6B protein, 37 (14%)
438.CAD10507 voltage-gated sodium channel, 37 (1%)
439.BAA82444 SET-binding protein (SEB), 37 (4%)
440.Q5XG74_HUMAN SEC31L1 protein, 37 (2%)
441.Q5SZZ1_HUMAN OTTHUMP00000039688 (Testis expressed sequence
27), 37 (12%)
442.FBX38_HUMAN F-box only protein 38 (Modulator of KLF7 activity
homolog) (MoKA), 36 (3%)
443.Q5VYL4_HUMAN Asp (Abnormal spindle)-like, microcephaly
associated (Drosophila), 36 (3%)
444.AAB87382 CHD2, 36 (2%)
445.BAA04750 Protein tyrosin phosphatase type 1, 36 (3%)
446.CAD34838 Sequence 146 from Patent WO0222660, 36 (5%)
447.CAD91029 Sequence 1 from Patent WO0220619 (Fragment), 36
(21%)
448.Q96Q06_HUMAN KIAA1881 protein (Fragment), 36 (10%)
449.RP1L1_HUMAN Retinitis pigmentosa 1-like 1 protein, 36 (4%)
450.O43469_HUMAN Natural killer cell receptor KIR3DS1 variant
(KIR3DS1), 36 (17%)
451.CAC88303 Sequence 3 from Patent WO0164871, 36 (2%)
452.AAD15903 sec7 domain family member, 36 (3%)
453.AAD43749 Protocadherin beta 1, 36 (2%)
454.Q5SQC5_HUMAN Calcium channel, voltage-dependent, L type, alpha
1B subunit, 36 (2%)
455.Q5SQC6_HUMAN Calcium channel, voltage-dependent, L type, alpha
1B subunit, 36 (2%)
456.Q13590_HUMAN Homo sapiens Cri-du-chat region (Fragment), 36
(24%)
457.Q8IV76_HUMAN PAS domain containing 1, 36 (4%)
458.Q9ULC9_HUMAN KIAA1291 protein (Fragment), 36 (6%)
459.BAA25465 KIAA0539 protein , 36 (1%)
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460.Q9H3T7_HUMAN MOP-4, 36 (6%)
461.Q6ICE0_HUMAN CSF2RB protein, 36 (2%)
462.AAC50214 Pro-a2(XI), 36 (5%)
463.Q5VXT8_HUMAN Nephronophthisis 4 (OTTHUMP00000044213), 36
(4%)
464.I38240 transcription factor SOX4, 36 (8%)
465.Q7Z4N1_HUMAN Melastatin 1 splicing variant, 36 (4%)
466.NU205_HUMAN Nuclear pore complex protein Nup205 (Nucleoporin
Nup205) (205 kDa nucleoporin), 36 (3%)
467.Q5VXI3_HUMAN Myosin IIIA, 36 (4%)
468.Q9H245_HUMAN C1orf28, 36 (17%)
469.Q8NF52_HUMAN FLJ00343 protein (Fragment), 36 (3%)
470.Q9UIW2_HUMAN NOV/plexin-A1 protein (Fragment), 36 (3%)
471.CAA70889 Miz-1 protein, 35 (6%)
472.BAA86546 KIAA1232 protein, 35 (9%)
473.Q5SYA9_HUMAN OTTHUMP00000046126
(OTTHUMP00000021391), 35 (3%)
474.Q5T8D5_HUMAN Novel protein kinase domain containing protein, 35
(3%)
475.BAA06801 Proteoglycan PG-M(V3), 35 (3%)
476.AAA59487 Laminin B1, 35 (4%)
477.Q6PD57_HUMAN EPRS protein (Fragment), 35 (7%)
478.DAAM1_HUMAN Disheveled associated activator of morphogenesis 1,
35 (6%)
479.B40016 matrin 3 (fragment), 35 (4%)
480.Q9UPN4_HUMAN KIAA1118 protein (Fragment), 35 (4%)
481.CGHU1E collagen alpha 1(XI) chain precursor, 35 (5%)
482.Q5TZA0_HUMAN Ciliary rootlet coiled-coil, rootletin (Fragment), 35
(2%)
483.CAD23837 Sequence 1 from Patent WO0204599, 35 (5%)
Gel Chunks 2-15 (see figure 4.2)
1. AAC08313 General transcription factor 2-I, 2820(59%),
2. JC5300 Ran GTPase activator 1, 2234 (61%)
3. AAH04978 Tripartate motif-containing 28 protein, 2057 (48%)
4. AAD23914 Ubiquitin-like protein activating enzyme; sentrin activating
enzyme, 660 (35%)
5. ROC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2
(hnRNP C1 / hnRNP C2), 604 (36%)
6. AAH08364 HNRPC protein, 603 (37%)
7. 1C3TA 1d8 ubiquitin mutant YES, 597 (94%)
8. Q5T5X7_HUMAN OTTHUMP00000040500 protein, 538 (20%)
9. T00034 SART-1 protein, 476 (19%)
10. AAH00036 Small ubiquitin-like modifier protein 3, 462 (54%)
11. CAA25855 alpha-tubulin, 439 (31%)
12. JC4760 SMT3 protein – human, 361 (61%)
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13. Q8N532_HUMAN TUBA6 protein, 359 (32%)
14. Q5T8B6_HUMAN OTTHUMP00000059759 protein, 352 (22%)
15. Q6DSU6_HUMAN GTF2I repeat domain containing protein 1, 346 (15%)
16. BAA09487 KIAA0138 protein, 338 (13%)
17. AAH20946 Tubulin, beta polypeptide, 335 (26%)
18. AAN16399 thymine-DNA glycosylase, 328 (20%)
19. AAP15181 Forkhead winged/helix transcription factor mutant 2, 322
(15%)
20. Q8WZB3_HUMAN N2B-Titin Isoform, 318 (3%)
21. AAC18697 Scaffold attachment factor B, 317 (20%)
22. ATCHSM actin gamma, smooth muscle – chicken, 269 (29 %)
23. A29821 dnaK-type molecular chaperone HSPA5 precursor, 267 (18%)
24. S64732 scaffold attachment factor B, 261 (20%)
25. A41137 heat shock transcription factor 1, 261 (19%)
26. Q8IWP6_HUMAN Class IVb beta tubulin, 255 (16%)
27. AAB41132 Microtubule associated protein 1a, 251 (12%)
28. CAA17879 novel protein similar to heterogeneous nuclear
ribonucleoprotein C (C1\/C2) (HNRPC), 250 (24%)
29. KPYM_HUMAN Pyruvate kinase, isozymes M1/M2 (EC 2.7.1.40)
(Pyruvate kinase muscle isozyme) (Cytosolic thyroid h, 238 (17%)
30. Q9BRZ9_HUMAN IRF2BP1 protein (Fragment), 234 (20%)
31. VIME_HUMAN Vimentin, 216 (20%)
32. JC5517 Gu/RNA helicase II binding protein, 200 (7%)
33. Q6EKJ0_HUMAN Transcription factor GTF2IRD2 beta, 198 (10%)
34. MAPA_HUMAN Microtubule-associated protein 1A (MAP 1A)
(Proliferation-related protein p80) [Contains: MAP1 ligh, 198 (6%)
35. Q6EKI9_HUMAN General transcription factor II i repeat domain 2, 197
(10%)
36. UBHU5B tubulin beta chain, 194 (14%)
37. AAG28523 Adenocarcinoma antigen ART1, 194 (14%)
38. Q86U45_HUMAN Full-length cDNA clone CS0DA009YK08 of
Neuroblastoma of Homo sapiens, 193 (32%)
39. LAP2B_HUMAN Lamina-associated polypeptide 2, isoforms
beta/gamma (Thymopoietin, isoforms beta/gamma) (TP beta/g, 189 (20%)
40. 1A5R sumo-1, 169 (34%)
41. Q9UPF6_HUMAN CD3e-associated protein, 166 (9%)
42. CC1_HUMAN Nuclear protein Hcc-1 (HSPC316) (Proliferation
associated cytokine- inducible protein CIP29), 145 (14%)
43. CAA69400 Mesenchyme Fork Head-1, 144 (5%)
44. Q5RI17_HUMAN Heterogeneous nuclear ribonucleoprotein U (Scaffold
attachment factor A) (Fragment), 141 (7%)
45. AAB60654 Neuronal nitric oxide synthase, 140 (7%)
46. Q6S382_HUMAN Plectin 2, 139 (7%)
47. AAB41497 beta-tubulin, 139 (12%)
48. AAC19382 Scaffold attachment factor A, 137 (6%)
49. AAR32531 Immunoglobulin heavy chain variable region, 135 (23%)
50. Q96D94_HUMAN SIAHBP1 protein, 133 (24%)
51. Q6P094_HUMAN LOC391257 protein, 133 (26%)
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52. AAD14062 90 kDa heat shock protein beta HSP90 beta, 132 (61%)
53. AAD11466 Heat shock protein, 132 (8%)
54. PWHUA H+-transporting two-sector ATPase (EC 3.6.3.14) alpha
chain precursor, 131 (16%)
55. A42184 nuclear mitotic apparatus protein NuMA , 130 (8%)
56. S69131 Ig heavy chain (DOT) (fragment), 129 (13%)
57. A59404 plectin [imported], 128 (6%)
58. AAR32405 Immunoglobulin heavy chain variable region, 128 (22%)
59. FNBP3_HUMAN Formin-binding protein 3 (Huntingtin yeast partner A)
(Huntingtin- interacting protein HYPA/FBP11), 125 (8%)
60. AAR02539 Immunoglobulin heavy chain variable region, 124 (26%)
61. CAI12817 FKHL18 protein, 123 (11%)
62. gamma heavy chain (Fragment), 123 (15%)
63. AAR02561 Immunoglobulin heavy chain variable region, 121 (24%)
64. Q9BV61_HUMAN TRAP1 protein (Fragment), 121 (5%)
65. CAD69623 Sequence 1187 from Patent EP1270724, 121 (21%)
66. LAP2A_HUMAN Lamina-associated polypeptide 2 isoform alpha,
(Thymopoietin isoform alpha) (TP alpha) (Thymopoietin, 120 (14%)
67. AAR32527 Immunoglobulin heavy chain variable region, 119 (23%)
68. Q5VYL3_HUMAN Asp (Abnormal spindle)-like, microcephaly
associated (Drosophila), 119 (4%)
69. Q7Z7P5_HUMAN IGHG1 protein, 118 (12%)
70. Q9UIE9_HUMAN WUGSC:H_DJ0687K01.2 protein, 117 (8%)
71. AAH14258 Similar to immunoglobulin heavy constant gamma 3 (G3m
marker), 117 (14%)
72. CAC49990 Sequence 22 from Patent WO0146261, 115 (11%)
73. Q8TD57_HUMAN Axonemal heavy chain dynein type 3, 115 (4%)
74. CAC60121 Axonemal beta heavy chain dynein type 11, 113 (4%)
75. BAC05013 CDNA FLJ40037 fis, clone SYNOV2000279, highly
similar to Human (hybridoma H210) anti-hepatitis A Ig, 113 (13%)
76. BAC05017 CDNA FLJ40041 fis, clone SYNOV2000700, highly
similar to Human (hybridoma H210) anti-hepatitis A Ig, 113 (13%)
77. CAC49992 Sequence 52 from Patent WO0146261, 112 (10%)
78. CAC22488 Sequence 24 from Patent WO0077179, 112 (8%)
79. Q5VUQ5_HUMAN OTTHUMP00000059860 protein, 111 (6%)
80. BAB71560 CDNA FLJ25025 fis, clone CBL01928, highly similar to Ig
gamma immunoglobulin heavy chain, 111 (12%)
81. AAH73789 IGHG1 protein, 109 (15%)
82. AAO17821 Anti-rabies SO57 immunoglobulin heavy chain, 109 (12%)
83. B35098 MHC class III histocompatibility antigen HLA-B-associated
protein 2 [imported], 109 (6%)
84. Q8WXI7_HUMAN Ovarian cancer related tumor marker CA125, 109
(1%)
85. AAL62061 Bullous pemphigoid antigen 1 eA, 108 (3%)
86. BAC05016 CDNA FLJ40040 fis, clone SYNOV2000426, highly
similar to Homo sapiens immunoglobulin lambda heavy chain, 107 (14%)
87. Q14214_HUMAN Nebulin (Fragment), 107 (7%)
88. Q9NR99_HUMAN Adlican, 107 (3%)
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89. S33124 tpr protein – human, 105 (6%)
90. AAD01550 RAB-R protein, 104 (3%)
91. Q695C7_HUMAN Paracingulin, 104 (3%)
92. AAA58669 HRX protein, 104 (2%)
93. Q99968_HUMAN Tpr, 104 (5%)
94. AAF69004 Ciliary dynein heavy chain 9, 101 (4%)
95. S72269 ryanodine receptor isoform 2, cardiac muscle, 100 (4%)
96. Q8TBA3_HUMAN TKT protein (Fragment), 100 (15%)
97. DYH5_HUMAN Ciliary dynein heavy chain 5 (Axonemal beta dynein
heavy chain 5) (HL1), 98 (3%)
98. VEHULA lamin A, 97 (12%)
99. JC7555 C14orf4 protein, 97 (3%)
100. AAB04636 Apolipoprotein B-100 precursor, 97 (4%)
101. AAC36704 Protein inhibitor of activated STAT protein PIASx-alpha,
95 (6%)
102. Q6P9C6_HUMAN AT rich interactive domain 3A (BRIGHT-like)
protein, 95 (10%)
103. Q5W9G1_HUMAN KIAA0216 splice variant 1 (Fragment), 94 (9%)
104. A56624 histone H2B.2, 94 (28%)
105. Q64I72_HUMAN Death domain-containing protein p84N5 short
isoform, 93 (6%)
106. CAC17315 Sequence 5 from Patent WO0066730 precursor, 93 (3%)
107. AAK85155 Kinesin superfamily protein 1B, 93 (11%)
108. Q7Z2L4_HUMAN KIAA0445 protein (Fragment), 92 (8%)
109. AAD17258 transcriptional intermediary factor 1 alpha; TIF1 alpha,
91 (5%)
110. Q7KZS0_HUMAN Ubiquitin-conjugating enzyme E2I (UBC9
homolog, yeast), 91 (22%)
111. Q6IEH8_HUMAN Transcriptional regulator, 90 (5%)
112. Q6NWQ4_HUMAN HIST1H2BM protein (Fragment), 89 (28%)
113. Q5SQ29_HUMAN HLA-B associated transcript 2, 88 (5%)
114. BAA74927 KIAA0904 protein, 88 (4%)
115. CAA28420 apo-B100 precursor, 88 (3%)
116. Q96Q89_HUMAN Mitotic kinesin-related protein, 87 (4%)
117. T08621 centrosome associated protein CEP250, 87 (5%)
118. Q7Z6E8_HUMAN Retinoblastoma binding protein 6 isoform 2, 86
(5%)
119. CAC38606 Sequence 229 from Patent WO0129221, 86 (12%)
120. A40201 artifact-warning sequence (translated ALU class A), 85
(21%)
121. Q5VT06_HUMAN OTTHUMP00000060646 (Novel protein), 85 (5%)
122. CAC20413 beta-myosin heavy chain, 84 (4%)
123. CAA48197 DNA topoisomerase II, 84 (9%)
124. AAK49332 Kinesin superfamily protein KIF1B, 84 (5%)
125. MBD1_HUMAN Methyl-CpG binding protein 1 (Methyl-CpG binding
domain protein 1) (Protein containing methyl-CpG-b, 83 (9%)
126. CAA01501 RYANODINE RECEPTOR PROTEIN, 83 (3%)
127. S22695 restin, 83 (9%)
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128. Q7KYL3_HUMAN Protein kinase ATR, 83 (4%)
129. G02311 FREAC-8 (fragment), 83 (13%)
130. TCF20_HUMAN Transcription factor 20 (Stromelysin 1 PDGF-
responsive element-binding protein) (SPRE-binding protein), 83 (4%)
131. Q9P216_HUMAN KIAA1512 protein (Fragment), 83 (7%)
132. AAK52750 Nuclear receptor transcription cofactor, 82 (4%)
133. Q5Y190_HUMAN Anchor protein, 82 (2%)
134. CGHU1E collagen alpha 1(XI) chain precursor, 81 (6%)
135. A59266 unconventional myosin-15, 80 (3%)
136. O75872_HUMAN Rab3-GAP regulatory domain, 79 (7%)
137. AA95972 KIAA1448 protein, 79 (10%)
138. CAC07498 Sequence 1 from Patent WO9961607, 79 (7%)
139. AAL33548 NUANCE, 79 (3%)
140. AAM77722 Midasin, 79 (4%)
141. BAA07652 KIAA0002 protein, 79 (15%)
142. Q9Y2F3_HUMAN KIAA0944 protein (Fragment), 79 (4%)
143. Q709C8_HUMAN VPS13C-2A protein, 79 (2%)
144. Q5VUM2_HUMAN OTTHUMP00000040303 (Laminin, alpha 2)
(Merosin, congenital muscular dystrophy), 78 (3%)
145. CAI17184 MADS box transcription enhancer factor 2, polypeptide D
(myocyte enhancer factor 2D), 78 (4%)
146. Q96JB1_HUMAN Axonemal dynein heavy chain 8, 78 (2%)
147. ALU7_HUMAN Alu subfamily SQ sequence contamination warning
entry, 78 (23%)
148. Q5W189_HUMAN OTTHUMP00000028696 protein, 77 (4%)
149. AAD04629 PCAF-associated factor 400, 77 (3%)
150. CAE75579 Subtilase, 77 (5%)
151. AAA92354 A-kinase anchor protein, 77 (3%)
152. CAC50170 Sequence 7 from Patent WO0146231, 77 (5%)
153. Q8TDJ6_HUMAN Rabconnectin, 77 (4%)
154. AAB63585 transcription intermediary factor 1, 76 (7%)
155. G59434 KIAA0411 protein [imported], 76 (6%)
156. AAH38596 CHD4 protein, 76 (6%)
157. Q5VTS4_HUMAN OTTHUMP00000016553 protein, 76 (6%)
158. A44265 trithorax homolog HTX, version 2, 76 (2%)
159. 1AO6A serum albumin, chain A – human, 76 (7%)
160. AAB03679 Myosin VIIA, 76 (4%)
161. ALU1_HUMAN Alu subfamily J sequence contamination warning
entry, 75 (22%)
162. HRX_HUMAN Zinc finger protein HRX (ALL-1) (Trithorax-like
protein), 75 (2%)
163. BAA23698 KIAA0402 protein, 75 (5%)
164. Q5THK1_HUMAN Novel protein, 75 (4%)
165. Q9UQ35_HUMAN RNA binding protein, 75 (3%)
166. Q5VVM7_HUMAN Centromere protein F, 350\/400ka (Mitosin), 75
(5%)
167. Q5VYL4_HUMAN Asp (Abnormal spindle)-like, microcephaly
associated (Drosophila), 75 (7%)
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168. AAD20946 silencing mediator of retinoic acid and thyroid hormone
receptor alpha, 74 (5%)
169. AAD00186 Envoplakin, 74 (3%)
170. AAR25662 Ankyrin repeat-containing protein, 74 (5%)
171. AAM69365 Eukaryotic translation initiation factor 4GI, 74 (4%)
172. Q76FK4_HUMAN Nucleolar protein 8, 73 (6%)
173. S09036 dnaK-type molecular chaperone HSPA6, 73 (11%)
174. MMHUMH laminin alpha-2 chain (fragment), 73 (5%)
175. CAC22372 Sequence 1 from Patent WO0075319, 73 (10%)
176. AAG01174 Smarce 1-related protein, 73 (19%)
177. Q9Y2I5_HUMAN KIAA0979 protein (Fragment), 73 (8%)
178. Q5T9S5_HUMAN Sarcoma antigen NY-SAR-41 (NY-SAR-41), 73
(7%)
179. Q6VMB5_HUMAN DNA polymerase theta, 73 (4%)
180. CAA31492 Myosin heavy chain, 72 (10%)
181. Q7Z561_HUMAN Acetyl-CoA carboxylase 1, 72 (6%)
182. Q5VZL5_HUMAN Zinc finger protein 262 (OTTHUMP00000046188),
72 (5%)
183. BAA78718 centrosome-and golgi-localized PKN-associated protein,
72 (3%)
184. CAC22378 Sequence 13 from Patent WO0075319, 72 (10%)
185. Q8TCU4_HUMAN ALMS1 protein, 72 (3%)
186. S42516 PML protein, splice form 1, 71 (4%)
187. Q7L576_HUMAN Cytoplasmic FMR1 interacting protein 1, 71 (7%)
188. AAC25051 Advillin; p92, 71 (5%)
189. Q9UIG2_HUMAN Bromodomain PHD finger transcription factor,71
(4%)
190. Q86VJ1_HUMAN E3 ligase for inhibin receptor, 71 (3%)
191. O43314_HUMAN KIAA0433 protein (Fragment), 71 (5%)
192. PZRN3_HUMAN PDZ domain containing RING finger protein 3
(Ligand of Numb-protein X 3) (Semaphorin cytoplasmic do, 71 (10%)
193. Q92954_HUMAN Megakaryocyte stimulating factor, 71 (4%)
194. CAD48779 Sequence 23 from Patent EP1229047, 70 (4%)
195. AAK29205 zinc finger protein 291, 70 ()6%)
196. O95714_HUMAN HERC2 protein, 70 (3%)
197. A55575 ankyrin 3, long splice form , 70 (3%)
198. CAB45385 trithorax homologue 2, 70 (3%)
199. A56539 giantin, 70 (4%)
200. A45259 desmoyokin (fragments), 70 (6%)
201. BAA25517 KIAA0591 protein. 70 (4%)
202. CAA09762 DNA topoisomerase (ATP-hydrolysing); topoisomerase II
alpha, 70 (6%)
203. Q96Q15_HUMAN Phosphatidylinositol 3-kinase-related protein kinase,
70 (3%)
204. O95996_HUMAN APCL protein, 70 (6%)
205. BAA22378 Myosin phophatase target subunit 1, 69 (6%)
206. KIHUPL pyruvate kinase (EC 2.7.1.40), hepatic splice form L, 69
(4%)
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207. CAC88303 Sequence 3 from Patent WO0164871, 69 (5%)
208. SKIV2_HUMAN Helicase SKI2W (Helicase-like protein) (HLP), 69
(3%)
209. Q6XDA8_HUMAN Acetyl-CoA carboxylase alpha, 69 (6%)
210. Q9Y5L9_HUMAN Transcriptional activator SRCAP, 69 (4%)
211. Q9H3T8_HUMAN MOP-3, 69 (3%)
212. AAH30221 ABI gene family, member 3 (NESH) binding protein, 68
(5%)
213. Q9UQ39_HUMAN RNA binding protein (Fragment), 68 (7%)
214. O75592_HUMAN Protein associated with Myc, 68 (2%)
215. ITSN2_HUMAN Intersectin 2 (SH3 domain-containing protein 1B)
(SH3P18) (SH3P18-like WASP associated protein), 68 (4%)
216. AAD10838 kendrin, 68 (5%)
217. Q69GU6_HUMAN Transcription factor GTF2IRD2 beta isoform 1, 68
(15%)
218. Q5VZ08_HUMAN OTTHUMP00000044920 protein, 68 (6%)
219. Q5TG72_HUMAN Tripartite motif-containing 33, 67 (4%)
220. A61231 myosin heavy chain nonmuscle form A , 67 (5%)
221. AAR25661 Ankyrin repeat-containing protein, 67 (4%)
222. JC6148 subtilisin-like proprotein convertase (EC 3.4.21.-) homolog,
67 (8%)
223. CAC19642 Nebulette, 67 (11%)
224. Q5TCU6_HUMAN OTTHUMP00000045364 protein, 67 (3%)
225. Q5VXR7_HUMAN OTTHUMP00000059760 protein, 66 (4%)
226. AAB40700 putative DNA dependant ATPase and helicase, 66 (6%)
227. Q86UP3_HUMAN Zinc finger homeodomain 4 protein, 66 (3%)
228. CAA62346 axonal transporter of synaptic vesicles, 66 (6%)
229. AAR32423 Immunoglobulin heavy chain variable region, 66 (20%)
230. CAI22960 Novel protein KIAA0117, 66 (12%)
231. AAL39080 transcription repressor p66, 66 (8%)
232. Q5THR3_HUMAN OTTHUMP00000028872 protein, 66 (7%)
233. CAA60685 Homologue of Drosophila Fat protein, 66 (3%)
234. Q9P2D7_HUMAN KIAA1410 protein, 66 (3%)
235. AAB49973 p97, 65 (10%)
236. BAA13200 KIAA0209 protein, 65 (4%)
237. A33370 H+-transporting two-sector ATPase (EC 3.6.3.14) beta
chain precursor, mitochondrial, 65 (9%)
238. Q7Z5C1_HUMAN Glycoprotein receptor gp330/megalin, 65 (2%)
239. Q8IZN0_HUMAN KIAA0377 splice variant 4, 65 (6%)
240. ALU5_HUMAN Alu subfamily SC sequence contamination warning
entry, 65 (17%)
241. ALU8_HUMAN Alu subfamily SX sequence contamination warning
entry, 64 (20%)
242. Q6IPT9_HUMAN Eukaryotic translation elongation factor 1 alpha 1, 64
(8%)
243. EFHUA2 translation elongation factor eEF-1 alpha-2 chain, 64 (9%)
244. AAH11684 GATA zinc finger domain containing 2A, 64 (9%)
239
245. S65824 reverse transcriptase homolog - human transposon L1.1, 63
(7%)
246. Q6PIY4_HUMAN TIP120A protein (Fragment), 63 (6%)
247. Q5THQ1_HUMAN OTTHUMP00000028520 protein, 63 (5%)
248. AAQ88893 Low temperature essential protein, 63 (6%)
249. Q9UHA8_HUMAN Splicing coactivator subunit SRm300, 63 (3%)
250. PCLO_HUMAN Piccolo protein (Aczonin), 63 (3%)
251. Q6DKQ9_HUMAN Cell division cycle 2-like 5 (Cholinesterase-related
cell division controller), 63 (5%)
252. CGHU6C collagen alpha 1(II) chain precursor [validated], 63 (10%)
253. AAD51793 GAG-PRO-POL-ENV PROTEIN, 63 (3%)
254. Q5SYA9_HUMAN OTTHUMP00000046126
(OTTHUMP00000021391), 63 (4%)
255. Q86U86_HUMAN Polybromo-1D, 63 (7%)
256. AAK00229 Myosin VI, 63 (4%)
257. BAA89209 Bromodomain adjacent to zinc finger domain 1A, 63
(5%)
258. Q86T11_HUMAN Full-length cDNA clone CS0DH002YN05 of T cells
(Jurkat cell line) of Homo sapiens (human) (Fragment), 62 (9%)
259. Q14333_HUMAN Facioscapulohumeral muscular dystrophy, 62 (7%)
260. ALU6_HUMAN Alu subfamily SP sequence contamination warning
entry, 62 (22%)
261. Q96L96_HUMAN Muscle alpha-kinase, 62 (5%)
262. AAC50893 FUSE binding protein 3, 62 (14%)
263. CAA34683 COL2A1, 62 (12%)
264. AAB87381 CHD1, 62 (6%)
265. ISHUT1 DNA topoisomerase (EC 5.99.1.2), 62 (9%)
266. AAC14667 Hsp27 ERE-TATA-binding protein, 62 (28%)
267. Q96DZ0_HUMAN GDAP2 protein (Ganglioside induced differentiation
associated protein 2), 61 (9%)
268. DNJCD_HUMAN DnaJ homolog subfamily C member 13, 61 (6%)
269. AAK19738 channel-kinase 1, 61 (7%)
270. Q8NF44_HUMAN FLJ00354 protein (Fragment), 61 (7%)
271. Q6PIC8_HUMAN AQR protein (Fragment), 61 (7%)
272. LRP4_HUMAN Low-density lipoprotein receptor-related protein 4
precursor (Multiple epidermal growth factor-like, 61 (2%)
273. Q5T9J7_HUMAN Spastic ataxia of Charlevoix-Saguenay (Sacsin), 61
(2%)
274. AAS85961 Immunoglobulin heavy chain, 61 (12%)
275. CGHU1B collagen alpha 4(IV) chain precursor, 61 (6%)
276. Q9GZR2_HUMAN XPMC2H (XPMC2 protein), 61 (22%)
277. SPTN4_HUMAN Spectrin beta chain, brain 3 (Spectrin, non-erythroid
beta chain 3) (Beta-IV spectrin), 61 (6%)
278. 1HJOA heat-shock 70kd protein 42kd atpase n-terminal fragment
(EC 3.6.1.3), 61 (10%)
279. Q5T2U8_HUMAN OTTHUMP00000059294 protein, 61 (4%)
280. S22610 DNA (cytosine-5-)-methyltransferase (EC 2.1.1.37), 61
(6%)
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281. Q6U276_HUMAN Krev interaction trapped 1 variant, 60 (6%)
282. I54251 translation elongation factor eEF-1 alpha (fragment), 60
(13%)
283. EGHU epidermal growth factor precursor [validated], 60 (4%)
284. Q5THM9_HUMAN OTTHUMP00000040219 protein, 60 (6%)
285. CAD70044 Sequence 2053 from Patent EP1270724 (Fragment), 60
(18%)
286. AAD29948 Myosin heavy chain, 60 (5%)
287. MLL3_HUMAN Myeloid/lymphoid or mixed-lineage leukemia protein
3 homolog (Histone- lysine N-methyltransferase, H3 lysine-4 specific
MLL3) (EC 2.1.1.43) (Homologous to ALR protein), 60 (2%)
288. SMRC1_HUMAN SWI/SNF-related matrix-associated actin-dependent
regulator of chromatin subfamily C member 1 (SWI/, 60 (8%)
289. BAC80154 Immunoglobulin heavy chain, 60 (21%)
290. AAA19604 Similar to Drosophila splicing regulator, suppressor-of
white-apricot: Swiss-Prot, 60 (6%)
291. Q9UL54_HUMAN Prostate derived STE20-like kinase PSK, 60 (6%)
292. AAH43399 Ets variant 6 gene, 60 (10%)
293. Q9HCD1_HUMAN KIAA1641 protein (Fragment), 60 (7%)
294. Q5VU48_HUMAN Phosphodiesterase 4D interacting protein
(Myomegalin), 60 (5%)
295. ZN646_HUMAN Zinc finger protein 646, 60 (4%)
296. A57570 Bloom's syndrome related protein BLM, 59 (7%)
297. AAC72361 Chromosome-associated protein-C, 59 (9%)
298. AAD00702 Myosin heavy chain 12, 59 (6%)
299. A59252 myosin heavy chain, nonmuscle, form IIB, 59 (3%)
300. AAF36817 Guanine necleotide exchange factor, 59 (3%)
301. Q60FE7_HUMAN Filamin B, 59 (3%)
302. Q5VWI4_HUMAN Nebulin-related anchoring protein, 59 (8%)
303. SIN3A_HUMAN Paired amphipathic helix protein Sin3a, 59 (6%)
304. Q5T4F9_HUMAN OTTHUMP00000044259 (SET and MYND domain
containing 3), 59 (15%)
305. Q5TCY3_HUMAN OTTHUMP00000016423 protein, 59 (3%)
306. G02093 glycerol-3-phosphate dehydrogenase (EC 1.1.99.5),
mitochondrial precursor, 59 (9%)
307. Q9Y474_HUMAN DNA-binding protein, 59 (6%)
308. Q5SW99_HUMAN OTTHUMP00000060857 protein, 59 (6%)
309. Q8IV76_HUMAN PAS domain containing 1, 59 (3%)
310. AAR02485 Immunoglobulin heavy chain variable region, 59 (23%)
311. Q9P2D9_HUMAN KIAA1408 protein (Fragment), 59 (5%)
312. A44125 high density lipoprotein-binding protein, 110K, 58 (8%)
313. Q5R3M6_HUMAN OTTHUMP00000028958 protein, 58 (4%)
314. I38928 acetyl-CoA carboxylase (EC 6.4.1.2), hepatic, 58 (6%)
315. CAD10507 Voltage-gated sodium channel, 58 (4%)
316. BAA22957 KIAA0288 protein, 58 (7%)
317. AAD56402 Cyclophilin-related protein, 58 (6%)
318. O95785_HUMAN Homolog of Mus musculus wizL protein (Fragment),
58 (5%)
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319. CHD7_HUMAN Chromodomain-helicase-DNA-binding protein 7
(CHD-7) (Fragment), 58 (4%)
320. AAK07692 NREBP, 58 (3%)
321. Q5TH00_HUMAN OTTHUMP00000031017
(OTTHUMP00000031013) protein, 58 (3%)
322. CAD89409 Immunoglobulin gamma heavy chain variable region
(Fragment), 58 (14%)
323. CAA09361 Hyperion protein, 58 (3%)
324. AAR32505 Immunoglobulin heavy chain variable region, 58 (13%)
325. Q96E87_HUMAN KIAA0690 protein, 58 (5%)
326. Q5TBJ7_HUMAN OTTHUMP00000018803 protein, 58 (4%)
327. Q8IVL1_HUMAN Steerin2 protein, 58 (3%)
328. AAD29951 Myosin heavy chain IIx/d, 58 (4%0
329. JQ0129 86K heat shock protein IV (fragment), 58 (9%)
330. Q8WXG9_HUMAN Very large G protein-coupled receptor 1b, 58 (1%)
331. HSHUA1 histone H2A.1, 58 (16%)
332. CAC60396 Sequence 77 from Patent WO0157209, 57 (6%)
333. Q6ZNJ1_HUMAN FLJ00341 protein (Fragment), 57 (4%)
334. AAC50218 Myosin-VIIa, 57 (7%)
335. Q69G40_HUMAN Transcription factor GTF2IRD2 isoform 2, 57 (20%)
336. RBM28_HUMAN RNA-binding protein 28 (RNA binding motif
protein 28), 57 (9%)
337. B40016 matrin 3 (fragment), 57 (9%)
338. A23767 myosin heavy chain, fast skeletal muscle (fragment), 57
(10%)
339. GP125_HUMAN Probable G protein-coupled receptor 125 precursor
(UNQ556/PRO1113), 57 (4%)
340. AAO18156 NALP5, 57 (5%)
341. AAB41533 Lysosomal traffic regulator, 57 (6%)
342. ALU2_HUMAN Alu subfamily SB sequence contamination warning
entry, 57 (15%)
343. BAA86596 KIAA1282 protein, 57 (6%)
344. Q68GC2_HUMAN SIN3B long isoform, 57 (7%)
345. AAD43749 Protocadherin beta, 57 (4%)
346. S32920 cell wall-associated protein precursor wapA [similarity] -
Bacillus subtilis, 57 (4%)
347. AAC09299 hoook2 protein, 57 (8%)
348. CAC25053 Sequence 3 from Patent WO0100849, 57 (5%)
349. AAD50325 RAD50-2 protein, 57 (6%)
350. Q5W0B2_HUMAN OTTHUMP00000016826 protein, 56 (3%)
351. Q5T0X9_HUMAN REV3-like, catalytic subunit of DNA polymerase
zeta (Yeast), 56 (3%)
352. AAF24858 Nebulette, 56 (11%)
353. S12788 transcription factor NF-IL6, 56 (10%)
354. AAL85487 Zinc finger 298, 56 (6%)
355. A39579 c-myc promoter-binding protein MBP-1, 56 (17%)
356. AAR02490 Immunnoglobulin heavy chain variable region, 56 (14%)
357. O00375_HUMAN Putative p150, 56 (7%)
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358. CAC22310 LAMA5, 56 (2%)
359. AAN46668 G-protein coupled receptor GPR112, 56 (2%)
360. Q8WWR6_HUMAN Beta 1,6-GlcNAc-transferase, 56 (6%)
361. Q5T1B0_HUMAN Novel protein (OTTHUMP00000060640), 56 (9%)
362. Q8N4P9_HUMAN PAXIP1L protein, 56 (13%)
363. AAH53903 SLIT-ROBO GTPase-activating protein 1, 56 (6%)
364. PUR4_HUMAN Phosphoribosylformylglycinamidine synthase (EC
6.3.5.3) (FGAM synthase) (FGAMS) (Formylglycinamide, 56 (3%)
365. T43483 translation initiation factor IF-2 homolog [similarity]
(fragment), 56 (3%)
366. AAC96010 Chaperone containing t-complex polypeptide 1, delta
subunit; CCT-delta, 56 (7%)
367. ALU3_HUMAN Alu subfamily SB1 sequence contamination warning
entry, 56 (18%)
368. JC5839 GTBP-N protein, 56 (6%)
369. DAHUAL arachidonate 5-lipoxygenase (EC 1.13.11.34) [validated],
56 (10%)
370. Q5VW08_HUMAN OTTHUMP00000042245 protein, 55 (9%)
371. I38110 1-phosphatidylinositol 3-kinase (EC 2.7.1.137) alpha
isoform, 55 (9%)
372. AAR32513 Immunoglobulin heavy chain variable region, 55 (13%)
373. AAR32515 Immunoglobulin heavy chain variable region, 55 (14%)
374. BAA20562 PKU-beta, 55 (7%)
375. IQGA2_HUMAN Ras GTPase-activating-like protein IQGAP2, 55
(7%)
376. Q9Y2J4_HUMAN Angiomotin like 2 (Fragment), 55 (7%)
377. Q6PRD1_HUMAN GPR158-like 1 receptor, 55 (4%)
378. BAB67794 KIAA1901 protein, 55 (6%)
379. S57342 endopeptidase La homolog (EC 3.4.21.-) precursor,
mitochondrial (version 1) , 55 (4%)
380. A25773 dnaK-type molecular chaperone (fragment), 55 (17%)
381. Q5VVL9_HUMAN Protein tyrosine phosphatase, receptor type, D, 55
(4%)
382. AAG09702 Zinc finger protein ZNF287, 55 (10%)
383. CAI14530 excision repair cross-complementing rodent repair
deficiency, complementation group 5 (xeroderma pigmentosum,
complementation group G (Cockayne syndrome)), 55 (5%)
384. AAF64304 Bcl2 associated transcription factor short form, 55 (7%)
385. AAC99959 DNA-directed RNA polymerase I, largest subunit, 55
(4%)
386. AAR02499 Immunoglobulin heavy chain variable region, 55 (13%)
387. AAR02507 Immunoglobulin heavy chain variable region, 55 (18%)
388. FLNC_HUMAN Filamin C (Gamma-filamin) (Filamin 2) (Protein
FLNc) (Actin-binding like protein) (ABP-L) (ABP-280-, 55 (6%)
389. Q5VYL1_HUMAN OTTHUMP00000060079 proten, 55 (4%)
390. AAC06147 RPOM,55 (6%)
391. CAA55632 Endosomal protein, 55 (5%)
392. AAR02562 Immunoglobulin heavy chain variable region, 54 (12%)
243
393. Q9UE80_HUMAN Signaling inositol polyphosphate phosphatase SHIP
II
394. AAA65018 Chondroitin sulfate proteoflycan versican V0 splice-
variant precursor peptide, 54 (1%)
395. Q7Z406_HUMAN Myosin heavy chain, 54 (3%)
396. NCOR1_HUMAN Nuclear receptor corepressor 1 (N-CoR1) (N-CoR),
54 (4%)
397. Q86Y04_HUMAN MAP4 protein (Fragment), 54 (13%)
398. CGHU2B collagen alpha 2(IV) chain precursor, 54 (5%)
399. AAR32448 Immunoglobulin heavy chain variable region, 54 (14%)
400. Q8TDA3_HUMAN Guanine nucleotide exchange factor GEF-H1
(Rho\/rac guanine nucleotide exchange factor (GEF) 2), 54 (8%)
401. AAA52420 Coagulation factor VIII, 54 (3%)
402. S28261 centromere protein E, 54 (6%)
403. Q5XJ05_HUMAN ZNF638 protein, 54 (4%)
404. CAC38608 Sequence 233 from Patent WO0129221, 54 (17%)
405. Q86YH7_HUMAN HDAC4 protein, 54 (8%)
406. A43932 mucin 2 precursor, intestinal (fragments), 53 (3%)
407. Q99736_HUMAN HsGCN1 (Fragment), 53 (3%)
408. O00362_HUMAN Putative p150, 53 (7%)
409. Q9Y4F4_HUMAN KIAA0423 protein (Fragment), 53 (3%)
410. BAA35073 Protein kinase, 53 (4%)
411. CAI19008 OTTHUMP00000039037, 53 (7%)
412. AAR02549 Immunoglobulin heavy chain variable region, 53 (12%)
413. AAF15452 Immunoglobulin heavy chain variable region (fragment),
53 (33%)
414. Q5VYK1_HUMAN Collagen, type XII, alpha 1
(OTTHUMP00000039322), 53 (2%)
415. Q5T1R5_HUMAN Immunodeficiency virus type I enhancer binding
protein 3, 53 (3%)
416. AAF31262 Sacsin, 53 (3%)
417. AAL83937 DLG5, 53 (4%)
418. AAQ94075 Truncated Krev interaction trapped 1 variant 1681 delTA,
53 (8%)
419. Q8WWZ7_HUMAN ATP-binding cassette A5, 53 (5%)
420. FBX38_HUMAN F-box only protein 38 (Modulator of KLF7 activity
homolog) (MoKA), 53 (3%)
421. CAC09161 Sequence 1 from Patent WO0043510, 53 (4%)
422. AAA52898 IMMUNOGLOBULIN HEAVY CHAIN (FRAGMENT),
53 (18%)
423. Q6PK08_HUMAN NOP5/NOP58 protein (Fragment), 53 (9%)
424. AAC50567 PTPsigma, 53 (5%)
425. A42566 omega-conotoxin-sensitive N-type calcium channel alpha
1B-1 subunit (alternatively spliced), 53 (4%)
426. Q7Z5J5_HUMAN SNF2 histone linker PHD RING helicase, 53 (6%)
427. JC2131 metabotropic glutamate receptor 5 B, 53 (6%)
428. O96028_HUMAN Putative WHSC1 protein (MMSET type II) (TRX5
protein), 53 (5%)
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429. Q5W0E7_HUMAN Neurobeachin, 53 (2%)
430. AAF21616 Ig heavy chain (fragment), 53 (19%)
431. Q9UCF5_HUMAN Interleukin 2 (Fragment), 52 (39%)
432. AAR32537 Immunoglobulin heavy chain variable region, 52 (14%)
433. Q5W041_HUMAN Novel protein, 52 (7%)
434. CAI15935 protein phosphatase 1, regulatory (inhibitor) subunit 12B,
52 (8%)
435. BAB33332 KIAA1662 protein, 52 (4%)
436. Q6PJ56_HUMAN TRDD3 protein, 52 (10%)
437. Q9H1S7_HUMAN BA56H7.1.2 (Nebulette protein (NEBL, actin-
binding Z-disc protein), 52 (14%)
438. A47008 transcription activator NF-IL6 beta, 52 (11%)
439. Q8IWV6_HUMAN Tumor-associated microtubule-associated protein,
52 (9%)
440. BAA13403 KIAA0274 protein, 52 (8%)
441. AAF75772 Ubiquitin-conjugating BIR-domain enzyme APOLLON,
52 (2%)
442. Q8WVW8_HUMAN COPG2 protein, 52 (14%)
443. S01991 transforming protein B-myb, 52 (7%)
444. Q86WG6_HUMAN Transforming acidic coiled coil 2, long isoform, 52
(3%)
445. Q66GS8_HUMAN Centrosome protein Cep290, 52 (4%)
446. AAH04274 H2A histone family, member V, isoform 1, 52 (19%)
447. Q70CQ2_HUMAN Ubiquitin-specific proteinase 34, 52 (2%)
448. BAC85687 cytochrome b – Macaca fascicularis, 52 (6%)
449. BAA23795 Brain ryanodine receptor, 52 (3%)
450. S41121 acetyl-CoA carboxylase (EC 6.4.1.2), 52 (4%)
451. AAR32444 Immunoglobulin heavy chain variable region, 52 (18%)
452. Q9BWP7_HUMAN Promyelocytic leukemia protein, isoform 11, 52
(2%)
453. BAA13198 KIAA0207 protein, 51 (8%)
454. AAG48558 LPS responsive and Beige-like anchor protein LBRA, 51
(3%)
455. CHTOG_HUMAN CH-TOG protein (Colonic and hepatic tumor over-
expressed protein) (Ch- TOG protein), 51 (4%)
456. Q14754_HUMAN ORFII, 8%)
457. Q5TBS9_HUMAN OTTHUMP00000040391 protein, 51 (4%)
458. CAC12756 dJ885L7.9.1 (Death associated transcription factor 1
(contains KIAA0333), isoform 1), 51 (9%)
459. S67527 protein kinase (EC 2.7.1.-) PRK2, 51 (5%)
460. Q5TH93_HUMAN Leucine zipper protein 1, 51 (6%)
461. A27816 phosphoglycerate kinase (EC 2.7.2.3) 2, 51 (15%)
462. AAS85951 Immunoglobulin heavy chain, 51 (15%)
463. AAR02512 Immunoglobulin heavy chain variable region, 51 (20%)
464. ITA3_HUMAN Integrin alpha-3 precursor (Galactoprotein B3)
(GAPB3) (VLA-3 alpha chain) (CD49c) (FRP-2), 51 (6%)
465. AAF78783 Myosin 5c, Myosin Vc, 51 (4%)
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466. BAA02185 eIF-4 gamma, 51 (4%)
467. Q8WWS6_HUMAN DJ537K23.3 (KIAA0266 protein) (Fragment), 51
(5%)
468. AAB87383 CHD3, 51 (4%)
469. ZCWC3_HUMAN Zinc finger CW-type coiled-coil domain protein 3,
51 (7%)
470. 1DFBH Ig gamma chain V-C region (Fab fragment 3D6), chain H,
51 (12%)
471. AAC51107 Telomerase-associated protein TP-1, 51 (3%)
472. Q5T5R0_HUMAN Protein tyrosine phosphatase, receptor type, C, 51
(4%)
473. Q9C099_HUMAN KIAA1764 protein (Fragment), 51 (3%)
474. Q5W0J4_HUMAN UPF2 regulator of nonsense transcripts homolog
(Yeast), 51 (7%)
475. A28372 insulin-like growth factor 2 receptor precursor, 50 (2%)
476. PTPRS_HUMAN Receptor-type tyrosine-protein phosphatase S
precursor (EC 3.1.3.48) (R-PTP-S) (Protein-tyrosine phosphatase sigma)
(R-PTP-sigma), 50 (5%)
477. CAC94915 Cyclin B3, 50 (4%)
478. AAC34245 Trio, 50 (3%)
479. AAK58565 Ubiquitin specific protease, 50 (7%)
480. NFM_HUMAN Neurofilament triplet M protein (160 kDa
neurofilament protein) (Neurofilament medium polypeptide), 50 (6%)
481. AAK16812 Cullin CUL4B, 50 (8%)
482. Q9UKZ4_HUMAN Tenascin-M1, 50 (2%)
483. Q68G51_HUMAN DDX42 protein (Fragment), 50 (5%)
484. AAC05243 Putative ATPase, 50 (5%)
485. Q695L1_HUMAN Striated muscle preferentially expressed protein
(Fragment), 50 (3%)
486. Q5SR01_HUMAN OTTHUMP00000060747 protein, 50 (4%)
487. CE135_HUMAN Centrosomal protein of 135 kDa (Cep135 protein), 50
(7%)
488. Q7Z478_HUMAN DEAH (Asp-Glu-Ala-His) box polypeptide 29, 50
(5%)
489. Q8IVL0_HUMAN Steerin3 protein, 50 (4%)
490. Q8IZK1_HUMAN Tripin, 50 (6%)
491. Q70CQ4_HUMAN Ubiquitin-specific proteinase 31, 50 (3%)
492. AAC51144 ATP-binding cassette transporter, 49 (3%)
493. Q5VXX7_HUMAN Chromodomain helicase DNA binding protein 1-
like, 49 (7%)
494. CAE55971 CaMK I Kinases regulated by Ca2+/CaM, 49 (11%)
495. SDG1_HUMAN Serologically defined colon cancer antigen 1 (Antigen
NY-CO-1), 49 (6%)
496. AAC24863 Gx protein, 49 (7%)
497. CAB61345 Integrin beta 4, 49 (2%)
498. Q5SZK8_HUMAN OTTHUMP00000018288 (Fragment), 49 (3%)
499. CAC39142 GD: RRBP1, 49 (3%)
500. AAH11451 Alanyl-tRNA synthetase, 49 (8%)
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501. BAB84894 FLJ00139 protein, 49 (7%)
502. A30789 creatine kinase (EC 2.7.3.2) precursor, mitochondrial, 49
(13%)
503. D40201 artifact-warning sequence (translated ALU class D), 49
(15%)
504. PLXB1_HUMAN Plexin B1 precursor (Semaphorin receptor SEP), 49
(4%)
505. Q7Z7G9_HUMAN Insulin-like growth factor 2 receptor, 49 (2%)
506. Q6YI51_HUMAN Ubiquitin ligase protein MIB1 (Mind bomb homolog
1), 49 (6%)
507. Q5SNV9_HUMAN Novel protein (Fragment), 49 (6%)
508. CAA04798 Ryanodine receptor 3, 49 (2%)
509. AAR02544 Immunoglobulin heavy chain variable region, 49 (17%)
510. Q9BZQ7_HUMAN C1orf26, 49 (8%)
511. BAB21799 KIAA1708 protein, 49 (3%)
512. AAR32459 Immunoglobulin heavy chain variable region, 49 (11%)
513. JC2460 pyruvate carboxylase (EC 6.4.1.1) precursor, 49 (4%)
514. BAA25471 KIAA0545 protein, 49 (2%)
515. AAF03094 Tousled-like kinase 1, 49 (7%)
516. Q8NHY3_HUMAN GAS2-related protein isoform beta, 49 (10%)
517. AAA17374 Human homologue of E. coli mutL gene product, Swiss-
Prot accession number P23367, 49 (8%)
518. BAA13379 Similar to S. cervisiea SEC7 protein, 49 (3%)
519. Q5M775_HUMAN NSP5beta3beta, 49 (5%)
520. AAR02513 Immunoglobulin heavy chain variable region, 49 (15%)
521. AAB31500 Pyruvate carboxylase; pyruvate:carbon dioxide ligase, 48
(5%)
522. AAS86021 Immunoglobulin heavy chain, 48 (11%)
523. NU205_HUMAN Nuclear pore complex protein Nup205 (Nucleoporin
Nup205) (205 kDa nucleoporin), 48 (5%)
524. Q8TF72_HUMAN Shroom-related protein, 48 (5%)
525. CING_HUMAN Cingulin, 48 (6%)
526. Q5W9G0_HUMAN KIAA0638 splice variant 2 (Fragment), 48 (9%)
527. CAI16671 OTTHUMP00000018074, 48 (7%)
528. CAC70714 Myosin heavy chain, 48 (2%)
529. I38155 DNA-binding regulatory factor X5, 48 (13%)
530. Q7Z6Q7_HUMAN DJ470B24.1.3 (Myeloid/lymphoid or mixed-lineage
leukemia (Trithorax (Drosophila) homolog); transloc, 48 (4%)
531. Q6P987_HUMAN Topoisomerase I binding, arginine/serine-rich, 48
(4%)
532. Q8IXU4_HUMAN RUN and TBC1 domain containing 1, 48 (4%)
533. O15090_HUMAN KIAA0390 protein (Fragment), 48 (4%)
534. Q6IPN1_HUMAN APG16L protein (Fragment), 48 (8%)
535. AAC18034 Colon cancer antigen NY-CO-45, 48 (8%)
536. AAF04726 collagen type XI alpha-a isoform B, 48 (6%)
537. AAF17217 Matrin 3, 48 (7%)
538. Q6VU68_HUMAN Laminin alpha 3 splice variant b1, 48 (2%)
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539. Q5T2B1_HUMAN ATP-binding cassette sub-family C (CFTR\/MRP)
member 2, 48 (4%)
540. Q8IXF4_HUMAN Fork head-related protein like B, 48 (3%)
541. AAK14062 Nucleosomal binding protein 1, 48 (13%)
542. AAC12728 ETS related protein-growth factor receptor tyrosine
kinase fusion proteins (Fragment), 48 (10%)
543. O95001_HUMAN WUGSC:H_267D11.3 protein (Fragment), 48 (3%)
544. Q96QH0_HUMAN WDR9 protein, form A, 48 (5%)
545. NFL_HUMAN Neurofilament triplet L protein (68 kDa neurofilament
protein) (Neurofilament light polypeptide), 48 (11%)
546. Q6PJJ8_HUMAN TBC1D1 protein (Fragment), 48 (7%)
547. Q5TFG6_HUMAN OTTHUMP00000028769 protein, 48 (6%)
548. CAD61491 Sequence 141 from Patent WO02083898, 48 (27%)
549. Q5QPB6_HUMAN OTTHUMP00000031267 protein, 48 (5%)
550. Q6KE87_HUMAN Acetyl-CoA carboxylase 2 (EC 6.4.1.2), 48 (3%)
551. Q5M774_HUMAN NSP5beta3alpha, 48 (7%)
552. Q96EB4_HUMAN Interleukin 11, 48 (13%)
553. CAC34694 Sequence 1 from Patent WO0114414, 48 (3%)
554. AAD51797 Gag-Pro-Pol protein, 48 (3%)
555. BAA74875 KIAA0852 protein, 48 (4%)
556. CAC69573 Sequence 1 from Patent WO0160985, 48 (12%)
557. AAA52880 IMMUNOGLOBULIN HEAVY CHAIN PRECURSOR
(FRAGMENT), 47 (17%)
558. Q5SNV6_HUMAN Novel protein (Fragment), 47 (11%)
559. CAE55978 CaMK II KIN1/SNF1/Nim1 family, 47 (12%)
560. BAC06833 HECT domain protein LASU1, 47 (3%)
561. MYH8_HUMAN Myosin heavy chain, skeletal muscle, perinatal
(MyHC-perinatal), 47 (3%)
562. Q5TIG6_HUMAN Myeloid\/lymphoid or mixed-lineage leukemia
(Trithorax homolog, Drosophila)\; translocated to, 4, 47 (3%)
563. Q5VYB2_HUMAN OTTHUMP00000039211
(OTTHUMP00000015997), 47 (4%)
564. Q9Y4D8_HUMAN KIAA0614 protein (Fragment), 47 (2%)
565. CAD58287 Sequence 1 from Patent WO02072826 precursor, 47
(28%)
566. Q5VSR3_HUMAN OTTHUMP00000044555 protein, 47 (10%)
567. AAS85940 Immunoglobulin heavy chain, 47 (19%)
568. RRP5_HUMAN RRP5 protein homolog (Programmed cell death
protein 11), 47 (4%)
569. DATF1_HUMAN Death associated transcription factor 1, 47 (9%)
570. Q96JI4_HUMAN KIAA1843 protein (Fragment), 47 (3%)
571. AAC37520 MLL-AF4 DER(11) FUSION PROTEIN, 47 (2%)
572. CU005_HUMAN Protein C21orf5, 47 (3%)
573. AAC39740 Immunoglobulin heavy chain variable region (Fragment),
47 (13%)
574. DDX21_HUMAN Nucleolar RNA helicase II (Nucleolar RNA helicase
Gu) (RH II/Gu) (DEAD-box protein 21), 47 (8%)
575. BAA89210 bromodomain adjacent to zinc finger domain 1B, 47 (4%)
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576. CAD69337 Sequence 609 from Patent EP1270724, 47 (6%)
577. AAG09279 Cytoplasmic protein, 47 (6%)
578. Q8TC46_HUMAN RBMY2FP protein, 47 (23%)
579. Q7Z7A1_HUMAN CENTRIOLIN, 47 (4%)
580. AAH09372 MBD3 protein, 47 (15%)
581. Q6P7T4_HUMAN IQCE protein (Fragment), 47 (12%)
582. AAK82958 pecanex-like protein 1, 47 (3%)
583. A47500 Ig mu chain switch region binding protein 2, 47 (7%)
584. S68142 probable transcription factor SMAP, 47 (6%)
585. BAA05384 type 2 inositol, 1,4,5-trisphosphate receptor, 47 (3%)
586. Q5T0F8_HUMAN Novel protein, 47 (7%)
587. AAS86039 Immunoglobulin heavy chain, 47 (13%)
588. Q9UPP2_HUMAN KIAA1110 protein (Fragment), 46 (5%)
589. AAR32397 Immunoglobulin heavy chain variable region, 46 (12%)
590. TB182_HUMAN 182 kDa tankyrase 1-binding protein, 46 (6%)
591. AAH01661 ATP-binding cassette, sub-family F, member 2, isoform
a, 46 (5%)
592. T43481 probable mucin DKFZp434C196.1 (fragment), 46 (13%)
593. AAD13352 Phospatidylinositol 4-kinase 230, 46 (3%)
594. A49873 inositol 1,4,5-triphosphate receptor, type 3, 46 (3%)
595. Q7Z2L5_HUMAN KIAA0580 protein (Fragment), 46 (3%)
596. Q5VTF9_HUMAN MAP\/microtubule affinity-regulating kinase, 46
(10%)
597. AAR02484 Immunoglobulin heavy chain variable region, 46 (15%)
598. AAO22172 Immunoglobulin heavy chain variable and constant
region (Fragment), 46 (10%)
599. Q5VTB3_HUMAN Component of oligomeric golgi complex 6
(Fragment), 46 (4%)
600. Q8IZC9_HUMAN Cardiac sodium channel alpha subunit Nav1.5, 46
(3%)
601. S21054 DNA-directed RNA polymerase (EC 2.7.7.6) II largest chain
, 46 (3%)
602. AAF05686 Anti-phospholipid immunoglobulin heavy chain VH-D-J
region (fragment), 46 (15%)
603. Q8IVG5_HUMAN KIAA2005 protein (Fragment), 46 (3%)
604. Q5VZ62_HUMAN Multiple PDZ domain protein, 46 (3%)
605. SM1L2_HUMAN Structural maintenance of chromosome 1-like 2
protein (SMC1beta protein), 46 (6%)
606. AAS85942 Immunoglobulin heavy chain, 46 (13%)
607. AAR32434 Immunoglobulin heavy chain variable region, 46 (17%)
608. AAS86004 Immunoglobulin heavy chain, 46 (15%)
609. Q5SZY9_HUMAN OTTHUMP00000020987
(OTTHUMP00000044319), 46 (9%)
610. Q6RI45_HUMAN Bromodomain and WD repeat domain containing 3
variant BRWD3-A, 46 (4%)
611. AAC51166 translation repressor NAT1, 46 (8%)
612. A33183 microtubule-associated protein 4, 46 (8%)
613. Q6ZT07_HUMAN Hypothetical protein FLJ45076, 46 (5%)
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614. CAC38829 OTT-MAL, 46 (4%)
615. ALU4_HUMAN Alu subfamily SB2 sequence contamination warning
entry, 46 (13%)
616. AAH68012 ATXN2L protein, 46 (7%)
617. AAF65516 voltage-gated potassium channel Kv4.1, 46 (8%)
618. O60293_HUMAN KIAA0546 protein (Fragment), 46 (3%)
619. E59431 phosphoinositide-binding protein [imported], 46 (3%)
620. Q9BXX2_HUMAN Breast cancer antigen NY-BR-1.1 (Fragment), 46
(6%)
621. AAF80245 filamin 2, 46 (7%)
622. AAH39174 Vinculin, isoform VCL, 46 (10%)
623. AAS85993 Immunoglobulin heavy chain, 45 (14%)
624. Q8IWZ2_HUMAN Multiple ankyrin repeats single KH domain protein
isoform 2, 45 (2%)
625. BAB21832 KIAA1741 protein, 45 (7%)
626. Q7Z460_HUMAN Multiple asters 1, 45 (6%)
627. JC5263 transmembrane tyrosine phosphatase-like protein, ICAAR,
45 (7%)
628. AAR32484 Immunoglobulin heavy chain variable region, 45 (17%)
629. Q5T655_HUMAN Novel protein, 45 (4%)
630. Q8TEN7_HUMAN FLJ00156 protein (Fragment), 45 (4%)
631. CAI22429 KIAA1404 protein, 45 (4%)
632. SYTL2_HUMAN Synaptotagmin-like protein 2 (Exophilin 4), 45 (4%)
633. AAR32416 Immunoglobulin heavy chain variable region, 45 (20%)
634. CT160_HUMAN Protein C20orf160, 45 (8%)
635. Q8WV45_HUMAN KIAA1217 protein, 45 (8%)
636. Q9UKW0_HUMAN T-cell lymphoma invasion and metastasis 2, 45
(5%)
637. BAA02794 KIAA0004 protein, 45 (9%)
638. AAA98443 TIAM1 protein, 45 (5%)
639. HELC1_HUMAN Activating signal cointegrator 1 complex subunit 3
(EC 3.6.1.-) (ASC-1 complex subunit p200) (Trip4), 45 (5%)
640. Q5T476_HUMAN OTTHUMP00000021504 (Fragment), 45 (1%)
641. Q6IPA9_HUMAN CLCN2 protein, 45 (7%)
642. BAP31_HUMAN B-cell receptor-associated protein 31 (BCR-
associated protein Bap31) (p28 Bap31) (CDM protein) (6C6), 45 (15%)
643. CAA75436 Cxorf5 (71-7A) protein, 45 (7%)
644. AAS86020 Immunoglobulin heavy chain, 45 (16%)
645. Q9UPP3_HUMAN KIAA1109 protein (Fragment), 45 (3%)
646. Q6P5V6_HUMAN SNX5 protein (Fragment), 45 (10%)
647. BAA12177 huMCM2, 45 (7%)
648. Q86UW7_HUMAN Ca2+-dependent activator protein for secretion 2,
45 (4%)
649. Q8TBI9_HUMAN Alpha isoform of regulatory subunit B56, protein
phosphatase 2A, 45 (12%)
650. CAD88683 Immunoglobulin heavy chain (Fragment), 45 (21%)
651. I38614 helicase II, 45 (6%)
652. Q5TFD7_HUMAN OTTHUMP00000016784 protein, 45 (3%)
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653. Q9Y2K2_HUMAN KIAA0999 protein (Fragment), 45 (4%)
654. CAC88675 Sequence 7 from Patent WO0166747, 45 (2%)
655. Q96JN2_HUMAN KIAA1793 protein (Fragment), 45 (5%)
656. AAA35913 Guanine nucleotide exchange factor, 45 (3%)
657. CAC70712 Myosin heavy chain, 45 (2%)
658. BAA76839 KIAA0995 protein, 45 (7%)
659. Q9P0K0_HUMAN Putative zinc finger protein, 44 (6%)
660. Q8IUS3_HUMAN NADPH oxidase activator 1, 44 (8%)
661. Q5VW04_HUMAN OTTHUMP00000063496 protein, 44 (3%)
662. Q6PK59_HUMAN C14orf43 protein (Fragment), 44 (8%)
663. BAA03406 LTG19 protein, 44 (9%)
664. BAB13393 KIAA1567 protein, 44 (8%)
665. JH0628 caldesmon , 44 (8%)
666. Q7Z3Z9_HUMAN L1 cell adhesion molecule (Fragment), 44 (4%)
667. POK5_HUMAN HERV-K_19p13.11 provirus ancestral Pol protein
(HERV-K113 Pol protein) [Includes: Reverse transcriptase (RT) (EC
2.7.7.49); Ribonuclease H (EC 3.1.26.4) (RNase H); Integrase (IN)], 44
(5%)
668. BAA92636 G protein alpha subunit i class, 44 (3%)
669. AAB25318 ANTI-TETANUS ANTIBODY HEAVY CHAIN
VARIABLE REGION (FRAGMENT), 44 (17%)
670. Q6P1M3_HUMAN LLGL2 protein, 44 (4%)
671. O15050_HUMAN KIAA0342 protein (Fragment), 44 (3%)
672. Q6P2Q9_HUMAN U5 snRNP-specific protein, 44 (2%)
673. S02004 phospholipase C (EC 3.1.4.3), phosphoinositol-specific, 44
(5%)
674. S10812 phosphatidylserine-binding phosphoprotein (fragments), 44
(45%)
675. Q5RGR9_HUMAN Novel protein similar to cell recognition molecule
CASPR3 (CASPR3), 44 (5%)
676. Q8NE12_HUMAN Suppression of tumorigenicity 5, isoform 1, 44 (7%)
677. Q9UNY1_HUMAN JAW1-related protein MRVI1B short isoform, 44
(7%)
678. A46054 GTP-binding protein ARD 1 , 44 (11%)
679. DHX34_HUMAN Probable ATP-dependent helicase DHX34 (DEAH-
box protein 34), 44 (11%)
680. BAA32700 beta-spectrin III, 44 (5%)
681. Q7L3D5_HUMAN KIAA0841 protein (Fragment), 44 (4%)
682. CAI17216 tetracopeptide repeat domain 13, 44 (5%)
683. MMHUB2 laminin gamma-1 chain precursor , 44 (4%)
684. AAM46640 Immunoglobulin heavy chain (Fragment, 44 (10%)
685. AAC05330 Cell adhesion kinase beta, 44 (5%)
686. AAA52897 IMMUNOGLOBULIN HEAVY CHAIN PRECURSOR
(FRAGMENT), 44 (18%)
687. Q6NXF6_HUMAN GPR protein, 44 (6%)
688. AAB39753 Phosphoinositide 3’-hydroxykinase p110-alpha subunit,
44 (8%)
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689. IQCB1_HUMAN IQ calmodulin-binding motif containing protein 1, 44
(9%)
690. Q7Z6T2_HUMAN DJ139D8.5.3 (Zinc finger transcription regulating
protein TReP-132 (RAPA-1), variant 3), 43 (6%)
691. Q5SQC9_HUMAN OTTHUMP00000063563 protein, 43 (3%)
692. S53869 laminin beta-2 chain precursor (version 2) , 43 (2%)
693. AAC39790 SP100-HMG nuclear autoantigen, 43 (3%)
694. CAC28482 Sequence 4 from Patent WO0104326 (Fragment), 43
(8%)
695. Q86Y92_HUMAN Similar to KIAA0922 protein (Fragment), 43 (5%)
696. Q6NVY5_HUMAN GPR89 protein, 43 (8%)
697. ZFP62_HUMAN Zinc finger protein 62 homolog (Zfp-62), 43 (9%)
698. Q9HCM1_HUMAN KIAA1551 protein (Fragment), 43 (3%)
699. BAA05392 KIAA0042 protein, 43 (6%)
700. Q9NS89_HUMAN Alpha1A-voltage-dependent calcium channel
(Fragment), 43 (4%)
701. CAD69830 Sequence 1613 from Patent EP1270724, 43 (18%)
702. Q709C6_HUMAN VPS13B-2A protein, 43 (2%)
703. Q5VUU2_HUMAN Leimodin 1 (Smooth muscle), 43 97%)
704. Q8TDM9_HUMAN Amplified in breast cancer 1, 43 (6%)
705. Q5VZB8_HUMAN OTTHUMP00000042486 protein, 43 (3%)
706. Q6P3W4_HUMAN Diacylglycerol kinase, theta, 43 (3%)
707. RP1L1_HUMAN Retinitis pigmentosa 1-like 1 protein, 43 (3%)
708. AAL62062 Bullous pemphigoid antigen 1 eB, 43 (2%)
709. Q9BR62_HUMAN LLGL2 protein, 43 (11%)
710. CAA66942 Ubiquitin hydroylase, 43 (1%)
711. Q5TI99_HUMAN OTTHUMP00000060449 protein, 43 (1%)
712. AAA36421 Protocadherin 43, 43 (7%)
713. CAD01139 Putative TRP cation channel, 43 (4%)
714. Q5U006_HUMAN Cyclin-dependent kinase 9 (CDC2-related kinase),
43 (11%)
715. GOGA3_HUMAN Golgi autoantigen, golgin subfamily A member 3
(Golgin-160) (Golgi complex-associated protein of 170 kDa) (GCP170),
43 (1%)
716. Q5T8A7_HUMAN OTTHUMP00000064652 protein, 43 (4%)
717. PDE6A_HUMAN Rod cGMP-specific 3',5'-cyclic phosphodiesterase
alpha-subunit (EC 3.1.4.17) (GMP-PDE alpha) (PDE V-B1), 43 (8%)
718. Q8IVF2_HUMAN KIAA2019 protein (Fragment), 43 (3%)
719. AAC03241 Homeobox protein, 43 (9%)
720. Q5VYM8_HUMAN Unc-13 homolog B (C. elegans), 43 (3%)
721. CAI12371 Rho GTPase activating protein 12, 43 (7%)
722. Q7Z5W9_HUMAN TCOF1 protein (Fragment), 43 (6%)
723. CAD69990 Sequence 1941 from Patent EP1270724, 43 (11%)
724. Q8TF46_HUMAN KIAA1955 protein (Fragment), 43 (4%)
725. Q76N46_HUMAN KIAA0432 protein (Fragment), 43 (7%)
726. Q8N607_HUMAN Bruno-like 6, RNA binding protein, 43 (9%)
727. S37431 ankyrin 2, neuronal long splice form, 42 (2%)
728. AAB58382 Acetyl-coA carboxylase, 42 (2%)
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729. CAE55946 Fatty acid CoA ligase-like AMP-binding enzyme, 42 (3%)
730. Q6ECI4_HUMAN Zinc finger protein 470, 42 (6%)
731. AAL93149 Golgin-160, 42 (1%)
732. Q6FI78_HUMAN LYAR protein, 42 (8%)
733. T44500 fls485 protein [imported] , 42 (9%)
734. B55282 neurofibromatosis-related protein NF1, 42 (4%)
735. Q5VUP7_HUMAN Leukemia-associated protein with a CXXC domain,
42 (2%)
736. AAL34497 SON DNA binding protein isoform A, 42 93%)
737. Q7Z7B6_HUMAN Putative sulfhydryl oxidase precursor, 42 (8%)
738. Q96JI7_HUMAN KIAA1840 protein (Fragment), 42 (2%)
739. BAA25465 KIAA0539 protein, 42 (5%)
740. AAC50059 ALL-1 fusion partner from chromosome 6, 42 (4%)
741. AAH00322 Mitotic spindle coiled-coil related protein, 42 (6%)
742. CAC15059 Putative protein kinase, 42 (5%)
743. AAL60502 Connector enhancer of KSR2A, 42 (5%)
744. BSN_HUMAN Bassoon protein (Zinc-finger protein 231), 42 (5%)
745. EMR1_HUMAN EGF-like module containing mucin-like hormone
receptor-like 1 precursor (Cell surface glycoprotein), 42 (4%)
746. I54378 gene X104 protein, 42 (4%)
747. ECT2_HUMAN ECT2 protein (Epithelial cell transforming sequence 2
oncogene), 42 (4%)
748. CAC16626 Sequence 5 from Patent WO0063381, 42 (2%)
749. Q6UWZ6_HUMAN Disulfide isomerase, 42 (5%)
750. B28096 line-1 protein ORF2, 42 (4%)
751. Q5VUY9_HUMAN Neuron navigator 1, 42 (5%)
752. AAG45223 Epsin 3, 42 (7%)
753. Q9ULE0_HUMAN KIAA1280 protein (Fragment), 42 (4%)
754. GNHUL1 retrovirus-related reverse transcriptase pseudogene , 42
(6%)
755. CAD22864 Sequence 4 from Patent WO0194390, 42 (4%)
756. Q5VYQ4_HUMAN OTTHUMP00000021403
(OTTHUMP00000046122), 42 (5%)
757. A46419 trophoblast-endothelial-activated lymphocyte surface
protein 721P , 42 (10%)
758. BAB13459 KIAA1633 protein, 42 (3%)
759. Q5T8W7_HUMAN Espin, 42 (12%)
760. AAD42072 Oxygen related protein 1, 42 (3%)
761. Q5SNV8_HUMAN Novel protein, 42 (8%)
762. AAA03354 Microtubule-associated protein 2, 42 (4%)
763. Q9UEH3_HUMAN Cytochrome P-450 2C (Fragment), 42 (15%)
764. Q5VY70_HUMAN OTTHUMP00000003454 protein, 42 (10%)
765. CGHU3A collagen alpha 3(VI) chain precursor [validated], 42 (3%)
766. Q9BWC2_HUMAN Glyceronephosphate O-acyltransferase, 42 (11%)
767. Q86X36_HUMAN DHX8 protein, 42 (6%)
768. S42167 190K protein, 42 (7%)
769. Q6Q377_HUMAN Melanin-concentrating hormone receptor 2, 42 (6%)
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770. AIP1_HUMAN Atrophin-1 interacting protein 1 (Atrophin-1
interacting protein A) (Membrane associated guanylate, 42 (4%)
771. Q8N5U2_HUMAN ATPase, H+/K+ transporting, nongastric, alpha
polypeptide, 42 (7%)
772. AAC39935 Alpha enolase like 1, 42 (17%)
773. Q5S053_HUMAN Secretory pathway calcium ATPase 2, 42 (6%)
774. AAC78790 Zonadhesin, 41 (1%)
775. Q5T795_HUMAN MDN1, midasin homolog (Yeast) (Fragment), 41
(4%)
776. Q9C0G6_HUMAN KIAA1697 protein (Fragment), 41 (2%)
777. Q8IWV8_HUMAN Ubiquitin ligase E3 alpha-II
(OTTHUMP00000039768), 41 (4%)
778. AAC72089 PITSLRE protein kinase beta SV12, 41 (30%)
779. Q5T1V6_HUMAN Novel protein, 41 (7%)
780. Q6UVW7_HUMAN F-box and leucine-rich repeat protein 13 transcript
variant 2, 41 (6%)
781. Q92815_HUMAN Cytoplasmic dynein 2 heavy chain (Fragment), 41
(9%)
782. RBHUAP adenomatous polyposis coli protein, 41 (5%)
783. Q9H4G2_HUMAN Novel protein (Fragment), 41 (3%)
784. KNTC1_HUMAN Kinetochore-associated protein 1 (Rough deal
homolog) (hRod) (HsROD) (Rod), 41 (3%)
785. AAC72360 Chromosome-associated protein-E, 41 (7%)
786. Q5VVN3_HUMAN Serine\/arginine repetitive matrix 1, 41 (8%)
787. A55178 neurotrophin receptor trkC precursor, 41 (6%)
788. AAD04160 RNA binding motif protein 6, 41 (5%)
789. CAC43730 Sequence 7 from Patent WO0142294, 41 (2%)
790. AAC51833 Ubiquitin specific protease 9, 41 (<1%)
791. Q9C0A8_HUMAN KIAA1755 protein (Fragment), 41 (6%)
792. A49651 replication factor C large subunit, 41 (7%)
793. AAM49063 Plexin D1, 41 (3%)
794. Q5XLT4_HUMAN Breast and ovarian cancer susceptibility protein
(Fragment), 41 (4%)
795. Q9C0D6_HUMAN KIAA1727 protein (Fragment), 41 (6%)
796. CK5P2_HUMAN CDK5 regulatory subunit associated protein 2
(CDK5 activator-binding protein C48), 41 (3%)
797. Q70Z35_HUMAN P-Rex2 protein, 41 (5%)
798. BAA92616 KIAA1378 protein, 41 (5%)
799. Q6DHZ8_HUMAN Activity-dependent neuroprotector, 41 (6%)
800. Q9P2N9_HUMAN KIAA1307 protein (Fragment), 41 (3%)
801. AAB38240 Huntington’s disease protein, 41 (3%)
802. MYH11_HUMAN Myosin heavy chain, smooth muscle isoform
(SMMHC), 41 (5%)
803. Q9Y485_HUMAN X-like 1 protein, 41 (5%)
804. CAA33387 Alpha-1 (III) collagen, 41 (11%)
805. CAA61132 SEX protein, 41 (3%)
806. AAH08825 DEAH (Asp-Glu-Ala-His) box polypeptide 16, 41 (6%)
807. P78409_HUMAN Butyrophilin, 41 (6%)
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808. BAB84925 FLJ00170 protein, 41 (5%)
809. Q5XKH0_HUMAN MGC42174 protein, 41 (7%)
810. Q9UP21_HUMAN Heparan N-deacetylase/N-sulfotransferase 3, 41
(5%)
811. Q8IVF9_HUMAN KIAA2012 protein (Fragment), 41 (10%)
812. Q7Z401_HUMAN C-MYC promoter-binding protein IRLB, 40 (4%)
813. BAB15795 Polyprotein, 40 (6%)
814. CAC15498 RP4-591C20.6, 40 (7%)
815. Q5VU37_HUMAN Formin 2, 40 (5%)
816. Q8WYK1_HUMAN Caspr5, 40 (5%)
817. Q5T0F6_HUMAN MAD, mothers against decapentaplegic homolog
(Drosophila) interacting protein, receptor activation, 40 (4%)
818. Q9NY74_HUMAN ETAA16 protein, 40 (5%)
819. Q6P4R7_HUMAN Sterol regulatory element binding transcription
factor 1, isoform a, 40 (5%)
820. Q5T5N2_HUMAN OTTHUMP00000043243 protein, 40 (5%)
821. JN0607 alpha-catenin 1, 40 (8%)
822. JC2542 alpha-2(E)-catenin, 40 (10%)
823. POK12_HUMAN HERV-K_1q22 provirus ancestral Pol protein
(HERV-K102 Pol protein) (HERV-K(III) Pol protein) [Includes: Reverse
transcriptase (RT) (EC 2.7.7.49); Ribonuclease H (EC 3.1.26.4) (RNase
H); Integrase (IN)], 40 (4%)
824. Q6PD62_HUMAN SH2 domain binding protein 1, 40 (5%)
825. Q7L8R2_HUMAN DJ691N24.1.1 (KIAA0980 protein, isoform 1)
(Fragment), 40 (3%)
826. CAD69495 Sequence 931 from Patent EP1270724, 40 (3%)
827. BAA86576 KIAA1262 protein, 40 (3%)
828. Q5T3W8_HUMAN Interferon, gamma-inducible protein 16, 40 (7%)
829. Q5W5T7_HUMAN Long transient receptor potential channel 3, 40
(3%)
830. Q8IUL8_HUMAN Cartilage intermediate layer protein-like protein
CLIP-2, 40 (5%)
831. G02257 NAD(P) transhydrogenase (B-specific) (EC 1.6.1.1)
precursor, mitochondrial, 40 (4%)
832. T09474 forkhead protein FREAC-2, 40 (9%)
833. FSCN1_HUMAN Fascin (Singed-like protein) (55 kDa actin bundling
protein) (p55), 40 (10%)
834. Q8TEN3_HUMAN FLJ00160 protein (Fragment), 40 (3%)
835. Q6H969_HUMAN Myomesin 1, 40 (6%)
836. Q9HBG5_HUMAN WDR10p-L, 40 (5%)
837. S59136 estradiol 17beta-dehydrogenase (EC 1.1.1.62) type 4, 40
(5%)
838. Q5T3F8_HUMAN OTTHUMP00000039890 protein, 40 (3%)
839. CAD42444 Sequence 1 from Patent WO0226817, 40 (4%)
840. Q5TBA0_HUMAN Novel protein similar to Drosophila CG11486
protein, variant 1 (Fragment), 40 (8%)
841. Q5VZ18_HUMAN Novel protein (LOC126669), 40 (7%)
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842. SLC2B_HUMAN Slp homolog lacking C2 domains-b (Exophilin 5), 40
(4%)
843. Q5VY62_HUMAN DEAH (Asp-Glu-Ala-His) box polypeptide 9
(OTTHUMP00000060702), 40 (5%)
844. I37183 gene APXL protein , 40 (4%)
845. Q6IBT3_HUMAN CCT7 protein, 40 (8%)
846. 1BF5A stat-1, chain A (fragments), 40 (8%)
847. Q96Q74_HUMAN Mitochondrial ribosomal protein L7/L12
(Fragment), 40 (54%)
848. AAF66048 Immunoglobulin kappa light chain variable region
(fragment), 40 (11%)
849. O43585_HUMAN CD2 binding protein 1 short form, 40 (9%)
850. CGHU7L collagen alpha 1(III) chain precursor, 40 (10%)
851. Q5VXU9_HUMAN OTTHUMP00000021923 protein, 40 (2%)
852. Q96BX6_HUMAN KIAA0252 protein, 40 (10%)
853. Q5VTC7_HUMAN Hexokinase domain containing 1, 40 (5%)
854. T50839 U4/U6 small nuclear ribonucleoprotein hPrp3 [imported], 40
(6%)
855. URA6_HUMAN Unknown protein from 2D-PAGE of red blood cells
(Spot 17) (Fragment), 40 (100%)
856. Q9UK88_HUMAN Genethonin 3 (Fragment), 40 (7%)
857. AAB60689 beta-adrenergic receptor kinse, 40 (12%)
858. Q8IVM0_HUMAN C3orf6 protein (Chromosome 3 open reading frame
6), 40 (7%)
859. Q5VV01_HUMAN OTTHUMP00000044924 protein, 40 (5%)
860. BAA20783 KIAA0325 protein, 40 (1%)
861. AAC41758 Nucleoporin, 40 (2%)
862. AAC50213 Pro-a2(XI), 40 (7%)
863. Q5T2F6_HUMAN Neurofascin (NFASC), 39 (7%)
864. Q5T0G1_HUMAN Novel protein (Fragment), 39 (8%)
865. PH0268 epidermal autoantigen 450K (clone pE450-C/D)(fragment),
39 (11%)
866. Q5TDR4_HUMAN OTTHUMP00000031418 protein, 39 (6%)
867. JC7988 uridine phosphorylase (EC 2.4.2.3)-2, 39 (17%)
868. CAC69377 Sequence 1 from Patent WO0144473, 39 (3%)
869. Q5T4W7_HUMAN Artemin, 39 (14%)
870. Q96IF6_HUMAN FBF1 protein (Fragment), 39 (6%)
871. BAA09762 KIAA0109 protein, 39 (5%)
872. Q86VN8_HUMAN Phospholipase C, delta 1, 39 (7%)
873. AAF60188 Toll-like receptor 7, 39 (3%)
874. I38240 transcription factor SOX4, 39 (5%)
875. AAC51202 Armadillo repeat protein, 39 (3%)
876. Q5T924_HUMAN Sorbin and SH3 domain containing 1, 39 (4%)
877. AAN40840 TBP-associated factor RNA polymerase 1-like, 39 (5%)
878. Q6ISK3_HUMAN Ubiquitin associated and SH3 domain containing, A,
long form, 39 (5%)
879. AAB93981 Pro-alpha 2(I) collagen, 39 (9%)
880. A57640 retinoblastoma binding protein RBQ-1, 39 (3%)
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881. Q6PI49_HUMAN LOC389008 protein (Fragment), 39 (11%)
882. S45344 TUP1 like enhancer, 39 (5%)
883. Q5T2T1_HUMAN Novel protein, 39 (7%)
884. BAA14323 Collagen alpha 1(V) chain precursor, 39 (7%)
885. JH0564 calcium channel alpha-1D chain, 39 (3%)
886. Q8IZA4_HUMAN ELYS transcription factor-like protein TMBS62, 39
(2%)
887. AAH68976 Phospholipase D1, phophatidycholine-specific, 39 (5%)
888. Q86YW9_HUMAN TRALPUSH, 39 (5%)
889. AAA18904 Microtubule associated protein 1B, 39 (5%)
890. AAA72125 Voltage-operated calcium channel, alpha-1 subunit, 39
(3%)
891. Q9ULE4_HUMAN KIAA1276 protein (Fragment), 39 (4%)
892. T02214 ubiquitous TPR motif isoform Y, 39 (4%)
893. Q8TF30_HUMAN KIAA1971 protein (Fragment), 39 (4%)
894. Q5T3H8_HUMAN OTTHUMP00000060347 protein, 39 (5%)
895. AAD45121 somatostatin receptor interactin protein splice variant, 39
(4%)
896. 1B3OB inosine monophosphate dehydrogenase 2 (EC 1.1.1.205),
chain B (fragments), 39 (5%)
897. Q5VZP5_HUMAN OTTHUMP00000060403 protein, 39 (6%)
898. AAH05022 sorting nexin 9, 39 (4%)
899. AAD43761 protocadherin beta 7, 39 (3%)
900. CAA71610 Ankyrin-like protein, 39 (6%)
901. AAC23915 ATP-binding cassette transporter, 39 (2%)
902. Q6ICE0_HUMAN CSF2RB protein, 39 (4%)
903. G01627 androgen receptor 1 , 39 (10%)
904. TCPZ_HUMAN T-complex protein 1, zeta subunit (TCP-1-zeta)
(CCT-zeta) (CCT-zeta-1) (Tcp20) (HTR3) (Acute morphine dependence
related protein 2), 39 (8%)
905. TLK2_HUMAN Serine/threonine-protein kinase tousled-like 2 (EC
2.7.1.37) (Tousled- like kinase 2) (PKU-alpha), 39 (5%)
906. Q9NZS4_HUMAN GR AF-1 specific protein phosphatase (Fragment),
39 (5%)
907. CAC09149 Sequence 1 from Patent DE19856882, 39 (6%)
908. O94943_HUMAN KIAA0863 protein (Fragment), 39 (5%)
909. Q8TD84_HUMAN Down syndrome cell adhesion molecule 2, 39 (3%)
910. Q9UPW7_HUMAN KIAA1033 protein (Fragment), 39 (4%)
911. Q8IVJ2_HUMAN ABCA5 transporter, 39 (8%)
912. Q8N4G8_HUMAN KIAA1683 protein, 39 (10%)
913. PCF11_HUMAN Pre-mRNA cleavage complex II protein Pcf11
(Fragment), 39 (6%)
914. Q9NRV0_HUMAN X 004 protein, 39 (9%)
915. AAK08131 Hephaestin, 39 (3%)
916. A56236 probable RNA helicase 1, 39 (6%)
917. 1SAV annexin v mutant P13, P87, P119, P163, AND P248
SUBSTITUTED WITH thioproline (prs) (fragments), 39 (5%)
918. Q7Z5R8_HUMAN Deleted in liver cancer 1, isoform 1, 38 (3%)
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919. AAH37964 DEAH (Asp-Glu-Ala-His) box polypeptide 37, 38(5%)
920. Q8N0X2_HUMAN PF20 variant 1a (Sperm-associated WD repeat
protein), 38 (11%)
921. Q9ULA1_HUMAN R31155_1, 38 (6%)
922. Q86TU7_HUMAN Full-length cDNA clone CS0DI069YD09 of
Placenta of Homo sapiens, 38 (5%)
923. Q5VX33_HUMAN ATP-binding cassette, sub-family A (ABC1),
member 1, 38 (4%)
924. Q9ULE3_HUMAN KIAA1277 protein (Fragment), 38 (2%)
925. AAF19816 Dynein intermediate chain DNAI1, 38 (6%)
926. Q92799_HUMAN Mitochondrial trifunctional protein beta subunit
(Fragment), 38 (8%)
927. AAV31784 B-cell CLL/lymphoma 11B/T-cell receptor delta constant
region fusion protein, 38 (9%)
928. Q8IVE8_HUMAN KIAA2023 protein (Fragment), 38 (4%)
929. AAF88143 Hyd protein, 38 (2%)
930. Q5UAW9_HUMAN G protein-coupled receptor 157, 38 (3%)
931. AAH06395 Cell division cycle 25B, isoform 3, 38 (9%)
932. Q5TG08_HUMAN OTTHUMP00000028720 protein, 38 (7%)
933. Q8TC05_HUMAN Nuclear protein double minute 1, 38 (9%)
934. Q7Z5V7_HUMAN Serine arginine-rich pre-mRNA splicing factor SR-
A1, 38 (4%)
935. A54600 1-phosphatidylinositol 3-kinase (EC 2.7.1.137) 110K chain
beta isoform , 38 (9%)
936. Q5T791_HUMAN OTTHUMP00000016860 (Fragment), 38 (4%)
937. Q7Z437_HUMAN Putative NFkB activating protein, 38 (6%)
938. CAD48663 Sequence 44 from Patent WO0220569, 38 (2%)
939. Q5TB80_HUMAN Chromosome 6 open reading frame 84, 38 (3%)
940. BAD16733 Fibrillin 3, 38 (3%)
941. BAB13469 KIAA1643 protein, 38 (7%)
942. BAB85807 Polycystin-1L1, 38 (2%)
943. Q8IXX8_HUMAN ProSAPiP1 protein, 38 (11%)
944. Q5SR00_HUMAN Novel protein (Fragment), 38 (6%)
945. WNK2_HUMAN Serine/threonine-protein kinase WNK2 (EC
2.7.1.37) (Protein kinase with no lysine 2) (Protein kinase, lysine-deficient
2) (P/OKcl.13), 38 (3%)
946. AAP97269 CDV protein, 38 (5%)
947. AAG03000 Vitronectin receptor alpha polypeptide, 38 (5%)
948. Q6P3U2_HUMAN BRD2 protein, 38 (7%)
949. AAC51331 CREB binding protein, 38 (3%)
950. Q8IZX7_HUMAN JNK-associated leucine-zipper protein, 38 (3%)
951. AAG33700 tensin, 38 (3%)
952. CAC33877 KIAA1404 protein, 38 (3%)
953. Q86WX7_HUMAN PRF1 protein (Fragment), 38 (3%)
954. ACSL6_HUMAN Long-chain-fatty-acid--CoA ligase 6 (EC 6.2.1.3)
(Long-chain acyl-CoA synthetase 6) (LACS 6), 38 (4%)
955. Q8WWW1_HUMAN Smoothelin-B3, 38 (7%)
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956. U520_HUMAN U5 small nuclear ribonucleoprotein 200 kDa helicase
(EC 3.6.1.-) (U5 snRNP-specific 200 kDa protein) (U5-200KD)
(Activating signal cointegrator 1 complex subunit 3-like 1), 38 (3%)
957. Q5TA69_HUMAN Nucleoporin 133kDa, 38 (3%)
958. Q9BSS5_HUMAN CLPTM1 protein (Cleft lip and palate associated
transmembrane protein 1), 38 (4%)
959. Q9P2H0_HUMAN KIAA1377 protein (Fragment), 38 (7%)
960. S45142 translation initiation factor eIF-4A2 homolog, 38 (9%)
961. Q8NFY8_HUMAN Neuroblastoma-amplified protein, 38 (4%)
962. JC7359 splicing factor, Ssf-1, 38 (5%)
963. Q5SZH6_HUMAN Novel protein, 38 (12%)
964. A38219 GAP-associated tyrosine phosphoprotein p62, 38 (12%)
965. AAC34210 tuberin, 38 (3%)
966. UN13C_HUMAN Unc-13 homolog C (Munc13-3) (Fragment), 38 (4%)
967. Q6PCB7_HUMAN Solute carrier family 27 (Fatty acid transporter),
member 1, 38 (7%)
968. JC7388 M83 protein
969. I38902 retinoblastoma binding protein RIZ, 38 (4%)
970. Q86WF7_HUMAN Sarcoma antigen NY-SAR-16 (Fragment), 38 (6%)
971. AAN45861 Scavenger receptor type F, 37 (5%)
972. Q9UNS1_HUMAN Timeless homolog, 37 (6%)
973. Q5QPI6_HUMAN OTTHUMP00000030478 (Fragment), 37 (8%)
974. AAA93229 ADP-ribosylation factor, 37 (14%)
975. Q5T5U3_HUMAN Rho GTPase activating protein 21, 37 (4%)
976. Q5VU18_HUMAN Nasopharyngeal epithelium specific protein 1
(NESG1), 37 (12%)
977. Q5R206_HUMAN Carbamoylphosphate synthetase I, 37 (2%)
978. Q8N2U5_HUMAN SYMPK protein, 37 (6%)
979. Q5VTE4_HUMAN OTTHUMP00000021897
(OTTHUMP00000063891), 37 (1%)
980. Q8WX93_HUMAN Myoneurin, 37 (5%)
981. Q9BSJ7_HUMAN CPSF6 protein, 37 (8%)
982. Q969N1_HUMAN Poly(A) polymerase gamma (EC 2.7.7.19) (Neo-
poly(A) polymerase), 37 (9%)
983. Q7Z6K9_HUMAN C22orf9 protein, 37 (16%)
984. O15129_HUMAN Breast and ovarian cancer susceptibility protein
splice variant, 37 (4%)
985. Q5T361_HUMAN OTTHUMP00000064771 protein, 37 (8%)
986. Q6IQ43_HUMAN PTPN9 protein, 37 (9%)
987. Q8TED9_HUMAN FLJ00258 protein (Fragment), 37 (6%)
988. A38197 protein kinase (EC 2.7.1.37) cdc2-like, 37 (11%)
989. AAC05370 Membrane associated guanylate kinase 2, 37 (2%)
990. Q86WG2_HUMAN ARM protein, 37 (8%)
991. CAI15569 Novel protein, 37 (12%)
992. Q8NEK9_HUMAN Chromosome 1 open reading frame 26, 37 (8%)
993. Q9NRH2_HUMAN HSNFRK protein, 37 (6%)
994. Q9BWX1_HUMAN NYD-SP6 (PHD finger protein 7, isoform 1), 37
(8%)
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995. Q5TCY1_HUMAN OTTHUMP00000016425 (Fragment), 37 (7%)
996. Q6P4I8_HUMAN IGHD protein, 37 (5%)
997. Q5Q9G7_HUMAN Polymerase kappa isoform 2, 37 (8%)
998. Q8IZC6_HUMAN Collagen XXVII proalpha 1 chain precursor
(OTTHUMP00000021970), 37 (6%)
999. BAB15783 FLJ00098 protein, 37 (5%)
1000.Q75T46_HUMAN SNAP-25-interacting protein, 37 (5%)
1001.CAI23322 ENPP3 protein, 37 (5%)
1002.Q96DI7_HUMAN U5 snRNP-specific 40 kDa protein (HPrp8-binding)
(HPRP8BP), 37 911%)
1003.AAC51105 Human reelin, 37 (1%)
1004.O14654_HUMAN Insulin receptor substrate 4 (DA24A23.2), 37 (3%)
1005.Q9HCE3_HUMAN KIAA1629 protein (Fragment), 37 (7%)
1006.AAF21944 Integrin alpha 10 subunit, 37 (2%)
1007.Q5T4T6_HUMAN Novel protein similar to synaptonemal complex
protein 2 (SYCP2), 37 (6%)
1008.Q5RGS1_HUMAN Novel protein similar to cell recognition molecule
CASPR3 (CASPR3) (Fragment), 37 (4%)
1009.AAB49993 N-methyl-D-aspartate receptor 2B subunit precursor, 37
(5%)
1010.Q96S80_HUMAN Transcription factor RFX4, 37 (10%)
1011.Q6IBF4_HUMAN HMGCS2 protein, 37 (8%)
1012.JN0599 DNA-binding protein PO-GA , 37 (8%)
1013.O94958_HUMAN KIAA0882 protein (Fragment), 37 (5%)
1014.DMN_HUMAN Desmuslin, 37 (5%)
1015.RASL1_HUMAN RasGAP-activating-like protein 1, 37 (6%)
1016.Q7Z3Y0_HUMAN Catenin, alpha 2, 37 (6%)
1017.KBTB3_HUMAN Kelch repeat and BTB domain containing protein 3
(BTB and kelch domain containing protein 3), 37 94%)
1018.Q71U35_HUMAN Transcription enhancer factor-5, 37 (12%)
1019.Q9UQ28_HUMAN KIAA0722 protein (Fragment), 37 96%)
1020.JC5785 ATP-dependent RNA helicase (EC 3.6.-.-), 37 (7%)
1021.Q6NUN1_HUMAN Chromosome 13 open reading frame 11, 37 (5%)
1022.Q9UL68_HUMAN Myelin transcription factor 1-like, 37 (6%)
1023.A57187 bumetanide-sensitive Na-K-Cl cotransporter, 37 (2%)
1024.CAI13886 N-acetylneuraminic acid synthase (sialic acid synthase), 37
(15%)
1025.Q8IV81_HUMAN Similar to splicing factor, arginine/serine-rich 8
(Suppressor-of- white-apricot homolog, Drosophila) (Fragment), 37 (5%)
1026.Q86YL4_HUMAN INM02, 36 (9%)
1027.CAC38936 Sequence 11 from Patent WO0131014, 36 (5%)
1028.Q6NXF1_HUMAN VCY2IP1 protein (Fragment), 36 (4%)
1029.A35363 synapsin I splice form a, 36 (12%)
1030.ARHG4_HUMAN Rho guanine nucleotide exchange factor 4 (APC-
stimulated guanine nucleotide exchange factor) (Asef), 36 (9%)
1031.COG5_HUMAN Conserved oligomeric Golgi complex component 5
(13S Golgi transport complex 90 kDa subunit) (GTC-90) (Golgi transport
complex 1), 36 (10%)
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1032.Q6P0M2_HUMAN Translocase of outer mitochondrial membrane 70
homolog A, 36 (4%)
1033.O94836_HUMAN KIAA0731 protein (Fragment), 36 (5%)
1034.CAE48436 p162XLC helicase, 36 (2%)
1035.Q5VSH6_HUMAN Melanoma antigen, family D, 1, 36 (3%)
1036.BAA11495 KIAA0178 protein, 36 (6%)
1037.Q8TF02_HUMAN P250R, 36 (6%)
1038.Q6UW90_HUMAN Sialyltransferase Hl, 36 (6%)
1039.Q6ZNL6_HUMAN FLJ00274 protein (Fragment), 36 (4%)
1040.Q5VUX1_HUMAN OTTHUMP00000017386
(OTTHUMP00000040156), 36 (6%)
1041.AAL57039 DNA sytosine methylytransferase 3 alpha, 36 (9%)
1042.Q8TC96_HUMAN AE2 protein, 36 )7%)
1043.Q8WWV6_HUMAN Fc alpha/mu receptor, 36 (5%)
1044.Q76I76_HUMAN Slingshot-2L, 36 (1%)
1045.S69211 serine/threonine-specific protein kinase (EC 2.7.1.-), Rho-
associated, 36 (7%)
1046.CAD10523 Sequence 1 from Patent WO0177323, 36 (5%)
1047.ZCC3_HUMAN Zinc finger CCCH type domain containing protein 3,
36 (9%)
1048.CAA44373 Human basement membrane heparan sulphate
proteoglycan core protein, 36 (2%)
1049.DAPK1_HUMAN Death-associated protein kinase 1 (EC 2.7.1.37)
(DAP kinase 1), 36 (5%)
1050.S27257 methionine adenosyltransferase (EC 2.5.1.6) 2 alpha chain,
36 (5%)
1051.Q9UPN4_HUMAN KIAA1118 protein (Fragment), 36 (7%)
1052.Q9HCD2_HUMAN KIAA1640 protein (Fragment), 36 (5%)
1053.Q9BTD3_HUMAN Hole protein, 36 (9%)
1054.Q9NS19_HUMAN HHM protein (Cyclin D-type binding-protein 1)
(CCNDBP1 protein), 36 (15%)
1055.Q96B88_HUMAN Zinc finger protein 37a (OTTHUMP00000046353),
36 (4%)
Gel chunks 10-13 (see figure 4.2)
1. BAA23486 Polyubiquitin, 539 (12%)
2. Q96H31_HUMAN UBC protein (Fragment), 488 (13%)
3. Q6FGD4_HUMAN SMT3H1 protein, 411 (48%)
4. Q96JJ2_HUMAN KIAA1835 protein (Fragment), 358 (17%)
5. HNRPC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2
(hnRNP C1 / hnRNP C2), 197 (18%)
6. Q7KZS0_HUMAN Ubiquitin-conjugating enzyme E2I (UBC9 homolog,
yeast), 150 (30%)
7. Q6PKD2_HUMAN LOC343069 protein (Fragment), 86 (18%)
8. Q6PK98_HUMAN H2A histone family, member V, isoform 1
(Fragment), 64 (14%)
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9. Q59GV8_HUMAN H2A histone family, member V isoform 1 variant
(Fragment), 61 (20%)
10. CAB35584 CALM2 P4 PROTEIN, 50 (16%)
11. SYNE2_HUMAN Nesprin 2 (Nuclear envelope spectrin repeat protein 2)
(Syne-2) (Synaptic nuclear envelope protein 2) (Nucleus and actin
connecting element protein) (NUANCE protein), 46 (<1%)
12. Q5T911_HUMAN OTTHUMP00000018392 (Fragment), 47 (1%)
13. Q9HCF8_HUMAN KIAA1614 protein (Fragment), 41 (2%)
14. Q8WXI7_HUMAN Ovarian cancer related tumor marker CA125, 41
(<1%)
15. SYTL2_HUMAN Synaptotagmin-like protein 2 (Exophilin 4), 40 (1%)
16. Q9UHA8_HUMAN Splicing coactivator subunit SRm300, 39 (1%)
17. Q6P158_HUMAN DHX57 protein (Fragment), 39 (2%)
18. Q5H9A2_HUMAN Alpha thalassemia\/mental retardation syndrome X-
linked (RAD54 homolog, S. cerevisiae), 39 (1%)
19. Q7L3D5_HUMAN KIAA0841 protein (Fragment), 38 (3%)
20. Q5T9M9_HUMAN M-phase phosphoprotein 1, 38 (2%)
21. Q5TBT1_HUMAN OTTHUMP00000040015 protein, 38 (1%)
22. Q9P2D7_HUMAN KIAA1410 protein (Fragment), 38 (1%)
23. Q9UQ39_HUMAN RNA binding protein (Fragment), 38 (2%)
24. AAH30018 RNA binding motif protein, Y-linked, family 1, member F,
37 (5%)
25. MMHUMH laminin alpha-2 chain (fragment), 37 (1%)
26. CNHUB chromogranin B precursor [validated] , 36 (2%)
27. CAC20413 Beta myosin heavy chain, 36 (2%)
28. Q6P4C7_HUMAN KRT8 protein (Fragment), 36 (6%)
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7.4 TAP-SUMO2 CELLS INFECTED WITH ADENOVIRUS TYPE 5
AT A M.O.I OF 10 FOR 24 HOURS (minus TAP cells uninfected data)
Accession number, name of protein, overall Mascot score and % peptide
coverage
Gel chunks 1-9 (see figure 4.6)
1.AAC08313 General transcription factor 2-I, 2498 (61%)
2.JC5300 Ran GTPase activator 1 – human, 2361 (63%)
3.AAH04978 Tripartate motif-containing 28 protein (TRIM 28), 1372
(41%)
4.Q5T5X7_HUMAN OTTHUMP00000040500, 1051 (33%)
5.AAD23914 Ubiquitin-like protein activating enzyme; sentrin activating
enzyme, 732 (40%)
6.AAF42836 Endoplasmic reticulum luminal Ca2= binding protein grp78;
BiP, 698 (64%)
7.I65237 ubiquitin / ribosomal protein L40, cytosolic [validated] – rat,
686 (64%)
8.BAA09860 Polyubiquitin, 657 (17%)
9.Q5T8B6_HUMAN OTTHUMP00000059759, 607 (33%)
10.1C3TA 1d8 ubiquitin mutant YES , 568 (94%)
11.ROC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2
(hnRNP C1 / hnRNP C2), 489 (33%)
12.Q6DC95_HUMAN Interferon regulatory factor 2 binding protein 1, 448
(29%)
13.A27077 dnaK-type molecular chaperone , 419 (27%)
15.Q6DSU6_HUMAN GTF2I repeat domain containing protein 1, 413
(18%)
16.AAF19786 General transcription factor 3, 412 (21%)
17.Q5SP17_HUMAN Heat shock 70kDa protein 1A, 381 (19%)
18.AAC18697 Scaffold attachment factor B, 356 (17%)
19.AAC00056 Hsp27-ERE-TATA binding protein, 342 (16%)
20.BAA09487 KIAA0138 protein, 341 (14%)
21.JC7555 C14orf4 protein – human, 334 (14%)
22.A41137 heat shock transcription factor 1, 322 (16%)
23.AAH00036 Small ubiquitin-like modifier protein 3, 307 (45%)
24.S64732 scaffold attachment factor B 303 (17%)
25.HHHU86 heat shock protein 90-alpha , 299 (10%)
26.S52863 DNA-binding protein R kappa B, 294 (14%)
27.HHHU27 heat shock protein 27 , 274 (40%)
28.Q969M9_HUMAN BRD8 protein, 274 (8%)
29.CAA98022 Plakophilin, 273 (24%)
30.Q96B34_HUMAN Beta actin, 266 (34%)
31.A25873 tubulin alpha chain (version 2) , 268 (39%)
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32.AAN16399 Thymine-DNA glycosylase, 246 (12%)
33.KPYM_HUMAN Pyruvate kinase, isozymes M1/M2 (EC 2.7.1.40)
(Pyruvate kinase muscle isozyme) (Cytosolic thyroid), 241 (23%)
34.VIME_HUMAN Vimentin, 239 (33%)
35.JC4760 SMT3 protein , 232 (57%)
36.T00034 SART-1 protein , 225 (17%)
37.AAH43399 Ets variant gene 6, 225 (16%)
38.1A5R sumo-1, 214 (48%)
39.Q8IWR2_HUMAN Class II beta tubulin isotype, 213 (33%)
40.Q8IWP6_HUMAN Class IVb beta tubulin, 213 (31%)
41.Q9UPF6_HUMAN CD3e-associated protein, 203 (16%)
42.Q5T8M7_HUMAN Actin, alpha 1, skeletal muscle, 194 (21%)
43.Q8IWI9_HUMAN MGA protein (Fragment), 185 (9%)
44.Q5TG72_HUMAN Tripartite motif-containing 33, 183 (7%)
45.ZCWC3_HUMAN Zinc finger CW-type coiled-coil domain protein 3,
182 (14%)
46.Q5RI17_HUMAN Heterogeneous nuclear ribonucleoprotein U
(Scaffold attachment factor A) (Fragment), 180 (7%)
47.HCC1_HUMAN Nuclear protein Hcc-1 (HSPC316) (Proliferation
associated cytokine- inducible protein CIP29), 178 (13%)
48.AAG28523 Adenocarcinoma antigen ART1, 163 (11%)
49.UBHU5B tubulin beta chain , 162 (28%)
50.Q6EEV6_HUMAN Small ubiquitin-like protein 4
(OTTHUMP00000040124), 161 (35%)
51.A57198 splicing factor, arginine/serine-rich 7, 160 (28%)
52.AAN60442 Nesprin-1, 154 (3%)
53.LAP2B_HUMAN Lamina-associated polypeptide 2, isoforms
beta/gamma (Thymopoietin, isoforms beta/gamma) (TP beta/g, 152 (13%)
54.S09036 dnaK-type molecular chaperone HSPA6, 151 (8%)
55.Q6EKI9_HUMAN General transcription factor II i repeat domain 2, 150
(8%)
56.Q9NZA0_HUMAN FBP-interacting repressor (Fuse-binding protein-
interacting repressor, isoform b), 149 (19%)
57.4PGTA glutathione s-transferase (EC 2.5.1.18) mutant VAL 104
VARIANT naturally occurring variants of hgst, 148 (29%)
58.CAI23317 Arginase, liver, 147 (28%)
59.EFHU1 translation elongation factor eEF-1 alpha-1 chain, 146
(14%)
60.CAA48197 DNA topoisomerase II, 144 (7%)
61.A43700 BN51 protein, 144 (14%)
62.Q719H9_HUMAN Potassium channel tetramerization domain-
containing 1 (KCTD1 protein), 136 (30%)
63.Q8IV76_HUMAN PAS domain containing 1, 135 (8%)
64.AAH10578 Threonyl-tRNA synthetase, 133 (6%)
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65.Q7KZS0_HUMAN Ubiquitin-conjugating enzyme E2I (UBC9
homolog, yeast), 129 (3)%)
66.A39579 c-myc promoter-binding protein MBP-1, 128 (19%)
67.Q5VY62_HUMAN DEAH (Asp-Glu-Ala-His) box polypeptide 9
(OTTHUMP00000060702), 125 (5%)
68.A47363 RNA helicase A, 120 (5%)
69.AAD10197 DNA recombination and repair protein, 119 (7%)
70.CAA09762 DNA topoisomerase (ATP-hydrolysing); topoisomerse II
alpha, 118 (7%)
71.Q5VZL5_HUMAN Zinc finger protein 262 (OTTHUMP00000046188),
116 (4%)
72.Q5SZY0_HUMAN Chaperonin containing TCP1, subunit 3 (Gamma),
115 (17%)
73.AAB63585 Transcription intermediary factor 1, 114 (8%)
74.AAA61281 Vimentin, 109 (34%)
75.Q5VT06_HUMAN OTTHUMP00000060646 (Novel protein), 109 (4%)
76.Q695C7_HUMAN Paracingulin, 107 (6%)
77.Q9H552_HUMAN OTTHUMP00000021786, 105 (5%)
78.AAH75846 IGHG1 protein, 101 (13%)
79.Q9BV61_HUMAN TRAP1 protein (Fragment), 101 (7%)
80.AAK57515 HBV pX protein 8 large isoform, 98 (6%)
81.Q5SQX9_HUMAN Novel protein similar to beta-tubulin 4Q (TUBB4Q)
(LOC253936) (Fragment), 97 (15%)
82.CAA28420 Apo-B100 precursor, 97 (4%)
83.AAH75842 IGHG1 protein, 97 (13%)
84.Q5T9J7_HUMAN Spastic ataxia of Charlevoix-Saguenay (Sacsin), 97
(2%)
85.CAC14658 BA332A4.3 protein (Fragment), 96 (17%)
86.CAC49990 Sequence 22 from Patent WO0146261, 96 (10%)
87.AAH78670 IGHG1 protein, 95 (14%)
88.BAC04226 CDNA FLJ36487 fis, clone THYMU2017844, highly
similar to Homo sapiens immunoglobulin lambda heavy chain, 94 (13%)
89.BAC05203 CDNA FLJ40631 fis, clone THYMU2014777, highly
similar to Homo sapiens immunoglobulin lambda heavy chain, 93 (14%)
90.FNBP3_HUMAN Formin-binding protein 3 (Huntingtin yeast partner
A) (Huntingtin- interacting protein HYPA/FBP11) , 92 (8%)
91.BAC05012 CDNA FLJ40035 fis, clone SYNOV2000173, highly
similar to Human (hybridoma H210) anti-hepatitis A Ig, 90 (13%)
92.AAP15181 Forkhead winged/helix transcription factor mutant 2, 90
(13%)
93.VEHULA lamin A , 89 (9%)
94.JC5517 Gu/RNA helicase II binding protein, 87 (5%)
95.JC1087 RNA helicase, ATP-dependent, 87 (9%)
96.Q6PK08_HUMAN NOP5/NOP58 protein (Fragment), 86 (13%)
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97.Q9BYF8_HUMAN SCCA1b, 85 (20%)
98.AAH15030 ZBED1 protein, 85 (7%)
99.A42184 nuclear mitotic apparatus protein NuMA, 85 (7%)
100.TVHUJB transforming protein jun-B, 84 (13%)
101.AAL33548 NUANCE (actin-binding protein associated with nuclear
envelope), 84 (4%)
102.AAK48938 PIAS-NY protein, 82 (16%)
103.SJHUA spectrin alpha chain, 81 (4%)
104.Q8TD57_HUMAN Axonemal heavy chain dynein type 3, 79 (3%)
105.AAL33798 Nesprin-1 beta, 77 (3%)
106.AAG00912 Recombinant IgG4 heavy chain (Fragment), 77 (8%)
107.RL18_HUMAN 60S ribosomal protein L18, 76 (13%)
108.AAG13404 Topoisomerase II alpha-3, 75 (9%)
109.AAB41497 beta-tubulin, 75 (15%)
110.Q6FGQ8_HUMAN NFIL3 protein (Fragment), 73 (10%)
111.Q7Z406_HUMAN Myosin heavy chain, 73 (5%)
112.Q8WXI7_HUMAN Ovarian cancer related tumor marker CA125, 72
(1%)
113.Q9NPL4_HUMAN Enolase (EC 4.2.1.11) (2-phospho-D-glycerate
hydro-lyase) (Fragment), 72 (24%)
114.AAB41132 Microtubule-associated protein 1a, 72 (6%)
115.TCPQ_HUMAN T-complex protein 1, theta subunit (TCP-1-theta)
(CCT-theta), 71 (8%)
116.Q6PFW1_HUMAN KIAA0377 gene product, 71 (3%)
117.TVHUJN transcription factor AP-1, 70 (4%)
118.Q96AA2_HUMAN Obscurin, 70 (3%)
119.AAG01174 smarce 1-related protein, 70 (11%)
120.Q99968_HUMAN Tpr, 69 (3%)
121.AAC41758 Nucleoporin, 67 (1%)
122.Q8IXV2_HUMAN ATP5A1 protein (Fragment), 67 (9%)
123.Q7Z791_HUMAN TKT protein, 66 (12%)
124.AAH10381 Nuclear matrix protein p84, 66 (9%)
125.Q5TEM5_HUMAN Myosin VI, 65 (6%)
126.Q5THR3_HUMAN OTTHUMP00000028872, 65 (4%)
127.BAA78718 Centrosome- and golgi-localized PKN-associated
protein (CG-NAP), 64 (3%)
128.Q7L576_HUMAN Cytoplasmic FMR1 interacting protein 1, 64 (4%)
129.Q5VUM2_HUMAN OTTHUMP00000040303 (Laminin, alpha 2)
(Merosin, congenital muscular dystrophy), 64 (4%)
130.Q6P158_HUMAN DHX57 protein (Fragment), 63 (4%)
131.LAP2A_HUMAN Lamina-associated polypeptide 2 isoform alpha
(Thymopoietin isoform alpha) (TP alpha) (Thymopoietin), 63 (4%)
132.Q96Q15_HUMAN Phosphatidylinositol 3-kinase-related protein
kinase, 62 (3%)
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133.Q5T7P4_HUMAN Involucrin, 62 (8%)
134.CAD23331 Sequence 1 from Patent WO0200863, 62 (8%)
135.A48133 pre-mRNA splicing SRp75, 62 (7%)
136.GCC2_HUMAN GRIP and coiled-coil domain-containing protein 2
(Golgi coiled coil protein GCC185) (CTCL tumor ant), 61 (3%)
137.Q16716_HUMAN Pyruvate kinase PK-L isoenzyme, 61 (5%)
138.AAD00186 Envoplakin, 61 (4%)
139.CAD48779 Sequence 23 from Patent EP1229047, 61 (5%)
140.D40201 artifact-warning sequence (translated ALU class D), 61
(22%)
141.Q5W9F9_HUMAN KIAA0216 splice variant 2 (Fragment), 61 (4%)
142.Q5VWP1_HUMAN Ryanodine receptor 2 (Cardiac), 61 (2%)
143.Q8NF44_HUMAN FLJ00354 protein (Fragment), 60 (5%)
144.BAC77401 Putative MAPK activating protein, 60 (9%)
145.A33370 H+-transporting two-sector ATPase (EC 3.6.3.14) beta
chain precursor, mitochondrial, 59 (13%)
146.BAC15608 FELE-2, 59 (3%)
147.HSHUA1 histone H2A.1, 59 (21%)
148.Q6PJT4_HUMAN MSN protein (Fragment), 59 (9%)
149.Q6PIK4_HUMAN DIX domain containing 1, 59 (6%)
150.AAC07988 centrosomal Nek2—associated protein 1, 59 (5%)
151.A43358 macrophage capping protein, 58 (3%)
152.PDRN4_HUMAN PDZ domain containing RING finger protein 4
(Ligand of Numb-protein X 4) (SEMACAP3-like protein), 58 (4%)
153.PCNT2_HUMAN Pericentrin 2 (Pericentrin B) (Kendrin), 58 (2%)
154.BAA75062 apg-2, 58 (5%)
155.AAD21786 Similar to clagizzarin; similar to PID:g3115349, 57
(38%)
156.MBD1_HUMAN Methyl-CpG binding protein 1 (Methyl-CpG
binding domain protein 1) (Protein containing methyl-CpG-b), 57 (8%)
157.BAA05384 Type 2 inositol 1,4,5-trisphosphate receptor, 57 (4%)
158.Q9UPP3_HUMAN KIAA1109 protein (Fragment), 57 (6%)
159.AAC50662 Monocytic leukemia zinc finger protein, 57 (3%)
160.Q5T9M9_HUMAN M-phase phosphoprotein 1, 56 (3%)
161.S43692 transcription factor erm , 56 (8%)
162.Q5T2F1_HUMAN Neurofascin (NFASC) (Fragment), 57 (5%)
163.BAA13192 KIAA0201 protein, 56 (7%)
164.Q6ZML1_HUMAN FLJ00298 protein (Fragment), 56 (5%)
165.Q9P2D7_HUMAN KIAA1410 protein (Fragment), 56 (2%)
166.TPIS_HUMAN Triosephosphate isomerase (EC 5.3.1.1) (TIM)
(Triose-phosphate isomerase), 55 (6%)
167.Q8TEP3_HUMAN FLJ00150 protein (Fragment), 55 (3%)
168.CAD19369 Sequence 5 from Patent WO0181417, 55 (12%)
169.CAA02940 SEQUENCE 2 FROM PATENT WO9527070, 55 (5%)
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170.Q5W0B2_HUMAN OTTHUMP00000016826, 55 (4%)
171.Q6PFW2_HUMAN ARHGEF11 protein (OTTHUMP00000060353),
54 (5%)
172.Q6FG89_HUMAN G22P1 protein, 54 (8%)
173.CAC22372 Sequence 1 from Patent WO0075319, 54 (8%)
174.Q5VZ08_HUMAN OTTHUMP00000044920, 54 (5%)
175.Q5VUA4_HUMAN OTTHUMP00000039830 (Zinc finger protein
318), 54 (3%)
176.AAH39612 MYO18A protein, 54 (3%)
177.O95996_HUMAN APCL protein, 53 (3%)
178.Q6IPN1_HUMAN APG16L protein (Fragment), 53 (7%)
179.Q6UXW4_HUMAN SSGL9393, 53 (11%)
180.Q6P9C6_HUMAN AT rich interactive domain 3A (BRIGHT-like)
protein, 53 (9%)
181.PKD1_HUMAN Polycystin 1 precursor (Autosomal dominant
polycystic kidney disease protein 1), 53 (2%)
182.CAD48781 Sequence 27 from Patent EP1229047, 53 (7%)
183.BAA86576 KIAA1262 protein, 53 (3%)
184.AAF87083 Tropomyosin isoform, 53 (29%)
185.Q9Y2J4_HUMAN Angiomotin like 2 (Fragment), 53 (6%)
186.EF1G_HUMAN Elongation factor 1-gamma (EF-1-gamma) (eEF-1B
gamma) (PRO1608), 53 (7%)
187.Q9UPS0_HUMAN KIAA1082 protein (Fragment), 53 3%)
188.CAC70712 Myosin heavy chain, 52 (6%)
189.Q6Q759_HUMAN PF6 (OTTHUMP00000059528), 52 (2%)
190.A46160 interferon alpha-induced transcription activator ISGF-3,
113K chain , 52 (5%)
191.TCPW_HUMAN T-complex protein 1, zeta-2 subunit (TCP-1-zeta-2)
(CCT-zeta-2) (TCP- 1-zeta-like) (CCT-zeta-like) (Testis-specific Tcp20)
(Testis-specific protein TSA303), 52 (5%)
192.CAC70714 Myosin heavy chain, 52 (6%)
193.CAI13123 PRP18 pre-mRNA processing factor 18 homolog, 52
(10%)
194.ITB4_HUMAN Integrin beta-4 precursor (GP150) (CD104 antigen),
52 (4%)
195.AAC51833 Ubiquitin specific protease 9, 52 (2%)
196.AAM19206 S100 calcium binding protein A14, 52 (10%)
197.Q9BYW2_HUMAN Huntingtin interacting protein 1 (HSPC069
isoform a), 51 (2%)
198.CSMSA peptidylprolyl isomerase (EC 5.2.1.8) A – mouse, 51
(21%)
199.Q5TZA2_HUMAN Ciliary rootlet coiled-coil, rootletin
(OTTHUMP00000044629), 50 (4%)
200.Q5R206_HUMAN Carbamoylphosphate synthetase I, 50 (4%)
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201.Q6R954_HUMAN Polymerase delta interacting protein 46, 50 (7%)
202.T08796 tropomyosin (fragment), 50 (18%)
203.AAH50321 TBC1 (tre-2/USP6, BUB2, cdc16) domain family,
member 1, 50 (4%)
204.SFRS1_HUMAN Splicing factor, arginine/serine-rich 1 (pre-mRNA
splicing factor SF2, P33 subunit) (Alternative sp), 50 (7%)
205.CAC69813 Sequence 6 from Patent WO0162928, 50 (5%)
206.Q8N4P9_HUMAN PAXIP1L protein, 50 (5%)
207.Q5W093_HUMAN OTTHUMP00000059187 (Programmed cell death
11), 50 (2%)
208.CAC22488 Sequence 24 from Patent WO0077179, 50 (4%)
209.Q99736_HUMAN HsGCN1 (Fragment), 50 (4%)
210.AAK52750 nuclear receptor transcription cofactor, 49 (1%)
211.AAF24980 voltage-gated sodium channel alpha subunit, alternate
splice variant SCN12A-s, 49 (4%)
212.Q5TBA9_HUMAN Chromosome 13 open reading frame 14, 49 (3%)
213.Q9H4G2_HUMAN Novel protein (Fragment), 49 (3%)
214.AAD00702 Myosin heavy chain 12, 49 (5%)
215.Q69GU6_HUMAN Transcription factor GTF2IRD2 beta isoform 1, 49
(18%)
216.DOCK2_HUMAN Dedicator of cytokinesis protein 2, 49 (1%)
217.Q7Z519_HUMAN Maid, 49 (7%)
218.NCOR1_HUMAN Nuclear receptor corepressor 1 (N-CoR1) (N-CoR),
49 (3%)
219.Q9UQB7_HUMAN Huntingtin, 49 (3%)
220.Q9P2N5_HUMAN KIAA1311 protein (Fragment), 48 (3%)
221.AAC96010 chaperonin containing t-complex polypeptide 1, delta
subunit; CCT-delta, 48 (13%)
222.Q8NFX2_HUMAN PI-3-kinase ATX, 48 (2%)
223.Q6P189_HUMAN Minor histocompatibility antigen HA-1, 48 (2%)
224.Q96SE4_HUMAN DNA polymerase theta, 48 (3%)
225.AAK40350 DNA-dependant protein kinase, 48 (12%)
226.AAR02550 Immunoglobulin heavy chain variable region, 48 (25%)
227.AAD29948 Myosin heavy chain, 48 (4%)
228.Q6PJ32_HUMAN FLJ11806 protein (Fragment), 48 (5%)
229.Q5VUA6_HUMAN OTTHUMP00000046844 (InaD-like protein)
(INADL), 48 (5%)
230.T08599 probable transcription factor CA150, 48 (2%)
231.AAM77722 Midasin, 48 (2%)
232.A24199 tropomyosin NM, skeletal muscle, 48 (22%)
233.JQ1348 carbamoyl-phosphate synthase (ammonia) (EC 6.3.4.16)
precursor, 48 (4%)
234.Q7Z5Y2_HUMAN Rho-interacting protein 3, 47 (7%)
235.Q5VXD5_HUMAN Ankyrin 3, node of Ranvier (Ankyrin G), 47 (1%)
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236.AAC43042 trio isoform, 47 (4%)
237.1B3OB inosine monophosphate dehydrogenase 2 (EC 1.1.1.205),
chain B (fragments), 47 (5%)
238.CAA99729 RAD50 homologue hsRAD50, 47 (5%)
239.BAC80154 Immunoglobulin gamma heavy chain, 47 (18%)
240.Q5TCZ0_HUMAN OTTHUMP00000059186, 46 (14%)
241.Q6I9V9_HUMAN LOC63929 protein, 46 (11%)
242.Q9NR99_HUMAN Adlican, 46 (6%)
243.A59404 plectin [imported] , 46 (2%)
244.CD2L2_HUMAN PITSLRE serine/threonine-protein kinase CDC2L2
(EC 2.7.1.37) (Galactosyltransferase associated protein, 46 (5%)
245.A59266 unconventional myosin-15, 46 (2%)
246.CAB61345 Integrin beta 4, 46 (4%)
247.Q5SYX5_HUMAN Golgi autoantigen, golgin subfamily a, 2
(Fragment), 46 (3%)
248.AAR02531 Immunoglobulin heavy chain variable region, 46 (24%)
249.G59434 KIAA0411 protein [imported] , 46 (3%)
250.Q5SQI3_HUMAN Calmodulin-like 5, 46 (7%)
251.T09551 ribosomal protein L4, 46 (8%)
252.AAF78783 Myosin Vc, 46 (6%)
253.2FB4H Ig heavy chain V region (Fab fragment KOL), chain H , 45
(18%)
254.Q9BS48_HUMAN HSF2 protein (Hypothetical protein), 45 (21%)
255.BAA20783 KIAA0325 protein, 45 (2%)
256.Q9HCD1_HUMAN KIAA1641 protein (Fragment), 45 (4%)
257.Q96BI2_HUMAN ARL6IP4 protein, 45 (14%)
258.CAC34694 Sequence 1 from Patent WO0114414, 45 (4%)
259.CAC38606 Sequence 229 from Patent WO0129221, 45 (3%)
260.Q86VH0_HUMAN KIF27C, 45 (5%)
261.Q5VVU8_HUMAN OTTHUMP00000059324 (Transcription
termination factor, RNA polymerase II), 45 (6%)
262.Q5VWI3_HUMAN Nebulin-related anchoring protein, 45 (8%)
263.Q8WXV8_HUMAN Alpha 1 chain-like collagen COLA1L precursor
(Collagen, type XXI, alpha 1), 44 (11%)
264.O95001_HUMAN WUGSC:H_267D11.3 protein (Fragment), 44 (4%)
265.Q76L81_HUMAN Chimeric MOZ-ASXH2 fusion protein, 44 (3%)
266.A47212 transcription factor TMF, TATA element modulatory
factor, 44 (5%)
267.Q86VH1_HUMAN KIF27B, 44 (5%)
268.Q9H281_HUMAN Serologically defined breast cancer antigen NY-
BR-49 (Fragment), 44 (16%)
269.Q6IC06_HUMAN RFPL1 protein, 44 (7%)
270.Q5T7X7_HUMAN OTTHUMP00000018794
(OTTHUMP00000040880) (Fragment), 44 (5%)
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271.Q66GS8_HUMAN Centrosome protein Cep290, 44 (5%)
272.AAR02539 Immunoglobulin heavy chain variable region, 44 (15%)
273.Q96PH3_HUMAN Proliferation potential-related protein, 44 (3%)
274.AAR32467 Immunoglobulin heavy chain variable region, 44 (29%)
275.Q7KZ68_HUMAN Putative M phase phosphoprotein (MPP1
(Fragment), 44 (8%)
276.Q6PIC7_HUMAN FLJ14503 protein (Fragment), 44 (6%)
277.Q9ULU8_HUMAN KIAA1121 protein (Fragment), 44 (6%)
278.PIAS3_HUMAN Protein inhibitor of activated STAT protein 3, 44
(3%)
279.CAI13459 Novel protein, 44 (17%)
280.BAA78533 Protein inhibitor of activated STAT3, 44 (3%)
281.Q5T9S5_HUMAN Sarcoma antigen NY-SAR-41 (NY-SAR-41), 44
(5%)
282.1P1GA macrophage migration inhibitory factor mutant P1G, chain
A, 43 (17%)
283.BAA22586 SCP-1, 43 (9%)
284.BAB21832 KIAA1741 protein, 43 (4%)
285.Q5VYQ4_HUMAN OTTHUMP00000021403
(OTTHUMP00000046122), 43 (5%)
286.Q8TBJ9_HUMAN RIC3 protein, 43 (13%)
287.BAA02054 Nucleotide pyrophosphatase, 43 (6%)
288.Q9NZE6_HUMAN BM-010, 43 (14%)
289.AAR32484 Immunoglobulin heavy chain variable region, 43 (27%)
290.A57169 [heparan sulfate]-glucosamine N-sulfotransferase (EC
2.8.2.8) , 43 (3%)
291.Q8NEQ7_HUMAN Interferon-inducible IFI 16, 43 (2%)
292.BAA20836 KIAA0382 protein, 43 (5%)
293.1FVEB Fab fragment of humanized antibody 4d5, version 7, chain
B, 43 (20%)
294.AAR02524 Immunoglobulin heavy chain variable region, 43 (29%)
295.Q5VVL9_HUMAN Protein tyrosine phosphatase, receptor type, D, 43
(5%)
296.AAC52012 SET-DOMAIN PROTEIN AND MARINER
TRANSPOSON HSMAR1 TRANSPOSASE FUSION PROTEIN, 43 (7%)
297.AAR00504 Immunoglobulin heavy chain, VH region, 43 (17%)
298.AAK19936 IgG1 immunoglobulin heavy chain variable region
(Fragment), 43 (22%)
299.ROCK2_HUMAN Rho-associated protein kinase 2 (EC 2.7.1.37)
(Rho-associated, coiled- coil containing protein kinase, 42 (5%)
300.MITF_HUMAN Microphthalmia-associated transcription factor, 42
(3%)
301.AAL62061 Bullous pemphigoid antigen 1 eA, 42 (2%)
302.Q76D35_HUMAN Nop132, 42 (4%)
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303.Q6IBF4_HUMAN HMGCS2 protein, 42 (5%)
304.AAD50325 RAD50-2 protein, 42 (5%)
305.AAA58669 HRX, 42 (1%)
306.BAA97670 Immunoglobulin gamma heavy chain (Fragment)
(OTTHUMP00000021970), 42 (15%)
307.O60307_HUMAN KIAA0561 protein (Fragment), 42 (3%)
308.Q6K0P6_HUMAN Interferon-inducible protein X beta 2 isoform
(IFIX), 42 (12%)
309.Q5VZN0_HUMAN OTTHUMP00000044227, 42 (9%)
310.AAR32419 Immunoglobulin heavy chain variable region, 41 (28%)
311.AAO22169 Immunoglobulin heavy chain variable and constant
region (Fragment), 41 (24%)
312.A40201 artifact-warning sequence (translated ALU class A), 41
(12%)
313.Q5TYR7_HUMAN Hemicentin (FIBL-6), 41 (1%)
314.Q6YMW8_HUMAN Rac-GTP binding protein-like protein, 41 (8%)
315.Q96I57_HUMAN MYH7B protein (Fragment), 41 (6%)
316.AAA52805 OMM protein (Ig gamma 3) heavy chain, 41 (7%)
317.BAA31614 KIAA0639 protein, 41 (4%)
318.AAL05571 SERPINB12, 41 (4%)
319.1GC1H antibody 17b antigen-binding fragment, fab cd4-induced
site on gp120, chain H, 41 (16%)
320.Q6Y1F2_HUMAN FHOS, 41 (2%)
321.Q5T749_HUMAN Novel protein, 41 (7%)
322.BAA95526 ANKRD3, 41 (6%)
323.Q8TB65_HUMAN Cytochrome c oxidase subunit Va, (COX5A
protein), 41 910%)
324.AAF07045 A-kinase anchoring protein 220, 41 (3%)
325.Q5T714_HUMAN OTTHUMP00000060031, 41 (3%)
326.S21424 nestin, 41 (3%)
327.I38510 neuronal kinesin heavy chain, 41 (8%)
328.CAC07506 Sequence 1 from Patent WO9960116, 41 (2%)
329.DDX21_HUMAN Nucleolar RNA helicase II (Nucleolar RNA
helicase Gu) (RH II/Gu) (DEAD-box protein 21), 41 (5%)
330.Q5T655_HUMAN Novel protein, 41 (5%)
331.AAC05330 Cell adhesion kinase beta, 40 (4%)
332.AAR32529 Immunoglobulin heavy chain variable region, 40 (25%)
333.AAC72089 PITSLRE protein kinase beta SV12 isoform, 40 (113%)
334.CAA55632 Endosomal protein, 40 (3%)
335.FLNC_HUMAN Filamin C (Gamma-filamin) (Filamin 2) (Protein
FLNc) (Actin-binding like protein) (ABP-L) (ABP-280), 40 (4%)
336.MYH6_HUMAN Myosin heavy chain, cardiac muscle alpha isoform
(MyHC-alpha), 40 (3%)
337.AAR32426 Immunoglobulin heavy chain variable region, 40 (16%)
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338.Q6KE87_HUMAN Acetyl-CoA carboxylase 2 (EC 6.4.1.2), 40 (1%)
339.AAP13528 rho/rac-interactin citron kinase, 40 (2%)
340.I39152 zinc finger protein, 40 (12%)
341.PEPL_HUMAN Periplakin (195 kDa cornified envelope precursor
protein) (190 kDa paraneoplastic pemphigus antigen), 40 (2%)
342.ZN292_HUMAN Zinc finger protein 292, 40 (5%)
343.MATN4_HUMAN Matrilin-4 precursor, 40 (7%)
344.AAF03782 Traf2 and NCK interacting kinase, splice variant 1, 40
(5%)
345.Q6PHY0_HUMAN CABIN1 protein, 40 (1%)
346.1SAV annexin v mutant P13, P87, P119, P163, AND P248
SUBSTITUTED WITH thioproline (prs) - human (fragment), 40 (8%)
347.Q9Y5L9_HUMAN Transcriptional activator SRCAP, 40 (2%)
348.Q8IYF3_HUMAN Testis expressed sequence 11, isoform 2, 40 (7%)
349.AAH53903 SLIT-ROBO Rho GTPase-activating protein 1, 40 (4%)
350.AAF75772 Ubiquitin-conjugating BIR-domain enzyme APOLLON,
40 (1%)
351.AAB87381 CHD1, 40 (2%)
352.Q7Z5J5_HUMAN SNF2 histone linker PHD RING helicase, 39 (2%)
353.BAB15795 FLJ00115 protein, 39 (8%)
354.Q5T527_HUMAN Small proline-rich protein 1A, 39 (34%)
355.Q96PY5_HUMAN KIAA1902 protein (Fragment), 39 (3%)
356.DDX18_HUMAN ATP-dependent RNA helicase DDX18 (EC 3.6.1.-)
(DEAD-box protein 18) (Myc-regulated DEAD-box protein) (MrDb), 39
(6%)
357.AAC39790 SP100-HMG nuclear autoantigen, 39 (2%)
358.AAF36817 Guanine nucleotide exchange factor, 39 (3%)
359.Q9UDT6_HUMAN KIAA0291; similar rodent cytoplasmic linker
protein CLIP-115 and restin, 39 (4%)
360.BAA08260 Phosphodiesterase I alpha, 39 (5%)
361.Q8N4H8_HUMAN Smoothelin, isoform b, 39 (4%)
362.AAD20946 Silencing mediator of retinoic acid and thyroid hormone
receptor alpha, 39 (3%)
363.Q6H969_HUMAN Myomesin 1, 39 (4%)
364.AAH25393 PSMA8 protein, 39 (15%)
365.CAC20413 beta-myosin heavy chain, 39 (5%)
366.I38155 DNA-binding regulatory factor X5 – human, 39 (12%)
367.AAC51331 CREB-binding protein, 39 (3%)
369.Q5TFG6_HUMAN OTTHUMP00000028769, 39 (4%)
370.CAC60121 Axonemal beta heavy chain dynein type 11, 39 (2%)
371.ABCA1_HUMAN ATP-binding cassette, sub-family A, member 1
(ATP-binding cassette transporter 1) (ATP-binding cassette 1) (ABC-1)
(Cholesterol efflux regulatory protein), 39 (2%)
372.AAF98175 ATP-binding cassette transporter 1, 39 (3%)
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373.Q5TIG6_HUMAN Myeloid\/lymphoid or mixed-lineage leukemia
(Trithorax homolog, Drosophila)\; translocated to, 4, 38 (4%)
374.CHSS3_HUMAN Chondroitin sulfate synthase 3 (EC 2.4.1.175)
(Glucuronosyl-N- acetylgalactosaminyl-proteoglycan 4, 38 (11%)
375.TVHUFF protein-tyrosine kinase (EC 2.7.1.112) fes/fps , 38 (5%)
376.CAA04747 IMMUNOGLOBULIN IGG2 (FRAGMENT), 38 (34%)
377.PDE6A_HUMAN Rod cGMP-specific 3',5'-cyclic phosphodiesterase
alpha-subunit (EC 3.1.4.17) (GMP-PDE alpha) (PDE V-B1), 38 (4%)
378.DYH5_HUMAN Ciliary dynein heavy chain 5 (Axonemal beta
dynein heavy chain 5) (HL1), 38 (2%)
379.AAH06536 Sympleki, 38 (1%)
380.A61231 myosin heavy chain nonmuscle form A , 38 (2%)
381.CAD61482 Sequence 132 from Patent WO02083898, 38 (20%)
382.Q5SZL2_HUMAN OTTHUMP00000040396, 38 (5%)
383.BAA20770 KIAA0311 protein, 38 (4%)
384.CAD33317 Sequence 44 from Patent WO0218424, 38 (3%)
385.Q9H430_HUMAN DJ756N5.1.1 (Continues in Em:AL133324 as
dJ1161H23.3 ) (Fragment), 38 (4%)
386.Q5TE18_HUMAN OTTHUMP00000030379, 38 (2%)
387.AAD29857 NAD+ ADP-ribosyltransferase 2, 38 (6%)
388.SPTN4_HUMAN Spectrin beta chain, brain 3 (Spectrin, non-erythroid
beta chain 3) (Beta-IV spectrin), 38 (6%)
390.Q6NZ98_HUMAN HIST1H2BA protein (Fragment), 38 (26%)
391.BAA82981 KIAA1029 protein, 38 (2%)
392.A54971 protein-tyrosine-phosphatase (EC 3.1.3.48) PTPN13,
nonreceptor type 13, splice form 1 [validated] , 38 (4%)
393.Q5VXF6_HUMAN Dedicator of cyto-kinesis 1 (Fragment), 38 (3%)
394.A43346 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase
(EC 3.1.4.11) beta-2, 38 (6%)
395.CAA93625 All-1 protein, 38 (2%)
396.BAA07536 PK-120 precursor, 38 (7%)
397.A32611 beta-galactosidase (EC 3.2.1.23) precursor, 38 (6%)
398.CAD33289 Sequence 16 from Patent WO0218424, 38 (20%)
399.Q5VYL3_HUMAN Asp (Abnormal spindle)-like, microcephaly
associated (Drosophila), 38 (2%)
400.Q86XK4_HUMAN PLCL3 protein (Fragment), 37 (4%)
401.CAC94536 Sequence 1 from Patent WO0170982, 37 (68%)
402.MYH3_HUMAN Myosin heavy chain, fast skeletal muscle,
embryonic (Muscle embryonic myosin heavy chain) (SMHCE), 37 (4%)
403.CAA67057 TCR JUNCTIONAL SEQUENCE (FRAGMENT), 37
(21%)
404.Q9Y6X6_HUMAN KIAA0865 protein (Fragment), 37 (3%)
405.AAL85487 Zinc finger 298, 37 (5%)
406.GAK_HUMAN Cyclin G-associated kinase (EC 2.7.1.-), 37 (5%)
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407.Q9P2N0_HUMAN KIAA1316 protein (Fragment), 37 (3%)
408.CAD10594 Sequence 2 from Patent WO0162977, 37 (2%)
409.Q5SZY9_HUMAN OTTHUMP00000020987
(OTTHUMP00000044319), 37 (5%)
410.Q9ULM3_HUMAN KIAA1197 protein (Fragment), 37 (3%)
411.A45259 desmoyokin (fragments), 37 (6%)
412.AAG16639 Helicase SMARCAD1, 37 (7%)
413.Q8N137_HUMAN LYST-interacting protein LIP8 (Hypothetical
protein DKFZp434I1519), 37 (4%)
414.AAF80245 Filamin 2, 37 (5%)
415.S45340 FKBP-rapamycin-associated protein (FRAP) , 37 (3%)
416.Q9UPU7_HUMAN KIAA1055 protein (Fragment), 37 (4%)
417.B28096 line-1 protein ORF2, 37 (3%)
418.Q6UWF7_HUMAN Brush border, 37 (2%)
419.AAD51797 Gag-Pro-Pol protein, 37 (3%)
420.Q6IQ54_HUMAN PTK7 protein tyrosine kinase 7, isoform a, 37 (4%)
421.Q5VT08_HUMAN OTTHUMP00000046616, 37 (1%)
422.Q5VT94_HUMAN Growth hormone inducible transmembrane protein,
37 (9%)
423.CO1A2_HUMAN Collagen alpha 2(I) chain precursor, 37 (4%)
424.Q8TD98_HUMAN MLL/AF4 fusion protein (Fragment), 37 (9%)
425.S31975 14-3-3 protein epsilon, renal – mouse, 37 (12%)
426.Q68GC2_HUMAN SIN3B long isoform, 37 (5%)
427.S12788 transcription factor NF-IL6, 37 (10%)
428.CAB65786 DJ269M15.1 (similar to peptidylprolyl isomerase
(cyclophilin)), 37 (15%)
429.AAA52897 IMMUNOGLOBULIN HEAVY CHAIN PRECURSOR
(FRAGMENT), 37 (13%)
430.AAD04629 PCAF-associated factor 400, 36 (3%)
431.S69211 serine/threonine-specific protein kinase (EC 2.7.1.-), Rho-
associated, 36 (7%)
432.A55575 ankyrin 3, long splice form , 36 91%)
433.QFHUH neurofilament triplet H protein, 36 (7%)
434.Q96P05_HUMAN Transient receptor potential channel 4 epsilon splice
variant (Transient receptor potential cation), 36 (6%)
435.E973183 TETRANECTIN, 36 (6%)
436.Q5U5L5_HUMAN Jumonji, AT rich interactive domain 2 protein
(OTTHUMP00000016058), 36 (5%)
437.Q9H1S7_HUMAN BA56H7.1.2 (Nebulette protein (NEBL, actin-
binding Z-disc protein)), 36 (8%)
438.AAH07557 F-box and leucine-rich repeat protein 20
439.AAC51202 Armadillo repeat protein, 36 (1%)
440.Q9UPP6_HUMAN KIAA1106 protein (Fragment), 36 (3%)
441.AAD28285 Bile salt export pump, 36 (7%)
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442.SIN3A_HUMAN Paired amphipathic helix protein Sin3a, 36 (1%)
443.CAE55985 PTX XI Eph/Elk/Eck orphan receptor family, 36 (3%)
444.G3P1_HUMAN Glyceraldehyde-3-phosphate dehydrogenase, muscle
(EC 1.2.1.12) (GAPDH), 36 (11%)
445.Q7Z4G5_HUMAN K-Cl cotransporter KCC3a-X2M isoform, 36 (2%)
446.Q9NS87_HUMAN Kinesin-like protein 2, 36 (5%)
447.AAN10118 cAMP-specific phosphodiesterase PDE4D7, 36 (5%)
448.Q6P9G1_HUMAN DHX57 protein, 36 (6%)
449.Q6WRI0_HUMAN Bone specific CMF608, 36 (3%)
450.Q5T791_HUMAN OTTHUMP00000016860 (Fragment), 35 (2%)
451.AAA52025 creatine kinase M, 35 (10%)
452.BAA82612 Neural adhesion molecule NB-3, 35 (5%)
453.DDX3_HUMAN DEAD-box protein 3 (Helicase-like protein 2)
(HLP2) (DEAD-box, X isoform), 35 (2%)
454.CAD32046 Sequence 1 from Patent WO0218544 (Fragment).-
synthetic construct, 35 (3%)
455.AAG33700 Tensin, 35 (4%)
456.BAA11423 Multifunctional protein CAD, 35 (4%)
457.O43598_HUMAN RCL (OTTHUMP00000016424) (Putative c-Myc-
responsive, isoform 1), 35 (14%)
458.CAD43233 Chondroitin synthase 2, 35 (13%)
459.Q8TES3_HUMAN FLJ00120 protein (Fragment), 35 (5%)
460.BAB17674 RFamide-related peptide precursor, 35 (5%)
461.Q8TC68_HUMAN MGC40042 protein (Fragment), 35 (7%)
462.A30789 creatine kinase (EC 2.7.3.2) precursor, mitochondrial, 35
(6%)
463.Q96E39_HUMAN Kynurenine aminotransferase III (Novel protein
similar to RNA binding motif protein, X-linked) (RBM), 35 (9%)
464.Q8IVF4_HUMAN KIAA2017 protein (Fragment), 35 (5%)
465.I67630 protein-tyrosine-phosphatase (EC 3.1.3.48) PTPN13,
nonreceptor type 13, splice form 3, 35 (4%)
466.Q5VW08_HUMAN OTTHUMP00000042245, 35 (5%)
467.Q96HU2_HUMAN SRPR protein, 35 (10%)
468.Q9Y4D8_HUMAN KIAA0614 protein (Fragment), 35 (2%)
469.Q5QPB6_HUMAN OTTHUMP00000031267, 35 91%)
470.Q5TG00_HUMAN OTTHUMP00000039711
(OTTHUMP00000017871), 35 (2%)
471.O00370_HUMAN Putative p150, 35 (2%)
472.AAH21908 Zinc finger, DHHC domain containing 1, 35 (7%)
473.Q6IEH8_HUMAN Transcriptional regulator, 35 (2%)
474.CAD69464 Sequence 867 from Patent EP1270724, 35 91%)
475.AAK29402 Nucleolar protein GU2, 35 (10%)
476.CHTOG_HUMAN CH-TOG protein (Colonic and hepatic tumor over-
expressed protein) (Ch- TOG protein), 35 92%)
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477.Q5TAP6_HUMAN KIAA0266 protein, 35 (4%)
478.Q8NET9_HUMAN Vanilloid receptor like 3 protein splice variant b,
35 (6%)
479.AAH41700 RABEP1 protein, 35 (2%)
480.SM1L2_HUMAN Structural maintenance of chromosome 1-like 2
protein (SMC1beta protein), 35 (5%)
481.AAS85957 Immunoglobulin heavy chain, 35 (15%)
482.I78879 retinoblastoma binding protein 2, 35 (3%)
483.Q14828_HUMAN MG44 protein (Fragment), 35 (8%)
484.CAA65265 Rox protein 35 (4%)
485.Q9C0D5_HUMAN KIAA1728 protein (Fragment), 34 (4%)
486.AAH07082 SMARCE 1 protein, 34 (3%)
487.Q8WU85_HUMAN RBM4 protein (Hypothetical protein
DKFZp547K0918), 34 (16%)
488.Q5TCU3_HUMAN Tropomyosin 2 (Beta), 34 (17%)
489.ALU3_HUMAN Alu subfamily SB1 sequence contamination warning
entry, 34 (15%)
490.Q5TGI4_HUMAN SAM domain containing 1, 34 (23%)
491.MCHUNB calmodulin-related protein NB-1, 34 (10%)
492.Q8WUG8_HUMAN MTB protein, 34 (5%)
493.Q9C0D4_HUMAN KIAA1729 protein (Fragment), 34 (2%)
494.AAH37964 DEAH (Asp-Glu-Ala-His) box polypeptide 37, 34 (5%)
495.BAA92573 KIAA1335 protein, 34 (2%)
496.E59435 myosin IXA [imported] , 34 (2%)
497.Q5VZN1_HUMAN Novel DnaJ domain-containing protein
(Fragment), 34 (10%)
498.MLL3_HUMAN Myeloid/lymphoid or mixed-lineage leukemia
protein 3 homolog (Histone- lysine N-methyltransferase, H3 lysine-4
specific MLL3) (EC 2.1.1.43) (Homologous to ALR protein), 34 (1%)
499.Q8IW75_HUMAN Serine (Or cysteine) proteinase inhibitor, clade A
(Alpha-1 antiproteinase, antitrypsin), member 12, 34 (9%)
500.AAH40945 PCMTD2 protein, 34 (14%)
501.Q9P2B8_HUMAN KIAA1429 protein (Fragment), 34 (3%)
Gel chunks 10-18 (see figure 4.6)
1.Q96JJ2_HUMAN KIAA1835 protein (Fragment), 709 (31%)
2.BAA09860 Polyubiquitin, 578 (12%)
3.Q96H31_HUMAN UBC protein (Fragment), 485 (13%)
4.1C3TA 1d8 ubiquitin mutant YES , 452 (94%)
5.AAH00036 Small ubiquitin-like modifier protein 3, 380 (48%)
6.Q96B34_HUMAN Beta actin, 340 (31%)
7.A57198 splicing factor, arginine/serine-rich 7 , 232 (28%)
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8.ROC_HUMAN Heterogeneous nuclear ribonucleoproteins C1/C2
(hnRNP C1 / hnRNP C2), 207 (25%)
9.Q8IWP6_HUMAN Class IVb beta tubulin, 206 (29%)
10.Q719H9_HUMAN Potassium channel tetramerization domain-
containing 1 (KCTD1 protein), 200 (30%)
11.R3HUS3 ribosomal protein S3, cytosolic , 192 (32%)
12.H2BE_HUMAN Histone H2B.e (H2B/e), 192 (54%)
13.Q7KZS0_HUMAN Ubiquitin-conjugating enzyme E2I (UBC9
homolog, yeast), 179 (30%)
14.DEHULH L-lactate dehydrogenase (EC 1.1.1.27) chain H, 179
(23%)
15.Q6EEV6_HUMAN Small ubiquitin-like protein 4
(OTTHUMP00000040124), 176 (26%)
16.SFRS1_HUMAN Splicing factor, arginine/serine-rich 1 (pre-mRNA
splicing factor SF2, P33 subunit) (Alternative sp), 172 (25%)
17.UBHU5B tubulin beta chain , 167 (21%)
18.DEHULM L-lactate dehydrogenase (EC 1.1.1.27) chain M, 164
(18%)
19.ENOA_HUMAN Alpha enolase (EC 4.2.1.11) (2-phospho-D-glycerate
hydro-lyase) (Non- neural enolase) (NNE) (Enolase), 163 (30%)
20.Q8IWR2_HUMAN Class II beta tubulin isotype, 147 (19%)
21.A33370 H+-transporting two-sector ATPase (EC 3.6.3.14) beta
chain precursor, mitochondrial, 142 (13%)
22.R5RTL8 ribosomal protein L8, cytosolic [validated] – rat, 119
(13%)
23.S00985 translation initiation factor eIF-4A II – mouse, 119 (10%)
24.FIMS4A translation initiation factor eIF-4A I – mouse, 118 (10%)
25.Q8N5Z7_HUMAN Ribosomal protein L6, 106 (15%)
26.R5HU7A ribosomal protein L7a, cytosolic, 106 (24%)
27.AAK58567 RBMX, 105 (19%)
28.Q5VWK1_HUMAN Voltage-dependent anion channel 2, 98 (13%)
29.MMHUP3 voltage-dependent anion channel 1 [validated] , 97 (28%)
30.KIHUG phosphoglycerate kinase (EC 2.7.2.3) , 96 (23%)
31.RL18_HUMAN 60S ribosomal protein L18, 96 (25%)
32.BAA77335 IDN3, 94 (3%)
33.AAA60288 Ribosomal protein S6, 93 (26%)
34.T03829 transcription factor TFII-I , 92 (6%)
35.CAI14804 FUS interacting protein (serine-arginine rich), 91 (17%)
36.AAB41497 Beta-tubulin, 90 (12%)
37.Q96E39_HUMAN Kynurenine aminotransferase III (Novel protein
similar to RNA binding motif protein, X-linked) (RBM), 87 (18%)
38.PWHUA H+-transporting two-sector ATPase (EC 3.6.3.14) alpha
chain precursor , 87 (6%)
39.AAA60287 Ribosomal protein S6, 85 (26%)
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40.G3P1_HUMAN Glyceraldehyde-3-phosphate dehydrogenase, muscle
(EC 1.2.1.12) (GAPDH), 84 (11%)
41.S08228 ribosomal protein S2, cytosolic (fragment), 80 (15%)
42.Q5SWL5_HUMAN Eukaryotic translation elongation factor 1 alpha 1,
77 (11%)
43.R5HU7 ribosomal protein L7, cytosolic , 76 (18%)
44.JE0241 Ig kappa chain Am37 precursor , 75 (23%)
45.R3RT8 ribosomal protein S8, cytosolic [validated] – rat, 72 (11%)
46.Q6NZ55_HUMAN Ribosomal protein L13, 71 (17%)
47.AAH75846 proteasome activator subunit 1, 70 (10%)
48.AAH04978 Tripartate motif-containing 28 protein, 69 (3%)
49.AAD23914 ubiquitin-like activating enzyme; sentrin activating
enzyme, 69 (8%)
50.Q5VUM2_HUMAN OTTHUMP00000040303 (Laminin, alpha 2)
(Merosin, congenital muscular dystrophy), 68 (3%)
51.BAC01761 Immunoglobulin kappa light chain VLJ region
(Fragment), 67 (18%)
52.BAC05014 CDNA FLJ40038 fis, clone SYNOV2000297, highly
similar to Human (hybridoma H210) anti-hepatitis A Ig, 66 (12%)
53.EFHU1 translation elongation factor eEF-1 alpha-1 chain , 66
(10%)
54.Q5T8U3_HUMAN Ribosomal protein L7a (Fragment), 65 (23%)
55.1IBRA ran, chain A, 63 (30%)
56.Q9P2D7_HUMAN KIAA1410 protein (Fragment), 63 (2%)
57.DEHULC L-lactate dehydrogenase (EC 1.1.1.27) chain X , 62 (9%)
58.Q5TBT0_HUMAN Bullous pemphigoid antigen 1, 230\/240kDa, 61
(2%)
59.AAA02914 IGG PRECURSOR, 60 (10%)
60.CAC49990 Sequence 22 from Patent WO0146261, 60 (9%)
61.EFHUA2 translation elongation factor eEF-1 alpha-2 chain, 60 (6%)
62.BPAEA_HUMAN Bullous pemphigoid antigen 1, isoforms 6/9/10
(Trabeculin-beta) (Bullous pemphigoid antigen) (BPA) , 59 (2%)
63.Q5TZA2_HUMAN Ciliary rootlet coiled-coil, rootletin
(OTTHUMP00000044629), 58 (4%)
64.G59434 KIAA0411 protein [imported] , 58 (2%)
65.BAC05012 CDNA FLJ40035 fis, clone SYNOV2000173, highly
similar to Human (hybridoma H210) anti-hepatitis A Ig, 58 (10%)
66.CAA73095 Golgi-associated microtubule-binding protein, 58 (6%)
67.AAH14667 Similar to immunoglobulin heavy constant gamma 3
(G3m marker), 58 (9%)
68.A45259 desmoyokin (fragments), 57 (4%)
69.AAH73789 IGHG1 protein, 57 (14%)
70.CAD42369 Sequence 11 from Patent WO0214368, 55 (17%)
71.CAI12385 Kinesin family member 21B, 54 (4%)
279
72.Q5VT06_HUMAN OTTHUMP00000060646 (Novel protein), 54 (3%)
73.AAB41132 Microtubule-associated protein 1a, 54 (4%)
74.CAC70714 Myosin heavy chain, 53 (4%)
75.AAD00186 Envoplakin, 53 (4%)
76.BAB71634 CDNA FLJ25308 fis, clone SYN00939, highly similar to
Ig gamma immunoglobulin heavy chain, 53 (7%)
77.Q8TD57_HUMAN Axonemal heavy chain dynein type 3, 53 (3%)
78.AAR32538 Immunoglobulin heavy chain variable region, 53 (23%)
79.CU005_HUMAN Protein C21orf5, 53 (3%)
80.HSHUA1 histone H2A.1, 52 (18%)
81.AAR32470 Immunoglobulin heavy chain variable region, 52 (23%)
82..CAI16903 Antigen identified by monoclonal antibody Ki-67, 52
(4%)
83.AAH50321 TBC1 (tre-2/USP6, BUB2, cdc16) domain family,
member 1, 52 (3%)
84.MLL3_HUMAN Myeloid/lymphoid or mixed-lineage leukemia protein
3 homolog (Histone- lysine N-methyltransferase, 51 (1%)
85.Q5VXD5_HUMAN Ankyrin 3, node of Ranvier (Ankyrin G), 51 (2%)
86.PGK2_HUMAN Phosphoglycerate kinase, testis specific (EC 2.7.2.3),
51 (5%)
87.PCLO_HUMAN Piccolo protein (Aczonin), 51 (1%)
88.Q6P158_HUMAN DHX57 protein (Fragment), 51 (2%)
89.CAD69623 Sequence 1187 from Patent EP1270724, 51 (19%)
90.AAR02489 Immunoglobulin heavy chain variable region, 51 (21%)
91.KAD2_HUMAN Adenylate kinase isoenzyme 2, mitochondrial (EC
2.7.4.3) (ATP-AMP transphosphorylase), 51 (18%)
92.CAD34981 Sequence 289 from Patent WO0222660, 50 (5%)
93.Q7L576_HUMAN Cytoplasmic FMR1 interacting protein 1, 50 (5%)
94.JC5423 2-hydroxyacylsphingosine 1-beta-galactosyltransferase (EC
2.4.1.45), 50 (7%)
95.Q5VW08_HUMAN OTTHUMP00000042245, 50 (3%)
96.Q5T7K0_HUMAN OTTHUMP00000040616, 50 (6%)
97.Q86YW0_HUMAN PLC-zeta, 49 (5%)
98.AAR32440 Immunoglobulin heavy chain variable region, 49 (33%)
99.AAS86025 Immunoglobulin heavy chain, 49 (21%)
100.SJHUA spectrin alpha chain , 48 (3%)
101.CAC70712 Myosin heavy chain, 48 (4%)
102.CAC08835 Sequence 36 from Patent WO0006605, 48 (6%)
103.AAC02903 eIF4GII, 48 (5%)
104.Q5T583_HUMAN Filaggrin, 48 (2%)
105.Q96L96_HUMAN Muscle alpha-kinase, 48 (2%)
106.A56236 probable RNA helicase 1, 48 (9%)
107.BAA37168 IgG heavy chain (Fragment), 48 (16%)
108.CAD33443 Sequence 170 from Patent WO0218424, 47 (2%)
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109.Q5T7Y7_HUMAN DKFZP547E1010 protein, 47 (40%)
110.AAC51833 Ubiquitin specific protease 9, 47 (1%)
111.AAF03881 IgG1 heavy chain (fragment), 47 (16%)
112.Q8IWV7_HUMAN Ubiquitin ligase E3 alpha-I, 47 (2%)
113.Q8WXI7_HUMAN Ovarian cancer related tumor marker CA125, 46
(<1%)
114.AAS86039 Immunoglobulin heavy chain, 46 (21%)
115.MCPH1_HUMAN Microcephalin, 46 (6%)
116.AAH14789 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-
acetylgalactosaminyltransferase-like 2, 46 (4%)
117.A42184 nuclear mitotic apparatus protein NuMA , 46 (3%)
118.Q96JP6_HUMAN Guanine nucleotide exchange factor Lbc, 46 (1%)
119.CAA28420 apo-B100 precursor, 46 (1%)
120.Q5RGR9_HUMAN Novel protein similar to cell recognition molecule
CASPR3 (CASPR3), 45 (3%)
121.AAL33548 NUANCE, 45 (2%)
122.AAF75772 ubiquitin-conjugating BIR-domain enzyme APOLLON,
45 (1%)
123.PDZK3_HUMAN PDZ domain containing protein 3 (PDZ domain
containing protein 2) (Activated in prostate cancer pro, 44 (2%)
124.PLXB1_HUMAN Plexin B1 precursor (Semaphorin receptor SEP), 44
(3%)
125.I37360 phosphopyruvate hydratase (EC 4.2.1.11), lung , 44 (9%)
126.Q5SPY5_HUMAN OTTHUMP00000064733, 44 (1%)
127.AAR88375 anti-HIV-1 gp120 immunoglobulin 23e heavy chain, 44
(18%)
128.I38869 transcription factor NFX1 [imported] , 44 (4%)
129.AAR25661 ankyrin repeat-containing protein, 43 (2%)
130.1A5R sumo-1, 43 (33%)
131.A59404 plectin [imported], 43 (3%)
132.AAS85951 Immunoglobulin heavy chain, 43 (26%)
133.AAR32396 Immunoglobulin heavy chain variable region, 43 (25%)
134.AAR32529 Immunoglobulin heavy chain variable region, 43 (25%)
135.Q5VW20_HUMAN OTTHUMP00000046304 (Microtubule-actin
crosslinking factor 1), 42 (2%)
136.AAR04774 Kinesin family member 21A, 42 (2%)
137.AAS85961 Immunoglobulin heavy chain, 42 (28%)
138.Q6RAS0_HUMAN Microcephalin (Fragment), 42 (9%)
139.E977534 H.SAPIENS PROTEIN FRAGMENT (PR14-5.3.3.1), 42
(2%)
140.ENOG_HUMAN Gamma enolase (EC 4.2.1.11) (2-phospho-D-
glycerate hydro-lyase) (Neural enolase) (Neuron-specific enolase, 42 (9%)
141.Q5THM4_HUMAN Chromosome 6 open reading frame 71, 41 (6%)
142.AAA19595 PITSLRE isoform PBETA2241 (6%)
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143.Q5T9J7_HUMAN Spastic ataxia of Charlevoix-Saguenay (Sacsin), 41
(2%)
144.CAI19680 DKFZP547E1010 protein, 41 (23%)
145.AAR02560 Immunoglobulin heavy chain, 41 (25%)
146.AAR32446 Immunoglobulin heavy chain variable region, 41 (30%)
147.AAA58669 HRX, 41 (2%)
148.Q5SVH7_HUMAN Neuron navigator 1, 41 (4%)
149.R3HDM_HUMAN R3H domain protein 1, 41 (5%)
150.Q5THJ0_HUMAN PR domain containing 2, with ZNF domain
(Fragment), 41 (5%)
151.AAB07496 leptin receptor, 41 (3%)
152.CAD33317 Sequence 44 from Patent WO0218424, 41 (4%)
153.BAA96000 KIAA1476 protein, 41 (1%)
154.Q8NGB0_HUMAN Seven transmembrane helix receptor
155.Q5R3M6_HUMAN OTTHUMP00000028958, 40 (3%)
156.Q5SYA9_HUMAN OTTHUMP00000046126
(OTTHUMP00000021391), 40 (2%)
157.AAC51202 armadillo repeat protein, 40 (3%)
158.Q8WY53_HUMAN PAD, 40 (6%)
159.Q5T791_HUMAN OTTHUMP00000016860 (Fragment), 40 (1%)
160.AAA85638 TFIIIC alpha subunit, 40 (3%)
161.AAF21616 Ig heavy chain (fragment), 40 (17%)
162.CAE11569 Sequence 9 from Patent WO03048202, 39 (1%)
163.S02392 alpha-2-macroglobulin receptor precursor, 39 (1%)
164.SYNE2_HUMAN Nesprin 2 (Nuclear envelope spectrin repeat protein
2) (Syne-2) (Synaptic nuclear envelope protein , 39 (1%)
165.Q5VUP7_HUMAN Leukemia-associated protein with a CXXC
domain, 39 (2%)
166.CAA69325 Mosaic protein LR11, 39 (2%)
167.Q6P4G7_HUMAN TRA@ protein, 39 (13%)
168.POK5_HUMAN HERV-K_19p13.11 provirus ancestral Pol protein
(HERV-K113 Pol protein) [Includes: Reverse transcrip, 39 (5%)
169.PSA7L_HUMAN Proteasome subunit alpha type 7-like (EC 3.4.25.1),
39 (6%)
170.Q6NSK0_HUMAN Serine/threonine kinase 10, 38 (<1%)
171.TP2B_HUMAN DNA topoisomerase II, beta isozyme (EC 5.99.1.3),
38 (4%)
172.Q5VZN6_HUMAN OTTHUMP00000018523
(OTTHUMP00000040824), 38 (1%)
173.PCNT2_HUMAN Pericentrin 2 (Pericentrin B) (Kendrin), 38 (2%)
174.AAF05687 Anti-phospholipid immunoglobulin heavy chain VH-D-
J-C region (fragment), 38 (18%)
175.ALU3_HUMAN Alu subfamily SB1 sequence contamination warning
entry, 38 (16%)
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176.Q8WWS6_HUMAN DJ537K23.3 (KIAA0266 protein) (Fragment), 38
(3%)
177.Q5THR3_HUMAN OTTHUMP00000028872, 37 (3%)
178.Q5SZY9_HUMAN OTTHUMP00000020987
(OTTHUMP00000044319), 37 (6%)
179.CAD01139 putative TRP cation channel, 37 (2%)
180.AAC51825 3-phosphoinositide dependent protein kinase-1, 37 (2%)
181.BAA20778 KIAA0320 protein, 37 (2%)
182.Q6GPH5_HUMAN Eukaryotic translation initiation factor 4B, 37 (5%)
183.AAL39000 Macrophin 1 isoform 2, 37 (1%)
184.Q5STU9_HUMAN HLA-B associated transcript 1, 37 (6%)
185.AAP13528 rho/rac-interacting citron kinase, 37 (3%)
186.Q9NZA0_HUMAN FBP-interacting repressor (Fuse-binding protein-
interacting repressor, isoform b), 37 (4%)
187.AAG43364 MAK-related kinase, 37 (9%)
188.AAK19738 channel-kinase 1, 37 (3%)
189.Q5THQ1_HUMAN OTTHUMP00000028520, 37 (2%)
190.Q6PFW1_HUMAN KIAA0377 gene product, 37 (3%)
191.JC2444 ribosomal protein L24, cytosolic [validated] – rat, 37 (8%)
192.AAH03413 Nucleolar protein family A, member 1, 37 (13%)
193.AAC26019 alpha-tectorin, 37 (2%)
194.YLPM1_HUMAN YLP motif containing protein 1 (Nuclear protein
ZAP3) (ZAP113), 37 (3%)
195.Q5TYR7_HUMAN Hemicentin (FIBL-6), 37 (1%)
196.Q13544_HUMAN Signaling inositol polyphosphate 5 phosphatase
SIP-110, 37 (10%)
197.SYTL2_HUMAN Synaptotagmin-like protein 2 (Exophilin 4), 36
(2%)
198.AAD51793 GAG-PRO-POL-ENV PROTEIN, 36 (1%)
199.A35938 profilaggrin (fragments), 36 (1%)
200.CAA32530 Eosinophil preperoxidase (AA-127 to 575), 36 (6%)
201.Q7LAX7_HUMAN CKII beta binding protein 2, 36 (16%)
202.JC7687 nucleolar protein p40/Epstein-Barr virus nuclear antigen 1
binding protein 2 , 36 (3%)
203.CAC20419 a disintergrin-like and metalloprotease (replosin type),
36 (2%)
204.Q5T1U7_HUMAN OTTHUMP00000021972 (Fragment), 36 (7%)
205.A59266 unconventional myosin-15, 36 (<1%)
206.Q8NG37_HUMAN Microtubule affinity-regulating kinase-like1, 36
(5%)
207.BAA05384 Type 2 inositol 1,4,5-trisphophate receptor, 36 (2%)
208.AAB38530 Plasma membrane calcium ATPase isoform 3x/b, 36
(4%)
209.RABE2_HUMAN Rab GTPase binding effector protein 2 (Rabaptin-
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5beta), 35 (8%)
210.DOC10_HUMAN Dedicator of cytokinesis protein 10 (Protein zizimin
3), 35 (2%)
211.AAD29948 Myosin heavy chain, 35 (2%)
212.Q9UPS0_HUMAN KIAA1082 protein (Fragment), 35 (3%)
213.T08711 gamma-adaptin homolog DKFZp564D066.1 , 35 (4%)
214.POK20_HUMAN HERV-K_3q27.3 provirus ancestral Pol protein
[Includes: Reverse transcriptase (RT) (EC 2.7.7.49); R, 35 (4%)
215.AAH45551 TSEN54 protein, 35 (4%)
216.Q8NHY3_HUMAN GAS2-related protein isoform beta, 35 (3%)
217.Q5SQZ8_HUMAN Thyroid hormone receptor interactor 8, 35 (3%)
218.AAC51191 Skeletal muscle ryanodine receptor, 35 (1%)
219.AAH09304 DDX27 protein, 35 (3%)
220.AAA51758 apolipoprotein B-100, 35 (1%)
221.CGHU2E collagen alpha 2(XI) chain precursor (fragment), 35
(4%)
222.O43149_HUMAN KIAA0399 protein (Fragment), 34 (3%)
223.AAR32522 Immunoglobulin heavy chain variable region, 34 (25%)
224.AAR25662 ankyrin repeat-containing protein, 34 (2%)
225.AAB04947 Inositol 1,4,5-trisphosphate receptor type 1, 34 (1%)
226.D56695 transducin-like enhancer-of-split homolog TLE-3, 34 (3%)
227.BAA20783 inositol 1,4,5-trisphophate receptor type 1, 34 (1%)
228.CAC38563 Sequence 143 from Patent WO0129221, 34 (9%)
229.CAC33149 Sequence 54 from Patent WO0100826, 34 (4%)
230.CGHU3A collagen alpha 3(VI) chain precursor [validated] , 34
(1%)
231.Q96CV2_HUMAN ACCN2 protein (Fragment), 34 (4%)
232.AAH00528 Arginyl-tRNA synthetase, 34 (7%)
233.ALU2_HUMAN Alu subfamily SB sequence contamination warning
entry, 34 (10%)
234.AAB08431 hGrbIRbeta/hGrb10, 34 (3%)
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7.5 PROTEINS IDENTIFIED IN ADENOVIRUS INFECTED TAP-
SUMO2 CELLS BUT NOT IN UNINFECTED CELLS (minus TAP
cells uninftected data)
Accession number, name of protein, overall Mascot score and % peptide
coverage
Gel chunks 1-9
1. AAF42836 Endoplasmic reticulum luminal Ca2= binding protein
grp78; BiP, 698 (64%)
2. BAA09860 Polyubiquitin, 657 (17%)
3.A27077 dnaK-type molecular chaperone , 419 (27%)
4.AAF19786 General transcription factor 3, 412 (21%)
5.Q5SP17_HUMAN Heat shock 70kDa protein 1A, 381 (19%)
6.HHHU86 heat shock protein 90-alpha , 299 (10%)
7.S52863 DNA-binding protein R kappa B, 294 (14%)
8.CAA98022 Plakophilin, 273 (24%)
9.Q96B34_HUMAN Beta actin, 266 (34%)
10. A25873 tubulin alpha chain (version 2) , 268 (39%)
11. Q8IWR2_HUMAN Class II beta tubulin isotype, 213 (33%)
12. Q5T8M7_HUMAN Actin, alpha 1, skeletal muscle, 194 (21%)
13. HCC1_HUMAN Nuclear protein Hcc-1 (HSPC316) (Proliferation
associated cytokine- inducible protein CIP29), 178 (13%)
14. Q6EEV6_HUMAN Small ubiquitin-like protein 4
(OTTHUMP00000040124), 161 (35%)
15. A57198 splicing factor, arginine/serine-rich 7, 160 (28%)
16. AAN60442 Nesprin-1, 154 (3%)
17. Q9NZA0_HUMAN FBP-interacting repressor (Fuse-binding
protein-interacting repressor, isoform b), 149 (19%)
18. 4PGTA glutathione s-transferase (EC 2.5.1.18) mutant VAL 104
VARIANT naturally occurring variants of hgst, 148 (29%)
19. CAI23317 Arginase, liver, 147 (28%)
20. A43700 BN51 protein, 144 (14%)
21. Q719H9_HUMAN Potassium channel tetramerization domain-
containing 1 (KCTD1 protein), 136 (30%)
22. AAH10578 Threonyl-tRNA synthetase, 133 (6%)
23. A47363 RNA helicase A, 120 (5%)
24. AAD10197 DNA recombination and repair protein, 119 (7%)
25. Q5SZY0_HUMAN Chaperonin containing TCP1, subunit 3
(Gamma), 115 (17%)
26. AAA61281 Vimentin, 109 (34%)
27. Q9H552_HUMAN OTTHUMP00000021786, 105 (5%)
28. AAH75846 IGHG1 protein, 101 (13%)
29. Q5SQX9_HUMAN Novel protein similar to beta-tubulin 4Q
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(TUBB4Q) (LOC253936) (Fragment), 97 (15%)
30. AAH75842 IGHG1 protein, 97 (13%)
31. AAH78670 IGHG1 protein, 95 (14%)
32. BAC04226 CDNA FLJ36487 fis, clone THYMU2017844, highly
similar to Homo sapiens immunoglobulin lambda heavy chain, 94
(13%)
33. BAC05203 CDNA FLJ40631 fis, clone THYMU2014777, highly
similar to Homo sapiens immunoglobulin lambda heavy chain, 93
(14%)
34. BAC05012 CDNA FLJ40035 fis, clone SYNOV2000173, highly
similar to Human (hybridoma H210) anti-hepatitis A Ig, 90 (13%)
35. JC1087 RNA helicase, ATP-dependent, 87 (9%)
36. Q9BYF8_HUMAN SCCA1b, 85 (20%)
37. AAH15030 ZBED1 protein, 85 (7%)
38. TVHUJB transforming protein jun-B, 84 (13%)
39. AAK48938 PIAS-NY protein, 82 (16%)
40. AAL33798 Nesprin-1 beta, 77 (3%)
41. AAG00912 Recombinant IgG4 heavy chain (Fragment), 77 (8%)
42. RL18_HUMAN 60S ribosomal protein L18, 76 (13%)
43. AAG13404 Topoisomerase II alpha-3, 75 (9%)
44. Q6FGQ8_HUMAN NFIL3 protein (Fragment), 73 (10%)
45. Q9NPL4_HUMAN Enolase (EC 4.2.1.11) (2-phospho-D-glycerate
hydro-lyase) (Fragment), 72 (24%)
46. TCPQ_HUMAN T-complex protein 1, theta subunit (TCP-1-theta)
(CCT-theta), 71 (8%)
47. Q6PFW1_HUMAN KIAA0377 gene product, 71 (3%)
48. TVHUJN transcription factor AP-1, 70 (4%)
49. Q96AA2_HUMAN Obscurin, 70 (3%)
50. Q8IXV2_HUMAN ATP5A1 protein (Fragment), 67 (9%)
51. Q7Z791_HUMAN TKT protein, 66 (12%)
52. Q5TEM5_HUMAN Myosin VI, 65 (6%)
53. Q5T7P4_HUMAN Involucrin, 62 (8%)
54. CAD23331 Sequence 1 from Patent WO0200863, 62 (8%)
55. A48133 pre-mRNA splicing SRp75, 62 (7%)
56. GCC2_HUMAN GRIP and coiled-coil domain-containing protein
2 (Golgi coiled coil protein GCC185) (CTCL tumor ant), 61 (3%)
57. Q16716_HUMAN Pyruvate kinase PK-L isoenzyme, 61 (5%)
58. Q5W9F9_HUMAN KIAA0216 splice variant 2 (Fragment), 61 (4%)
59. BAC77401 Putative MAPK activating protein, 60 (9%)
60. BAC15608 FELE-2, 59 (3%)
61. Q6PJT4_HUMAN MSN protein (Fragment), 59 (9%)
62. Q6PIK4_HUMAN DIX domain containing 1, 59 (6%)
63. A43358 macrophage capping protein, 58 (3%)
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64. PDRN4_HUMAN PDZ domain containing RING finger protein 4
(Ligand of Numb-protein X 4) (SEMACAP3-like protein), 58 (4%)
65. PCNT2_HUMAN Pericentrin 2 (Pericentrin B) (Kendrin), 58 (2%)
66. BAA75062 apg-2, 58 (5%)
67. AAD21786 Similar to clagizzarin; similar to PID:g3115349, 57
(38%)
68. AAC50662 Monocytic leukemia zinc finger protein, 57 (3%)
69. S43692 transcription factor erm , 56 (8%)
70. Q5T2F1_HUMAN Neurofascin (NFASC) (Fragment), 57 (5%)
71. BAA13192 KIAA0201 protein, 56 (7%)
72. Q6ZML1_HUMAN FLJ00298 protein (Fragment), 56 (5%)
73. Q8TEP3_HUMAN FLJ00150 protein (Fragment), 55 (3%)
74. CAD19369 Sequence 5 from Patent WO0181417, 55 (12%)
75. CAA02940 SEQUENCE 2 FROM PATENT WO9527070, 55
(5%)
76. Q6PFW2_HUMAN ARHGEF11 protein
(OTTHUMP00000060353), 54 (5%)
77. Q6FG89_HUMAN G22P1 protein, 54 (8%)
78. Q5VUA4_HUMAN OTTHUMP00000039830 (Zinc finger protein
318), 54 (3%)
79. AAH39612 MYO18A protein, 54 (3%)
80. Q6UXW4_HUMAN SSGL9393, 53 (11%)
81. CAD48781 Sequence 27 from Patent EP1229047, 53 (7%)
82. AAF87083 Tropomyosin isoform, 53 (29%)
83. EF1G_HUMAN Elongation factor 1-gamma (EF-1-gamma) (eEF-
1B gamma) (PRO1608), 53 (7%)
84. Q9UPS0_HUMAN KIAA1082 protein (Fragment), 53 3%)
85. Q6Q759_HUMAN PF6 (OTTHUMP00000059528), 52 (2%)
86. A46160 interferon alpha-induced transcription activator ISGF-3,
113K chain , 52 (5%)
87. TCPW_HUMAN T-complex protein 1, zeta-2 subunit (TCP-1-zeta-
2) (CCT-zeta-2) (TCP- 1-zeta-like) (CCT-zeta-like) (Testis-specific
Tcp20) (Testis-specific protein TSA303), 52 (5%)
88. CAI13123 PRP18 pre-mRNA processing factor 18 homolog, 52
(10%)
89. ITB4_HUMAN Integrin beta-4 precursor (GP150) (CD104
antigen), 52 (4%)
90. AAM19206 S100 calcium binding protein A14, 52 (10%)
91. Q9BYW2_HUMAN Huntingtin interacting protein 1 (HSPC069
isoform a), 51 (2%)
92. CSMSA peptidylprolyl isomerase (EC 5.2.1.8) A – mouse, 51
(21%)
93. Q5TZA2_HUMAN Ciliary rootlet coiled-coil, rootletin
(OTTHUMP00000044629), 50 (4%)
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94. Q6R954_HUMAN Polymerase delta interacting protein 46, 50 (7%)
95. T08796 tropomyosin (fragment), 50 (18%)
96. AAH50321 TBC1 (tre-2/USP6, BUB2, cdc16) domain family,
member 1, 50 (4%)
97. SFRS1_HUMAN Splicing factor, arginine/serine-rich 1 (pre-mRNA
splicing factor SF2, P33 subunit) (Alternative sp), 50 (7%)
98. CAC69813 Sequence 6 from Patent WO0162928, 50 (5%)
99. Q5W093_HUMAN OTTHUMP00000059187 (Programmed cell
death 11), 50 (2%)
100.AAF24980 voltage-gated sodium channel alpha subunit, alternate
splice variant SCN12A-s, 49 (4%)
101.Q5TBA9_HUMAN Chromosome 13 open reading frame 14, 49
(3%)
102.Q7Z519_HUMAN Maid, 49 (7%)
103.Q9P2N5_HUMAN KIAA1311 protein (Fragment), 48 (3%)
104.Q8NFX2_HUMAN PI-3-kinase ATX, 48 (2%)
105.Q6P189_HUMAN Minor histocompatibility antigen HA-1, 48 (2%)
106.AAK40350 DNA-dependant protein kinase, 48 (12%)
107.AAR02550 Immunoglobulin heavy chain variable region, 48
(25%)
108.Q6PJ32_HUMAN FLJ11806 protein (Fragment), 48 (5%)
109.Q5VUA6_HUMAN OTTHUMP00000046844 (InaD-like protein)
(INADL), 48 (5%)
110.T08599 probable transcription factor CA150, 48 (2%)
111.A24199 tropomyosin NM, skeletal muscle, 48 (22%)
112.JQ1348 carbamoyl-phosphate synthase (ammonia) (EC
6.3.4.16) precursor, 48 (4%)
113.Q7Z5Y2_HUMAN Rho-interacting protein 3, 47 (7%)
114.Q5VXD5_HUMAN Ankyrin 3, node of Ranvier (Ankyrin G), 47
(1%)
115.AAC43042 trio isoform, 47 (4%)
116.CAA99729 RAD50 homologue hsRAD50, 47 (5%)
117.Q6I9V9_HUMAN LOC63929 protein, 46 (11%)
118.CD2L2_HUMAN PITSLRE serine/threonine-protein kinase
CDC2L2 (EC 2.7.1.37) (Galactosyltransferase associated protein, 46
(5%)
119.AAR02531 Immunoglobulin heavy chain variable region, 46
(24%)
120.Q5SQI3_HUMAN Calmodulin-like 5, 46 (7%)
121.T09551 ribosomal protein L4, 46 (8%)
122.2FB4H Ig heavy chain V region (Fab fragment KOL), chain H ,
45 (18%)
123.Q9BS48_HUMAN HSF2 protein (Hypothetical protein), 45 (21%)
124.Q96BI2_HUMAN ARL6IP4 protein, 45 (14%)
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125.Q86VH0_HUMAN KIF27C, 45 (5%)
126.Q5VVU8_HUMAN OTTHUMP00000059324 (Transcription
termination factor, RNA polymerase II), 45 (6%)
127.Q5VWI3_HUMAN Nebulin-related anchoring protein, 45 (8%)
128.Q8WXV8_HUMAN Alpha 1 chain-like collagen COLA1L
precursor (Collagen, type XXI, alpha 1), 44 (11%)
129.Q76L81_HUMAN Chimeric MOZ-ASXH2 fusion protein, 44 (3%)
130.A47212 transcription factor TMF, TATA element modulatory
factor, 44 (5%)
131.Q86VH1_HUMAN KIF27B, 44 (5%)
132.Q9H281_HUMAN Serologically defined breast cancer antigen NY-
BR-49 (Fragment), 44 (16%)
133.Q6IC06_HUMAN RFPL1 protein, 44 (7%)
134.Q96PH3_HUMAN Proliferation potential-related protein, 44 (3%)
135.AAR32467 Immunoglobulin heavy chain variable region, 44
(29%)
136.Q7KZ68_HUMAN Putative M phase phosphoprotein (MPP1
(Fragment), 44 (8%)
138.Q6PIC7_HUMAN FLJ14503 protein (Fragment), 44 (6%)
139.Q9ULU8_HUMAN KIAA1121 protein (Fragment), 44 (6%)
140.PIAS3_HUMAN Protein inhibitor of activated STAT protein 3, 44
(3%)
141.CAI13459 Novel protein, 44 (17%)
142.BAA78533 Protein inhibitor of activated STAT3, 44 (3%)
143.1P1GA macrophage migration inhibitory factor mutant P1G,
chain A, 43 (17%)
144.BAA22586 SCP-1, 43 (9%)
145.Q8TBJ9_HUMAN RIC3 protein, 43 (13%)
146.BAA02054 Nucleotide pyrophosphatase, 43 (6%)
147.Q9NZE6_HUMAN BM-010, 43 (14%)
148.A57169 [heparan sulfate]-glucosamine N-sulfotransferase (EC
2.8.2.8) , 43 (3%)
149.Q8NEQ7_HUMAN Interferon-inducible IFI 16, 43 (2%)
150.BAA20836 KIAA0382 protein, 43 (5%)
151.1FVEB Fab fragment of humanized antibody 4d5, version 7,
chain B, 43 (20%)
152.AAR02524 Immunoglobulin heavy chain variable region, 43
(29%)
153.AAC52012 SET-DOMAIN PROTEIN AND MARINER
TRANSPOSON HSMAR1 TRANSPOSASE FUSION PROTEIN, 43
(7%)
154.AAR00504 Immunoglobulin heavy chain, VH region, 43 (17%)
155.AAK19936 IgG1 immunoglobulin heavy chain variable region
(Fragment), 43 (22%)
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156.ROCK2_HUMAN Rho-associated protein kinase 2 (EC 2.7.1.37)
(Rho-associated, coiled- coil containing protein kinase, 42 (5%)
157.MITF_HUMAN Microphthalmia-associated transcription factor,
42 (3%)
158.Q76D35_HUMAN Nop132, 42 (4%)
159.BAA97670 Immunoglobulin gamma heavy chain (Fragment)
160.(OTTHUMP00000021970), 42 (15%)
161.O60307_HUMAN KIAA0561 protein (Fragment), 42 (3%)
162.Q6K0P6_HUMAN Interferon-inducible protein X beta 2 isoform
(IFIX), 42 (12%)
163.Q5VZN0_HUMAN OTTHUMP00000044227, 42 (9%)
164.AAR32419 Immunoglobulin heavy chain variable region, 41
(28%)
165.AAO22169 Immunoglobulin heavy chain variable and constant
region (Fragment), 41 (24%)
166.Q6YMW8_HUMAN Rac-GTP binding protein-like protein, 41
(8%)
167.Q96I57_HUMAN MYH7B protein (Fragment), 41 (6%)
168.AAA52805 OMM protein (Ig gamma 3) heavy chain, 41 (7%)
169.BAA31614 KIAA0639 protein, 41 (4%)
170.AAL05571 SERPINB12, 41 (4%)
171.Q6Y1F2_HUMAN FHOS, 41 (2%)
172.Q5T749_HUMAN Novel protein, 41 (7%)
173.BAA95526 ANKRD3, 41 (6%)
174.Q8TB65_HUMAN Cytochrome c oxidase subunit Va, (COX5A
protein), 41 910%)
175.AAF07045 A-kinase anchoring protein 220, 41 (3%)
176.S21424 nestin, 41 (3%)
177.I38510 neuronal kinesin heavy chain, 41 (8%)
178.CAC07506 Sequence 1 from Patent WO9960116, 41 (2%)
179.AAR32529 Immunoglobulin heavy chain variable region, 40
(25%)
180.MYH6_HUMAN Myosin heavy chain, cardiac muscle alpha
isoform (MyHC-alpha), 40 (3%)
181.AAR32426 Immunoglobulin heavy chain variable region, 40
(16%)
182.AAP13528 rho/rac-interactin citron kinase, 40 (2%)
183.I39152 zinc finger protein, 40 (12%)
184.PEPL_HUMAN Periplakin (195 kDa cornified envelope precursor
protein) (190 kDa paraneoplastic pemphigus antigen), 40 (2%)
185.ZN292_HUMAN Zinc finger protein 292, 40 (5%)
186.MATN4_HUMAN Matrilin-4 precursor, 40 (7%)
187.AAF03782 Traf2 and NCK interacting kinase, splice variant 1,
40 (5%)
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188.Q8IYF3_HUMAN Testis expressed sequence 11, isoform 2, 40
(7%)
189.Q5T527_HUMAN Small proline-rich protein 1A, 39 (34%)
190.Q96PY5_HUMAN KIAA1902 protein (Fragment), 39 (3%)
191.DDX18_HUMAN ATP-dependent RNA helicase DDX18 (EC
3.6.1.-) (DEAD-box protein 18) (Myc-regulated DEAD-box protein)
(MrDb), 39 (6%)
192.Q9UDT6_HUMAN KIAA0291; similar rodent cytoplasmic linker
protein CLIP-115 and restin, 39 (4%)
193.BAA08260 Phosphodiesterase I alpha, 39 (5%)
194.Q8N4H8_HUMAN Smoothelin, isoform b, 39 (4%)
195.AAH25393 PSMA8 protein, 39 (15%)
196.ABCA1_HUMAN ATP-binding cassette, sub-family A, member 1
(ATP-binding cassette transporter 1) (ATP-binding cassette 1) (ABC-1)
(Cholesterol efflux regulatory protein), 39 (2%)
197.AAF98175 ATP-binding cassette transporter 1, 39 (3%)
198.CHSS3_HUMAN Chondroitin sulfate synthase 3 (EC 2.4.1.175)
(Glucuronosyl-N- acetylgalactosaminyl-proteoglycan 4, 38 (11%)
199.TVHUFF protein-tyrosine kinase (EC 2.7.1.112) fes/fps , 38
(5%)
200.CAA04747 IMMUNOGLOBULIN IGG2 (FRAGMENT), 38
(34%)
201.CAD61482 Sequence 132 from Patent WO02083898, 38 (20%)
202.Q5SZL2_HUMAN OTTHUMP00000040396, 38 (5%)
203.CAD33317 Sequence 44 from Patent WO0218424, 38 (3%)
204.Q9H430_HUMAN DJ756N5.1.1 (Continues in Em:AL133324 as
dJ1161H23.3 ) (Fragment), 38 (4%)
205.Q5TE18_HUMAN OTTHUMP00000030379, 38 (2%)
206.AAD29857 NAD+ ADP-ribosyltransferase 2, 38 (6%)
207.Q6NZ98_HUMAN HIST1H2BA protein (Fragment), 38 (26%)
208.BAA82981 KIAA1029 protein, 38 (2%)
209.A54971 protein-tyrosine-phosphatase (EC 3.1.3.48) PTPN13,
nonreceptor type 13, splice form 1 [validated] , 38 (4%)
210.Q5VXF6_HUMAN Dedicator of cyto-kinesis 1 (Fragment), 38
(3%)
211.A43346 1-phosphatidylinositol-4,5-bisphosphate
phosphodiesterase (EC 3.1.4.11) beta-2, 38 (6%)
212.BAA07536 PK-120 precursor, 38 (7%)
213.A32611 beta-galactosidase (EC 3.2.1.23) precursor, 38 (6%)
214.CAD33289 Sequence 16 from Patent WO0218424, 38 (20%)
215.Q86XK4_HUMAN PLCL3 protein (Fragment), 37 (4%)
216.CAC94536 Sequence 1 from Patent WO0170982, 37 (68%)
217.MYH3_HUMAN Myosin heavy chain, fast skeletal muscle,
embryonic (Muscle embryonic myosin heavy chain) (SMHCE), 37 (4%)
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218.Q9Y6X6_HUMAN KIAA0865 protein (Fragment), 37 (3%)
219.GAK_HUMAN Cyclin G-associated kinase (EC 2.7.1.-), 37 (5%)
220.Q9P2N0_HUMAN KIAA1316 protein (Fragment), 37 (3%)
221.CAD10594 Sequence 2 from Patent WO0162977, 37 (2%)
222.Q9ULM3_HUMAN KIAA1197 protein (Fragment), 37 (3%)
223.AAG16639 Helicase SMARCAD1, 37 (7%)
224.Q8N137_HUMAN LYST-interacting protein LIP8 (Hypothetical
protein DKFZp434I1519), 37 (4%)
225.S45340 FKBP-rapamycin-associated protein (FRAP) , 37 (3%)
226.Q9UPU7_HUMAN KIAA1055 protein (Fragment), 37 (4%)
227.Q6UWF7_HUMAN Brush border, 37 (2%)
228.Q6IQ54_HUMAN PTK7 protein tyrosine kinase 7, isoform a, 37
(4%)
229.Q5VT08_HUMAN OTTHUMP00000046616, 37 (1%)
230.Q5VT94_HUMAN Growth hormone inducible transmembrane
protein, 37 (9%)
231.CO1A2_HUMAN Collagen alpha 2(I) chain precursor, 37 (4%)
232.Q8TD98_HUMAN MLL/AF4 fusion protein (Fragment), 37 (9%)
233.S31975 14-3-3 protein epsilon, renal – mouse, 37 (12%)
234.CAB65786 DJ269M15.1 (similar to peptidylprolyl isomerase
(cyclophilin)), 37 (15%)
235.QFHUH neurofilament triplet H protein, 36 (7%)
236.Q96P05_HUMAN Transient receptor potential channel 4 epsilon
splice variant (Transient receptor potential cation), 36 (6%)
237.E973183 TETRANECTIN, 36 (6%)
238.Q5U5L5_HUMAN Jumonji, AT rich interactive domain 2 protein
(OTTHUMP00000016058), 36 (5%)
239.AAH07557 F-box and leucine-rich repeat protein 20
240.Q9UPP6_HUMAN KIAA1106 protein (Fragment), 36 (3%)
241. AAD28285 Bile salt export pump, 36 (7%)
242.CAE55985 PTX XI Eph/Elk/Eck orphan receptor family, 36
(3%)
243.G3P1_HUMAN Glyceraldehyde-3-phosphate dehydrogenase,
muscle (EC 1.2.1.12) (GAPDH), 36 (11%)
244.Q7Z4G5_HUMAN K-Cl cotransporter KCC3a-X2M i
245.AAN10118 cAMP-specific phosphodiesterase PDE4D7, 36 (5%)
246.Q6P9G1_HUMAN DHX57 protein, 36 (6%)
247.Q6WRI0_HUMAN Bone specific CMF608, 36 (3%)
248.AAA52025 creatine kinase M, 35 (10%)
249.DDX3_HUMAN DEAD-box protein 3 (Helicase-like protein 2)
(HLP2) (DEAD-box, X isoform), 35 (2%)
250.BAA11423 Multifunctional protein CAD, 35 (4%)
251.O43598_HUMAN RCL (OTTHUMP00000016424) (Putative c-
Myc-responsive, isoform 1), 35 (14%)
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252.CAD43233 Chondroitin synthase 2, 35 (13%)
253.Q8TES3_HUMAN FLJ00120 protein (Fragment), 35 (5%)
254.Q8TC68_HUMAN MGC40042 protein (Fragment), 35 (7%)
255.Q96E39_HUMAN Kynurenine aminotransferase III (Novel protein
similar to RNA binding motif protein, X-linked) (RBM), 35 (9%)
256.Q8IVF4_HUMAN KIAA2017 protein (Fragment), 35 (5%)
257.I67630 protein-tyrosine-phosphatase (EC 3.1.3.48) PTPN13,
nonreceptor type 13, splice form 3, 35 (4%)
259.Q96HU2_HUMAN SRPR protein, 35 (10%)
260.Q5TG00_HUMAN OTTHUMP00000039711
(OTTHUMP00000017871), 35 (2%)
261.O00370_HUMAN Putative p150, 35 (2%)
262.AAH21908 Zinc finger, DHHC domain containing 1, 35 (7%)
263.CAD69464 Sequence 867 from Patent EP1270724, 35 91%)
264.AAK29402 Nucleolar protein GU2, 35 (10%)
265.Q5TAP6_HUMAN KIAA0266 protein, 35 (4%)
266.Q8NET9_HUMAN Vanilloid receptor like 3 protein splice variant
b, 35 (6%)
267.AAH41700 RABEP1 protein, 35 (2%)
268.AAS85957 Immunoglobulin heavy chain, 35 (15%)
269.I78879 retinoblastoma binding protein 2, 35 (3%)
270.Q14828_HUMAN MG44 protein (Fragment), 35 (8%)
271.CAA65265 Rox protein 35 (4%)
272.Q9C0D5_HUMAN KIAA1728 protein (Fragment), 34 (4%)
273.AAH07082 SMARCE 1 protein, 34 (3%)
274.Q8WU85_HUMAN RBM4 protein (Hypothetical protein
DKFZp547K0918), 34 (16%)
275.Q5TCU3_HUMAN Tropomyosin 2 (Beta), 34 (17%)
276.Q5TGI4_HUMAN SAM domain containing 1, 34 (23%)
277.MCHUNB calmodulin-related protein NB-1, 34 (10%)
278.Q8WUG8_HUMAN MTB protein, 34 (5%)
279.Q9C0D4_HUMAN KIAA1729 protein (Fragment), 34 (2%)
280.BAA92573 KIAA1335 protein, 34 (2%)
281.E59435 myosin IXA [imported] , 34 (2%)
282.Q5VZN1_HUMAN Novel DnaJ domain-containing protein
(Fragment), 34 (10%)
283.Q8IW75_HUMAN Serine (Or cysteine) proteinase inhibitor, clade
A (Alpha-1 antiproteinase, antitrypsin), member 12, 34 (9%)
284.AAH40945 PCMTD2 protein, 34 (14%)
285.Q9P2B8_HUMAN KIAA1429 protein (Fragment), 34 (3%)
293
Gel chunks 10-18
1. Q96B34_HUMAN Beta actin, 340 (31%)
2. A57198 splicing factor, arginine/serine-rich 7 , 232 (28%)
3. Q719H9_HUMAN Potassium channel tetramerization domain-
containing 1 (KCTD1 protein), 200 (30%)
4. R3HUS3 ribosomal protein S3, cytosolic , 192 (32%)
5. H2BE_HUMAN Histone H2B.e (H2B/e), 192 (54%)
6. DEHULH L-lactate dehydrogenase (EC 1.1.1.27) chain H, 179
(23%)
7. Q6EEV6_HUMAN Small ubiquitin-like protein 4
(OTTHUMP00000040124), 176 (26%)
8. SFRS1_HUMAN Splicing factor, arginine/serine-rich 1 (pre-mRNA
splicing factor SF2, P33 subunit) (Alternative sp), 172 (25%)
9. DEHULM L-lactate dehydrogenase (EC 1.1.1.27) chain M, 164
(18%)
10. ENOA_HUMAN Alpha enolase (EC 4.2.1.11) (2-phospho-D-
glycerate hydro-lyase) (Non- neural enolase) (NNE) (Enolase), 163
(30%)
11. Q8IWR2_HUMAN Class II beta tubulin isotype, 147 (19%)
12. R5RTL8 ribosomal protein L8, cytosolic [validated] – rat, 119
(13%)
13. S00985 translation initiation factor eIF-4A II – mouse, 119
(10%)
14. FIMS4A translation initiation factor eIF-4A I – mouse, 118
(10%)
15. Q8N5Z7_HUMAN Ribosomal protein L6, 106 (15%)
16. R5HU7A ribosomal protein L7a, cytosolic, 106 (24%)
17. AAK58567 RBMX, 105 (19%)
18. Q5VWK1_HUMAN Voltage-dependent anion channel 2, 98 (13%)
19. MMHUP3 voltage-dependent anion channel 1 [validated] , 97
(28%)
20. KIHUG phosphoglycerate kinase (EC 2.7.2.3) , 96 (23%)
21. RL18_HUMAN 60S ribosomal protein L18, 96 (25%)
22. BAA77335 IDN3, 94 (3%)
23. AAA60288 Ribosomal protein S6, 93 (26%)
24. T03829 transcription factor TFII-I , 92 (6%)
25. CAI14804 FUS interacting protein (serine-arginine rich), 91
(17%)
26. Q96E39_HUMAN Kynurenine aminotransferase III (Novel protein
similar to RNA binding motif protein, X-linked) (RBM), 87 (18%)
27. AAA60287 Ribosomal protein S6, 85 (26%)
28. G3P1_HUMAN Glyceraldehyde-3-phosphate dehydrogenase,
muscle (EC 1.2.1.12) (GAPDH), 84 (11%)
29. S08228 ribosomal protein S2, cytosolic (fragment), 80 (15%)
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30. Q5SWL5_HUMAN Eukaryotic translation elongation factor 1 alpha
1, 77 (11%)
31. R5HU7 ribosomal protein L7, cytosolic , 76 (18%)
32. JE0241 Ig kappa chain Am37 precursor , 75 (23%)
33. R3RT8 ribosomal protein S8, cytosolic [validated] – rat, 72
(11%)
34. Q6NZ55_HUMAN Ribosomal protein L13, 71 (17%)
35. AAH75846 proteasome activator subunit 1, 70 (10%)
36. BAC01761 Immunoglobulin kappa light chain VLJ region
(Fragment), 67 (18%)
37. BAC05014 CDNA FLJ40038 fis, clone SYNOV2000297, highly
similar to Human (hybridoma H210) anti-hepatitis A Ig, 66 (12%)
38. Q5T8U3_HUMAN Ribosomal protein L7a (Fragment), 65 (23%)
39. 1IBRA ran, chain A, 63 (30%)
40. DEHULC L-lactate dehydrogenase (EC 1.1.1.27) chain X , 62
(9%)
41. Q5TBT0_HUMAN Bullous pemphigoid antigen 1, 230\/240kDa, 61
(2%)
42. AAA02914 IGG PRECURSOR, 60 (10%)
43. BPAEA_HUMAN Bullous pemphigoid antigen 1, isoforms 6/9/10
(Trabeculin-beta) (Bullous pemphigoid antigen) (BPA) , 59 (2%)
44. Q5TZA2_HUMAN Ciliary rootlet coiled-coil, rootletin
(OTTHUMP00000044629), 58 (4%)
45. BAC05012 CDNA FLJ40035 fis, clone SYNOV2000173, highly
similar to Human (hybridoma H210) anti-hepatitis A Ig, 58 (10%)
46. CAA73095 Golgi-associated microtubule-binding protein, 58
(6%)
47. AAH14667 Similar to immunoglobulin heavy constant gamma 3
(G3m marker), 58 (9%)
48. CAD42369 Sequence 11 from Patent WO0214368, 55 (17%)
49. CAI12385 Kinesin family member 21B, 54 (4%)
50. BAB71634 CDNA FLJ25308 fis, clone SYN00939, highly similar
to Ig gamma immunoglobulin heavy chain, 53 (7%)
51. AAR32538 Immunoglobulin heavy chain variable region, 53
(23%)
52. AAR32470 Immunoglobulin heavy chain variable region, 52
(23%)
53. CAI16903 Antigen identified by monoclonal antibody Ki-67, 52
(4%)
54. AAH50321 TBC1 (tre-2/USP6, BUB2, cdc16) domain family,
member 1, 52 (3%)
55. Q5VXD5_HUMAN Ankyrin 3, node of Ranvier (Ankyrin G), 51
(2%)
56. PGK2_HUMAN Phosphoglycerate kinase, testis specific (EC
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2.7.2.3), 51 (5%)
57. AAR02489 Immunoglobulin heavy chain variable region, 51
(21%)
58. KAD2_HUMAN Adenylate kinase isoenzyme 2, mitochondrial
(EC 2.7.4.3) (ATP-AMP transphosphorylase), 51 (18%)
59. CAD34981 Sequence 289 from Patent WO0222660, 50 (5%)
60. JC5423 2-hydroxyacylsphingosine 1-beta-galactosyltransferase
(EC 2.4.1.45), 50 (7%)
61. Q5T7K0_HUMAN OTTHUMP00000040616, 50 (6%)
62. Q86YW0_HUMAN PLC-zeta, 49 (5%)
63. AAR32440 Immunoglobulin heavy chain variable region, 49
(33%)
64. CAC08835 Sequence 36 from Patent WO0006605, 48 (6%)
65. AAC02903 eIF4GII, 48 (5%)
66. BAA37168 IgG heavy chain (Fragment), 48 (16%)
67. Q5T7Y7_HUMAN DKFZP547E1010 protein, 47 (40%)
68. AAF03881 IgG1 heavy chain (fragment), 47 (16%)
69. Q8IWV7_HUMAN Ubiquitin ligase E3 alpha-I, 47 (2%)
70. MCPH1_HUMAN Microcephalin, 46 (6%)
71. AAH14789 UDP-N-acetyl-alpha-D-galactosamine: polypeptide
N-acetylgalactosaminyltransferase-like 2, 46 (4%)
72. Q96JP6_HUMAN Guanine nucleotide exchange factor Lbc, 46 (1%)
73. PDZK3_HUMAN PDZ domain containing protein 3 (PDZ domain
containing protein 2) (Activated in prostate cancer pro, 44 (2%)
74. I37360 phosphopyruvate hydratase (EC 4.2.1.11), lung , 44 (9%)
75. Q5SPY5_HUMAN OTTHUMP00000064733, 44 (1%)
76. AAR88375 anti-HIV-1 gp120 immunoglobulin 23e heavy chain,
44 (18%)
77. I38869 transcription factor NFX1 [imported] , 44 (4%)
78. AAR32396 Immunoglobulin heavy chain variable region, 43
(25%)
79. AAR32529 Immunoglobulin heavy chain variable region, 43
(25%)
80. Q6RAS0_HUMAN Microcephalin (Fragment), 42 (9%)
81. E977534 H.SAPIENS PROTEIN FRAGMENT (PR14-5.3.3.1),
42 (2%)
82. ENOG_HUMAN Gamma enolase (EC 4.2.1.11) (2-phospho-D-
glycerate hydro-lyase) (Neural enolase) (Neuron-specific enolase, 42
(9%)
83. Q5THM4_HUMAN Chromosome 6 open reading frame 71, 41 (6%)
84. AAA19595 PITSLRE isoform PBETA2241 (6%)
85. CAI19680 DKFZP547E1010 protein, 41 (23%)
86. AAR02560 Immunoglobulin heavy chain, 41 (25%)
87. Q5SVH7_HUMAN Neuron navigator 1, 41 (4%)
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88. R3HDM_HUMAN R3H domain protein 1, 41 (5%)
89. Q5THJ0_HUMAN PR domain containing 2, with ZNF domain
(Fragment), 41 (5%)
90. AAB07496 leptin receptor, 41 (3%)
91. CAD33317 Sequence 44 from Patent WO0218424, 41 (4%)
92. BAA96000 KIAA1476 protein, 41 (1%)
93. Q8NGB0_HUMAN Seven transmembrane helix receptor
94. Q8WY53_HUMAN PAD, 40 (6%)
95. AAA85638 TFIIIC alpha subunit, 40 (3%)
96. CAE11569 Sequence 9 from Patent WO03048202, 39 (1%)
97. S02392 alpha-2-macroglobulin receptor precursor, 39 (1%)
98. CAA69325 Mosaic protein LR11, 39 (2%)
99. Q6P4G7_HUMAN TRA@ protein, 39 (13%)
100.PSA7L_HUMAN Proteasome subunit alpha type 7-like (EC
3.4.25.1), 39 (6%)
101.TP2B_HUMAN DNA topoisomerase II, beta isozyme (EC
5.99.1.3), 38 (4%)
102.Q5VZN6_HUMAN OTTHUMP00000018523
(OTTHUMP00000040824), 38 (1%)
103.PCNT2_HUMAN Pericentrin 2 (Pericentrin B) (Kendrin), 38 (2%)
104.AAF05687 Anti-phospholipid immunoglobulin heavy chain VH-
D-J-C region (fragment), 38 (18%)
105.AAC51825 3-phosphoinositide dependent protein kinase-1, 37
(2%)
106.BAA20778 KIAA0320 protein, 37 (2%)
107.Q6GPH5_HUMAN Eukaryotic translation initiation factor 4B, 37
(5%)
108.AAL39000 Macrophin 1 isoform 2, 37 (1%)
109.Q5STU9_HUMAN HLA-B associated transcript 1, 37 (6%)
110.AAP13528 rho/rac-interacting citron kinase, 37 (3%)
111.AAG43364 MAK-related kinase, 37 (9%)
112.Q6PFW1_HUMAN KIAA0377 gene product, 37 (3%)
113.JC2444 ribosomal protein L24, cytosolic [validated] – rat, 37
(8%)
114.AAH03413 Nucleolar protein family A, member 1, 37 (13%)
115.AAC26019 alpha-tectorin, 37 (2%)
116.YLPM1_HUMAN YLP motif containing protein 1 (Nuclear
protein ZAP3) (ZAP113), 37 (3%)
117.Q13544_HUMAN Signaling inositol polyphosphate 5 phosphatase
SIP-110, 37 (10%)
118.A35938 profilaggrin (fragments), 36 (1%)
119.CAA32530 Eosinophil preperoxidase (AA-127 to 575), 36 (6%)
120.Q7LAX7_HUMAN CKII beta binding protein 2, 36 (16%)
121.JC7687 nucleolar protein p40/Epstein-Barr virus nuclear
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antigen 1 binding protein 2 , 36 (3%)
122.CAC20419 a disintergrin-like and metalloprotease (replosin
type), 36 (2%)
123.Q5T1U7_HUMAN OTTHUMP00000021972 (Fragment), 36 (7%)
124.Q8NG37_HUMAN Microtubule affinity-regulating kinase-like1,
36 (5%)
125.AAB38530 Plasma membrane calcium ATPase isoform 3x/b, 36
(4%)
126.RABE2_HUMAN Rab GTPase binding effector protein 2
(Rabaptin-5beta), 35 (8%)
128.DOC10_HUMAN Dedicator of cytokinesis protein 10 (Protein
zizimin 3), 35 (2%)
129.Q9UPS0_HUMAN KIAA1082 protein (Fragment), 35 (3%)
130.T08711 gamma-adaptin homolog DKFZp564D066.1 , 35 (4%)
131.POK20_HUMAN HERV-K_3q27.3 provirus ancestral Pol protein
[Includes: Reverse transcriptase (RT) (EC 2.7.7.49); R, 35 (4%)
132.AAH45551 TSEN54 protein, 35 (4%)
133.Q5SQZ8_HUMAN Thyroid hormone receptor interactor 8, 35 (3%)
134.AAC51191 Skeletal muscle ryanodine receptor, 35 (1%)
135.AAH09304 DDX27 protein, 35 (3%)
136.AAA51758 apolipoprotein B-100, 35 (1%)
137.CGHU2E collagen alpha 2(XI) chain precursor (fragment), 35
(4%)
138.O43149_HUMAN KIAA0399 protein (Fragment), 34 (3%)
139.AAR32522 Immunoglobulin heavy chain variable region, 34
(25%)
140.AAB04947 Inositol 1,4,5-trisphosphate receptor type 1, 34 (1%)
141.CAC38563 Sequence 143 from Patent WO0129221, 34 (9%)
142.CAC33149 Sequence 54 from Patent WO0100826, 34 (4%)
143.Q96CV2_HUMAN ACCN2 protein (Fragment), 34 (4%)
144.AAH00528 Arginyl-tRNA synthetase, 34 (7%)
145.AAB08431 hGrbIRbeta/hGrb10, 34 (3%)
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